N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

ABSTRACT

The present invention provides for compounds of formula (I) 
                         
wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren&#39;s syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/287,911 filed on Oct. 7, 2016, which claims priority to U.S. Provisional Application No. 62/239,647, filed Oct. 9, 2015 and U.S. Provisional Application No. 62/309,794, filed Mar. 17, 2016, all of which are incorporated herein by reference for all purposes.

BACKGROUND OF THE INVENTION Technical Field

The invention relates to compounds that are modulators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, useful in treating diseases and conditions mediated and modulated by CFTR. Additionally, the invention relates to compositions containing compounds of the invention and processes for their preparation.

Description of Related Technology

ATP-Binding Cassette (“ABC”) transporters are a family of homologous membrane transporter proteins regulating the transport of a wide variety of pharmacological agents (for example drugs, xenobiotics, anions, etc.) that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were found to defend malignant cancer cells against chemotherapeutic agents, acting as multidrug resistance proteins (like the MDR1-P glycoprotein, or the multidrug resistance protein, MRP 1). So far, 48 ABC transporters, grouped into 7 families based on their sequence identity and function, have been identified.

ABC transporters provide protection against harmful environmental compounds by regulating a variety of important physiological roles within the body, and therefore represent important potential drug targets for the treatment of diseases associated with transporter defects, outwards cell drug transport, and other diseases in which modulation of ABC transporter activity may be beneficial.

The cAMP/ATP-mediated anion channel, CFTR, is one member of the ABC transporter family commonly associated with diseases, which is expressed in a variety of cell types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. The activity of CFTR in epithelial cells is essential for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue (Quinton, P. M., 1990. Cystic fibrosis: a disease in electrolyte transport. FASEB J. 4, 2709-2717).

The gene encoding CFTR has been identified and sequenced (Kerem, B., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., Tsui, L. C., 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080). CFTR comprises about 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The pair of transmembrane domains is linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.

Cystic fibrosis is (CF) caused by a defect in this gene which induces mutations in CFTR. Cystic fibrosis is the most common fatal genetic disease in humans and affects ˜0.04% of white individuals (Bobadilla, J. L., Macek, M., Jr, Fine, J. P., Farrell, P. M., 2002. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum. Mutat. 19, 575-606. doi:10.1002/humu.10041), for example, in the United States, about one in every 2,500 infants is affected, and up to 10 million people carry a single copy of the defective gene without apparent ill effects; moreover subjects bearing a single copy of the gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea. This effect might explain the relatively high frequency of the CF gene within the population.

In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung infections.

In cystic fibrosis patients, mutations in endogenous respiratory epithelial CFTR fail to confer chloride and bicarbonate permeability to epithelial cells in lung and other tissues, thus leading to reduced apical anion secretion and disruptions of the ion and fluid transport. This decrease in anion transport causes an enhanced mucus and pathogenic agent accumulation in the lung triggering microbial infections that ultimately cause death in CF patients.

Beyond respiratory disease, CF patients also suffer from gastrointestinal problems and pancreatic insufficiency that result in death if left untreated. Furthermore, female subjects with cystic fibrosis suffer from decreased fertility, whilst males with cystic fibrosis are infertile.

A variety of disease causing mutations have been identified through sequence analysis of the CFTR gene of CF chromosomes (Kerem, B., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., Tsui, L. C., 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080). ΔF508-CFTR, the most common CF mutation (present in at least 1 allele in ˜90% of CF patients) and occurring in approximately 70% of the cases of cystic fibrosis, contains a single amino acid deletion of phenylalanine 508. This deletion prevents the nascent protein from folding correctly, which protein in turn cannot exit the endoplasmic reticulum (ER) and traffic to the plasma membrane, and then is rapidly degraded. As a result, the number of channels present in the membrane is far less than in cells expressing wild-type CFTR. In addition to impaired trafficking, the mutation results in defective channel gating. Indeed, even if ΔF508-CFTR is allowed to reach the cell plasma membrane by low-temperature (27° C.) rescue where it can function as a cAMP-activated chloride channel, its activity is decreased significantly compared with WT-CFTR (Pasyk, E. A., Foskett, J. K., 1995. Mutant (ΔF508) Cystic Fibrosis Transmembrane Conductance Regulator Cl⁻ Channel Is Functional When Retained in Endoplasmic Reticulum of Mammalian Cells. J. Biol. Chem. 270, 12347-12350).

Other mutations with lower incidence have also been identified that alter the channel regulation or the channel conductance. In case of the channel regulation mutants, the mutated protein is properly trafficked and localized to the plasma membrane but either cannot be activated or cannot function as a chloride channel (e.g. missense mutations located within the nucleotide binding domains), examples of these mutations are G551D, G178R, and G1349D. Mutations affecting chloride conductance have a CFTR protein that is correctly trafficked to the cell membrane but that generates reduced chloride flow (e.g. missense mutations located within the membrane-spanning domain), examples of these mutations are R117H and R334W.

In addition to cystic fibrosis, CFTR activity modulation may be beneficial for other diseases not directly caused by mutations in CFTR, such as, for example, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's syndrome.

COPD is characterized by a progressive and non-reversible airflow limitation, which is due to mucus hypersecretion, bronchiolitis, and emphysema. A potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD could consist in using activators of mutant or wild-type CFTR. In particular, the anion secretion increase across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimize periciliary fluid viscosity. The resulting enhanced mucociliary clearance would help in reducing the symptoms associated with COPD.

Dry eye disease is characterized by a decrease in tear production and abnormal tear film lipid, protein and mucin profiles. Many factors may cause dry eye disease, some of which include age, arthritis, LASIK eye surgery, chemical/thermal burns, medications, allergies, and diseases, such as cystic fibrosis and Sjogrens's syndrome. Increasing anion secretion via CFTR could enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye, and eventually improve corneal hydration, thus helping to alleviate dry eye disease associated symptoms. Sjogrens's syndrome is an autoimmune disease where the immune system harms moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. The ensuing symptoms, include, dry eye, mouth, and vagina, as well as lung disease. Sjogrens's syndrome is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymyositis/dermatomyositis. The cause of the disease is believed to lie in defective protein trafficking, for which treatment options are limited. As a consequence, modulation of CFTR activity may help hydrate the various organs and help alleviate the associated symptoms.

In addition to CF, the defective protein trafficking induced by the ΔF508-CFTR has been shown to be the underlying basis for a wide range of other diseases, in particular diseases where the defective functioning of the endoplasmic reticulum (ER) may either prevent the CFTR protein to exit the cell, and/or the misfolded protein is degraded (Morello, J.-P., Bouvier, M., Petaja-Repo, U. E., Bichet, D. G., 2000. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. 21, 466-469. doi:10.1016/S0165-6147(00)01575-3; Shastry, B. S., 2003. Neurodegenerative disorders of protein aggregation. Neurochem. Int. 43, 1-7. doi:10.1016/S0197-0186(02)00196-1; Zhang, W., Fujii, N., Naren, A. P., 2012. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. Future Med. Chem. 4, 329-345. doi:10.4155/fmc.12.1).

A number of genetic diseases are associated with a defective ER processing equivalent to the defect observed with CFTR in CF such as glycanosis CDG type 1, hereditary emphysema (α-1-antitrypsin (PiZ variant)), congenital hyperthyroidism, osteogenesis imperfecta (Type I, II, or IV procollagen), hereditary hypofibrinogenemia (fibrinogen), ACT deficiency (α-1-antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (vasopvessin hormoneN₂-receptor), neprogenic DI (aquaporin II), Charcot-Marie Tooth syndrome (peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease (APP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's disease, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (prion protein processing defect), Fabry disease (lysosomal α-galactosidase A), Straussler-Scheinker syndrome, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.

In addition to up-regulation of the activity of CFTR, anion secretion reduction by CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport. The mechanism involves elevation of cAMP and stimulation of CFTR.

Regardless of the cause, excessive chloride transport is seen in all diarrhoeas, and results in dehydration, acidosis, impaired growth and death. Acute and chronic diarrhoeas remain a major medical problem worldwide, and are a significant factor in malnutrition, leading to death in children of less than five years old (5,000,000 deaths/year). Furthermore, in patients with chronic inflammatory bowel disease (IBD) and/or acquired immunodeficiency syndrome (AIDS), diarrhoea is a dangerous condition.

Accordingly, there is a need for novel compounds able to modulate CFTR. In particular, the present invention discloses compounds that may act as CFTR modulators for the treatment of cystic fibrosis. The present invention also provides methods for the preparation of these compounds, pharmaceutical compositions comprising these compounds and methods for the treatment of cystic fibrosis by administering the compounds of the invention.

SUMMARY

In one aspect the present invention provides for compounds of formula (I)

or a pharmaceutically acceptable salt thereof, wherein

-   -   R¹ is G^(1A), C₁-C₆ haloalkyl, or C₁-C₆ alkyl; wherein the C₁-C₆         haloalkyl and the C₁-C₆ alkyl are each optionally substituted         with one G^(1A);     -   G^(1A), at each occurrence, is independently phenyl, 5-6         membered monocyclic heteroaryl, 4-7 membered monocyclic         heterocycle, 5-11 membered fused bicyclic heterocycle, or C₃-C₆         monocyclic cycloalkyl; wherein each G^(1A) is optionally         substituted with 1, 2, 3, or 4 substituents independently         selected from the group consisting of R^(1a) and G^(1B);     -   G^(1B), at each occurrence, is independently 4-7 membered         monocyclic heterocycle which is optionally substituted with 1,         2, 3, or 4 independently selected R^(1b) groups;     -   R² is hydrogen, C₂-C₄ alkenyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl,         —OR^(2xa), —N(R^(2xa))(R^(2xb)), or G^(2A);     -   R^(2xa), at each occurrence, is independently C₁-C₆ alkyl, C₁-C₆         haloalkyl, or G^(2B);     -   R^(2xb) is hydrogen, C₁-C₃ alkyl, or C₁-C₃ haloalkyl;     -   G^(2A) and G^(2B) are each independently a 4-7 membered         monocyclic heterocycle or a C₃-C₆ monocyclic cycloalkyl; wherein         G^(2A) and G^(2B) are each optionally substituted with 1, 2, or         3 independently selected R^(2a) groups;     -   R³ is G^(3A), -G^(3B)-L¹-G^(3C), -G^(3B)-L³-G^(3C)-G^(3E),         —(C₁-C₆ alkylenyl)-G^(3D), —OR^(3a), or —N(R^(3a))(R^(3b));     -   R^(3a), at each occurrence, is independently G^(3D), C₁-C₆         haloalkyl, or C₁-C₆ alkyl; wherein the C₁-C₆ haloalkyl and the         C₁-C₆ alkyl are each optionally substituted with one or two         substituents independently selected from the group consisting of         G^(3D), —OR^(3xa), and —N(R^(3xb))₂;     -   R^(3xa) and R^(3xb), at each occurrence, are each independently         hydrogen, C₁-C₆ haloalkyl, C₁-C₆ alkyl, or G^(3D);     -   R^(3b) is hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;     -   L¹ is a bond, C₁-C₆ alkylenyl, (C₁-C₆ alkylenyl)_(r)-L²-(C₁-C₆         alkylenyl)_(s), or O—(C₁-C₆ alkylenyl)-C(O), wherein the left         end of the L¹ moiety is attached to G^(3B);     -   L² is O, N(R^(x)), C(O), N(R^(x))C(O), or C(O)N(R^(x)); wherein         each R^(x) is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆         haloalkyl;     -   L³ is a bond or C₁-C₆ alkylenyl;     -   r is 0 or 1;     -   s is 0 or 1;     -   G^(3A), G^(3B), and G^(3C) and each independently C₃-C₁₁         cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, or 4-11         membered heterocycle; wherein G^(3A), G^(3B), and G^(3C) are         each optionally substituted with 1, 2, 3, or 4 independently         selected R^(e) groups;     -   G^(3D), at each occurrence, is independently C₃-C₈ monocyclic         cycloalkyl, 4-7 membered monocyclic heterocycle, a 5-11 membered         fused bicyclic heterocycle, or a 5-11 membered spiro         heterocycle; wherein each G^(3D) is optionally substituted with         1, 2, 3, or 4 substituents independently selected from the group         consisting of R^(e) and G^(3E);     -   G^(3E), at each occurrence, is independently C₃-C₈ monocyclic         cycloalkyl or 4-7 membered monocyclic heterocycle; wherein each         G^(3E) is optionally substituted with 1, 2, 3, or 4         independently selected R^(e) groups;     -   R⁴ is hydrogen, C₁-C₃ alkyl, or C₁-C₃ haloalkyl;     -   R⁵ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, —N(R^(5ax))(R^(5bx)), —OR^(5dx) or G^(5A); wherein         the C₁-C₆ alkyl and the C₁-C₆ haloalkyl are each optionally         substituted with one or two substituents independently selected         from the group consisting of G^(5A), —CN, —N₃, —OR^(5ax),         —S(O)₂R^(5ax), —S(O)₂N(R^(5ax))(R^(5bx)), —N(R^(5ax))(R^(5bx)),         —N(R^(5bx))S(O)₂R^(5ex), —N(R^(5bx))C(O)R^(5cx),         —N(R^(5bx))C(O)N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)OR^(5cx),         —C(O)R^(5ax), —C(O)OR^(5ax), —C(O)N(R^(5bx))S(O)₂R^(5cx), and         —C(O)N(R^(5ax))(R^(5bx));     -   R^(5ax) and R^(5bx), at each occurrence, are each independently         hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —OR^(5ex), —(C₁-C₆         alkylenyl)-OR^(5ex), G^(5A), or —(C₁-C₆ alkylenyl)-G^(5A);     -   R^(5cx), at each occurrence, is independently C₁-C₆ alkyl, C₁-C₆         haloalkyl, G^(5A), or —(C₁-C₆ alkylenyl)-G^(5A);     -   R^(5dx) is C₁-C₆ alkyl, or C₁-C₆ haloalkyl;     -   R^(5ex) is hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;     -   G^(5A), at each occurrence, is independently C₃-C₁₁ cycloalkyl,         phenyl, 5-6 membered monocyclic heteroaryl, or 4-11 membered         heterocycle; wherein each G^(5A) is optionally substituted with         1, 2, 3, or 4 independently selected R^(5a) groups;     -   R^(5a), at each occurrence, is independently C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ haloalkyl, oxo, G^(5B),         —CN, NO₂, —OR^(b), —OC(O)R^(c), —OC(O)N(R^(d))₂, —SR^(b),         —S(O)₂R^(b), —S(O)₂N(R^(d))₂, —C(O)R^(b), —C(O)OR^(b),         —C(O)N(R^(d))₂, —C(O)N(R^(d))S(O)₂R^(c), —N(R^(d))₂,         —N(R^(d))C(O)R^(c), —N(R^(d))S(O)₂R^(c), —N(R^(d))C(O)O(R^(b)),         —N(R^(d))C(O)N(R^(d))₂, —N(R^(d))S(O)₂N(R^(d))₂, —(C₁-C₆         alkylenyl)-CN, —(C₁-C₆ alkylenyl)-G^(5B), —(C₁-C₆         alkylenyl)-OR^(b), —(C₁-C₆ alkylenyl)-OC(O)R^(c), —(C₁-C₆         alkylenyl)-OC(O)N(R^(d))₂, —(C₁-C₆ alkylenyl)-SR^(b), —(C₁-C₆         alkylenyl)-S(O)₂R^(b), —(C₁-C₆ alkylenyl)-S(O)₂N(R^(d))₂,         —(C₁-C₆ alkylenyl)-C(O)R^(b), —(C₁-C₆ alkylenyl)-C(O)OR^(b),         —(C₁-C₆ alkylenyl)-C(O)N(R^(d))₂, —(C₁-C₆         alkylenyl)-C(O)N(R^(d))S(O)₂R^(c), —(C₁-C₆ alkylenyl)-N(R^(d))₂,         —(C₁-C₆ alkylenyl)-N(R^(d))C(O)R^(c), —(C₁-C₆         alkylenyl)-N(R^(d))S(O)₂R^(c), —(C₁-C₆         alkylenyl)-N(R^(d))C(O)O(R), —(C₁-C₆         alkylenyl)-N(R^(d))C(O)N(R^(d))₂, or —(C₁-C₆         alkylenyl)-N(R^(d))S(O)₂N(R^(d))₂;     -   R^(b) and R^(d), at each occurrence, are each independently         hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, alkoxyalkyl, G^(5B), or         —(C₁-C₆ alkylenyl)-G^(5B);     -   R^(c), at each occurrence, is independently C₁-C₆ alkyl, C₁-C₆         haloalkyl, alkoxyalkyl, G^(5B), or —(C₁-C₆ alkylenyl)-G^(5B);     -   G^(5B), at each occurrence, is independently C₃-C₆ monocyclic         cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, or 4-7         membered monocyclic heterocycle; wherein each G^(5B) is         optionally substituted with 1, 2, 3, or 4 independently selected         R^(5b) groups;     -   R^(e), at each occurrence, is independently C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, oxo, —CN, —N₃,         NO₂, —OR, —OC(O)R^(g), —OC(O)NR^(f)R^(h), —SR^(f), —S(O)₂R^(f),         —S(O)₂NR^(f)R^(h), —C(O)R^(f), —C(O)OR^(f), —C(O)NR^(f)R^(h),         —C(O)N(R^(h))S(O)₂R^(f), —N(R^(f))₂, —N(R^(h))C(O)R^(h),         —N(R^(h))S(O)₂R^(g), —N(R^(h))C(O)O(R^(g)),         —N(R^(h))C(O)NR^(f)R^(h), or —N(R^(h))S(O)₂NR^(f)R^(h); wherein         the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each optionally         substituted with 1 or 2 substituents independently selected from         the group consisting of —CN, NO₂, —OR, —OC(O)R^(g),         —OC(O)NR^(f)R^(h), —SR^(f), —S(O)₂R^(f), —S(O)₂NR^(f)R^(h),         —C(O)R^(f), —C(O)OR^(f), —C(O)NR^(f)R^(h),         —C(O)N(R^(h))S(O)₂R^(f), —N(R^(f))₂, —N(R^(h))C(O)R^(g),         —N(R^(h))S(O)₂R^(g), —N(R^(h))C(O)O(R^(g)),         —N(R^(h))C(O)NR^(f)R^(h), and —N(R^(h))S(O)₂NR^(f)R^(h);     -   R^(f), at each occurrence, is independently hydrogen, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, —(C₁-C₆         alkylenyl)-CN, —(C₁-C₆ alkylenyl)-OR^(m), —(C₁-C₆         alkylenyl)-OC(O)R^(n), —(C₁-C₆ alkylenyl)-OC(O)N(R^(m))₂,         —(C₁-C₆ alkylenyl)-SR^(m), —(C₁-C₆ alkylenyl)-S(O)₂R^(m),         —(C₁-C₆ alkylenyl)-S(O)₂N(R^(m))₂, —(C₁-C₆ alkylenyl)-C(O)R^(m),         —(C₁-C₆ alkylenyl)-C(O)OR^(m), —(C₁-C₆ alkylenyl)-C(O)N(R^(m))₂,         —(C₁-C₆ alkylenyl)-C(O)N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))₂, —(C₁-C₆ alkylenyl)-N(R^(m))C(O)R^(n),         —(C₁-C₆ alkylenyl)-N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)O(R^(n)), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)N(R^(m))₂, or —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂N(R^(m))₂;     -   R^(g), at each occurrence, is independently C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, —(C₁-C₆ alkylenyl)-CN,         —(C₁-C₆ alkylenyl)-OR^(m), —(C₁-C₆ alkylenyl)-OC(O)R^(n),         —(C₁-C₆ alkylenyl)-OC(O)N(R^(m))₂, —(C₁-C₆ alkylenyl)-SR^(m),         —(C₁-C₆ alkylenyl)-S(O)₂R^(m), —(C₁-C₆         alkylenyl)-S(O)₂N(R^(m))₂, —(C₁-C₆ alkylenyl)-C(O)R^(m), —(C₁-C₆         alkylenyl)-C(O)OR^(m), —(C₁-C₆ alkylenyl)-C(O)N(R^(m))₂, —(C₁-C₆         alkylenyl)-C(O)N(R^(m))S(O)₂R^(n), —(C₁-C₆ alkylenyl)-N(R^(m))₂,         —(C₁-C₆ alkylenyl)-N(R^(m))C(O)R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)O(R^(n)), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)N(R^(m))₂, or —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂N(R^(m))₂;     -   R^(h), at each occurrence, is independently hydrogen, C₁-C₆         alkyl, C₁-C₆ haloalkyl, or —(C₁-C₆ alkylenyl)-OR^(m);     -   R^(1a), R^(1b), R^(2a), and R^(5b), at each occurrence, are each         independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,         halogen, C₁-C₆ haloalkyl, oxo, —CN, —NO₂, —OR^(m), —OC(O)R^(n),         —OC(O)N(R^(m))₂, —SR^(m), —S(O)₂R^(m), —S(O)₂N(R^(m))₂,         —C(O)R^(m), —C(O)OR^(m), —C(O)O(benzyl), —C(O)N(R^(m))₂,         —C(O)N(R^(m))S(O)₂R^(n), —N(R^(m))₂, —N(R^(m))(alkoxyalkyl),         —N(alkoxyalkyl)₂, —N(R^(m))C(O)R^(n), —N(R^(m))S(O)₂R^(n),         —N(R^(m))C(O)O(R^(n)), —N(R^(m))C(O)N(R^(m))₂,         —N(R^(m))S(O)₂N(R^(m))₂, —(C₁-C₆ alkylenyl)-CN, —(C₁-C₆         alkylenyl)-OR^(m), —(C₁-C₆ alkylenyl)-OC(O)R^(n), —(C₁-C₆         alkylenyl)-OC(O)N(R^(m))₂, —(C₁-C₆ alkylenyl)-SR^(m), —(C₁-C₆         alkylenyl)-S(O)₂R^(m), —(C₁-C₆ alkylenyl)-S(O)₂N(R^(m))₂,         —(C₁-C₆ alkylenyl)-C(O)R^(m), —(C₁-C₆ alkylenyl)-C(O)OR^(m),         —(C₁-C₆ alkylenyl)-C(O)N(R^(m))₂, —(C₁-C₆         alkylenyl)-C(O)N(R^(m))S(O)₂R^(n), —(C₁-C₆ alkylenyl)-N(R^(m))₂,         —(C₁-C₆ alkylenyl)-N(R^(m))C(O)R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)O(R), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)N(R^(n))₂, or —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂N(R^(n))₂;     -   R^(m), at each occurrence, is independently hydrogen, C₁-C₆         alkyl, or C₁-C₆ haloalkyl;     -   R^(n), at each occurrence, is independently C₁-C₆ alkyl or C₁-C₆         haloalkyl;     -   R⁶ is hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; or     -   R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(Z))—(C₁-C₆         alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety         of formula (I); and     -   R^(z) is hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

Another aspect of the invention relates to pharmaceutical compositions comprising a compound of the invention, and a pharmaceutical carrier. Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to Cystic Fibrosis Transmembrane Conductance Regulator activity. In a particular aspect, the pharmaceutical compositions may additionally comprise further therapeutically active ingredients suitable for use in combination with the compounds of the invention. In a more particular aspect, the further therapeutically active ingredient is an agent for the treatment of cystic fibrosis.

Moreover, the compounds of the invention, useful in the pharmaceutical compositions and treatment methods disclosed herein, are pharmaceutically acceptable as prepared and used.

Yet another aspect of the invention relates to a method for treating, or preventing conditions and disorders related to Cystic Fibrosis Transmembrane Conductance Regulator activity in mammals. More particularly, the method is useful for treating or preventing conditions and disorders related to cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, or chronic obstructive airway disease. Accordingly, the compounds and compositions of the invention are useful as a medicament for treating or preventing Cystic Fibrosis Transmembrane Conductance Regulator modulated disease.

The compounds, compositions comprising the compounds, methods for making the compounds, and methods for treating or preventing conditions and disorders by administering the compounds are further described herein.

In a particular aspect, the compounds of the invention are provided for use in the treatment of cystic fibrosis. In a particular aspect, the compounds of the invention are provided for use in the treatment of cystic fibrosis caused by class I, II, III, IV, V, and/or VI mutations.

The present invention also provides pharmaceutical compositions comprising a compound of the invention, and a suitable pharmaceutical carrier for use in medicine. In a particular aspect, the pharmaceutical composition is for use in the treatment of cystic fibrosis.

These and other objects of the invention are described in the following paragraphs. These objects should not be deemed to narrow the scope of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Described herein are compounds of formula (I)

wherein R¹, R², R³, R⁴, R⁵, and R⁶, are defined above in the Summary of the Invention and below in the Detailed Description. Further, compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also described.

Compounds included herein may contain one or more variable(s) that occur more than one time in any substituent or in the formulae herein. Definition of a variable on each occurrence is independent of its definition at another occurrence. Further, combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds, which can be isolated from a reaction mixture.

Definitions

It is noted that, as used in this specification and the intended claims, the singular form “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes a single compound as well as one or more of the same or different compounds; reference to “a pharmaceutically acceptable carrier” means a single pharmaceutically acceptable carrier as well as one or more pharmaceutically acceptable carriers, and the like.

As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated:

The term “alkenyl” as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond. The term “C₂-C₆ alkenyl” means an alkenyl group containing 2-6 carbon atoms. Non-limiting examples of C₂-C₆ alkenyl include buta-1,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, and 5-hexenyl.

The term “alkoxy” as used herein, means a C₁-C₆ alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

The term “alkoxyalkyl” as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a C₁-C₆ alkyl group, as defined herein. Non-limiting examples of alkoxyalkyl include tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl.

The term “alkyl” as used herein, means a saturated, straight or branched hydrocarbon chain radical. In some instances, the number of carbon atoms in an alkyl moiety is indicated by the prefix “C_(x)-C_(y)”, wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, “C₁-C₆ alkyl” means an alkyl substituent containing from 1 to 6 carbon atoms and “C₁-C₃ alkyl” means an alkyl substituent containing from 1 to 3 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 3,3-dimethylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-methylpropyl, 2-methylpropyl, 1-ethylpropyl, and 1,2,2-trimethylpropyl. The terms “alkyl,” “C₁-C₆ alkyl,” “C₁-C₄ alkyl,” and “C₁-C₃ alkyl” used herein are unsubstituted, unless otherwise indicated.

The term “alkylene” or “alkylenyl” means a divalent radical derived from a straight or branched, saturated hydrocarbon chain, for example, of 1 to 10 carbon atoms or of 1 to 6 carbon atoms (C₁-C₆ alkylenyl) or of 1 to 4 carbon atoms or of 1 to 3 carbon atoms (C₁-C₃ alkylenyl) or of 2 to 6 carbon atoms (C₂-C₆ alkylenyl). Examples of C₁-C₆ alkylenyl include, but are not limited to, —CH₂—, —CH₂CH₂—, —C(CH₃)₂—CH₂CH₂CH₂—, —C(CH₃)₂—CH₂CH₂—, —CH₂CH₂CH₂CH₂—, and —CH₂CH(CH₃)CH₂—.

The term “C₂-C₆ alkynyl” as used herein, means a straight or branched chain hydrocarbon radical containing from 2 to 6 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of C₂-C₆ alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

The term “C₃-C₁₁ cycloalkyl” as used herein, means a hydrocarbon ring radical containing 3-11 carbon atoms, zero heteroatom, and zero double bond. The C₃-C₁₁ cycloalkyl group may be a single-ring (monocyclic) or have two or more rings (polycyclic or bicyclic). Monocyclic cycloalkyl groups typically contain from 3 to 8 carbon ring atoms (C₃-C₈ monocyclic cycloalkyl), and even more typically 3-6 carbon ring atoms (C₃-C₆ monocyclic cycloalkyl). Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups contain two or more rings, and bicyclic cycloalkyls contain two rings. In certain embodiments, the polycyclic cycloalkyl groups contain 2 or 3 rings. The rings within the polycyclic and the bicyclic cycloalkyl groups may be in a bridged, fused, or spiro orientation, or combinations thereof. In a spirocyclic cycloalkyl, one atom is common to two different rings. An example of a spirocyclic cycloalkyl is spiro[4.5]decane. In a bridged cycloalkyl, the rings share at least two non-adjacent atoms. Examples of bridged cycloalkyls include, but are not limited to, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, and bicyclo[4.2.1]nonyl, tricyclo[3.3.1.0^(3,7)]nonyl (octahydro-2,5-methanopentalenyl or noradamantyl), tricyclo[3.3.1.1^(3,7)]decyl (adamantyl), and tricyclo[4.3.1.1^(3,8)]undecyl (homoadamantyl). In a fused ring cycloalkyl, the rings share one common bond. Examples of fused-ring cycloalkyl include, but not limited to, decalin (decahydronaphthyl) and bicyclo[2.2.0]octyl.

The term “C₄-C₇ monocyclic cycloalkenyl” as used herein, means cyclobutenyl, cyclopentenyl, cyclohexenyl, and cycloheptyl.

The term “halo” or “halogen” as used herein, means Cl, Br, I, and F.

The term “haloalkyl” as used herein, means an alkyl group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen. The term “C₁-C₆ haloalkyl” means a C₁-C₆ alkyl group, as defined herein, in which one, two, three, four, five, or six hydrogen atoms are replaced by halogen. The term “C₁-C₃ haloalkyl” means a C₁-C₃ alkyl group, as defined herein, in which one, two, three, four, or five hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, fluoromethyl, 2,2,2-trifluoroethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, trifluorobutyl, and trifluoropropyl. The terms “haloalkyl,” “C₁-C₆ haloalkyl,” and “C₁-C₃ haloalkyl” used herein are unsubstituted, unless otherwise indicated.

The term “4-11 membered heterocycle” as used herein, means a hydrocarbon ring radical of 4-11 carbon ring atoms wherein at least one carbon atom is replaced by a heteroatom(s) independently selected from the group consisting of O, N, and S. The 4-11 membered heterocycle ring may be a single ring (monocyclic) or have two or more rings (bicyclic or polycyclic). In certain embodiments, the monocyclic heterocycle is a four-, five-, six-, seven-, or eight-membered hydrocarbon ring wherein at least one carbon ring atom is replaced by a heteroatom(s) independently selected from the group consisting of O, N, and S. In certain embodiments, the monocyclic heterocycle is a 4-7 membered hydrocarbon ring wherein at least one carbon ring atom is replaced by a heteroatom(s). A four-membered monocyclic heterocycle contains zero or one double bond, and one heteroatom selected from the group consisting of O, N, and S. A five-membered monocyclic heterocycle contains zero or one double bond and one, two, or three heteroatoms selected from the group consisting of O, N, and S. Examples of five-membered monocyclic heterocycles include those containing in the ring: 1 O; 1 S; 1 N; 2 N; 3N; 1 Sand 1 N; 1 S, and 2 N; 1 O and 1 N; or 1 O and 2 N. Non-limiting examples of 5-membered monocyclic heterocyclic groups include 1,3-dioxolanyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, imidazolidinyl, oxazolidinyl, imidazolinyl, imidazolidinyl, isoxazolidinyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, thiazolinyl, and thiazolidinyl. A six-membered monocyclic heterocycle contains zero, one, or two double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. Examples of six-membered monocyclic heterocycles include those containing in the ring: 1 O; 2 O; 1 S; 2 S; 1 N; 2 N; 3 N; 1 S, 1 O, and 1 N; 1 S and 1 N; 1 S and 2 N; 1 S and 1 O; 1 S and 2 O; 1 O and 1 N; and 1 O and 2 N. Examples of six-membered monocyclic heterocycles include 1,6-dihydropyridazinyl, dihydropyranyl, 1,3-dioxanyl, 1,4-dithianyl, hexahydropyrimidine, morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridinyl, tetrahydrothiopyranyl, thiomorpholinyl, thioxanyl, and trithianyl. Seven- and eight-membered monocyclic heterocycles contains zero, one, two, or three double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. Examples of monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, 1,4-diazepanyl, dihydropyranyl, 1,6-dihydropyridazinyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxazepanyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydropyranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, thiopyranyl, and trithianyl. Polycyclic heterocycle groups contain two or more rings, and bicyclic heterocycles contain two rings. In certain embodiments, the polycyclic heterocycle groups contain 2 or 3 rings. The rings within the polycyclic and the bicyclic heterocycle groups may be in a bridged, fused, or spiro orientation, or combinations thereof. In a spirocyclic heterocycle, one atom is common to two different rings. Non-limiting examples of the spirocyclic heterocycle include 2-azaspiro[3.3]heptyl, 5-azaspiro[2.4]heptyl, 5-azaspiro[2.5]octyl, 2-azaspiro[3.5]nonyl, 2-azaspiro[3.4]octyl, 3-azaspiro[5.5]undecyl, 5-azaspiro[3.4]octyl, 2-oxaspiro[3.3]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 6-oxa-2-azaspiro[3.4]octyl, 6-azaspiro[3.4]octyl, 7-azaspiro[3.5]nonyl, 8-azaspiro[4.5]decyl, 1-oxa-7-azaspiro[4.4]nonyl, 1-oxa-7-azaspiro[3.5]nonyl, 1-oxa-8-azaspiro[4.5]decyl, 1-oxa-3,8-diazaspiro[4.5]decyl, 1-oxa-4,9-diazaspiro[5.5]undecyl, 3,9-diazaspiro[5.5]undecyl, 2-oxa-7-azaspiro[3.5]nonyl, 5-oxa-2-azaspiro[3.5]nonyl, 6-oxa-2-azaspiro[3.5]nonyl, 2-oxa-5,8-diazaspiro[3.5]nonyl, 7-oxa-2-azaspiro[3.5]nonyl, 8-oxa-1-azaspiro[4.5]decyl, 8-oxa-2-azaspiro[4.5]decyl, 2,7-diazaspiro[4.4]nonyl, 1,4-dioxa-8-azaspiro[4.5]decyl, 1,3,8-triazaspiro[4.5]decyl. In a fused ring heterocycle, the rings share one common bond. Examples of fused bicyclic heterocycles are a 4-6 membered monocyclic heterocycle fused to a phenyl group, or a 4-6 membered monocyclic heterocycle fused to a C₃-C₆ monocyclic cycloalkyl, or a 4-6 membered monocyclic heterocycle fused to a C₄-C₇ monocyclic cycloalkenyl, or a 4-6 membered monocyclic heterocycle fused to a 4-7 membered monocyclic heterocycle. Examples of fused bicyclic heterocycles include, but are not limited to, 1,3-benzodioxolyl, 3-azabicyclo[3.1.0]hexyl, benzopyranyl, benzothiopyranyl, indolinyl, decahydropyrrolo[3,4-b]azepinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, 2,3-dihydro-1H-indolyl, 3,4-dihydroisoquinolin-2(1H)-yl, 2,3,4,6-tetrahydro-1H-pyrido[1,2-a]pyrazin-2-yl, hexahydropyrano[3,4-b][1,4]oxazin-1 (5H)-yl, hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, hexahydrocyclopenta[c]pyrrol-3a(1H)-yl, hexahydro-1H-oxazolo[3,4-a]pyrazinyl, octahydropyrrolo[3,4-b][1,4]oxazinyl, octahydroimidazo[1,5-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl, octahydro-1H-pyrrolo[3,2-c]pyridinyl, and octahydropyrrolo[3,4-c]pyrrolyl. In a bridged heterocycle, the rings share at least two non-adjacent atoms. Examples of such bridged heterocycles include, but are not limited to, azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl and 2-oxa-5-azabicyclo[2.2.1]heptyl), 8-azabicyclo[3.2.1]oct-8-yl, octahydro-2,5-epoxypentalene, 8-oxa-3-azabicyclo[3.2.1]octyl, hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-admantane (1-azatricyclo[3.3.1.1^(3,7)]decane), and oxa-adamantane (2-oxatricyclo[3.3.1.1^(3,7)]decane). The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized (e.g. 1,1-dioxidotetrahydrothienyl, 1,1-dioxido-1,2-thiazolidinyl, 1,1-dioxidothiomorpholinyl) and the nitrogen atoms may optionally be quaternized.

The term “5-11 membered heteroaryl” as used herein, means a monocyclic heteroaryl and a bicyclic heteroaryl. The monocyclic heteroaryl is a five- or six-membered ring. The five-membered ring contains two double bonds. The five membered ring may contain one heteroatom selected from O or S; or one, two, three, or four nitrogen atoms and optionally one oxygen or one sulfur atom. The six-membered ring contains three double bonds and one, two, three or four nitrogen atoms. Examples of 5-6 membered monocyclic heteroaryl include, but are not limited to, furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a C₃-C₆ monocyclic cycloalkyl, or a monocyclic heteroaryl fused to C₄-C₇ monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a 4-7 membered monocyclic heterocycle. Representative examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, phthalazinyl, 2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl, 6,7-dihydro-pyrazolo[1,5-a]pyrazin-5(4H)-yl, 6,7-dihydro-1,3-benzothiazolyl, imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl, naphthyridinyl, pyridoimidazolyl, quinolinyl, 2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl, thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-d]pyrimidin-2-yl, and 5,6,7,8-tetrahydroquinolin-5-yl. The nitrogen atom in the heteroaryl rings may optionally be oxidized and may optionally be quaternized.

The phenyl, the cycloalkyls, the cycloalkenyls, the heterocycles, and the heteroaryls, including the exemplary rings, are optionally substituted unless otherwise indicated; and are attached to the parent molecular moiety through any substitutable atom contained within the ring system.

The term “heteroatom” as used herein, means a nitrogen, oxygen, and sulfur.

The term “oxo” as used herein, means a ═O group.

The term “radiolabel” means a compound of the invention in which at least one of the atoms is a radioactive atom or a radioactive isotope, wherein the radioactive atom or isotope spontaneously emits gamma rays or energetic particles, for example alpha particles or beta particles, or positrons. Examples of such radioactive atoms include, but are not limited to, ³H (tritium), ¹⁴C, ¹¹C, ¹⁵O, ¹⁸F, ³⁵S, ¹²³I, and ¹²⁵I.

A moiety is described as “substituted” when a non-hydrogen radical is in the place of hydrogen radical of any substitutable atom of the moiety. Thus, for example, a substituted heterocycle moiety is a heterocycle moiety in which at least one non-hydrogen radical is in the place of a hydrogen radical on the heterocycle. It should be recognized that if there are more than one substitution on a moiety, each non-hydrogen radical may be identical or different (unless otherwise stated).

If a moiety is described as being “optionally substituted,” the moiety may be either (1) not substituted or (2) substituted. If a moiety is described as being optionally substituted with up to a particular number of non-hydrogen radicals, then that moiety may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the moiety, whichever is less. Thus, for example, if a moiety is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.

The terms “treat”, “treating”, and “treatment” refer to a method of alleviating or abrogating a disease and/or its attendant symptoms. In certain embodiments, “treat,” “treating,” and “treatment” refer to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treat”, “treating”, and “treatment” refer to modulating the disease or disorder, either physically (for example, stabilization of a discernible symptom), physiologically (for example, stabilization of a physical parameter), or both. In a further embodiment, “treat”, “treating”, and “treatment” refer to slowing the progression of the disease or disorder.

The terms “prevent”, “preventing”, and “prevention” refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, “prevent”, “preventing” and “prevention” also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring or developing a disease or disorder.

The phrase “therapeutically effective amount” means an amount of a compound, or a pharmaceutically acceptable salt thereof, sufficient to prevent the development of or to alleviate to some extent one or more of the symptoms of the condition or disorder being treated when administered alone or in conjunction with another therapeutic agent for treatment in a particular subject or subject population. The “therapeutically effective amount” may vary depending on the compound, the disease and its severity, and the age, weight, health, etc., of the subject to be treated. For example in a human or other mammal, a therapeutically effective amount may be determined experimentally in a laboratory or clinical setting, or may be the amount required by the guidelines of the United States Food and Drug Administration, or equivalent foreign agency, for the particular disease and subject being treated.

The term “subject” is defined herein to refer to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, pigs, horses, dogs, cats, rabbits, rats, mice and the like. In one embodiment, the subject is a human. The terms “human,” “patient,” and “subject” are used interchangeably herein.

The term ‘one or more’ refers to one to four. In one embodiment it refers to one or three. In another embodiment it refers to one to three. In a further embodiment it refers to one to two. In yet other embodiment it refers to two. In yet other further embodiment it refers to one.

As used herein, “Class I mutation(s)” refers to mutations which interfere with protein synthesis. They result in the introduction of a premature signal of termination of translation (stop codon) in the mRNA. The truncated CFTR proteins are unstable and rapidly degraded, so, the net effect is that there is no protein at the apical membrane. In particular, Class I mutation(s) refers to p.Gly542X (G542X), W1282X, c.489+1G>T (621+1G>T), or c.579+1G>T (711+1G>T) mutation. More particularly, Class I mutation(s) refers to G542X; or W1282X mutations.

As used herein, “Class II mutation(s)” refers to mutations which affect protein maturation. These lead to the production of a CFTR protein that cannot be correctly folded and/or trafficked to its site of function on the apical membrane. In particular, Class II mutation(s) refers to p.Phe508del (F508del), p.Ile507del, or p.Asn1303Lys (N₁₃₀₃K) mutations. More particularly, Class II mutation(s) refers to F508del or N₁₃₀₃K mutations.

As used herein, “Class III mutation(s)” refers to mutations which alter the regulation of the CFTR channel. The mutated CFTR protein is properly trafficked and localized to the plasma membrane but cannot be activated, or it cannot function as a chloride channel. In particular, Class III mutation(s) refers to p.Gly551Asp (G551D), G551S, R553G, G1349D, S1251N, G178R, S549N mutations. More particularly, Class III mutation(s) refers to G551D, R553G, G1349D, S1251N, G178R, or S549N mutations.

As used herein, “Class IV mutation(s)” refers to mutations which affect chloride conductance. The CFTR protein is correctly trafficked to the cell membrane but generates reduced chloride flow or a “gating defect” (most are missense mutations located within the membrane-spanning domain). In particular, Class IV mutation(s) refers to p.Arg117His (R117H), R347P, or p.Arg334Trp (R334W) mutations.

As used herein, “Class V mutation(s)” refers to mutations which reduce the level of normally functioning CFTR at the apical membrane or result in a “conductance defect” (for example partially aberrant splicing mutations or inefficient trafficking missense mutations). In particular, Class V mutation(s) refers to c.1210-12T[5] (5T allele), c.S3140-26A>G (3272-26A>G), c.3850-2477C>T (3849+10 kbC>T) mutations.

As used herein, “Class VI mutation(s)” refers to mutations which decrease the stability of the CFTR which is present or which affect the regulation of other channels, resulting in inherent instability of the CFTR protein. In effect, although functional, the CFTR protein is unstable at the cell surface and it is rapidly removed and degraded by cell machinery. In particular, Class VI mutation(s) refers to Rescued F508del, 120del23, N₂₈₇Y, 4326dellTC, or 4279insA mutations. More particularly, Class VI mutation(s) refers to Rescued F508del mutations.

Compounds

Compounds of the invention have the general formula (I) as described above.

Particular values of variable groups in compounds of formula (I) are as follows. Such values may be used where appropriate with any of the other values, definitions, claims or embodiments defined hereinbefore or hereinafter.

In certain embodiments of formula (I), R¹ is G^(1A), C₁-C₆ haloalkyl, or C₁-C₆ alkyl.

In certain embodiments of formula (I), R¹ is G^(1A).

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is phenyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, dihydropyranyl, 1,6-dihydropyridazinyl, tetrahydropyranyl, tetrahydrothienyl, piperidinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is phenyl, pyridinyl, tetrahydrofuranyl, tetrahydropyranyl, cyclopropyl, cyclopentyl, or cyclohexyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is phenyl, pyridinyl, or cyclohexyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is 4-7 membered monocyclic heterocycle. In some such embodiments, the 4-7 membered monocyclic heterocycle is tetrahydrofuranyl or tetrahydropyranyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is C₃-C₆ monocyclic cycloalkyl. In some such embodiments, the C₃-C₆ monocyclic cycloalkyl is cyclohexyl. In some such embodiments, the C₃-C₆ monocyclic cycloalkyl is cyclopentyl. In some such embodiments, the C₃-C₆ monocyclic cycloalkyl is cyclopropyl.

In certain embodiments, R¹ is G^(1A) wherein G^(1A) is 5-11 membered fused bicyclic heterocycle. In some such embodiments, the 5-11 membered fused bicyclic heterocycle is 1,3-benzodioxolyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is phenyl or 5-6 membered monocyclic heteroaryl. In some such embodiments, the 5-6 membered monocyclic heteroaryl is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl. In some such embodiments, the 5-6 membered monocyclic heteroaryl is pyridinyl or pyrimidinyl. In some such embodiments, the 5-6 membered monocyclic heteroaryl is pyridinyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is phenyl.

In certain embodiments of formula (I), R¹ is G^(1A) wherein G^(1A) is 5-6 membered monocyclic heteroaryl. In some such embodiments, the 5-6 membered monocyclic heteroaryl is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl. In some such embodiments, the 5-6 membered monocyclic heteroaryl is pyridinyl or pyrimidinyl. In some such embodiments, the 5-6 membered monocyclic heteroaryl is pyridinyl.

In certain embodiments, G^(1A), including the exemplary rings, are optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of R^(1a) and G^(1B).

In certain embodiments, G^(1A), including the exemplary rings, are optionally substituted with 1, 2, 3, or 4 independently selected R^(1a).

In certain embodiments, G^(1A), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(1a).

In certain embodiments, G^(1A), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(1a).

In certain embodiments, G^(1A), including the exemplary rings, are unsubstituted.

In certain embodiments, G^(1A), including the exemplary rings, are substituted with one G^(1B), and said G^(1A), including the exemplary rings, are optionally further substituted with 1, 2, or 3 independently selected R^(1a). In some such embodiments, said G^(1A), including the exemplary rings, are optionally further substituted with 1 or 2 independently selected R^(1a). In some such embodiments, said G^(1A), including the exemplary rings, are optionally further substituted with one R^(1a). In some such embodiments, said G^(1A), including the exemplary rings, are not further substituted.

In certain embodiments of formula (I), each R^(1a) is independently C₁-C₆ alkyl, halogen, C₁-C₆ haloalkyl, oxo, —CN, —OR^(m), —S(O)₂R^(m), —S(O)₂N(R^(m))₂, —C(O)R^(m), —C(O)OR^(m), —C(O)N(R^(m))₂, —N(R^(m))₂, —N(R^(m))(alkoxyalkyl), —N(alkoxyalkyl)₂, or —(C₁-C₆ alkylenyl-CN).

In certain embodiments of formula (I), each R^(1a) is independently C₁-C₆ alkyl, halogen, C₁-C₆ haloalkyl, —CN, —OR^(m), —N(R^(m))₂, —N(R^(m))(alkoxyalkyl), or —N(alkoxyalkyl)₂.

In certain embodiments of formula (I), each R^(1a) is independently C₁-C₃ alkyl, halogen, C₁-C₃ haloalkyl, —CN, —OR^(m), or —N(R^(m))₂.

In certain embodiments of formula (I), G^(1B) is a 4-7 membered monocyclic heterocycle.

In certain embodiments of formula (I), G^(1B) is azetidinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, or morpholinyl.

In certain embodiments, G^(1B), including the exemplary rings, are optionally substituted with 1, 2, 3, or 4 independently selected R^(1b) groups.

In certain embodiments, G^(1B), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(1b) groups.

In certain embodiments, G^(1B), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(1b).

In certain embodiments, G^(1B), including the exemplary rings, are unsubstituted.

In certain embodiments of formula (I), each R^(1b) is independently C₁-C₃ alkyl, halogen, C₁-C₃ haloalkyl, or —OR^(m).

In certain embodiments of formula (I), R¹ is C₁-C₆ alkyl. In some such embodiments, R¹ is —C(CH₃)₃, —C(H)(CH₃)₂, or —CH₂—CH(CH₃)₂. In some such embodiments, R¹ is —C(H)(CH₃)₂ or —CH₂—CH(CH₃)₂. In some such embodiments, R¹ is —C(H)(CH₃)₂.

In certain embodiments of formula (I), R¹ is C₁-C₆ alkyl substituted with one G^(1A). In some such embodiments, G^(1A) is optionally substituted C₃-C₆ monocyclic cycloalkyl. In some such embodiments, G^(1A) is optionally substituted cyclobutyl. In some such embodiments, G^(1A) is unsubstituted cyclobutyl.

In certain embodiments of formula (I), R² is C₁-C₆ alkyl, C₁-C₆ haloalkyl, —OR^(2xa), —N(R^(2xa))(R^(2xb)), or G^(2A).

In certain embodiments of formula (I), R² is C₁-C₆ alkyl, C₁-C₆ haloalkyl, —OR^(2xa), or G^(2A).

In certain embodiments of formula (I), R² is C₁-C₆ alkyl, C₁-C₆ haloalkyl, or G^(2A).

In certain embodiments of formula (I), R² is C₁-C₆ alkyl or G^(2A).

In certain embodiments of formula (I), R² is —CH₃, —C(H)(CH₃)₂, —C(CH₃)₃, or G^(2A).

In certain embodiments of formula (I), R² is —CH₃, —C(H)(CH₃)₂, or G^(2A).

In certain embodiments of formula (I), R² is —C(H)(CH₃)₂ or G^(2A).

In certain embodiments of formula (I), R² is C₁-C₆ alkyl.

In certain embodiments of formula (I), R² is —CH₃, —C(H)(CH₃)₂, or —C(CH₃)₃.

In certain embodiments of formula (I), R² is —CH₃ or —C(H)(CH₃)₂.

In certain embodiments of formula (I), R² is G^(2A).

In certain embodiments, G^(2A) is a C₃-C₆ monocyclic cycloalkyl. In some such embodiments, G^(2A) is cyclopropyl or cyclobutyl. In some such embodiments, G^(2A) is cyclobutyl.

In certain embodiments, G^(2A) is a 4-7 membered monocyclic heterocycle. In some such embodiments, G^(2A) is azetidinyl, oxetanyl, pyrrolidinyl, or tetrahydrofuranyl. In some such embodiments, G^(2A) is azetidinyl or oxetanyl. In some such embodiments, G^(2A) is azetidinyl.

In certain embodiments, G^(2A) is azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, cyclopropyl, or cyclobutyl.

In certain embodiments, G^(2A) is azetidinyl, pyrrolidinyl, cyclopropyl, or cyclobutyl.

In certain embodiments, G^(2A) is azetidinyl or cyclobutyl.

In certain embodiments, G^(2A) is azetidinyl.

In certain embodiments, G^(2A) is cyclobutyl.

In certain embodiments of formula (I), G^(2A), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(2a) groups.

In certain embodiments of formula (I), G^(2A), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(2a) groups.

In certain embodiments of formula (I), G^(2A), including the exemplary rings, are unsubstituted.

In certain embodiments of formula (I), R² is —OR^(2xa).

In certain embodiments of formula (I), R² is —OR^(2xa) wherein R^(2xa) is C₁-C₆ alkyl or G²B.

In certain embodiments, G^(2B) is a 4-7 membered monocyclic heterocycle.

In certain embodiments, G^(2B) is azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl.

In certain embodiments, G^(2B) is piperidinyl, oxetanyl, or tetrahydrofuranyl.

In certain embodiments, G^(2B) is oxetanyl.

In certain embodiments, G^(2B) is a C₃-C₆ monocyclic cycloalkyl. In some such embodiments, the C₃-C₆ monocyclic cycloalkyl is cyclobutyl.

In certain embodiments of formula (I), G^(2B), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(2a) groups.

In certain embodiments of formula (I), G^(2B), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(2a) groups.

In certain embodiments of formula (I), G^(2B), including the exemplary rings, are unsubstituted.

In certain embodiments of formula (I), each R^(2a) is independently C₁-C₆ alkyl, halogen, C₁-C₆ haloalkyl, oxo, —CN, —OR^(m), —C(O)R^(m), —C(O)OR^(m), or —(C₁-C₆ alkylenyl)-CN.

In certain embodiments of formula (I), each R^(2a) is independently C₁-C₃ alkyl, halogen, C₁-C₃ haloalkyl, —OR^(m), or —C(O)OR^(m).

In certain embodiments of formula (I), R³ is G^(3A), -G^(3B)-L¹-G^(3C), -G^(3B)-L³-G^(3C)-G^(3E), —(C₁-C₆ alkylenyl)-G^(3D), or —OR^(3a).

In certain embodiments of formula (I), R³ is G^(3A), -G^(3B)-L¹-G^(3C), or —OR^(3a).

In certain embodiments of formula (I), R³ is G^(3A) or -G^(3B)-L¹-G^(3C).

In certain embodiments of formula (I), R³ is G^(3A).

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is phenyl, 5-6 membered monocyclic heteroaryl, or 4-11 membered heterocycle.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is phenyl or 5-6 membered monocyclic heteroaryl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is phenyl, pyrazolyl, pyrrolyl, pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is phenyl, pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is phenyl, pyridinyl, or pyrimidinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is phenyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is pyridinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is a 4-11 membered heterocycle.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is azetidinyl, pyrrolidinyl, piperidinyl, dihydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl, azepanyl, 1,4-oxazepanyl, 1,4-diazepanyl, 2-azaspiro[3.3]heptyl, 2-oxaspiro[3.3]heptyl, 5-azaspiro[2.4]heptyl, 2-azaspiro[3.4]octyl, 5-azaspiro[2.5]octyl, 5-azaspiro[3.4]octyl, 5-oxa-2-azaspiro[3.5]nonyl, 6-oxa-2-azaspiro[3.4]octyl, 6-oxa-2-azaspiro[3.5]nonyl, 7-oxa-2-azaspiro[3.5]nonyl, 1-oxa-7-azaspiro[3.5]nonyl, 1-oxa-7-azaspiro[4.4]nonyl, 2-oxa-7-azaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 2-azaspiro[3.5]nonyl, 1,3,8-triazaspiro[4.5]decyl, 8-azaspiro[4.5]decyl, 8-oxa-2-azaspiro[4.5]decyl, 1-oxa-8-azaspiro[4.5]decyl, 1-oxa-3,8-diazaspiro[4.5]decyl, 1-oxa-4,9-diazaspiro[5.5]undecyl, 1,4-dioxa-8-azaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, octahydropyrrolo[3,4-c]pyrrolyl, hexahydro-1H-oxazolo[3,4-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl, octahydroimidazo[1,5-a]pyrazinyl, octahydro-1H-pyrrolo[3,2-c]pyridinyl, decahydropyrrolo[3,4-b]azepinyl, or isoindolinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is azetidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 2-azaspiro[3.3]heptyl, 5-azaspiro[2.4]heptyl, 2-azaspiro[3.4]octyl, 5-azaspiro[2.5]octyl, 5-oxa-2-azaspiro[3.5]nonyl, 6-oxa-2-azaspiro[3.5]nonyl, 7-oxa-2-azaspiro[3.5]nonyl, 1-oxa-7-azaspiro[3.5]nonyl, 2-azaspiro[3.5]nonyl, 1,3,8-triazaspiro[4.5]decyl, 8-oxa-2-azaspiro[4.5]decyl, 1-oxa-8-azaspiro[4.5]decyl, 1-oxa-3,8-diazaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 3-azabicyclo[3.1.0]hexyl, or octahydro-1H-pyrrolo[3,2-c]pyridinyl.

In certain embodiments of formula (I), R³ is G^(3A) is a 4-7 membered monocyclic heterocycle.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is azetidinyl, pyrrolidinyl, piperidinyl, dihydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl, azepanyl, 1,4-oxazepanyl, or 1,4-diazepanyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is azetidinyl, piperidinyl, or piperazinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is piperidinyl or piperazinyl.

In certain embodiments of formula (I), R³ is G^(3A) wherein G^(3A) is piperidinyl.

In certain embodiments, each of the aforementioned G^(3A), including the exemplary rings, are optionally substituted with 1, 2, 3, or 4 independently selected R^(e) groups.

In certain embodiments, each of the aforementioned G^(3A), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(e) groups.

In certain embodiments, each of the aforementioned G^(3A), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(e) groups.

In certain embodiments, G^(3A), including the exemplary rings, are unsubstituted.

In certain embodiments, each of the optional substituents of G^(3A) is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, oxo, —CN, —N₃, —OR^(f), —S(O)₂R, —C(O)R^(f), —C(O)OR^(f), —C(O)NR^(f)R^(h), —N(R)₂, —N(R^(h))C(O)R^(h), —N(R^(h))S(O)₂R^(g), or —N(R^(h))C(O)O(R^(g)); wherein the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of —CN, —OR^(f), —N(R^(f))₂, —C(O)N(R^(f))₂, and —N(R^(h))C(O)O(R^(g)).

In certain embodiments, each of the optional substituents of G^(3A) is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, oxo, —CN, —N₃, —OR, —S(O)₂R^(f), —C(O)OR, —N(R)₂, or —N(R^(h))C(O)R^(h); wherein the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of —CN, —OR, and —N(R^(f))₂; and each R^(f) is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(C₁-C₆ alkylenyl)-OR^(m), or —(C₁-C₆ alkylenyl)-N(R^(m))₂.

In certain embodiments, each of the optional substituents of G^(3A) is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, —OR, or —N(R^(f))₂; wherein the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of —OR^(f) and —N(R^(f))₂; and each R^(f) is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(C₁-C₆ alkylenyl)-OR^(m), or —(C₁-C₆ alkylenyl)-N(R^(m))₂.

In certain embodiments of formula (I), R³ is -G^(3B)-L¹-G^(3C).

In certain embodiments of formula (I), G^(3B) is phenyl, 5-6 membered monocyclic heteroaryl, or 4-7 membered monocyclic heterocycle.

In certain embodiments of formula (I), G^(3B) is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1-oxa-8-azaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, octahydro-1H-pyrrolo[3,2-c]pyridinyl, or 1,4-diazepanyl.

In certain embodiments of formula (I), G^(3B) is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, piperidinyl, or piperazinyl.

In certain embodiments of formula (I), G^(3B) is phenyl, pyridinyl, pyrimidinyl, piperidinyl, or piperazinyl.

In certain embodiments of formula (I), G^(3B) is a 4-7 membered monocyclic heterocycle.

In certain embodiments of formula (I), G^(3B) is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or 1,4-diazepanyl.

In certain embodiments of formula (I), G^(3B) is piperidinyl or piperazinyl.

In certain embodiments of formula (I), G^(3B) is piperidinyl.

In certain embodiments of formula (I), G^(3B) is piperazinyl.

In certain embodiments of formula (I), G^(3C) is C₃-C₆ monocyclic cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, or 4-7 membered monocyclic heterocycle.

In certain embodiments of formula (I), G^(3C) is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, thiomorpholinyl, 2-oxa-5,8-diazaspiro[3.5]nonyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, hexahydropyrrolo[3,4-c]pyrrolyl, or morpholinyl.

In certain embodiments of formula (I), G^(3C) is 4-7 membered monocyclic heterocycle.

In certain embodiments of formula (I), G^(3C) is azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, thiomorpholinyl, or morpholinyl.

In certain embodiments of formula (I), G^(3C) is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydropyranyl, or morpholinyl.

In certain embodiments of formula (I), G^(3C) is pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl.

In certain embodiments, each of the aforementioned G^(3B) and G^(3C), including the exemplary rings, are optionally substituted with 1, 2, 3, or 4 independently selected R^(e) groups.

In certain embodiments, each of the aforementioned G^(3B) and G^(3C), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(e) groups.

In certain embodiments, each of the aforementioned G^(3B) and G^(3C), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(e) groups.

In certain embodiments, G^(3B) and G^(3C), including the exemplary rings, are unsubstituted.

In certain embodiments, each of the optional substituents of G^(3B) is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, —OR^(f), or —CN. In some such embodiments, R^(f) is hydrogen, C₁-C₃ alkyl, or C₁-C₃ haloalkyl.

In certain embodiments, each of the optional substituents of G^(3B) is independently —CH₃, —CH₂F, —CHF₂, —CF₃, or F.

In certain embodiments, each of the optional substituents of G^(3C) is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, oxo, —OR^(f), —N(R^(f))₂, —C(O)OR^(f), or —CN; wherein the C₁-C₆ alkyl is optionally substituted with one —OR^(f).

In certain embodiments, each of the optional substituents of G^(3C) is independently —CH₃, —CH₂F, —CHF₂, —CF₃, F, or —CN.

In certain embodiments, L¹ is a bond, C₁-C₃ alkylenyl, or (C₁-C₃ alkylenyl)_(r)-L²-(C₁-C₃ alkylenyl)_(s).

In certain embodiments, L² is O, N(R^(x)), or C(O).

In certain embodiments, L² is O or N(R^(x)).

In certain embodiments of formula (I), R³ is —OR^(3a).

In certain embodiments of formula (I), R³ is —OR^(3a) wherein R^(3a) is G^(3D), C₁-C₆ haloalkyl, or C₁-C₆ alkyl; wherein the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each substituted with one or two substituents independently selected from the group consisting of G^(3D), —OR^(3xa), and —N(R^(3xb))₂.

In certain embodiments of formula (I), R³ is —OR^(3a); and R^(3a) is C₁-C₆ haloalkyl and C₁-C₆ alkyl; wherein the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each substituted with one G^(3D).

In certain embodiments, G^(3D) is oxetanyl, pyrrolidinyl, tetrahydrofuranyl, imidazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl, 1,3-dioxolanyl, azepanyl, 1,4-diazepanyl, 1,3-dioxanyl, 1,4-dioxanyl, 8-azaspiro[4.5]decyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

In certain embodiments, G^(3D) is a 4-7 membered monocyclic heterocycle.

In certain embodiments, G^(3D) is oxetanyl, pyrrolidinyl, tetrahydrofuranyl, imidazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl, 1,3-dioxolanyl, azepanyl, 1,4-diazepanyl, 1,3-dioxanyl, or 1,4-dioxanyl.

In certain embodiments, G^(3D) is tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl, or 1,4-dioxanyl.

In certain embodiments, G^(3D) is tetrahydropyranyl.

In certain embodiments, each of the aforementioned G^(3D), including the exemplary rings, are optionally substituted with 1, 2, 3, or 4 independently substituents independently selected from the group consisting of R^(e) and G^(3E).

In certain embodiments, each of the aforementioned G^(3D), including the exemplary rings, are optionally substituted with 1, 2, or 3 independently selected R^(e) groups.

In certain embodiments, each of the aforementioned G^(3D), including the exemplary rings, are optionally substituted with 1 or 2 independently selected R^(e) groups.

In certain embodiments, each of the aforementioned G^(3D), including the exemplary rings, are optionally substituted with one G^(3E) and optionally with 1 or 2 independently selected R^(e) groups. Examples of G^(3E) include cyclobutyl, cyclohexyl, and tetrahydropyranyl, each of which is optionally substituted.

In certain embodiments, G^(3D), including the exemplary rings, are unsubstituted. In certain embodiments, each of the R^(e) groups of G^(3D) is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, oxo, —OR^(f), —C(O)R^(f), —C(O)OR^(f), or —CN.

In certain embodiments of formula (I), R³ is —N(R^(3a))(R^(3b)).

In certain embodiments of formula (I), R³ is —N(R^(3a))(R^(3b)) wherein R^(3a) is C₁-C₃ haloalkyl or C₁-C₃ alkyl; wherein the C₁-C₃ haloalkyl and the C₁-C₃ alkyl are each substituted with one substituent independently selected from the group consisting of —OR^(3xa) and —N(R^(3xb))₂. In some such embodiments, R^(3xa) and R^(3xb), at each occurrence, are each independently hydrogen, C₁-C₃ haloalkyl, or C₁-C₃ alkyl.

In certain embodiments of formula (I), R³ is -G^(3B)-L³-G^(3C)-G^(3E). In some such embodiments, G^(3B) is phenyl, 5-6 membered heteroaryl, or 4-11 membered heterocycle, G^(3C) is 4-11 membered heterocycle; and G^(3E) is C₃-C₈ monocyclic cycloalkyl. Examples of G^(3B) are phenyl, pyridinyl, piperidinyl, and piperazinyl. In some such embodiments, G^(3C) is piperidinyl or piperazinyl. In some such embodiments, G^(3E) is cyclopropyl. G^(3B), G^(3C), and G^(3E), including the exemplary rings, are each optionally substituted as described in the summary and embodiments herein above.

In certain embodiments, R³ is-(C₁-C₆ alkylenyl)-G^(3D). In some such embodiments, G^(3D) is 4-7 membered monocyclic heterocycle. In some such embodiments, G^(3D) is piperidinyl, piperazinyl or morpholinyl. G^(3D), including the exemplary rings are each optionally substituted as described in the Summary and embodiments herein above.

In certain embodiments of formula (I), R⁴ is hydrogen or C₁-C₃ alkyl.

In certain embodiments of formula (I), R⁴ is hydrogen.

In certain embodiments of formula (I), R⁵ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or C₁-C₆ haloalkyl; wherein the C₁-C₆ alkyl and the C₁-C₆ haloalkyl are each optionally substituted with one or two substituents independently selected from the group consisting of G^(5A), —CN, —N₃, —OR^(5ax), —S(O)₂R^(5ax), —S(O)₂N(R^(5ax))(R^(5bx)), —N(R^(5ax))(R^(5bx)), —N(R^(5bx))S(O)₂R^(5cx), —N(R^(5bx))C(O)R^(5cx), —N(R^(5bx))C(O)N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)OR⁵C_(x), —C(O)R^(5ax), —C(O)OR^(5ax), —C(O)N(R^(5bx))S(O)₂R^(5cx), and —C(O)N(R^(5ax))(R^(5bx)).

In certain embodiments of formula (I), R⁵ is C₁-C₆ alkyl or C₁-C₆ haloalkyl.

In certain embodiments of formula (I), R⁵ is —CH₃, —CH₂CH₃, —CH₂C(H)C(CH₃)₂, —C(CH₃)₃, —CF₃, —CH₂Cl, —CH₂CF₃, or —CH₂CH₂CF₃.

In certain embodiments of formula (I), R⁵ is —CH₃.

In certain embodiments of formula (I), R⁵ is C₁-C₆ alkyl which is substituted with one substituent selected from the group consisting of G^(5A), —CN, —N₃, —OR^(5ax), —S(O)₂R^(5ax), —S(O)₂N(R^(5ax))(R^(5bx)), N(R^(5ax))(R^(5bx)), —N(R^(5bx))S(O)₂R^(5cx), —N(R^(5bx))C(O)R^(5cx), —N(R^(5bx))C(O)N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)OR^(5cx), —C(O)R^(5ax), —C(O)OR^(5ax), —C(O)N(R^(5bx))S(O)₂R^(5cx), and —C(O)N(R^(5ax))(R^(5bx)).

In certain embodiments of formula (I), R⁵ is C₁-C₆ alkyl which is substituted with one substituent selected from the group consisting of G^(5A), —CN, —N₃, —OR^(5ax), —N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)R^(5cx), —N(R^(5bx))C(O)OR^(5cx), —C(O)OR^(5ax), and —C(O)N(R^(5ax))(R^(5bx)).

In certain embodiments of formula (I), R⁵ is C₁-C₆ alkyl substituted with one G^(5A). In some such embodiments, G^(5A) is 5-6 membered monocyclic heteroaryl or a 4-11 membered heterocycle.

In certain embodiments of formula (I), R⁵ is —N(R^(5ax))(R^(5bx)). In some such embodiments, R^(5ax) is hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and R^(5bx) is C₁-C₆ alkyl, C₁-C₆ haloalkyl or G^(5A). In some such embodiments, R^(5ax) and R^(5bx) are each C₁-C₆ alkyl.

In certain embodiments of formula (I), R⁵ is G^(5A).

In certain embodiments of formula (I), R⁵ is G^(5A) wherein G^(5A) is C₃-C₆ monocyclic cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, or 4-11 membered heterocycle.

In certain embodiments, each of the aforementioned G^(5A) is optionally substituted with 1, 2, 3, or 4 independently selected R^(5a) groups.

In certain embodiments, G^(5A) is optionally substituted with 1, 2, or 3, independently selected R^(5a) groups.

In certain embodiments, G^(5A) is optionally substituted with 1, or 2 independently selected R^(5a) groups.

In certain embodiments, G^(5A) is unsubstituted.

In certain embodiments of formula (I), R⁶ is hydrogen.

In certain embodiments of formula (I), R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl.

In certain embodiments of formula (I), R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In certain embodiments of formula (I), R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R)—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In certain embodiments of formula (I), R⁵ and R⁶ together form a C₁-C₆ alkylenyl.

In certain embodiments of formula (I), R⁵ and R⁶ together form a —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

Various embodiments of substituents R¹, R², R³, R⁴, R⁵, R⁶, G^(1A), R^(1a), G^(1B), R^(1b), G^(2A), G²B, R^(2a), R^(2xa), G^(3A), G^(3B), G^(3C), R^(e), R^(f), L¹, L², R^(3a), G^(3D), G^(5A), R^(5ax), and R^(5bx) have been discussed above. These substituents embodiments can be combined to form various embodiments of the invention. All embodiments of present compounds, formed by combining the substituent embodiments discussed above are within the scope of Applicant's invention, and some illustrative embodiments of present compounds are provided below.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A), C₁-C₆ haloalkyl, or C₁-C₆ alkyl; and R² is C₁-C₆ alkyl, C₁-C₆ haloalkyl, or G^(2A). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); and R² is C₁-C₆ alkyl or G^(2A). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(Z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A) wherein G^(1A) is phenyl or 5-6 membered monocyclic heteroaryl; and R² is C₁-C₆ alkyl or G^(2A) wherein G^(2A) is C₃-C₆ monocyclic cycloalkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A) wherein G^(1A) is phenyl or pyridinyl; and R² is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A) wherein G^(1A) is phenyl or pyridinyl; and R² is G^(2A) wherein G^(2A) is C₃-C₆ monocyclic cycloalkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(Z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A) wherein G^(1A) is phenyl or pyridinyl; and R² is G^(2A) wherein G^(2A) is unsubstituted cyclobutyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); R² is C₁-C₆ alkyl or G^(2A); and R³ is G^(3A), -G^(3B)-L¹-G^(3C), or —OR^(3a). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); R² is C₁-C₆ alkyl or G^(2A); and R⁵ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); R² is C₁-C₆ alkyl or G^(2A); and R⁵ is C₁-C₆ alkyl which is substituted with one substituent selected from the group consisting of G^(5A), —CN, —N₃, —OR^(5ax), —N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)R^(5cx), —N(R^(5bx))C(O)OR^(5cx), —C(O)OR^(5ax), and —C(O)N(R^(5ax))(R^(5bx)). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); R² is C₁-C₆ alkyl or G^(2A); and R⁵ is —N(R^(5ax))(R^(5bx)). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); R² is C₁-C₆ alkyl or G^(2A); and R⁵ is G^(5A). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl or 5-6 membered monocyclic heteroaryl; R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is a C₃-C₆ monocyclic cycloalkyl; R³ is G^(3A), -G^(3B)-L¹-G^(3C), or —OR^(3a); and R⁵ is C₁-C₆ alkyl which is substituted with one substituent selected from the group consisting of G^(5A), —CN, —N₃, —OR^(5ax), —N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)R^(5cx), —N(R^(5bx))C(O)OR^(5cx), —C(O)OR^(5ax), and —C(O)N(R^(5ax))(R^(5bx)). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl or 5-6 membered monocyclic heteroaryl; R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is a C₃-C₆ monocyclic cycloalkyl; R³ is G^(3A), -G^(3B)-L^(L)-G^(3C), or —OR^(3a); and R⁵ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl or 5-6 membered monocyclic heteroaryl; R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is a C₃-C₆ monocyclic cycloalkyl; R³ is G^(3A), -G^(3B)-L^(L)-G^(3C), or —OR^(3a); and R⁵ is —N(R^(5ax))(R^(5bx)) or —OR^(5dx). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl or 5-6 membered monocyclic heteroaryl; R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is a C₃-C₆ monocyclic cycloalkyl; R³ is G^(3A), -G^(3B)-L¹-G^(3C), or —OR^(3a); and R⁵ is G^(5A) In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl optionally substituted with 1, 2, 3, or 4 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is G^(3A) wherein G^(3A) is a 4-11 membered heterocycle; and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl substituted with one G^(1B), and said phenyl is optionally further substituted with 1, 2, or 3 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is G^(3A) wherein G^(3A) is a 4-11 membered heterocycle; and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl optionally substituted with 1, 2, 3, or 4 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is -G^(3B)-L¹-G^(3C); and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl optionally substituted with 1, 2, 3, or 4 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is -G^(3B)-L¹-G^(3C); G^(3B) and G^(3C) are 4-7 membered monocyclic heterocycle; and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl substituted with one G^(1B), and said phenyl is optionally further substituted with 1, 2, or 3 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is -G^(3B)-L^(L)-G^(3C); G^(3B) and G^(3C) are 4-7 membered monocyclic heterocycle; and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl optionally substituted with 1, 2, 3, or 4 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is —OR^(3a); R^(3a) is C₁-C₆ alkyl or C₁-C₆ haloalkyl wherein the C₁-C₆ alkyl and the C₁-C₆ haloalkyl are each substituted with one G^(3D); G^(3D) is a 4-7 membered monocyclic heterocycle; and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl substituted with one G^(1B), and said phenyl is optionally further substituted with 1, 2, or 3 independently selected R^(1a); R² is C₁-C₆ alkyl or G^(2A); wherein G^(2A) is unsubstituted cyclobutyl; R³ is —OR^(3a); R^(3a) is C₁-C₆ alkyl or C₁-C₆ haloalkyl wherein the C₁-C₆ alkyl and the C₁-C₆ haloalkyl are each substituted with one G^(3D); G^(3D) is a 4-7 membered monocyclic heterocycle; and R⁵ is C₁-C₆ alkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein R³ is -G^(3B)-L³-G^(3C)-G^(3E); G^(3B) is phenyl, 5-6 membered heteroaryl, or 4-11 membered heterocycle; each of which is optionally substituted; G^(3C) is optionally substituted 4-11 membered heterocycle; and G^(3E) is optionally substituted C₃-C₈ monocyclic cycloalkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl, 5-6 membered monocyclic heteroaryl, or C₃-C₆ monocyclic cycloalkyl; R² is C₁-C₆ alkyl, —OR^(2xa), or G^(2A); wherein G^(2A) is an optionally substituted C₃-C₆ monocyclic cycloalkyl; and R³ is G^(3A), -G^(3B)-L¹-G^(3C), -G^(3B)-L³-G^(3C)-G^(3E), —(C₁-C₆ alkylenyl)-G^(3D), or —OR^(3a). In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃. In some such embodiments, R⁵ and R⁶ together form a C₁-C₆ alkylenyl or —N(R^(z))—(C₁-C₆ alkylenyl)- wherein the N(R^(z)) is attached to the S(O)₂ moiety of formula (I).

In one embodiment, the invention is directed to compounds wherein R¹ is G^(1A); wherein G^(1A) is phenyl, 5-6 membered monocyclic heteroaryl, or C₃-C₆ monocyclic cycloalkyl; R² is C₁-C₆ alkyl, —OR^(2xa), or G^(2A); wherein G^(2A) is an optionally substituted C₃-C₆ monocyclic cycloalkyl; R³ is G^(3A), -G^(3B)-L¹-G^(3C), -G^(3B)-L³-G^(3C)-G^(3E), —(C₁-C₆ alkylenyl)-G^(3D), or —OR^(3a); and R⁵ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is hydrogen. In some such embodiments, R⁶ is C₁-C₆ alkyl or C₁-C₆ haloalkyl. In some such embodiments, R⁶ is C₁-C₆ alkyl. In some such embodiments, R⁶ is —CH₃.

In one embodiment, the invention is directed to compounds wherein

-   -   R¹ is G^(1A), C₁-C₆ haloalkyl, or C₁-C₆ alkyl; wherein the C₁-C₆         haloalkyl and the C₁-C₆ alkyl are each optionally substituted         with one G^(1A);     -   G^(1A), at each occurrence, is independently phenyl, 5-6         membered monocyclic heteroaryl, 4-7 membered monocyclic         heterocycle, or C₃-C₆ monocyclic cycloalkyl; wherein each G^(1A)         is optionally substituted with 1, 2, 3, or 4 substituents         independently selected from the group consisting of R^(1a) and         G^(1B);     -   G^(1B), at each occurrence, is independently 4-7 membered         monocyclic heterocycle which is optionally substituted with 1,         2, 3, or 4 independently selected R^(1b) groups;     -   R² is hydrogen, C₂-C₄ alkenyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl,         —OR^(2xa), —N(R^(2xa))(R^(2xb)), or G^(2A);     -   R^(2xa), at each occurrence, is independently C₁-C₆ alkyl, C₁-C₆         haloalkyl, or G^(2B);     -   R^(2xb) is hydrogen, C₁-C₃ alkyl, or C₁-C₃ haloalkyl;     -   G^(2A) and G^(2B) are each independently a 4-7 membered         monocyclic heterocycle or a C₃-C₆ monocyclic cycloalkyl; wherein         G^(2A) and G^(2B) are each optionally substituted with 1, 2, or         3 independently selected R^(2a) groups;     -   R³ is G^(3A), -G^(3B)-L¹-G^(3C), —OR^(3a), or         —N(R^(3a))(R^(3b));     -   R^(3a), at each occurrence, is independently G^(3D), C₁-C₆         haloalkyl, or C₁-C₆ alkyl; wherein the C₁-C₆ haloalkyl and the         C₁-C₆ alkyl are each optionally substituted with one or two         substituents independently selected from the group consisting of         G^(3D), —OR^(3xa), and —N(R^(3xb))₂;     -   R^(3xa) and R^(3xb), at each occurrence, are each independently         hydrogen, C₁-C₆ haloalkyl, C₁-C₆ alkyl, or G^(3D);     -   R^(3b) is hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;     -   L¹ is a bond, C₁-C₆ alkylenyl, (C₁-C₆ alkylenyl)_(r)-L²-(C₁-C₆         alkylenyl)_(s), or O—(C₁-C₆ alkylenyl)-C(O), wherein the left         end of the L¹ moiety is attached to G^(3B);     -   L² is O, N(R^(x)), C(O), N(R^(x))C(O), or C(O)N(R^(x)); wherein         each R^(x) is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆         haloalkyl;     -   r is 0 or 1;     -   s is 0 or 1;     -   G^(3A), G^(3B), and G^(3C) and each independently         C₃-C₁₁cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, or         4-11 membered heterocycle; wherein G^(3A), G^(3B), and G^(3C)         are each optionally substituted with 1, 2, 3, or 4 independently         selected R^(e) groups;     -   G^(3D), at each occurrence, is independently C₃-C₈ monocyclic         cycloalkyl or 4-7 membered monocyclic heterocycle; wherein each         G^(3D) is optionally substituted with 1, 2, 3, or 4         independently selected R^(e) groups;     -   R⁴ is hydrogen, C₁-C₃ alkyl, or C₁-C₃ haloalkyl;     -   R⁵ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, —N(R^(5ax))(R^(5bx)), or G^(5A); wherein the C₁-C₆         alkyl and the C₁-C₆ haloalkyl are each optionally substituted         with one or two substituents independently selected from the         group consisting of G^(5A), —CN, —N₃, —OR^(5ax), —S(O)₂R^(5ax),         —S(O)₂N(R^(5ax))(R^(5bx)), —N(R^(5ax))(R^(5bx)),         —N(R^(5bx))S(O)₂R^(5cx), —N(R^(5bx))C(O)R^(5cx),         —N(R^(5bx))C(O)N(R^(5ax))(R^(5bx)), —N(R^(5bx))C(O)OR^(5cx),         —C(O)R^(5ax), —C(O)OR^(5ax), —C(O)N(R^(5bx))S(O)₂R^(5cx), and         —C(O)N(R^(5ax))(R^(5bx));     -   R^(5ax) and R^(5bx), at each occurrence, are each independently         hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, G^(5A), or —(C₁-C₆         alkylenyl)-G^(5A);     -   R^(5cx), at each occurrence, is independently C₁-C₆ alkyl, C₁-C₆         haloalkyl, G^(5A), or —(C₁-C₆ alkylenyl)-G^(5A);     -   G^(5A), at each occurrence, is independently C₃-C₁₁ cycloalkyl,         phenyl, 5-6 membered monocyclic heteroaryl, or 4-11 membered         heterocycle; wherein each G^(5A) is optionally substituted with         1, 2, 3, or 4 independently selected R^(5a) groups;     -   R^(5a), at each occurrence, is independently C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ haloalkyl, oxo, G^(5B),         —CN, NO₂, —OR^(b), —OC(O)R^(c), —OC(O)N(R^(d))₂, —SR^(b),         —S(O)₂R^(b), —S(O)₂N(R^(d))₂, —C(O)R^(b), —C(O)OR^(b),         —C(O)N(R^(d))₂, —C(O)N(R^(d))S(O)₂R^(c), —N(R^(d))₂,         —N(R^(d))C(O)R^(c), —N(R^(d))S(O)₂R^(c), —N(R^(d))C(O)O(R^(b)),         —N(R^(d))C(O)N(R^(d))₂, —N(R^(d))S(O)₂N(R^(d))₂, —(C₁-C₆         alkylenyl)-CN, —(C₁-C₆ alkylenyl)-G^(5B), —(C₁-C₆         alkylenyl)-OR^(b), —(C₁-C₆ alkylenyl)-OC(O)R^(c), —(C₁-C₆         alkylenyl)-OC(O)N(R^(d))₂, —(C₁-C₆ alkylenyl)-SR^(b), —(C₁-C₆         alkylenyl)-S(O)₂R^(b), —(C₁-C₆ alkylenyl)-S(O)₂N(R^(d))₂,         —(C₁-C₆ alkylenyl)-C(O)R^(b), —(C₁-C₆ alkylenyl)-C(O)OR^(b),         —(C₁-C₆ alkylenyl)-C(O)N(R^(d))₂, —(C₁-C₆         alkylenyl)-C(O)N(R^(d))S(O)₂R^(c), —(C₁-C₆ alkylenyl)-N(R^(d))₂,         —(C₁-C₆ alkylenyl)-N(R^(d))C(O)R^(c), —(C₁-C₆         alkylenyl)-N(R^(d))S(O)₂R^(c), —(C₁-C₆         alkylenyl)-N(R^(d))C(O)O(R), —(C₁-C₆         alkylenyl)-N(R^(d))C(O)N(R^(d))₂, or —(C₁-C₆         alkylenyl)-N(R^(d))S(O)₂N(R^(d))₂;     -   R^(b) and R^(d), at each occurrence, are each independently         hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, alkoxyalkyl, G^(5B), or         —(C₁-C₆ alkylenyl)-G^(5B);     -   R^(c), at each occurrence, is independently C₁-C₆ alkyl, C₁-C₆         haloalkyl, alkoxyalkyl, G^(5B), or —(C₁-C₆ alkylenyl)-G^(5B);     -   G^(5B), at each occurrence, is independently C₃-C₆ monocyclic         cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, or 4-7         membered monocyclic heterocycle; wherein each G^(5B) is         optionally substituted with 1, 2, 3, or 4 independently selected         R^(5b) groups;     -   R^(e), at each occurrence, is independently C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, oxo, —CN, —N₃,         NO₂, —OR, —OC(O)R^(g), —OC(O)NR^(f)R^(h), —SR^(f), —S(O)₂R^(f),         —S(O)₂NR^(f)R^(h), —C(O)R^(f), —C(O)OR^(f), —C(O)NR^(f)R^(h),         —C(O)N(R^(h))S(O)₂R^(f), —N(R^(f))₂, —N(R^(h))C(O)R^(h),         —N(R^(h))S(O)₂R^(g), —N(R^(h))C(O)O(R^(g)),         —N(R^(h))C(O)NR^(f)R^(h), or —N(R^(h))S(O)₂NR^(f)R^(h); wherein         the C₁-C₆ haloalkyl and the C₁-C₆ alkyl are each optionally         substituted with 1 or 2 substituents independently selected from         the group consisting of —CN, NO₂, —OR, —OC(O)R^(g),         —OC(O)NR^(f)R^(h), —SR^(f), —S(O)₂R^(f), —S(O)₂NR^(f)R^(h),         —C(O)R^(f), —C(O)OR^(f), —C(O)NR^(f)R^(h),         —C(O)N(R^(h))S(O)₂R^(f), —N(R^(f))₂, —N(R^(h))C(O)R^(g),         —N(R^(h))S(O)₂R^(g), —N(R^(h))C(O)O(R^(g)),         —N(R^(h))C(O)NR^(f)R^(h), and —N(R^(h))S(O)₂NR^(f)R^(h);     -   R^(f), at each occurrence, is independently hydrogen, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, —(C₁-C₆         alkylenyl)-CN, —(C₁-C₆ alkylenyl)-OR^(m), —(C₁-C₆         alkylenyl)-OC(O)R^(n), —(C₁-C₆ alkylenyl)-OC(O)N(R^(m))₂,         —(C₁-C₆ alkylenyl)-SR^(m), —(C₁-C₆ alkylenyl)-S(O)₂R^(m),         —(C₁-C₆ alkylenyl)-S(O)₂N(R^(m))₂, —(C₁-C₆ alkylenyl)-C(O)R^(m),         —(C₁-C₆ alkylenyl)-C(O)OR^(m), —(C₁-C₆ alkylenyl)-C(O)N(R^(m))₂,         —(C₁-C₆ alkylenyl)-C(O)N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))₂, —(C₁-C₆ alkylenyl)-N(R^(m))C(O)R^(n),         —(C₁-C₆ alkylenyl)-N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)O(R^(n)), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)N(R^(m))₂, or —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂N(R^(m))₂;     -   R^(g), at each occurrence, is independently C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, —(C₁-C₆ alkylenyl)-CN,         —(C₁-C₆ alkylenyl)-OR^(m), —(C₁-C₆ alkylenyl)-OC(O)R^(n),         —(C₁-C₆ alkylenyl)-OC(O)N(R^(m))₂, —(C₁-C₆ alkylenyl)-SR^(m),         —(C₁-C₆ alkylenyl)-S(O)₂R^(m), —(C₁-C₆         alkylenyl)-S(O)₂N(R^(m))₂, —(C₁-C₆ alkylenyl)-C(O)R^(m), —(C₁-C₆         alkylenyl)-C(O)OR^(m), —(C₁-C₆ alkylenyl)-C(O)N(R^(m))₂, —(C₁-C₆         alkylenyl)-C(O)N(R^(m))S(O)₂R^(n), —(C₁-C₆ alkylenyl)-N(R^(m))₂,         —(C₁-C₆ alkylenyl)-N(R^(m))C(O)R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)O(R^(n)), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)N(R^(m))₂, or —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂N(R^(m))₂;     -   R^(h), at each occurrence, is independently hydrogen, C₁-C₆         alkyl, C₁-C₆ haloalkyl, or —(C₁-C₆ alkylenyl)-OR^(m);     -   R^(1a), R^(1b), R^(2a), and R^(5b), at each occurrence, are each         independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,         halogen, C₁-C₆ haloalkyl, oxo, —CN, —NO₂, —OR^(m), —OC(O)R^(n),         —OC(O)N(R^(m))₂, —SR^(m), —S(O)₂R^(m), —S(O)₂N(R^(m))₂,         —C(O)R^(m), —C(O)OR^(m), —C(O)O(benzyl), —C(O)N(R^(m))₂,         —C(O)N(R^(m))S(O)₂R^(n), —N(R^(m))₂, —N(R^(m))(alkoxyalkyl),         —N(alkoxyalkyl)₂, —N(R^(m))C(O)R^(n), —N(R^(m))S(O)₂R^(n),         —N(R^(m))C(O)O(R^(n)), —N(R^(m))C(O)N(R^(m))₂,         —N(R^(m))S(O)₂N(R^(m))₂, —(C₁-C₆ alkylenyl)-CN, —(C₁-C₆         alkylenyl)-OR^(m), —(C₁-C₆ alkylenyl)-OC(O)R^(n), —(C₁-C₆         alkylenyl)-OC(O)N(R^(m))₂, —(C₁-C₆ alkylenyl)-SR^(m), —(C₁-C₆         alkylenyl)-S(O)₂R^(m), —(C₁-C₆ alkylenyl)-S(O)₂N(R^(m))₂,         —(C₁-C₆ alkylenyl)-C(O)R^(m), —(C₁-C₆ alkylenyl)-C(O)OR^(m),         —(C₁-C₆ alkylenyl)-C(O)N(R^(m))₂, —(C₁-C₆         alkylenyl)-C(O)N(R^(m))S(O)₂R^(n), —(C₁-C₆ alkylenyl)-N(R^(m))₂,         —(C₁-C₆ alkylenyl)-N(R^(m))C(O)R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂R^(n), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)O(R^(n)), —(C₁-C₆         alkylenyl)-N(R^(m))C(O)N(R^(n))₂, or —(C₁-C₆         alkylenyl)-N(R^(m))S(O)₂N(R^(n))₂;     -   R^(m), at each occurrence, is independently hydrogen, C₁-C₆         alkyl, or C₁-C₆ haloalkyl;     -   R^(n), at each occurrence, is independently C₁-C₆ alkyl or C₁-C₆         haloalkyl; and     -   R⁶ is hydrogen.

Exemplary compounds of formula (I) include, but are not limited to:

-   N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(benzenesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-N-(trifluoromethanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(cyclopropanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-[3-(trifluoromethoxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(dimethylamino)phenyl]-N-(methanesulfonyl)-1-phenyl-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[2-(dimethylamino)pyrimidin-5-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(azetidin-1-yl)phenyl]-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-[2-(morpholin-4-yl)pyrimidin-5-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-tert-butyl-1-cyclopentyl-N-(methanesulfonyl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-methyl-1-phenyl-4-(piperidin-1-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1-[3-(pyrrolidin-1-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(dimethylamino)phenyl]-N-(methanesulfonyl)-1-(6-methoxypyridin-3-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3-chloro-4-methylphenyl)-N-(methanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-3-methyl-1-phenyl-4-(piperidin-1-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[2-(morpholin-4-yl)pyrimidin-5-yl]-1-phenyl-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(2,4-difluorophenyl)-N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[6-(dimethylamino)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,5-difluorophenyl)-N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,5-dimethylphenyl)-N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,4-difluorophenyl)-N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(dimethylamino)phenyl]-N-(methanesulfonyl)-3-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1-(3-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1-(3-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[2-(dimethylamino)pyrimidin-5-yl]-N-(methanesulfonyl)-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[2-(dimethylamino)pyrimidin-5-yl]-N-(ethanesulfonyl)-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(dimethylamino)pyridin-3-yl]-N-(methanesulfonyl)-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(dimethylamino)pyridin-3-yl]-N-(ethanesulfonyl)-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(dimethylamino)phenyl]-N-(methanesulfonyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-1-phenyl-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-1-phenyl-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-1-[3-(3-methoxyazetidin-1-yl)phenyl]-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4,4-difluorocyclohexyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-(oxan-3-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-(oxan-3-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{4-[3-(dimethylamino)azetidin-1-yl]phenyl}-N-(methanesulfonyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{4-[3-(dimethylamino)azetidin-1-yl]phenyl}-N-(ethanesulfonyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(3,3-dimethylazetidin-1-yl)phenyl]-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(ethanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(3-fluoropyrrolidin-1-yl)phenyl]-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(ethanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[2-(dimethylamino)pyrimidin-5-yl]-N-(methanesulfonyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[2-(dimethylamino)pyrimidin-5-yl]-N-(ethanesulfonyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     3-{1-cyclohexyl-4-[2-(dimethylamino)pyrimidin-5-yl]-6-[(ethanesulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}azetidine-1-carboxylate; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(ethanesulfonyl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclopentyl-4-[6-(dimethylamino)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclopentyl-4-[6-(dimethylamino)pyridin-3-yl]-N-(ethanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-[2-(morpholin-4-yl)pyrimidin-5-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(2,4-difluorophenyl)-N-(methanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(2,4-difluorophenyl)-N-(ethanesulfonyl)-3-methyl-4-[6-(morpholin-4-yl)pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(ethanesulfonyl)-4-[2-(morpholin-4-yl)pyrimidin-5-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{6-[(2-methoxyethyl)(methyl)amino]pyridin-3-yl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[6-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3-chlorophenyl)-N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3-chlorophenyl)-N-(ethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3-fluorophenyl)-N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-1-(3-fluorophenyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-1-(3-methoxyphenyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-1-(3-methoxyphenyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{4-[(2-methoxyethyl)(methyl)amino]phenyl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-1-{3-[(2-methoxyethyl)(methyl)amino]phenyl}-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-4-[2-(dimethylamino)pyrimidin-5-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-4-[2-(dimethylamino)pyrimidin-5-yl]-N-(ethanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-acetamidophenyl)-1-cyclohexyl-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-1-cyclohexyl-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-{4-[(2-methoxyethyl)(methyl)amino]phenyl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-{6-[(2-methoxyethyl)(methyl)amino]pyridin-3-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{6-[(2-methoxyethyl)(methyl)amino]pyridin-3-yl}-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{4-[(2-methoxyethyl)(methyl)amino]phenyl}-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(ethanesulfonyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-{2-[methyl(oxan-4-yl)amino]pyrimidin-5-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-3-cyclopropyl-4-[6-(dimethylamino)pyridin-3-yl]-N-(ethanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[6-(2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[6-(2,2-dimethylmorpholin-4-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[2-(4-cyanopiperidin-1-yl)pyrimidin-5-yl]-1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-{4-[methyl(oxan-4-yl)amino]phenyl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{4-[methyl(oxan-4-yl)amino]phenyl}-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyano-4-methylpiperidin-1-yl)pyridin-3-yl]-1-cyclohexyl-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[2-(4-cyanopiperidin-1-yl)pyrimidin-5-yl]-N-(methanesulfonyl)-1-[3-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}-N-(methanesulfonyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-1-(3-methylphenyl)-4-(piperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-1-(3-methylphenyl)-4-(piperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-3-cyclobutyl-1-cyclohexyl-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-cyclobutyl-1-cyclohexyl-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(3-hydroxyazetidin-1-yl)phenyl]-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-[6-(3-methoxypyrrolidin-1-yl)pyridin-3-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     3-{4-(4-acetamidophenyl)-1-(3,5-difluorophenyl)-6-[(methanesulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}azetidine-1-carboxylate; -   1-cyclohexyl-4-[6-(3-fluoropiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{4-[(2-methoxyethyl)(methyl)amino]phenyl}-3-(propan-2-yl)-1-[3-(pyrrolidin-1-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{4-[methyl(oxan-4-yl)amino]phenyl}-3-(propan-2-yl)-1-[3-(pyrrolidin-1-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{4-[methyl(oxan-4-yl)amino]phenyl}-1-[3-(pyrrolidin-1-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-[2-(morpholin-4-yl)pyrimidin-5-yl]-1-phenyl-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(2,4-difluorophenyl)-N-(ethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3-chloro-4-methylphenyl)-N-(ethanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,5-dimethylphenyl)-N-(ethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,4-difluorophenyl)-N-(ethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-(4-methoxypiperidin-1-yl)-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[2-(4-cyanopiperidin-1-yl)pyrimidin-5-yl]-1-cyclohexyl-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{2-[(2-methoxyethyl)(methyl)amino]pyrimidin-5-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{6-[bis(2-methoxyethyl)amino]pyridin-3-yl}-1-cyclohexyl-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{6-[methyl(oxolan-3-yl)amino]pyridin-3-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{2-[methyl(oxan-4-yl)amino]pyrimidin-5-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[6-(dimethylamino)pyridin-2-yl]-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1-[3-(trifluoromethoxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,4-difluorophenyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-[6-(morpholin-4-yl)pyridin-2-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(2,6-difluoro-4-methoxyphenyl)-1-(3-fluoro-5-methoxyphenyl)-N-(methanesulfonyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-1-(3,5-difluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-1-(3-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{4-[(2-methoxyethyl)(methyl)amino]phenyl}-3-(propan-2-yl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-3-(propan-2-yl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{2-[methyl(oxan-4-yl)amino]pyrimidin-5-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-N-(methanesulfonyl)-3-(propan-2-yl)-1-[3     (trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-[2-(morpholin-4-yl)pyridin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-3-(1-methylcyclobutyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-3-(1-methylcyclobutyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[2-(4-cyanopiperidin-1-yl)pyrimidin-5-yl]-1-(2,4-difluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-1-(2,4-difluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-1-(2,4-difluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(1,1-dioxo-1λ⁶-thiolane-3-sulfonyl)-4-(4-methoxypiperidin-1-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-1-(oxan-3-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-4-(4-methoxypiperidin-1-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(4-methoxypiperidin-1-yl)-1-phenyl-N-(3,3,3-trifluoropropane-1-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(1,1-difluoro-5-azaspiro[2.4]heptan-5-yl)-N-(methanesulfonyl)-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-{4-[(propan-2-yl)oxy]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-(4-propoxypiperidin-1-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[3-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{4-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]piperidin-1-yl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-(piperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1-[2-(pyrrolidin-1-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-cyanopiperidin-1-yl)-1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(2-methoxyethyl)piperidin-1-yl]-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(3-methoxypiperidin-1-yl)-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-4-(3-methoxypiperidin-1-yl)-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(fluoromethyl)piperidin-1-yl]-N-(methanesulfonyl)-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(methanesulfonyl)piperidin-1-yl]-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyanopiperidin-1-yl)phenyl]-N-(methanesulfonyl)-3-(propan-2-yl)-1-[2-(pyrrolidin-1-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[(2-methoxyethyl)(methyl)amino]-1-(3-methylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-1-(3-methylphenyl)-4-(8-oxa-2-azaspiro[4.5]decan-2-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-butoxypiperidin-1-yl)-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(4-methoxy-4-methylpiperidin-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   2-[(2-{[3-cyclobutyl-4-(4-methoxypiperidin-1-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl]sulfamoyl}ethyl)carbamoyl]benzoic     acid; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(2-methylpropoxy)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(4-methoxypiperidin-1-yl)-1-phenyl-N-(2,2,2-trifluoroethanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[3-(difluoromethyl)piperidin-1-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(1-oxa-8-azaspiro[4.5]decan-8-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(cyclohexylmethoxy)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-(piperidin-1-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(2-methoxyethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(2-azaspiro[3.4]octan-2-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(3-azabicyclo[3.1.0]hexan-3-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-1-[2-(morpholin-4-yl)pyridin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-3-(propan-2-yl)-1-[2-(pyrrolidin-1-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-cyclobutyl-N-(methanesulfonyl)-1-[2-(pyrrolidin-1-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methanesulfonyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-cyanopiperidin-1-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(2-azaspiro[3.5]nonan-2-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[3-(methoxymethyl)azetidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(cis-3-methoxycyclobutyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-(3,3-difluorocyclobutyl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-(3,3-dimethylcyclobutyl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-(3-fluorocyclobutyl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[2-(oxan-4-yl)ethoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(2S)-2-fluoro-2-(oxan-4-yl)ethoxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-cyclobutyl-N-(methanesulfonyl)-1-[2-(morpholin-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(1,1-difluoro-5-azaspiro[2.4]heptan-5-yl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-(5-oxa-2-azaspiro[3.5]nonan-2-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(5-azaspiro[2.5]octan-5-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[(2-methoxyethyl)(methyl)amino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(4-methoxypiperidin-1-yl)-N-(oxane-4-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   benzyl     4-{[3-cyclobutyl-4-(4-methoxypiperidin-1-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl]sulfamoyl}piperidine-1-carboxylate; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-(cis-3-fluorocyclobutyl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-(trans-3-fluorocyclobutyl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[(cis-4-methoxycyclohexyl)oxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[(trans-4-methoxycyclohexyl)oxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{4-[(benzyloxy)methyl]piperidin-1-yl}-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(2-azaspiro[3.3]heptan-2-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     5-{3-cyclobutyl-6-[(methanesulfonyl)carbamoyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl}octahydro-1H-pyrrolo[3,2-c]pyridine-1l-carboxylate; -   4-(1-acetyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-(4-methoxypiperidin-1-yl)-1-[6-(morpholin-4-yl)pyridin-2-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-{4-[(1S)-2-(dimethylamino)-1-fluoroethyl]piperidin-1-yl}-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(fluoromethyl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(2-methoxypropan-2-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(3-azaspiro[5.5]undecan-3-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(3,4-difluorophenyl)-N-(ethanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-1-(3-fluorophenyl)-4-{6-[methyl(oxan-4-yl)amino]pyridin-3-yl}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(cyclopropanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-1-[2-(morpholin-4-yl)pyridin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(cyclopentyloxy)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(cyclohexyloxy)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(cyclopropylmethoxy)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1-(2-methylpropyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-(oxolan-3-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-(4-methoxyphenyl)-3-methyl-1-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclopropyl-N-(2-methoxyethanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(2R)-2-fluoro-2-(oxan-4-yl)ethoxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(3,3-difluorocyclopentyl)methoxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(cyclopropanesulfonyl)-3-methyl-4-[4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-cyanopiperidin-1-yl)-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(1-methoxyethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-[4-(1,1,1-trifluoro-2-methoxypropan-2-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[2-(1,1-dioxo-1λ⁶,4-thiazinan-4-yl)ethoxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(hydroxymethyl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(1-methyl-1H-pyrazole-4-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{6-[bis(2-methoxyethyl)amino]pyridin-3-yl}-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-methoxy-4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(morpholin-4-yl)pyridin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(morpholin-4-yl)pyridin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{6-[bis(2-methoxyethyl)amino]pyridin-3-yl}-N-(methanesulfonyl)-1-[2-(morpholin-4-yl)pyridin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-(1H-pyrazole-4-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[(3-methyloxetan-3-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-{4-[(1,1-dioxo-1λ⁶,4-thiazinan-4-yl)methyl]-4-methoxypiperidin-1-yl}-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-(trans-3-methylcyclobutyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-1-phenyl-3-[(piperidin-4-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   tert-butyl     4-({4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-6-[(methanesulfonyl)carbamoyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl}oxy)piperidine-1-carboxylate; -   3-cyclobutyl-N-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethanesulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-aminoethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(cyclobutylmethyl)-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(cyclobutylmethyl)-N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methylpropyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methylpropyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-4-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-[2-(morpholin-4-yl)ethanesulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-4-[(3-methyloxetan-3-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-[4-(propan-2-yl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-1-phenyl-4-[4-(propan-2-yl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[2-(dimethylamino)ethanesulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(1-acetyl-4-fluoropiperidin-4-yl)methoxy]-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1l-yl)pyridin-3-yl]-N-(2-methoxyethanesulfonyl)-3-[(oxolan-3-yl)oxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1l-yl)pyridin-3-yl]-N-(2-methoxyethanesulfonyl)-3-(trans-3-methylcyclobutyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1l-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-[(oxolan-3-yl)oxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-[3-(dimethylamino)phenyl]-N-(methanesulfonyl)-4-[(oxan-4-yl)methoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(morpholin-4-yl)pyrimidin-4-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-cyclobutylpiperazin-1-yl)-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[3-(morpholin-4-yl)propoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(3,3-difluoro-1-methylcyclobutyl)methoxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[(oxolan-2-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(oxan-4-yl)methoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[2-(oxan-4-yl)ethoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(1-methyl-1H-imidazole-4-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(3,5-dimethyl-1,2-oxazole-4-sulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     3-({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)propanoate; -   3-({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)propanoic     acid; -   N-[3-(dimethylamino)propane-1-sulfonyl]-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-N-[3-(pyrrolidin-1-yl)propane-1-sulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[3-(morpholin-4-yl)propoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(3-methyloxetan-3-yl)methoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(2-methoxypropan-2-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(oxolan-2-yl)methoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(1-acetylpiperidin-4-yl)methoxy]-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     4-[({3-cyclobutyl-6-[(methanesulfonyl)carbamoyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)methyl]piperidine-1-carboxylate; -   3-cyclobutyl-N-[3-(dimethylamino)-3-oxopropane-1-sulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[3-(dimethylamino)propoxy]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-3-[(oxetan-3-yl)oxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(2-methoxyethyl)(methyl)amino]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-[3-(azetidin-1-yl)propane-1-sulfonyl]-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[3-(dimethylamino)propoxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-4-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[2-(1-methylpiperidin-2-yl)ethoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(3,3-difluoro-1-methylcyclobutyl)methoxy]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[3-(piperidin-1-yl)propoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(1-acetyl-4-fluoropiperidin-4-yl)methoxy]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{2-[(oxetan-3-yl)(propan-2-yl)amino]ethoxy}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-4-{[4-(propan-2-yl)morpholin-3-yl]methoxy}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(1,3-dimethoxypropan-2-yl)oxy]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(1,4-dioxan-2-yl)methoxy]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{2-[(oxetan-3-yl)oxy]ethoxy}-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-[3-(piperidin-1l-yl)propoxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(oxan-4-yl)methoxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(dimethylamino)piperidin-1-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(1′-methyl[4,4′-bipiperidin]-1-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(1-acetylpiperidin-4-yl)methoxy]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     4-({[1-(4-fluorophenyl)-6-[(methanesulfonyl)carbamoyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]oxy}methyl)piperidine-1-carboxylate; -   3-cyclobutyl-N-(methanesulfonyl)-4-[2-(1-methylpiperidin-2-yl)ethoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(1,3-dimethoxypropan-2-yl)oxy]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{2-[(oxetan-3-yl)(propan-2-yl)amino]ethoxy}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(cyanomethyl)-4-hydroxypiperidin-1-yl]-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-azidophenyl)-N-(3-azidopropane-1-sulfonyl)-1-[3-(dimethylamino)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-4-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-1-phenyl-4-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   rac-4-[(3     aR,7aS)-1-acetyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(cyclopropanesulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(methanesulfonyl)-1-[2-(morpholin-4-yl)pyridin-4-yl]-4-[(oxan-4-yl)methoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-[1-(4-fluorophenyl)-6-[(methanesulfonyl)carbamoyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]piperazine-1-carboxylate; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-4-[3-(trifluoromethyl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(2-methoxyethyl)piperazin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(ethoxymethyl)-4-fluoropiperidin-1-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{4-fluoro-4-[(2-methoxyethoxy)methyl]piperidin-1-yl}-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(3R,4R)-3-fluoro-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-fluoro-4-(methoxymethyl)piperidin-1-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-{3-fluoro-3-[(2-methoxyethoxy)methyl]piperidin-1-yl}-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-1-(4-fluorophenyl)-N-(methanesulfonyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(3R)-3-(hydroxymethyl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(3R)-3-(hydroxymethyl)piperidin-1-yl]-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(oxan-4-yl)methoxy]-1-phenyl-N-[4-(pyrrolidin-1-yl)piperidine-1-sulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[(2S)-2-(4-methylpiperazine-1-carbonyl)pyrrolidine-1-sulfonyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-([1,4′-bipiperidine]-1′-sulfonyl)-3-cyclobutyl-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[methyl(propyl)sulfamoyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[ethyl(propyl)sulfamoyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-[({3-cyclobutyl-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)amino]piperidine-1-carboxylate; -   N-(4-acetyl-1,4-diazepane-1-sulfonyl)-3-cyclobutyl-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(morpholine-4-sulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[4-(morpholin-4-yl)piperidine-1-sulfonyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[4-(4-methylpiperazine-1-carbonyl)piperidine-1-sulfonyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(4-methylpiperazine-1-sulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methylpropane-2-sulfonyl)-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-azidophenyl)-N-(but-3-yne-1-sulfonyl)-1-[3-(dimethylamino)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(cyanomethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-hydroxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(3-hydroxypropane-1-sulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-(piperidine-4-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(oxolane-3-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(2,6-dimethylpyridin-4-yl)-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(1,1-dioxo-1λ⁶,4-thiazinan-4-yl)-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-[2-(1H-pyrazol-1-yl)ethanesulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   benzyl     [2-({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)ethyl]carbamate; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(1-methylcyclopropane-1-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(2-methylpropane-1-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     ({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)acetate; -   benzyl     3-({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)pyrrolidine-1-carboxylate; -   tert-butyl     4-[1-(4-fluorophenyl)-6-[(methanesulfonyl)carbamoyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]piperidine-1-carboxylate; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[2-(methoxymethyl)morpholin-4-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(morpholine-4-sulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[4-(propan-2-yl)piperazin-1-yl]piperidin-1-yl})-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(morpholine-4-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-amino-2-oxoethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methoxypyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-acetamidoethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-(pyrrolidine-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-[4-(pyrrolidin-1-yl)piperidine-1-sulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-[(2S)-2-(4-methylpiperazine-1-carbonyl)pyrrolidine-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-{4-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]piperidine-1-sulfonyl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-[methyl(propyl)sulfamoyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[ethyl(propyl)sulfamoyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-[({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)amino]piperidine-1-carboxylate; -   N-(4-acetyl-1,4-diazepane-1-sulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-{4-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]piperidine-1-sulfonyl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(morpholine-4-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-[4-(morpholin-4-yl)piperidine-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-[4-(4-methylpiperazine-1-carbonyl)piperidine-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(4-fluoropiperidine-1-sulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-N-(4-methylpiperazine-1-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(cyclopropanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{4-[(morpholin-4-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(2-methoxyethanesulfonyl)-4-{4-[(morpholin-4-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[(morpholin-4-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(2-methoxyethanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[(morpholin-4-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{4-[(morpholin-4-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(ethanesulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(cyclopropanesulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(2-methoxyethanesulfonyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[(1,4-dioxan-2-yl)methanesulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(2-methoxyethanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-[4-(4-methylpiperazine-1-carbonyl)phenyl]-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(dimethylsulfamoyl)-4-[4-(4-methylpiperazine-1-carbonyl)phenyl]-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[(morpholin-4-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(dimethylsulfamoyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(ethanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(cyclopropanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-N-(oxolane-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methylpyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[methyl(propyl)sulfamoyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-[({3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)amino]piperidine-1-carboxylate; -   3-cyclobutyl-N-(4-fluoropiperidine-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(1-methylcyclopropane-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(cyclopropanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-{4-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]piperidine-1-sulfonyl}-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[1-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[(piperidin-1-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(dimethylsulfamoyl)-3-[(propan-2-yl)oxy]-4-{4-[(pyrrolidin-1-yl)methyl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{4-[1-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-1-(4-fluorophenyl)-4-{4-[1-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(2-methoxyethanesulfonyl)-4-{4-[(morpholin-4-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(2-hydroxyethanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(chloromethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-1-(4-fluorophenyl)-N-(oxolane-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-N-(oxolane-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-([1,4′-bipiperidine]-1′-sulfonyl)-3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(4-methylpiperazine-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-{[(3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carbonyl)sulfamoyl]amino}piperidine-1-carboxylate; -   3-cyclobutyl-N-{4-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]piperidine-1-sulfonyl}-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(4-fluoropiperidine-1-sulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(4-methylpiperazine-1-sulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(1-methylcyclopropane-1-sulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(cyclopropanesulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methoxyethanesulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(2-methylpropane-2-sulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-(cyclobutyloxy)-1-cyclohexyl-4-{4-[(morpholin-4-yl)methyl]phenyl}-N-(oxolane-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(oxolane-3-sulfonyl)-4-[4-(pyridin-4-yl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-[4-(pyridin-4-yl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(ethanesulfonyl)-4-[4-(pyridin-4-yl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-[(2-methoxyethyl)(methyl)sulfamoyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-(2-methoxypyridin-4-yl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[(morpholin-4-yl)methyl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(but-3-yne-1-sulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(ethanesulfonyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[(1R)-1-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[(1S)-1-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-(cyclobutyloxy)-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[(morpholin-4-yl)methyl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-[methyl(propan-2-yl)sulfamoyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-[ethyl(methyl)sulfamoyl]-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(3-methoxyazetidine-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-N-(pyrrolidine-1-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-N-(2,2,2-trifluoroethanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(morpholine-4-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-1-(4-fluorophenyl)-N-(2-methoxyethanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(dimethylsulfamoyl)-1-[2-(morpholin-4-yl)pyridin-4-yl]-4-[(oxan-4-yl)methoxy]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(2-hydroxyethanesulfonyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     4-(1-{3-cyclobutyl-6-[(dimethylsulfamoyl)carbamoyl]-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl}piperidin-4-yl)piperazine-1-carboxylate; -   4-[4-(4-acetylpiperazin-1-yl)piperidin-1-yl]-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-1-(4-fluorophenyl)-4-{4-[(morpholin-4-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-{4-[(morpholin-4-yl)methyl]piperidin-1-yl}-N-(oxolane-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-[1-(4-fluorophenyl)-6-[(methanesulfonyl)carbamoyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]piperidine-1-carboxylate; -   ethyl     4-{6-[(dimethylsulfamoyl)carbamoyl]-1-(4-fluorophenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl}piperidine-1-carboxylate; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(3-methylphenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(3-methoxyphenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(ethoxymethyl)-4-fluoropiperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-{4-fluoro-4-[(2-methoxyethoxy)methyl]piperidin-1-yl}-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-{3-fluoro-3-[(2-methoxyethoxy)methyl]piperidin-1-yl}-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-fluoro-4-(methoxymethyl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(4-cyanopiperidine-1-sulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-N-(oxetane-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(cyclopropanesulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(1-methylcyclopropane-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-1-(3-methylphenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluoro-3-methylphenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(3-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluoro-3-methylphenyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(3-fluorophenyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(4-methylpiperazin-1-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[(morpholin-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[(morpholin-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{[4-(methoxymethyl)piperidin-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(4-cyano[1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(3-cyanoazetidin-1-yl)piperidin-1-yl]-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(3-methoxypyrrolidin-1-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-(4-fluoro[1,4′-bipiperidin]-1′-yl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(4,4-difluoro[1,4′-bipiperidin]-1′-yl)-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(2-cyanomorpholin-4-yl)piperidin-1-yl]-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[methyl(oxan-4-yl)amino]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-{2-[(propan-2-yl)oxy]pyridin-4-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-{2-[(propan-2-yl)oxy]pyridin-4-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[3-(morpholin-4-yl)-1-oxa-8-azaspiro[4.5]decan-8-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(dimethylsulfamoyl)-3-[(propan-2-yl)oxy]-4-{4-[4-(propan-2-yl)piperazin-1-yl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-[4-(2-methylpyridin-4-yl)piperazin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-4-[6-(4-cyclopropylpiperazin-1-yl)pyridin-3-yl]-N-(dimethylsulfamoyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(3-fluoropyrrolidine-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(3-methoxypyrrolidine-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-cyclobutyl-N-(dimethylsulfamoyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-[4-(methoxymethyl)piperidine-1-sulfonyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(3-fluoropyrrolidin-1-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{6-[4-(propan-2-yl)piperazin-1-yl]pyridin-3-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[1-(morpholin-4-yl)ethyl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}-N-(2-methoxyethanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}-N-(dimethylsulfamoyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[4-(propan-2-yl)piperazin-1-yl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-(dimethylsulfamoyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(cyclopropanesulfonyl)-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{6-[4-(2-methoxyethyl)piperazin-1-yl]pyridin-3-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-4-{4-[4-(propan-2-yl)piperazin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-[methyl(propyl)sulfamoyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-(morpholine-4-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-(1-methylcyclopropane-1-sulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-(methylsulfamoyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[4-(4-cyclopropylpiperazin-1-yl)phenyl]-N-(dimethylsulfamoyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[3-(trifluoromethyl)pyrrolidin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(3-cyanopyrrolidin-1-yl)piperidin-1-yl]-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(3-cyano[1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-(3-fluoro[1,4′-bipiperidin]-1′-yl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{4-[3-(trifluoromethyl)pyrrolidin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(3-cyanopyrrolidin-1-yl)piperidin-1-yl]-3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-(3-cyano[1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(3-fluoro[1,4′-bipiperidin]-1′-yl)-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-N-(piperidine-1-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(3-fluoroazetidine-1-sulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[3-(trifluoromethyl)[1,4′-bipiperidin]-1′-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-(3-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(2,2-dimethylmorpholin-4-yl)piperidin-1-yl]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(2-acetamidoethanesulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-[2-(difluoromethoxy)pyridin-4-yl]-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(azetidine-1-sulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-[(2R)-2-(methoxymethyl)pyrrolidine-1-sulfonyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-N-[(oxan-4-yl)sulfamoyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-[methyl(oxan-4-yl)sulfamoyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(3,3-difluoroazetidine-1-sulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(3S)-4-benzyl-3-methylpiperazin-1-yl]-3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[(3R)-4-benzyl-3-methylpiperazin-1-yl]-3-cyclobutyl-1-cyclohexyl-N-(dimethylsulfamoyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(9-cyclopropyl-3,9-diazaspiro[5.5]undecan-3-yl)-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[3-(trifluoromethyl)[1,4′-bipiperidin]-1′-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(3-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[4-(2,2-dimethylmorpholin-4-yl)piperidin-1-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-(1-{3-cyclobutyl-6-[(dimethylsulfamoyl)carbamoyl]-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl}piperidin-4-yl)piperazine-1-carboxylate; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[(2-methoxyethyl)(methyl)amino]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methoxysulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{[4-(morpholin-4-yl)piperidin-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{[4-(morpholin-4-yl)piperidin-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-{4-[(4-cyclopropylpiperazin-1-yl)methyl]phenyl}-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[1-(propan-2-yl)piperidin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[1-(oxan-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-{1-[(oxan-4-yl)methyl]piperidin-4-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{1-[(oxan-4-yl)methyl]piperidin-4-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-{1-[(2,5-dimethoxyoxolan-3-yl)methyl]piperidin-4-yl}-1-(4-fluorophenyl)-N-(methanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carb     oxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-(4-hydroxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   methyl     {3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamate; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[4-(2-methoxyethyl)piperazin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-[3-(morpholin-4-yl)pyrrolidine-1-sulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(4-cyclopropylpiperazine-1-sulfonyl)-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-[4-(2-methoxyethyl)piperazine-1-sulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[1-(propan-2-yl)piperidin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[1-(oxan-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[1-(cyclopropylmethyl)piperidin-4-yl]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[9-(oxetan-3-yl)-3,9-diazaspiro[5.5]undecan-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[4-(oxetan-3-yl)piperazin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(1-cyclopropylpiperidin-4-yl)methoxy]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(1-cyclobutylpiperidin-4-yl)methoxy]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-[(1-cyclohexylpiperidin-4-yl)methoxy]-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{[1-(oxan-4-yl)piperidin-4-yl]methoxy}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-{1-[(2,5-dimethoxyoxolan-3-yl)methyl]piperidin-4-yl}-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-{2-[(propan-2-yl)oxy]pyrimidin-4-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(2-ethoxypyrimidin-4-yl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(4-methylpiperazine-1-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[1-(propan-2-yl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(1-cyclobutyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[1-(oxetan-3-yl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[1-(oxan-4-yl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-N-(methyl     sulfamoyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-N-sulfamoyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-[4-(hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carbonyl)phenyl]-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(azetidine-1-sulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-(4-{[3-(dimethylamino)azetidin-1-yl]methyl}phenyl)-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-4-(4-{[4-(propan-2-yl)piperazin-1-yl]methyl}phenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{4-[(4-methoxypiperidin-1-yl)methyl]phenyl)}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{4-[(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-[4-(5-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carbonyl)phenyl]-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methylsulfamoyl)-4-{4-[4-(propan-2-yl)piperazin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   4-[4-(4-cyano-1-methylpiperidin-4-yl)phenyl]-1-cyclohexyl-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-{4-[3-(dimethylamino)azetidine-1-carbonyl]phenyl}-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-N-(methanesulfonyl)-4-{4-[(8-methyl-2-oxa-5,8-diazaspiro[3.5]nonan-5-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-cyclohexyl-4-(4-{[4-(dimethylamino)piperidin-1-yl]methyl}phenyl)-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   1-(4-fluorophenyl)-N-(methanesulfonyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(3-methoxyazetidine-1-sulfonyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(3-fluoroazetidine-1-sulfonyl)-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-11′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-N-(morpholine-4-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)cyclohexyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)cyclohexyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-4-(4-fluoro[1,4′-bipiperidin]-1′-yl)-1-(4-fluorophenyl)-N-(methyl     sulfamoyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   N-(azetidine-1-sulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-{4-[4-(propan-2-yl)piperazin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-[3-(difluoromethoxy)phenyl]-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(methanesulfonyl)-N-methyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-N-methyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-N-methyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-N-(ethanesulfonyl)-N-methyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   2-(3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carbonyl)-6-methyl-1λ⁶,2,6-thiadiazinane-1,1-dione; -   2-(3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carbonyl)-1λ⁶,2-thiazolidine-1,1-dione; -   3-cyclobutyl-N-(methanesulfonyl)-N-methyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   2-(3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carbonyl)-1λ⁶,2-thiazinane-1,1-dione; -   2-{3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}-6-methyl-λ⁶,2,6-thiadiazinane-1,1-dione; -   2-{3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}-1λ⁶,2-thiazolidine-1,1-dione; -   2-{3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}-1λ⁶,2-thiazinane-1,1-dione; -   2-{3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}-1λ⁶,2-thiazolidine-1,1-dione; -   2-{3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}-1λ⁶,2-thiazinane-1,1-dione; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-(methylsulfamoyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-(morpholine-4-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-N-(3-hydroxypropane-1-sulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-[({3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)amino]piperidine-1-carboxylate; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-[(oxetan-3-yl)sulfamoyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-[(oxan-4-yl)sulfamoyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-[4-(morpholin-4-yl)piperidine-1-sulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide; -   ethyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(2-methoxyethanesulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   ethyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(morpholine-4-sulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   ethyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(methanesulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   ethyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(methylsulfamoyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   2-methylpropyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(methanesulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   2-methylpropyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(morpholine-4-sulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   2-methylpropyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(2-methoxyethanesulfonyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   2-methylpropyl     4-{3-cyclobutyl-1-(4-fluorophenyl)-6-[(methylsulfamoyl)carbamoyl]-1H-pyrazolo[3,4-b]pyridin-4-yl}piperazine-1-carboxylate; -   3-cyclobutyl-1-(4-fluorophenyl)-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)-N-(morpholine-4-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide;     and -   N-(2-aminopyridine-3-sulfonyl)-3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide.

Compounds of the invention are named by using Name 2015 naming algorithm by Advanced Chemical Development, Struct=Name naming algorithm as part of CHEMDRAW® ULTRA v. 12.0.2.1076, or Accelrys Draw 4.2.

Compounds of the invention may exist as stereoisomers wherein asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom. The terms “R” and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 1976, 45: 13-30. The invention contemplates various stereoisomers and mixtures thereof and these are specifically included within the scope of this invention. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by methods of resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Furniss, Hannaford, Smith, and Tatchell, “Vogel's Textbook of Practical Organic Chemistry”, 5th edition (1989), Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns or (3) fractional recrystallization methods.

Compounds of the invention may exist as cis or trans isomers, wherein substituents on a ring may attached in such a manner that they are on the same side of the ring (cis) relative to each other, or on opposite sides of the ring relative to each other (trans). For example, cyclobutane may be present in the cis or trans configuration, and may be present as a single isomer or a mixture of the cis and trans isomers. Individual cis or trans isomers of compounds of the invention may be prepared synthetically from commercially available starting materials using selective organic transformations, or prepared in single isomeric form by purification of mixtures of the cis and trans isomers. Such methods are well-known to those of ordinary skill in the art, and may include separation of isomers by recrystallization or chromatography.

It should be understood that the compounds of the invention may possess tautomeric forms, as well as geometric isomers, and that these also constitute an aspect of the invention.

The present disclosure includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Examples of isotopes suitable for inclusion in the compounds of the disclosure include isotopes of hydrogen, such as ²H and ³H, carbon, such as ¹¹C, ¹³C and ¹⁴C, chlorine, such as ³⁶Cl, fluorine, such as ¹⁸F, iodine, such as ¹²³I and ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen, such as ¹⁵O, ¹⁷O and ¹⁸O, phosphorus, such as ³²P, and sulphur, such as ³⁵S. Certain isotopically-labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e. ²H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and ¹³N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of formula (I) may generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.

Thus, the formula drawings within this specification can represent only one of the possible tautomeric, geometric, or stereoisomeric forms. It is to be understood that the invention encompasses any tautomeric, geometric, or stereoisomeric form, and mixtures thereof, and is not to be limited merely to any one tautomeric, geometric, or stereoisomeric form utilized within the formula drawings.

Compounds of formula (I) may be used in the form of pharmaceutically acceptable salts. The phrase “pharmaceutically acceptable salt” means those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.

Pharmaceutically acceptable salts have been described in S. M. Berge et al. J. Pharmaceutical Sciences, 1977, 66: 1-19.

Compounds of formula (I) may contain either a basic or an acidic functionality, or both, and can be converted to a pharmaceutically acceptable salt, when desired, by using a suitable acid or base. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention.

Examples of acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, malate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides such as, but not limited to, methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as, but not limited to, decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid and such organic acids as acetic acid, fumaric acid, maleic acid, 4-methylbenzenesulfonic acid, succinic acid, and citric acid.

Basic addition salts may be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as, but not limited to, the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as, but not limited to, lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other examples of organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.

The term “pharmaceutically acceptable prodrug” or “prodrug” as used herein refers to derivatives of the compounds of the invention which have cleavable groups. Such derivatives become, by solvolysis or under physiological conditions, the compounds of the invention which are pharmaceutically active in vivo. Prodrugs of the compounds of the invention are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.

The invention contemplates compounds of formula (I) formed by synthetic means or formed by in vivo biotransformation of a prodrug.

Compounds described herein may exist in unsolvated as well as solvated forms, including hydrated forms, such as hemi-hydrates. In general, the solvated forms, with pharmaceutically acceptable solvents such as water and ethanol among others are equivalent to the unsolvated forms for the purposes of the invention.

Pharmaceutical Compositions

When employed as a pharmaceutical, a compound of the invention is typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. The phrase “pharmaceutical composition” refers to a composition suitable for administration in medical or veterinary use.

The pharmaceutical compositions that comprise a compound of formula (I), alone or in combination with further therapeutically active ingredient, may be administered to the subjects orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray. The term “parenterally” as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The term “pharmaceutically acceptable carrier” as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which may serve as pharmaceutically acceptable carriers are sugars such as, but not limited to, lactose, glucose and sucrose; starches such as, but not limited to, corn starch and potato starch; cellulose and its derivatives such as, but not limited to, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as, but not limited to, cocoa butter and suppository waxes; oils such as, but not limited to, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as, but not limited to, ethyl oleate and ethyl laurate; agar; buffering agents such as, but not limited to, magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as, but not limited to, sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may also be present in the composition, according to the judgment of the formulator.

Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), vegetable oils (such as olive oil), injectable organic esters (such as ethyl oleate), and suitable mixtures thereof. Proper fluidity may be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it may be desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release may be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In certain embodiments, solid dosage forms may contain from 1% to 95% (w/w) of a compound of formula (I). In certain embodiments, the compound of formula (I), or pharmaceutically acceptable salts thereof, may be present in the solid dosage form in a range of from 5% to 70% (w/w). In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable carrier, such as sodium citrate or dicalcium phosphate and/or a), fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

The pharmaceutical composition may be a unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampules. Also, the unit dosage form may be a capsule, tablet, cachet, or lozenge itself, or it may be the appropriate number of any of these in packaged form. The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1000 mg, from 1 mg to 100 mg, or from 1% to 95% (w/w) of a unit dose, according to the particular application and the potency of the active component. The composition may, if desired, also contain other compatible therapeutic agents.

The dose to be administered to a subject may be determined by the efficacy of the particular compound employed and the condition of the subject, as well as the body weight or surface area of the subject to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound in a particular subject. In determining the effective amount of the compound to be administered in the treatment or prophylaxis of the disorder being treated, the physician may evaluate factors such as the circulating plasma levels of the compound, compound toxicities, and/or the progression of the disease, etc.

For administration, compounds may be administered at a rate determined by factors that may include, but are not limited to, the LD₅₀ of the compound, the pharmacokinetic profile of the compound, contraindicated drugs, and the side-effects of the compound at various concentrations, as applied to the mass and overall health of the subject. Administration may be accomplished via single or divided doses.

The compounds utilized in the pharmaceutical method of the invention may be administered at the initial dosage of about 0.001 mg/kg to about 100 mg/kg daily. In certain embodiments, the daily dose range is from about 0.1 mg/kg to about 10 mg/kg. The dosages, however, may be varied depending upon the requirements of the subject, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Treatment may be initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such carriers as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds may also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned carriers.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitan and mixtures thereof.

Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents. Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which may be prepared by mixing the compounds with suitable non-irritating carriers or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds may also be administered in the form of liposomes. Liposomes generally may be derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used. The present compositions in liposome form may contain, in addition to a compound of the invention, stabilizers, preservatives, excipients, and the like. Examples of lipids include, but are not limited to, natural and synthetic phospholipids, and phosphatidyl cholines (lecithins), used separately or together.

Methods to form liposomes have been described, see example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq. Dosage forms for topical administration of a compound described herein include powders, sprays, ointments, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants which may be required. Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

A compound of the invention may also be administered in sustained release forms or from sustained release drug delivery systems.

Methods of Use

The compounds and compositions using any amount and any route of administration may be administered to a subject for the treatment or prevention of cystic fibrosis, pancreatic insufficiency, Sjögren's Syndrome (SS), chronic obstructive lung disease (COLD), or chronic obstructive airway disease (COAD).

The term “administering” refers to the method of contacting a compound with a subject. Thus, the compounds may be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, parentally, or intraperitoneally. Also, the compounds described herein may be administered by inhalation, for example, intranasally. Additionally, the compounds may be administered transdermally, topically, and via implantation. In certain embodiments, the compounds and compositions thereof may be delivered orally. The compounds may also be delivered rectally, bucally, intravaginally, ocularly, or by insufflation. CFTR-modulated disorders and conditions may be treated prophylactically, acutely, and chronically using compounds and compositions thereof, depending on the nature of the disorder or condition. Typically, the host or subject in each of these methods is human, although other mammals may also benefit from the administration of compounds and compositions thereof as set forth hereinabove.

Compounds of the invention are useful as modulators of CFTR. Thus, the compounds and compositions are particularly useful for treating or lessening the severity or progression of a disease, disorder, or a condition where hyperactivity or inactivity of CFTR is involved. Accordingly, the invention provides a method for treating cystic fibrosis, pancreatic insufficiency, Sjögren's Syndrome (SS), chronic obstructive lung disease (COLD), or chronic obstructive airway disease (COAD) in a subject, wherein the method comprises the step of administering to said subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a preferred embodiment thereof as set forth above, with or without a pharmaceutically acceptable carrier. Particularly, the method is for the treatment or prevention of cystic fibrosis. In a more particular embodiment, the cystic fibrosis is caused by a Class I, II, III, IV, V, and/or VI mutation.

One embodiment is directed to a compound of the invention or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions comprising a compound of the invention for use in medicine. One embodiment is directed to a compound of the invention or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions thereof, for use in the treatment of cystic fibrosis, pancreatic insufficiency, Sjögren's Syndrome (SS), chronic obstructive lung disease (COLD) or chronic obstructive airway disease (COAD). In a more particular embodiment, the present invention provides compounds of the invention or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising thereof, for use in the treatment of cystic fibrosis. In a more particular embodiment, the cystic fibrosis is caused by a Class I, II, III, IV, V, and/or VI mutation.

One embodiment is directed to the use of a compound according to formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament. The medicament optionally can comprise one or more additional therapeutic agents. In some embodiments, the medicament is for use in the treatment of cystic fibrosis, pancreatic insufficiency, Sjögren's Syndrome (SS), chronic obstructive lung disease (COLD) or chronic obstructive airway disease (COAD). In a particular embodiment, the medicament is for use in the treatment of cystic fibrosis. In a more particular embodiment, the cystic fibrosis is caused by a Class I, II, III, IV, V, and/or VI mutation.

This invention also is directed to the use of a compound according to formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. The medicament optionally can comprise one or more additional therapeutic agents. In a particular embodiment, the invention is directed to the use of a compound according to formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cystic fibrosis. In a more particular embodiment, the cystic fibrosis is caused by a Class I, II, III, IV, V, and/or VI mutation.

In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents. In a particular embodiment, the other therapeutic agent is a cystic fibrosis treatment agent. In a more particular embodiment, the cystic fibrosis is caused by a Class I, II, III, IV, V, and/or VI mutation.

The present compounds or pharmaceutically acceptable salts thereof may be administered as the sole active agent or it may be co-administered with other therapeutic agents, including other compounds or pharmaceutically acceptable salts thereof that demonstrate the same or a similar therapeutic activity and that are determined to be safe and efficacious for such combined administration. The present compounds may be co-administered to a subject. The term “co-administered” means the administration of two or more different therapeutic agents to a subject in a single pharmaceutical composition or in separate pharmaceutical compositions. Thus co-administration involves administration at the same time of a single pharmaceutical composition comprising two or more therapeutic agents or administration of two or more different compositions to the same subject at the same or different times.

The compounds of the invention or a pharmaceutically acceptable salt thereof may be co-administered with a therapeutically effective amount of one or more additional therapeutic agents to treat a CFTR mediated disease, where examples of the therapeutic agents include, but are not limited to antibiotics (for example, aminoglycosides, colistin, aztreonam, ciprofloxacin, and azithromycin), expectorants (for example, hypertonic saline, acetylcysteine, dornase alfa, and denufosol), pancreatic enzyme supplements (for example, pancreatin, and pancrelipase), epithelial sodium channel blocker (ENaC) inhibitors, CFTR modulators (for example, CFTR potentiators, CFTR correctors), and CFTR amplifiers. In one embodiment, the CFTR mediated disease is cystic fibrosis, chronic obstructive pulmonary disease (COPD), dry eye disease, pancreatic insufficiency, or Sjogren's syndrome. In one embodiment, the CFTR mediated disease is cystic fibrosis. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one or two CFTR modulators and one CFTR amplifier. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one potentiator, one or more correctors, and one CFTR amplifier. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one or more CFTR modulators. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one CFTR modulators. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with two CFTR modulators. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with three CFTR modulators. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one potentiator and one or more correctors. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one potentiator and one corrector. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one potentiator and two correctors. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one potentiator. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one or more correctors. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with one corrector. In one embodiment, the compounds of the invention or pharmaceutically acceptable salts thereof may be co-administered with two correctors.

Examples of CFTR potentiators include, but are not limited to, Ivacaftor (VX-770), CTP-656, NVS-QBW251, FD1860293, PTI-808, GLPG2451, GLPG1837, N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide and 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide. Examples of potentiators are also disclosed in publications: WO2005120497, WO2008147952, WO2009076593, WO2010048573, WO2006002421, WO2011072241, WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO2013038386, WO2013038390, WO2014180562, WO2015018823; and U.S. application Ser. Nos. 14/271,080, 14/451,619, and 15/164,317.

In one embodiment, the potentiator can be selected from the group consisting of:

-   Ivacaftor (VX-770,     N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide); -   CTP-656; -   NVS-QBW251; -   FD1860293; -   PTI-808; -   GLPG1837; -   GLPG2451; -   2-(2-fluorobenzamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide; -   2-(2-hydroxybenzamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-(1-hydroxycyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-(2-hydroxy-2-methylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-(1-(hydroxymethyl)cyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-(3-hydroxy-2,2-dimethylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-methyl-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-cyclopropyl-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-isopropyl-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide; -   5-tert-butyl-N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-ethyl-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-3-ethyl-4-methyl-1H-pyrazole-5-carboxamide; -   2-(2-hydroxypropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxamide; -   4-bromo-N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-5-methyl-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-methyl-1H-pyrazole-3-carboxamide; -   2-(2-hydroxy-3,3-dimethylbutanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-[(2-hydroxy-4-methyl-pentanoyl)amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; -   5-(2-methoxy-ethoxy)-1H-pyrazole-3-carboxylic acid     (3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-amide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-4-(3-methoxypropyl)-1H-pyrazole-3-carboxamide; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-4-(2-ethoxyethyl)-1H-pyrazole-3-carboxamide; -   2-[[(2S)-2-hydroxy-3,3-dimethyl-butanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-[[(2R)-2-hydroxy-3,3-dimethyl-butanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-[(2-hydroxy-2,3,3-trimethyl-butanoyl)amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; -   [5-[(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)carbamoyl]pyrazol-1-yl]methyl     dihydrogen phosphate; -   [3-[(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)carbamoyl]pyrazol-1-yl]methyl     dihydrogen phosphate; -   N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-4-(1,4-dioxan-2-yl)-1H-pyrazole-3-carboxamide; -   5,5,7,7-tetramethyl-2-[[(2S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propanoyl]amino]-4H-thieno[2,3-c]pyran-3-carboxamide; -   2-[[(2S)-2-hydroxypropanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; -   3-amino-N-(2-hydroxy-2-methylpropyl)-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   3-amino-N-[(4-hydroxy-1-methylpiperidin-4-yl)methyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   3-amino-N-(3-hydroxy-2,2-dimethylpropyl)-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   3-amino-5-[(4-fluorophenyl)sulfonyl]-N-[(1-hydroxycyclopropyl)methyl]pyridine-2-carboxamide; -   3-amino-5-[(4-fluorophenyl)sulfonyl]-N-[(2R)-3,3,3-trifluoro-2-hydroxypropyl]pyridine-2-carboxamide; -   3-amino-5-[(3-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-methylpropyl)pyridine-2-carboxamide; -   3-amino-N-[2-(cyclopropylamino)-2-oxoethyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   (3-amino-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(azetidin-1-yl)methanone; -   (3-amino-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)[3-(hydroxymethyl)azetidin-1-yl]methanone; -   (3-amino-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone; -   3-amino-N-[(2R)-2-hydroxy-3-methoxypropyl]-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; -   (3-amino-5-{[2-fluoro-4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(3-hydroxyazetidin-1-yl)methanone; -   (3-amino-5-{[2-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(3,3-difluoroazetidin-1-yl)methanone; -   rac-3-amino-N-[(3R,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-5-{[2-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   3-amino-5-[(4,4-difluoropiperidin-1-yl)sulfonyl]-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-2-carboxamide; -   (3-amino-5-{[2-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; -   3-amino-N-(2-hydroxy-4-methylpentyl)-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   (3-amino-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridin-2-yl)(3-hydroxy-3-methylazetidin-1-yl)methanone; -   3-amino-N-(3,3,3-trifluoro-2-hydroxypropyl)-5-{[4-(trifluoromethyl)piperidin-1-yl]sulfonyl}pyridine-2-carboxamide; -   3-amino-N-[2-hydroxy-1-(4-methoxyphenyl)ethyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; -   3-amino-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-2-carboxamide; -   3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(2S)-2-hydroxypropyl]pyridine-2-carboxamide; -   3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(2R)-2-hydroxy-3-methoxypropyl]pyridine-2-carboxamide; -   3-amino-N-[2-oxo-2-(propan-2-ylamino)ethyl]-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; -   (3-amino-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridin-2-yl)[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; -   3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(3R)-tetrahydrofuran-3-ylmethyl]pyridine-2-carboxamide; -   (3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}pyridin-2-yl)[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; -   3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(3S)-tetrahydrofuran-3-ylmethyl]pyridine-2-carboxamide; -   3-amino-5-{[2-fluoro-4-(trifluoromethoxy)phenyl]sulfonyl}-N-[(3S)-tetrahydrofuran-3-ylmethyl]pyridine-2-carboxamide; -   3-amino-N-[2-hydroxy-3-(2,2,2-trifluoroethoxy)propyl]-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; -   3-amino-N-(3-tert-butoxy-2-hydroxypropyl)-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; -   [3-amino-5-(phenylsulfonyl)pyridin-2-yl][3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; -   {3-amino-5-[(3-fluorophenyl)sulfonyl]pyridin-2-yl}[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone;     and -   3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide.

Non-limiting examples of correctors include Lumacaftor (VX-809), 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)}cyclopropanecarboxamide (VX-661), VX-983, GLPG2222, GLPG2665, GLPG2851, VX-152, VX-440, FDL169, FDL304, FD2052160, FD2035659 and PTI-801. Examples of correctors are also disclosed in U.S. application Ser. Nos. 14/925,649, 14/926,727, 15/205,512, and 62/239,475.

In one embodiment, the corrector(s) can be selected from the group consisting of:

-   Lumacaftor (VX-809); -   1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide     (VX-661); -   PTI-801; -   VX-983; -   GLPG2665; -   VX-152; -   VX-440; -   FDL169; -   FDL304; -   FD2052160; -   FD2035659; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-methyl-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methyl-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]cyclohexanecarboxylic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]cyclohexanecarboxylic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-fluoro-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-({3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methyl-3,4-dihydro-2H-chromen-2-yl]benzoyl}amino)-1-methylcyclopentanecarboxylic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methyl-3,4-dihydro-2H-chromen-2-yl]-N-[(2R)-2,3-dihydroxypropyl]benzamide; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(2-methoxyethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-7-(benzyloxy)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(2-fluoroethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-2-yl]cyclohexanecarboxylic     acid; -   4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-8-fluoro-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic     acid; -   rac-3-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic     acid; -   rac-4-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic     acid; -   3-[(2S,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic     acid; -   3-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic     acid; -   rac-3-[(2R,4S,6S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-phenyltetrahydro-2H-pyran-2-yl]benzoic     acid; -   3-[(2S,4R,6R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-phenyltetrahydro-2H-pyran-2-yl]benzoic     acid; -   3-[(2R,4S,6S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-phenyltetrahydro-2H-pyran-2-yl]benzoic     acid; -   4-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic     acid; -   3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic     acid; -   3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylic     acid; -   5-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]pyrazine-2-carboxylic     acid; -   6-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]pyridine-3-carboxylic     acid; -   trans-4-[(2S,4S)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   6-[(2R,4R)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]pyridine-3-carboxylic     acid; -   trans-4-[(2S,4S)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   ethyl     trans-4-[(2S,4S)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylate; -   cis-4-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   trans-4-[(2S,4S)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   1-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclopropane-1-carboxylic     acid; -   trans-4-[(2R,4R)-4-{[(5S)-2,2-difluoro-5-methyl-6,7-dihydro-2H,5H-indeno[5,6-d][1,3]dioxole-5-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   trans-4-[(2R,4R)-4-{[(5S)-2,2-difluoro-5-methyl-6,7-dihydro-2H,5H-indeno[5,6-d][1,3]dioxole-5-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   trans-4-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; -   trans-4-[(2R,4R)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid; and -   trans-4-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic     acid.

In one embodiment, the additional therapeutic agent is a CFTR amplifier. CFTR amplifiers enhance the effect of known CFTR modulators, such as potentiators and correctors. Examples of CFTR amplifiers are PTI130 and PTI-428. Examples of amplifiers are also disclosed in publications: WO2015138909 and WO2015138934.

In one embodiment, the additional therapeutic agent is a CFTR stabilizer. CFTR stabilizers enhance the stability of corrected CFTR that has been treated with a corrector, corrector/potentiator or other CFTR modulator combination(s). An example of a CFTR stabilizer is cavosonstat. Examples of stabilizers are also disclosed in publication: WO2012048181.

In one embodiment, the additional therapeutic agent is an agent that reduces the activity of the epithelial sodium channel blocker (ENaC) either directly by blocking the channel or indirectly by modulation of proteases that lead to an increase in ENaC activity (e.g., serine proteases, channel-activating proteases). Exemplary of such agents include camostat (a trypsin-like protease inhibitor), QAU145, 552-02, GS-9411, INO-4995, Aerolytic, amiloride, and VX-371. Additional agents that reduce the activity of the epithelial sodium channel blocker (ENaC) can be found, for example, in PCT Publication No. WO2009074575 and WO2013043720; and U.S. Pat. No. 8,999,976.

In one embodiment, the ENaC inhibitor is VX-371.

In one embodiment, the ENaC inhibitor is SPX-101 (S18).

In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents. In a particular embodiment, the additional therapeutic agents are selected from the group consisting of CFTR modulators and CFTR amplifiers. In a further embodiment, the additional therapeutic agents are CFTR modulators. In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, one potentiator, and one or more additional correctors.

This invention also is directed to kits that comprise one or more compounds and/or salts of the invention, and, optionally, one or more additional therapeutic agents.

This invention also is directed to methods of use of the compounds, salts, compositions, and/or kits of the invention to, with or without one or more additional therapeutic agents, for example, modulate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, and treat a disease treatable by modulating the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein (including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease).

EXAMPLES

Chemical Synthetic Procedures

General

The compounds of the invention can be better understood in connection with the following synthetic schemes and methods which illustrate a means by which the compounds may be prepared.

The compounds of this invention can be prepared by a variety of synthetic procedures. Representative procedures are shown in, but are not limited to, Schemes 1-6. In Schemes 1-6, the variables R¹, R², R³, R⁴, R⁵ and R⁶ are as described in the Summary.

Optimum reaction conditions and reaction times for each individual step may vary depending on the particular reactants employed and substituents present in the reactants used. Unless otherwise specified, solvents, temperatures and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Reactions may be further processed in the conventional manner, e.g. by eliminating the solvent from the residue and further purified according to methodologies generally known in the art such as, but not limited to, crystallization, distillation, extraction, trituration and chromatography. Unless otherwise described, the starting materials and reagents are either commercially available or may be prepared by one skilled in the art from commercially available materials using methods described in the chemical literature.

Routine experimentations, including appropriate manipulation of the reaction conditions, reagents and sequence of the synthetic route, protection of any chemical functionality that may not be compatible with the reaction conditions, and deprotection at a suitable point in the reaction sequence of the method are included in the scope of the invention. Suitable protecting groups and the methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which can be found in T. Greene and P. Wuts, Protecting Groups in Organic Synthesis (3^(rd) ed.), John Wiley & Sons, NY (1999), which is incorporated herein by reference in its entirety. Synthesis of the compounds of the invention can be accomplished by methods analogous to those described in the synthetic schemes described hereinabove and in specific examples.

Starting materials, if not commercially available, can be prepared by procedures selected from standard organic chemical techniques, techniques that are analogous to the synthesis of known, structurally similar compounds, or techniques that are analogous to the above described schemes or the procedures described in the synthetic examples section.

When an optically active form of a compound is required, it can be obtained by carrying out one of the procedures described herein using an optically active starting material (prepared, for example, by asymmetric induction of a suitable reaction step), or by resolution of a mixture of the stereoisomers of the compound or intermediates using a standard procedure (such as chromatographic separation, recrystallization or enzymatic resolution).

Similarly, when a pure geometric isomer of a compound is required, it can be prepared by carrying out one of the above procedures using a pure geometric isomer as a starting material, or by resolution of a mixture of the geometric isomers of the compound or intermediates using a standard procedure such as chromatographic separation.

The compounds of the invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) were given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

The following methods are presented with details as to the preparation of a compound of the invention as defined hereinabove and the comparative examples. A compound of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.

All reagents were of commercial grade and were used as received without further purification, unless otherwise stated. Commercially available anhydrous solvents were used for reactions conducted under inert atmosphere. Reagent grade solvents were used in all other cases, unless otherwise specified. Column chromatography was performed on silica gel 60 (35-70 μm). Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). ¹H NMR spectra were recorded on a Bruker Advance 300 NMR spectrometer (300 MHz) unless otherwise noted. Chemical shifts (δ) for ¹H NMR spectra were reported in parts per million (ppm) relative to tetramethylsilane (δ 0.00) or the appropriate residual solvent peak, i.e. CHCl₃ (δ 7.27), as internal reference. Multiplicities were given as singlet (s), doublet (d), triplet (t), quartet (q), quintuplet (quin), multiplet (m) and broad (br). Electrospray MS spectra were obtained on a Waters platform LC/MS spectrometer or with Waters Acquity H-Class UPLC coupled to a Waters Mass detector 3100 spectrometer. Columns used: Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm ID×50 mm L, Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm ID×30 mm L, or Waters Xterra® MS 5 m C18, 100×4.6 mm. The methods were using either MeCN/H₂O gradients (H₂O contains either 0.1% TFA or 0.1% NH₃) or Methanol/H₂O gradients (H₂O contains 0.05% TFA). Microwave heating was performed with a Biotage® Initiator. Electrospray MS spectra were obtained on Waters Acquity UPLC systems coupled to Waters SQD or SQD2 mass spectrometers. Columns used: Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm ID×50 mm L or Waters Acquity UPLC BEH C18 1.7 m, 2.1 mm ID×30 mm L. The methods were using MeCN/H₂O gradients (both MeCN and H₂O contained either 0.1% formic acid or 0.05% NH₃).

For the compounds purified by preparative chromatography, an XSelect™ CSH Prep Guard Column, C18 19×10 mm 5 m (Waters) with an XSelect™ CSH Prep OBD Column, C18 19×100 mm 5 μm (Waters) and a gradient of 0.1% formic acid in water (A) and acetonitrile (B) at a flow rate of 20 mL/minute is used. Alternatively, an XBridge™ Prep Guard Column, C18 19×10 mm 5 m (Waters) with a XBridge™ Prep OBD Column, C18 19×100 mm 5 m (Waters) and a gradient of 0.5% NH₃ in water (A) and acetonitrile (B) at a flow rate of 20 mL/minute is used. After elution, the solvent was removed under vacuum to provide the product. For the compounds purified by preparative chromatography, an XBridge™ Prep Guard Column, C18 19×10 mm 5 m (Waters) with a XBridge™ Prep OBD Column, C18 30×100 mm 5 μm (Waters) and a gradient of 0.1% formic acid in water (A) and acetonitrile (B) at a flow rate of 50 mL/minute were used. Alternatively, a gradient of 0.1% DEA in water (A) and acetonitrile (B) at a flow rate of 50 mL/minute was used on the same references of guard column and column. After elution, the solvent was removed under vacuum to provide the dry product.

Alternatively, compounds were purified by automated reversed phase HPLC, using a Phenomenex® Luna® C8(2), 5 μm, 100 Å, 50×30 mm, with a SecurityGuard™ 15×30 mm guard column, and a gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B), at a flow rate of 40 mL/min (0-1.0 minute 10% A, 1.0-9.0 minutes linear gradient 10-100% A, 9.0-9.5 minutes 100% A, 9.5-10.0 minutes linear gradient 100-10% A). After elution, solvent was removed under vacuum to provide the pure product.

Racemic mixtures were separated on an Agilent HP1100 system with UV detection. Column used: Chiralpak® IA (10×250 mm, 5 μm). Solvents used: iPrOH and tBME. Enantiomeric purity was determined on an Agilent HP1100 system with UV detection. Column used: Chiralpak IA (4.6×250 mm, 5 μm). Solvents used: iPrOH and tBME.

List of abbreviations used in the experimental section: Abbreviation Definition Bn benzyl Boc tert-butoxycarbonyl Et ethyl Me methyl Ph phenyl Pr propyl Tf trifluoromethanesulfonyl OTf trifluormethanesulfonate DCM dichloromethane MeCN acetonitrile DMA N,N-dimethylacetamide DMF N,N-dimethylformamide AcOH or HOAc acetic acid eq or equiv equivalents TFA trifluoroacetic acid THF tetrahydrofuran NMR nuclear magnetic resonance DMSO dimethyl sulfoxide LC/MS or LCMS liquid chromatography-mass spectrometry EtOAc ethyl acetate EtOH ethanol MeOH methanol tBuOH or t-BuOH tert-butanol tBME or MTBE tert-butyl methyl ether s singlet br s broad singlet d duplet dd double duplet m multiplet min minute h hours mL milliliter μL microliter g gram mg milligram kg kilogram atm atmosphere w/w weight/weight RT room(ambient) temperature NEt₃ triethylamine BOP (benzotriazol- yloxy)tris(dimethylamino)phosphonium hexafluorophosphate DIPEA diisopropylethylamine DMAP dimethylaminopyridine EDC N-ethyl-N′-(3- dimethylaminopropyl)carbodiimide mmol millimoles HPLC high pressure liquid chromatography MS mass spectrum NMR nuclear magnetic resonance TLC thin layer chromatography NMP N-methylpyrrolidone ppm parts per million psi pounds per square inch Pd(OAc)₂ palladium(II) acetate Xantphos 4,5-bis(diphenylphosphino)-9,9- dimethylxanthene SM starting material Cpd compound Int intermediate MW molecular weight Mes molecular weight measured NA not active Pd(dppf)Cl₂ [1,1′- bis(diphenylphosphino)ferrocene]dichloro- palladium(II) Pd(dppf)Cl₂•CH₂Cl₂ or [1,1′- Pd(dppf)Cl₂•DCM bis(diphenylphosphino)ferrocene]dichloro- palladium(II) complex with dichloromethane μm micrometer iPrOH iso-propanol DBU 1,8-diazabicycloundec-7-ene DPPA diphenylphosphoryl azide LiHMDS lithium hexamethyldisilazide or lithium bis(trimethylsilyl)amide rac-BINAP rac-1,1′-binaphthyl-2,2′-diamine TfOH trifluoromethanesulfonic acid Tf₂O trifluoromethanesulfonic anhydride XPhos 2-dicyclohexylphosphino-2′,4′,6′- triisopropylbiphenyl XPhos Pd G1 (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl- 1,1′-biphenyl)[2-(2- aminoethyl)phenyl)]palladium(II) chloride K₂CO₃ potassium carbonate MgSO₄ magnesium sulfate NaHCO₃ sodium hydrogencarbonate or sodium bicarbonate Na₂CO₃ sodium carbonate Na₂SO₄ sodium sulfate CO carbon monoxide NaCl sodium chloride NaH sodium hydride LiOH lithium hydroxide Pd(amphos)Cl₂ bis(di-tert-butyl(4- dimethylaminophenyl)phosphine)dichloro- palladium(II) SPhos 2-dicyclohexylphosphino-2′,6′- dimethoxybiphenyl Synthetic Preparation of the Compounds of the Invention

General Synthetic Routes

The compounds of the invention and the comparative examples can be produced according to the following schemes.

Method A: Synthesis of Benzyl Esters

To a solution of the carboxylic acid (1.0 equiv) in either dry DMF or dry acetonitrile is added K₂CO₃ (1.3 equiv) followed by benzyl bromide (1.1 equiv). The reaction mixture is heated at a temperature ranging from RT to 85° C. for 2-4 h and then partitioned between brine and either ethyl acetate or dichloromethane. The organic layer is separated, washed with brine and saturated ammonium chloride, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue is purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate) to afford the titled compound.

Illustrative Synthesis of Intermediate BE01: 1-Methyl-cyclobutanecarboxylic Acid Benzyl Ester

To a solution of 1-methylcyclobutanecarboxylic acid (CAS: 32936-76-8, 0.5 g, 4.38 mmol, 1.0 equiv) in dry DMF was added K₂CO₃ (0.787 g, 5.69 mmol, 1.3 equiv) followed by benzyl bromide (CAS: 100-39-0, 0.57 mL, 4.82 mmol, 1.1 equiv). The reaction mixture was stirred at RT for 2.5 h and then diluted with ethyl acetate and brine. The organic layer was separated, washed with a saturated solution of ammonium chloride and brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 90/10) to afford the titled compound.

TABLE I List of benzyl esters Int. Structure Name SM method MW BE01

1-Methyl- cyclobutanecarboxylic acid benzyl ester 32936-76-8 A, Specific example 204 BE02

3-Methoxy- cyclobutanecarboxylic acid benzyl ester 552849-35-1 A 220 BE03

3-Fluoro- cyclobutanecarboxylic acid benzyl ester 122665-96-7 A 208 BE04

3-Methyl- cyclobutanecarboxylic acid benzyl ester 87863-09-0 A 204 Method B: Cyanoketone Formation

A flame-dried round bottom flask is cooled down to RT under nitrogen. A solution of 1 M LiHMDS in THF (1.5 equiv) is introduced into the flask, and then it is cooled down to −78° C. (acetone/dry ice bath). Dry MeCN (from 1.5 to 1.7 equiv) is then added dropwise under nitrogen, and the reaction mixture is stirred for 30 min at −78° C. At this point a solution of ester (1.0 equiv) in dry THF is added dropwise, and then the reaction mixture is stirred at −78° C. for 1-2 h. The reaction mixture is quenched with cold H₂O, partitioned between ethyl acetate (or diethyl ether) and H₂O. The organic layer is separated, and the aqueous layer is extracted with ethyl acetate (or diethyl ether). The aqueous fraction is then acidified to pH=1 with 2 N HCl and extracted with ethyl acetate (or diethyl ether). The combined organic layers are then washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or purified by flash chromatography on silica gel.

Illustrative Synthesis of CK01: Cyclobutyl-3-oxo-propionitrile

A 1 L 4 neck round bottom flask was equipped with 2 dropping funnels and a septum on top of the apparatus. The whole system was flame-dried (heat gun) for 10 minutes under vacuum and then cooled down to RT under a positive stream of nitrogen (balloon). A low-temperature thermometer was adapted under a positive stream of nitrogen, then a 1 N LiHMDS solution in THF (468.0 mL, 468.0 mmol, 1.5 equiv) was cannulated into the flask using a positive stream of nitrogen. The solution was cooled down to −78° C. (dry ice/acetone cooling bath) as confirmed with the thermometer. Dry MeCN (24.4 mL, 468.0 mmol, 1.5 equiv) was added via syringe into the first dropping funnel, and then added dropwise (over 20 min) into the reaction mixture. After the end of the addition, the mixture was stirred at −78° C. for 1 h. At this point, cyclobutanecarboxylic acid ethyl ester (CAS: 14924-53-9, 43.1 mL, 312.1 mmol, 1.0 equiv) as a solution in dry THF (106 mL) was introduced into the second dropping funnel. This solution was slowly added over 2 h into the reaction mixture at −78° C. The mixture was stirred at −78° C. for 2 h. The reaction mixture was poured into 300 mL of cold water, stirred for 30 min and allowed to warm to RT. The mixture was then partitioned between ethyl acetate and H₂O. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3×300 mL). The combined organic phases were discarded. The aqueous layer was then acidified with 100 mL of 2 N HCl, then extracted with ethyl acetate (3×300 mL), washed with 50 mL of brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which was used without further purification.

TABLE II List of cyanoketones Int. Structure Name SM method MW Mes 29509-06-6

4-Methyl-3-oxo- pentanenitrile 111 29509-06-6

4-Methyl-3-oxo- pentanenitrile 111 CK01, 118431-89-3

3-Cyclobutyl-3- oxo-propionitrile 14924- 53-9 B, Specific example 123 59997-51-2

4,4-Dimethyl-3- oxo-pentanenitrile 125 887594-13-0

3-(2-Cyano- acetyl)-azetidine-1- carboxylic acid tert-butyl ester 224 118431-88-2

3-Cyclopropyl-3- oxo-propionitrile 109 CK02

3-(1-Methyl- cyclobutyl)-3-oxo- propionitrile BE01 B 137 138 CK03

3-(cis-3-Methoxy- cyclobutyl)-3-oxo- propionitrile BE02 B 153 29509-06-6

4-Methyl-3-oxo- pentanenitrile 111 1234616-26-2

3-(3,3-Difluoro- cyclobutyl)-3-oxo- propionitrile 159 CK04

3-(3,3-Dimethyl- cyclobutyl)-3-oxo- propionitrile 3854- 83-9 B 151 CK05

3-(3-Fluoro- cyclobutyl)-3-oxo- propionitrile BE03 B 141 CK06

3-(trans-3-Methyl- cyclobutyl)-3-oxo- propionitrile BE04 B 137 Method C: Hydrazine Formation

Method C1: Reductive Amination

To a solution of ketone (1 equiv) and tert-butyl carbazate (CAS: 870-46-2, 1.0 equiv) in anhydrous dichloromethane at 0° C. is added acetic acid (2.0 equiv) and sodium triacetoxyborohydride (CAS: 56553-60-7, 3.0 equiv). The reaction mixture is warmed up to RT and stirred for 1 h to several days (up to 8). The reaction mixture is then basified with a solution of 2 M sodium hydroxide and a saturated solution of sodium hydrogencarbonate. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with a saturated solution of sodium hydrogencarbonate and brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the tert-butoxy carbonyl hydrazine which is used as such or purified by flash chromatography on silica gel.

Method C2: Reductive Amination

To the ketone (1 equiv) in anhydrous methanol at RT is added tert-butyl carbazate (CAS: 870-46-2, 1.0 equiv). The reaction mixture is stirred for 20 minutes at RT, then acetic acid (3.0 equiv) and sodium cyanoborohydride (CAS: 25895-60-7, 1.5 equiv) are added. The reaction mixture is stirred at RT for 1 h to several days (up to 8). The reaction mixture is then basified with a solution of 2 M sodium hydroxide and a saturated solution of sodium hydrogencarbonate. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with a saturated solution of sodium hydrogencarbonate and brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the tert-butoxy carbonyl hydrazine which is used as such or purified by flash chromatography on silica gel.

Method C3: Tert-Butoxy Carbonyl-Deprotection

To a solution of a tert-butoxy carbonyl hydrazine intermediate from Methods C1 or C2 in anhydrous dichloromethane at RT is added 4 M HCl in dioxane (20 equiv). The reaction mixture is stirred at RT until the reaction is finished. The solids are collected by filtration, washed twice with diethyl ether, and dried in vacuo to afford the hydrazine which is used as such.

Method C4: Tert-Butoxy Carbonyl-Deprotection

A tert-butoxy carbonyl hydrazine intermediate from Methods C1 or C2 is stirred at RT in a 1:1 mixture of dichloromethane and trifluoroacetic acid until the reaction is finished. The reaction mixture is concentrated in vacuo. The residue is taken up three times with toluene and concentrated in vacuo to afford the hydrazine which is used as such.

Illustrative Synthesis of H01: (Tetrahydro-pyran-3-yl)-hydrazine Di-hydrochloride Salt

Step 1: Tert-butyl N-(tetrahydropyran-3-ylamino)carbamate

To a solution of dihydro-2H-pyran-3(4H)-one (CAS: 23462-75-1, 0.6 g, 5.99 mmol, 1.0 equiv) and tert-butyl carbazate (CAS: 870-46-2, 0.792 g, 5.99 mmol, 1.0 equiv) in anhydrous dichloromethane (20 mL) at 0° C. was added acetic acid (0.685 mL, 11.98 mmol, 2.0 equiv) and sodium triacetoxyborohydride (CAS: 56553-60-7, 3.81 g, 17.97 mmol, 3.0 equiv). The reaction mixture was warmed up to RT and stirred for 24 h. The reaction mixture was then basified with a solution of 2 M sodium hydroxide (45 mL) and a saturated solution of sodium hydrogencarbonate (30 mL). The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with a saturated solution of sodium hydrogencarbonate and brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate 70/30) to afford tert-butyl 2-(oxan-3-yl)hydrazine-1-carboxylate.

Step 2: (Tetrahydro-pyran-3-yl)-hydrazine Di-hydrochloride Salt

To a solution of tert-butyl 2-(oxan-3-yl)hydrazine-1-carboxylate from Step 1 (0.534 g, 2.46 mmol, 1 equiv) in anhydrous dichloromethane (1.74 mL) at RT was added 4 M HCl in dioxane (12.34 mL, 49.38 mmol, 20 equiv). The reaction mixture was stirred at RT overnight, and then the solid was collected by filtration. The solid was washed twice with diethyl ether and dried in vacuo to afford the titled compound, H01.

Illustrative Synthesis of H02: 4,4-Difluoro-cyclohexyl)-hydrazine Bis(trifluoroacetate)

Step 1: Tert-butyl N-[(4,4-difluorocyclohexyl)amino]carbamate

To 4,4-difluorocyclohexanone (CAS: 22515-18-0, 0.4 g, 2.98 mmol, 1.0 equiv) in anhydrous methanol (8.5 mL) at RT was added tert-butyl carbazate (CAS: 870-46-2, 0.394 g, 2.98 mmol, 1.0 equiv). The reaction mixture was stirred for 20 minutes at RT, and then acetic acid (0.51 mL, 8.95 mmol, 3.0 equiv) and sodium cyanoborohydride (CAS: 25895-60-7, 0.281 g, 4.47 mmol, 1.5 equiv) were added. The reaction mixture was stirred at RT overnight. The reaction mixture was then basified with a solution of 2 M sodium hydroxide (22 mL) and a saturated solution of sodium hydrogencarbonate (15 mL). The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with a saturated solution of sodium hydrogencarbonate and brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 50/50) to afford tert-butyl 2-(4,4-difluorocyclohexyl)hydrazine-1-carboxylate.

Step 2: 4,4-Difluoro-cyclohexyl)-hydrazine Bis(trifluoroacetate)

The tert-butyl 2-(4,4-difluorocyclohexyl)hydrazine-1-carboxylate intermediate from Step 1 (0.2 g, 0.8 mmol, 1 equiv) was stirred at RT in a 1:1 mixture of dichloromethane (0.65 mL) and trifluoroacetic acid (0.65 mL) for 1.5 h. The reaction mixture was concentrated in vacuo. The residue was taken up three times with toluene and concentrated in vacuo to afford the titled compound, H02.

Synthesis of H04: (2,4-Dimethoxy-benzyl)-hydrazine Di-hydrochloride Salt

Step 1: Tert-butyl N-[(E)-(2,4-dimethoxyphenyl)methyleneamino]carbamate

To 2,4-dimethoxybenzaldehyde (CAS: 613-45-6, 37.82 g, 228 mmol, 1.0 equiv) in methanol at RT was added tert-butyl carbazate (CAS: 870-46-2, 30.08 g, 228 mmol, 1.0 equiv) and MgSO₄ (18.9 g). The reaction mixture was stirred at RT overnight. The reaction mixture was filtered through a pad of diatomaceous earth. The solids were washed with dichloromethane, and the filtrate was concentrated in vacuo. The residue was taken up in diethyl ether (120 mL) and stirred at RT. The resulting slurry was filtered. The solid was washed three times with diethyl ether and dried in vacuo to afford tert-butyl 2-[(2,4-dimethoxyphenyl)methylidene]hydrazine-1-carboxylate.

Step 2: Tert-butyl N-[(2,4-dimethoxyphenyl)methylamino]carbamate

A 2-L round bottom flask under nitrogen atmosphere was charged with methanol (1.3 L), 10% palladium on carbon (13.6 g), and tert-butyl 2-[(2,4-dimethoxyphenyl)methylidene]hydrazine-1-carboxylate from Step 1 (68.41 g, 228 mmol, 1 equiv). The reaction mixture was placed under vacuum then filled with hydrogen and kept under a hydrogen atmosphere (balloon). The reaction mixture was stirred at RT for 5 h. The reaction mixture was filtered through a pad of diatomaceous earth. The solids were washed with methanol, and the filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate, gradient from 50/50 to 40/60) to afford tert-butyl 2-[(2,4-dimethoxyphenyl)methyl]hydrazine-1-carboxylate.

Step 3: (2,4-Dimethoxy-benzyl)-hydrazine Di-hydrochloride Salt

A 2-L round bottom flask was charged with tert-butyl 2-[(2,4-dimethoxyphenyl)methyl]hydrazine-1-carboxylate from Step 2 (59.8 g, 211 mmol, 1.0 equiv), then a solution of 4 M HCl in dioxane (600 mL, 2400 mmol, 11.35 equiv) was added. The reaction mixture was stirred at RT overnight. The reaction mixture was filtered. The solid was washed three times with diethyl ether and dried in vacuo to afford the titled compound, H04.

TABLE III List of Hydrazines Int. Structure Name SM method MW Mes H01

(Tetrahydro-pyran-3- yl)-hydrazine di-hydrochloride salt 23462- 75-1 C1, C3 Specific example 116 H02

(4,4-Difluoro- cyclohexyl)- hydrazine di-trifluoroacetic acid salt 22515- 18-0 C2, C4 Specific example 150 H03

(Tetrahydro-furan-3- yl)-hydrazine di-hydrochloride salt 22929- 52-8 C2, C3 102 H04

(2,4-Dimethoxy- benzyl)-hydrazine di-hydrochloride salt 613-45- 6 Specific example 182 183 Method D: Aryl Hydrazones Formation

R¹=phenyl or 5-6 membered monocyclic heteroaryl

An aryl bromide (1.05 equiv), benzophenone hydrazone (CAS: 5350-57-2, 1.0 equiv) and rac-BINAP (CAS: 98327-87-8, 0.06 equiv) are introduced in a round bottom flask at RT and suspended in anhydrous toluene. The slurry is purged with argon (bubbling). Then palladium(II) acetate (CAS: 3375-31-3, 0.02 equiv) and sodium tert-butoxide (CAS: 865-48-5, 1.3 equiv) are added, and the resulting slurry is purged with argon again. The reaction mixture is heated at 100° C. until the reaction is finished. The reaction mixture is cooled down to RT and filtered through a pad of diatomaceous earth. Solids were washed with ethyl acetate, and the filtrate is concentrated in vacuo. The titled compound is obtained from the crude filtrate either by precipitation from a suitable solvent or by purification by flash chromatography on silica gel (eluent system: heptane/ethyl acetate).

Illustrative Synthesis of ArH01: [3-(N′-Benzhydrylidene-hydrazino)-phenyl]-dimethyl-amine

3-Bromo-N,N-dimethylaniline (CAS: 16518-62-0, 18.55 mL, 130 mmol, 1.05 equiv), benzophenone hydrazone (CAS: 5350-57-2, 24.29 g, 124 mmol, 1.0 equiv) and rac-BINAP (CAS: 98327-87-8, 4.62 g, 7.43 mmol, 0.06 equiv) were combined in a round bottom flask at RT and suspended in anhydrous toluene (80 mL). The slurry was purged with argon (bubbling), and then palladium(II) acetate (CAS: 3375-31-3, 0.556 g, 2.48 mmol, 0.02 equiv) and sodium tert-butoxide (CAS: 865-48-5, 15.46 g, 161 mmol, 1.3 equiv) were added. The resulting slurry was purged with argon again, and the reaction mixture was heated at 100° C. for 1.5 h. The reaction mixture was cooled down to RT and filtered through a pad of diatomaceous earth. The solids were washed with ethyl acetate, and the filtrate was concentrated in vacuo. The residue was taken up in diethyl ether, and stirred at RT. The resulting slurry was filtered. The collected solid was washed twice with diethyl ether and dried in vacuo to afford the titled compound.

TABLE IV List of Arylhydrazones Int. Structure Name SM method MW Mes ArH01

[3-(N′- Benzhydrylidene- hydrazino)-phenyl]- dimethyl-amine 16518-62-0 D Specific example 315 316 ArH02

N-Benzhydrylidene- N′-(3-morpholin-4- yl-phenyl)-hydrazine 197846- 82-5 D 357 358 ArH03

N-Benzhydrylidene- N′-(3-fluoro-5- methoxy-phenyl)- hydrazine 29578-39- 0 D 320 321 ArH04

N-Benzhydrylidene- N′-(6-fluoro-pyridin- 2-yl)-hydrazine 144100- 07-2 D 291 292 ArH05

N-Benzhydrylidene- N′-(2-chloro-pyridin- 4-yl)-hydrazine 73583-37- 6 D 308 309 Methods E1-E7: Synthesis of Aminopyrazoles Method E1: Cyclization of Hydrazines with 3-aminocrotononitrile

3-Aminocrotononitrile (CAS: 1118-61-2, 1.1 equiv), the hydrazine hydrochloride (1.0 equiv) and few drops of 1 N HCl solution are heated in EtOH at reflux until the reaction is finished. The reaction mixture is cooled down to RT and then is diluted with a saturated solution of sodium hydrogencarbonate. The aqueous phase is extracted with dichloromethane. The combined organic phases are filtered through a phase separator and concentrated under vacuum to afford the aminopyrazole which is used as such.

Illustrative Synthesis of AMP01: (5-Methyl-2-(3-trifluoromethoxy-phenyl)-2H-pyrazol-3-ylamine

3-Aminocrotononitrile (CAS: 1118-61-2, 0.5 g, 6.09 mmol, 1.1 eq;), 3-(trifluoromethoxy)phenylhydrazine hydrochloride (1.27 g, 5.54 mmol, 1.0 equiv) and two drops of 1 N HCl solution were heated in EtOH (1.5 mL) at reflux overnight. The reaction mixture was diluted with a saturated solution of sodium hydrogencarbonate, and the aqueous phase was extracted with dichloromethane. The combined organic phases were filtered through a phase separator and concentrated under vacuum to afford the titled compound which was used as such.

Method E2: Cyclization of Hydrochloride Salts of Hydrazines with Cyano Ketones

A round bottom flask is charged with the cyanoketone (from 1.0 to 1.5 equiv), the hydrazine hydrochloride or dihydrochloride (1 equiv) and EtOH. This mixture is stirred at a temperature ranging from RT to refluxing ethanol until the reaction is finished. Then the reaction mixture is concentrated in vacuo to afford a crude mixture which is used as such or undergoes one of the following processes:

Either the crude mixture is taken up in a suitable solvent. The resulting slurry is filtered, and the solids are washed with the same solvent and dried in vacuo to afford the aminopyrazole as its hydrochloride salt which is used as such or is taken up in either ethyl acetate or dichloromethane and basified with a saturated solution of either potassium carbonate or sodium hydrogencarbonate. The two phases are separated, and the aqueous phase is extracted with either ethyl acetate or dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the aminopyrazole as its free base which is used as such or further purified by flash chromatography on silica gel.

Or alternatively this crude mixture is partitioned between water and either ethyl acetate or dichloromethane. The two phases are separated, and the aqueous phase is washed with either ethyl acetate or dichloromethane, basified with a saturated solution of sodium hydrogencarbonate and extracted with either ethyl acetate or dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the aminopyrazole as its free base which is used as such or further purified by flash chromatography on silica gel.

Illustrative Synthesis of AMP29: 5-Cyclobutyl-2-phenyl-2H-pyrazol-3-ylamine

A round bottom flask was charged with 3-cyclobutyl-3-oxo-propionitrile (CK01, 19.6 g, 159 mmol, 1.1 equiv), phenylhydrazine hydrochloride (CAS: 59-88-1, 20.92 g, 145 mmol, 1.0 equiv) and EtOH (210 mL). The reaction mixture was stirred at reflux for 1 h. Then the reaction mixture was concentrated in vacuo to afford a crude mixture which was taken up in diethyl ether. The resulting slurry was filtered, and the solid was washed with diethyl ether and dried in vacuo to afford the titled compound as its hydrochloride salt which was taken up in dichloromethane and basified with a saturated solution of sodium hydrogencarbonate. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound as its free base.

Illustrative Synthesis of AMP 35: 5-Cyclobutyl-2-cyclohexyl-2H-pyrazol-3-ylamine

A round bottom flask was charged with 3-cyclobutyl-3-oxo-propionitrile (CK01, [118431-89-3], 20.4 g, 166 mmol), cyclohexylhydrazine hydrochloride ([24214-73-1], 25 g, 166 mmol) and EtOH (200 mL). The reaction mixture was refluxed overnight and cooled down to RT. Next, the mixture was concentrated and water (150 mL) was added. The pH was modified till pH=7 with a saturated K₂CO₃ solution. Subsequently, the aqueous phase was extracted with DCM. The obtained organic phase was dried and concentrated to give a yellow solid. Trituration with MTBE gave the titled compound.

Illustrative Synthesis of AMP93: 3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazol-5-amine

A round bottom flask was charged with 3-cyclobutyl-3-oxo-propionitrile (CK01, 10 g, 81.4 mmol), 4-fluorophenylhydrazine hydrochloride ([823-85-8], 12 g, 74 mmol) and EtOH (35 mL). The reaction mixture was refluxed for 2 hours and cooled down to RT. Half of the solvent was removed in vacuo. The mixture was vigorously stirred and diisopropyl ether (350 mL) was added. The stirring was continued for 1 hour, and the formed precipitate was filtered, washed with diisopropyl ether and dried at 40° C. under reduced pressure to give the titled compound.

Illustrative Synthesis of AMP94: 1-tert-butyl-3-cyclobutyl-1H-pyrazol-5-amine

A round bottom flask was charged with 3-cyclobutyl-3-oxo-propionitrile (CK01, 12.3 g, 0.1 mol), tert-butylhydrazine hydrochloride ([7400-27-3], 13.5 g, 0.11 mol) and EtOH (150 mL). The reaction mixture was refluxed for 20 hours and cooled down to RT. Half of the solvent was removed by concentration in vacuo, and the mixture was cooled in an ice bath. The formed precipitate was collected by filtration and washed successively with diethyl ether and n-pentane. The filtrate was allowed to stand for 1 hour, and the formed precipitate was again collected by filtration and washed with diethyl ether and n-pentane. The combined solids were stirred in ethyl acetate and a saturated solution of NaHCO₃. The organic phase was dried over sodium sulfate, filtered and evaporated under reduced pressure to give the titled compound.

Method E3: Cyclization of Cyano Ketones with Hydrazines Either as Free Base, Hydrochloride or TFA Salt, in the Presence of an Organic Base

To the hydrazine either as free base or as a hydrochloride or a trifluoroacetic acid mono or di-salt (1 equiv) and the cyanoketone (from 1.0 to 1.5 equiv) in ethanol or toluene at RT is added DIPEA (from 0 to 2.0 equiv). Then the reaction mixture is heated at reflux until the reaction is finished. The reaction mixture is concentrated in vacuo to afford a crude mixture which is used as such or purified by flash chromatography on silica gel to afford the aminopyrazole as its free base.

Illustrative Synthesis of AMP26: 2-Cyclopentyl-5-isopropyl-2H-pyrazol-3-ylamine

To cyclopentylhydrazine hydrochloride (CAS: 24214-72-0, 0.35 g, 2.56 mmol, 1.0 equiv) and 4-methyl-3-oxo-pentanenitrile (CAS: 29509-06-6, 0.33 mL, 2.82 mmol, 1.1 equiv) in toluene (12.8 mL) at RT was added DIPEA (0.82 mL, 5.12 mmol, 2.0 equiv). Then the reaction mixture was heated at reflux for 1.5 h. The reaction mixture was cooled down to RT and concentrated in vacuo to afford a crude mixture which was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 30/70) to afford the titled compound.

Method E4: Cyclization of Arylhydrazones with Cyanoketones

To the arylhydrazone (1 equiv) and the cyanoketone (from 1.0 to 2 equiv) in ethanol at RT is added an aqueous solution of 2 M HCl or 12 M HCl (5 equiv). Then the reaction mixture is heated at reflux until the reaction is finished. Then the reaction mixture is cooled down to RT and undergoes one of the following processes.

The reaction mixture is concentrated to dryness in vacuo to afford a crude mixture. The aminopyrazole is obtained from this crude mixture by precipitation from a suitable solvent to afford the aminopyrazole as its hydrochloride salt and used as such.

Ethanol from the reaction mixture is removed in vacuo. The resulting aqueous residue is diluted with an aqueous solution of 2 M HCl, washed with dichloromethane, then basified with a saturated solution of sodium hydrogencarbonate and extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the aminopyrazole as a free base which is used as such or further purified by flash chromatography on silica gel.

Illustrative Synthesis of AMP06: 2-(3-Dimethylamino-phenyl)-5-isopropyl-2H-pyrazol-3-ylamine

To [3-(N′-benzhydrylidene-hydrazino)-phenyl]-dimethyl-amine (ArH01, 25.57 g, 81 mmol, 1 equiv) and 4-methyl-3-oxo-pentanenitrile (CAS: 29509-06-6, 10.57 mL, 89.2 mmol, 1.1 equiv) in ethanol (255 mL) at RT was added an aqueous solution of 2 M HCl (203 mL, 405 mmol, 5 equiv). Then the reaction mixture was heated at reflux overnight. The reaction mixture was cooled down to RT, and ethanol from the reaction mixture was removed in vacuo. The resulting aqueous residue was diluted with an aqueous solution of 2 M HCl, washed with dichloromethane, then basified with a saturated solution of sodium hydrogencarbonate and extracted twice with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which was used as such.

Method E5: SNAr on 2-(2-chloro-pyridin-4-yl)-yl-2H-pyrazol-3-ylamine Intermediates

A sealed tube is charged with the 2-(2-chloro-pyridin-4-yl)-yl-2H-pyrazol-3-ylamine intermediate (1 equiv), the amine (from 10 to 15 equiv), DIPEA (3 equiv) and DMA. This mixture is heated at a temperature ranging from 130° C. to 160° C. until the reaction is finished. Then the reaction mixture is cooled down to RT and partitioned between ethyl acetate and water. The two phases are separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo. The substituted aminopyrazole is obtained from the crude mixture either by precipitation or by purification by flash chromatography on silica gel.

Illustrative Synthesis of AMP22: 5-Isopropyl-2-(2-pyrrolidin-1-yl-pyridin-4-yl)-2H-pyrazol-3-ylamine

A sealed tube was charged with 2-(2-chloro-pyridin-4-yl)-yl-2H-pyrazol-3-ylamine intermediate (AMP20, 1.2 g, 5.07 mmol, 1 equiv), pyrrolidine (CAS: 123-75-1, 4 mL, 50.7 mmol, 10 equiv), DIPEA (2.6 mL, 15.2 mmol, 3 equiv) and DMA (10 mL). This mixture was heated at 130° C. for 2 h. Then the reaction mixture was cooled down to RT, and additional pyrrolidine (CAS: 123-75-1, 1 mL, 12.67 mmol, 2.5 equiv) was introduced, and the reaction mixture was heated at 130° C. for 30 minutes. Then the reaction mixture was cooled down to RT and partitioned between ethyl acetate and water. The two phases were separated, and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with water (three times) and brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel (eluent system: dichloromethane/methanol gradient from 100/0 to 97/3) to afford the titled compound.

Method E6: Buchwald Coupling

To the 2-(3-bromo-phenyl)-2H-pyrazol-3-ylamine hydrochloride salt intermediate (1 equiv) in anhydrous THF at RT under a nitrogen atmosphere is added the amine (1.2 equiv), a solution of 1 N LiHMDS in THF (5 equiv) and XPhos Pd G1 (CAS 1028206-56-5, 0.1 equiv). The reaction mixture is stirred at RT until the reaction is finished. The reaction mixture is hydrolyzed with a saturated solution of ammonium chloride and diluted with dichloromethane. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The substituted aminopyrazole is obtained from the crude mixture by purification with flash chromatography on silica gel (eluent system: heptane/ethyl acetate).

Illustrative Synthesis of AMP11: 5-Isopropyl-2-(3-pyrrolidin-1-yl-phenyl)-2H-pyrazol-3-ylamine

To 2-(3-bromo-phenyl)-5-isopropyl-2H-pyrazol-3-ylamine hydrochloride salt (AMP05, 0.5 g, 1.58 mmol, 1 equiv) in anhydrous THF (5 mL) at RT under nitrogen atmosphere was added pyrrolidine (CAS: 123-75-1, 0.16 mL, 1.9 mmol, 1.2 equiv), a solution of 1 N LiHMDS in THF (8 mL, 8 mmol, 5 equiv) and XPhos Pd G1 (CAS 1028206-56-5, 0.117 g, 0.16 mmol, 0.1 equiv). The reaction mixture was stirred at RT for 5 h. The reaction mixture was treated with a saturated solution of ammonium chloride and diluted with dichloromethane. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 65/35) to afford the titled compound.

Method E7: O-Alkylation of 5-aminopyrazol-3-ol Analogues

A suspension of 5-aminopyrazol-3-ol derivative (1 equiv), cesium carbonate (1.2 equiv) and 2-bromopropane (1 equiv) in N-methylpyrrolidine is stirred at RT for 20 to 72 hours. The reaction mixture is diluted with DCM and washed with water. The organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure. The O-alkylated product is purified by flash column chromatography on silica gel.

Illustrative Synthesis of AMP96: 1-(4-fluorophenyl)-3-[(propan-2-yl)oxy]-1H-pyrazol-5-amine

A suspension of 5-amino-1-(4-fluorophenyl)-1H-pyrazol-3-ol ([1247169-18-1], 800 mg, 4.14 mmol), cesium carbonate (2.15 g, 4.97 mmol) and 2-bromopropane (516 μL, 4.14 mmol) in N-methylpyrrolidine (8 mL) was stirred at RT for 20 hours. The reaction mixture was diluted with DCM and washed with water. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with ethyl acetate/n-heptane to yield the titled compound.

Synthesis of Intermediates AMP18 and AMP19: [6-(5-Amino-3-isopropyl-pyrazol-1-yl)-pyridin-2-yl]-dimethyl-amine and 5-Isopropyl-2-(6-morpholin-4-yl-pyridin-2-yl)-2H-pyrazol-3-ylamine

A sealed tube was charged with 2-(6-fluoro-pyridin-2-yl)-5-isopropyl-2H-pyrazol-3-ylamine (AMP17, 0.2 g, 0.91 mmol, 1 equiv), morpholine (CAS: 110-91-8, 0.12 mL, 1.37 mmol, 1.5 equiv), DIPEA (0.19 mL, 1.09 mmol, 1.2 equiv) and DMF (2 mL). This mixture was heated at 100° C. overnight. Then the reaction mixture was cooled down to RT and partitioned between ethyl acetate and water. The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with water (three times) and brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 60/40) to afford the two titled compounds.

TABLE V List of aminopyrazoles Int. Structure Name SM method MW Mes 70373- 98-7

5-Amino-1-phenyl- 1,2-dihydro- pyrazol-3-one 175 826-85- 7

2-Phenyl-2H- pyrazol-3-ylamine 159 1131- 18-6

5-Methyl-2-phenyl- 2H-pyrazol-3- ylamine 173 345-07- 3

5-Methyl-2-(3- trifluoromethyl- phenyl)-2H- pyrazol-3-ylamine 241 866472- 29-9

2-(3-Chloro-4- methyl-phenyl)-5- methyl-2H-pyrazol- 3-ylamine 221 380569- 79-9

2-(2,4-Difluoro- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 209 1232796- 65-4

2-(3,5-Difluoro- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 209 890010- 89-6

2-(3,5-Dimethyl- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 201 92721- 83-0

5-Methyl-2-m-tolyl- 2H-pyrazol-3- ylamine 187 56547- 82-1

2-Cyclohexyl-5- methyl-2H-pyrazol- 3-ylamine 179 40401- 41-0

2-(3-Chloro- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 207 105438- 45-7

2-(3-Fluoro- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 191 497141- 59-0

5-Methyl-2-(4- trifluoromethoxy- phenyl)-2H- pyrazol-3-ylamine 257 92721- 94-3

2-(3-Methoxy- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 203 3524- 36-5

2-Isobutyl-5- methyl-2H-pyrazol- 3-ylamine 153 1124- 16-9

2-Isopropyl-5- methyl-2H-pyrazol- 3-yL amine 139 436088- 86-7

5-Amino-1- cyclohexyl-1H- pyrazol-3-ol 181 1247169- 18-1

5-Amino-1-(4- fluorophenyl)-1H- pyrazol-3-ol 193 AMP01

5-Methyl-2-(3- trifluoromethoxy- phenyl)-2H- pyrazol-3-ylamine 133115- 55-6, 1118-61- 2 E1 Specific example 257 258 AMP02

2-(3,4-Difluoro- phenyl)-5-methyl- 2H-pyrazol-3- ylamine 161886- 22-2, 1118-22- 2 E1 209 210 AMP03

2-(3-Fluoro-5- methoxy-phenyl)-5- methyl-2H-pyrazol- 3-ylamine ArH03, 1118-61- 2 E4 221 222 AMP04

5-Isopropyl-2- phenyl-2H-pyrazol- 3-ylamine 100-63- 0, 29509- 06-6 E3 201 202 AMP05

2-(3-Bromo- phenyl)-5- isopropyl-2H- pyrazol-3-ylamine 27246- 81-7, 29509- 06-6 E2 280 281 AMP06

2-(3- Dimethylamino- phenyl)-5- isopropyl-2H- pyrazol-3-ylamine ArH01, 29509- 06-6 E4 Specific example 244 245 AMP07

5-Isopropyl-2-m- tolyl-2H-pyrazol-3- ylamine 637-04- 7, 29509- 06-6 E2 215 216 AMP08

5-Isopropyl-2-(3- trifluoromethyl- phenyl)-2H- pyrazol-3-ylamine 368-78- 5, 29509- 06-6 E3 269 270 AMP09

2-(3,5-Difluoro- phenyl)-5- isopropyl-2H- pyrazol-3-ylamine 134993- 88-7, 29509- 06-6 E2 237 238 AMP10

5-Isopropyl-2-(3- morpholin-4-yl- phenyl)-2H- pyrazol-3-ylamine ArH02, 29509- 06-6 E4 286 287 AMP11

5-Isopropyl-2-(3- pyrrolidin-1-yl- phenyl)-2H- pyrazol-3-ylamine AMP05 E6 Specific example 270 271 AMP12

2-(3-Fluoro- phenyl)-5- isopropyl-2H- pyrazol-3-ylamine 502496- 27-7, 2950906- 6 E2 219 220 AMP13

2-(4-Fluoro- phenyl)-5- isopropyl-2H- pyrazol-3-ylamine 823-85- 8, 29509- 06-6 E2 219 220 AMP14

2-(2,4-Difluoro- phenyl)-5- isopropyl-2H- pyrazol-3-ylamine 51523- 79-6, 29509- 06-6 E2 237 238 AMP15

2-Cyclopropyl-5- methyl-2H-pyrazol- 3-ylamine 213764- 25-1, 1118-61- 2 E1 137 138 AMP16

5-Isopropyl-2-(6- methoxy-pyridin-3- yl)-2H-pyrazol-3- ylamine 179543- 88-5, 29509- 06-6 E2 232 233 AMP17

2-(6-Fluoro- pyridin-2-yl)-5- isopropyl-2H- pyrazol-3-ylamine ArH04, 29509- 06-6 E4 220 221 AMP18

[6-(5-Amino-3- isopropyl-pyrazol- 1-yl)-pyridin-2-yl]- dimethyl-amine AMP17 Specific example 245 246 AMP19

5-Isopropyl-2-(6- morpholin-4-yl- pyridin-2-yl)-2H- pyrazol-3-ylamine AMP17 Specific example 287 288 AMP20

2-(2-Chloro- pyridin-4-yl)-5- isopropyl-2H- pyrazol-3-ylamine ArH05, 29509- 06-6 E4 237 238 AMP21

5-Isopropyl-2-(2- morpholin-4-yl- pyridin-4-yl)-2H- pyrazol-3-ylamine AMP20 E5 287 288 AMP22

5-Isopropyl-2-(2- pyrrolidin-1-yl- pyridin-4-yl)-2H- pyrazol-3-ylamine AMP20 E5 Specific example 271 272 AMP23

2-Cyclohexyl-5- isopropyl-2H- pyrazol-3-ylamine 30929- 57-8, 29509- 06-6 E2 207 208 AMP24

2-(4,4-Difluoro- cyclohexyl)-5- isopropyl-2H- pyrazol-3-ylamine H02, 29509- 06-6 E3 243 244 AMP25

5-Isopropyl-2- (tetrahydro-pyran- 3-yl)-2H-pyrazol-3- ylamine H01, 29509- 06-6 E3 209 210 AMP26

2-Cyclopentyl-5- isopropyl-2H- pyrazol-3-ylamine 24214- 72-0, 29509- 06-6 E3 Specific example 193 194 AMP27

5-Isopropyl-2- (tetrahydro-furan-3- yl)-2H-pyrazol-3- ylamine H03, 29509- 06-6 E3 195 196 AMP28

2-(2,4-Dimethoxy- benzyl)-5- isopropyl-2H- pyrazol-3-ylamine H04, 29509- 06-6 E2 275 276 AMP29

5-Cyclobutyl-2- phenyl-2H-pyrazol- 3-ylamine 59-88-1, CK01 E2 Specific example 213 214 AMP30

2-(3-Bromo- phenyl)-5- cyclobutyl-2H- pyrazol-3-ylamine 27246- 81-7, CK01 E3 292 293 AMP31

5-Cyclobutyl-2-(3- pyrrolidin-1-yl- phenyl)-2H- pyrazol-3-ylamine AMP30 E6 282 283 AMP32

2-(2-Chloro- pyridin-4-yl)-5- cyclobutyl-2H- pyrazol-3-ylamine 700811- 29-6, CK01 E3 248 249 AMP33

5-Cyclobutyl-2-(2- morpholin-4-yl- pyridin-4-yl)-2H- pyrazol-3-ylamine AMP32 E5 299 300 AMP34

5-Cyclobutyl-2-(2- pyrrolidin-1-yl- pyridin-4-yl)-2H- pyrazol-3-ylamine AMP32 E5 283 284 AMP35

5-Cyclobutyl-2- cyclohexyl-2H- pyrazol-3-ylamine 30929- 57-8, CK01 E2, Specific Example 219 220 AMP36

5-Cyclobutyl-2- (2,4-dimethoxy- benzyl)-2H- pyrazol-3-ylamine H04, CK01 E2 287 288 AMP37

5-tert-Butyl-2- cyclopentyl-2H- pyrazol-3-ylamine 24214- 72-0, 599917- 51-2 E2 207 208 AMP38

3-(5-Amino-1- cyclohexyl-1H- pyrazol-3-yl)- azetidine-1- carboxylic acid tert- butyl ester 30929- 57-8, 887594- 13-0 E2 320 321 AMP39

2-Cyclohexyl-5- cyclopropyl-2H- pyrazol-3-ylamine 30929- 57-8, 118431- 88-2 E2 205 206 AMP40

3-[5-Amino-1-(3,5- difluoro-phenyl)- 1H-pyrazol-3-yl]- azetidine-1- carboxylic acid tert- butyl ester 134993- 88-7, 887594- 13-0 E2 350 295¹ AMP41

5-(1-Methyl- cyclobutyl)-2- phenyl-2H-pyrazol- 3-ylamine 100-63- 0, CK02 E3 227 228 AMP42

5-(3-Methoxy- cyclobutyl)-2- phenyl-2H-pyrazol- 3-ylamine 59-88-1, CK03 E2 243 AMP43

5-(3,3-Difluoro- cyclobutyl)-2- phenyl-2H-pyrazol- 3-ylamine 59-88-1, 1234616- 26-2 E2 249 AMP44

5-(3,3-Dimethyl- cyclobutyl)-2- phenyl-2H-pyrazol- 3-ylamine 59-88-1, CK04 E2 241 AMP45

5-(3-Fluoro- cyclobutyl)-2- phenyl-2H-pyrazol- 3-ylamine 59-88-1, CK05 E2 231 AMP46

5-(trans-3-Methyl- cyclobutyl)-2- phenyl-2H-pyrazol- 3-ylamine 59-88-1, CK06 E2 227.31 AMP93

3-Cyclobutyl-1-(4- fluorophenyl)-1H- pyrazol-5-amine 823-85- 8, CK01 Specific example 231 232 AMP94

1-tert-Butyl-3- cyclobutyl-1H- pyrazol-5-amine 7400-27- 3, 118431- 89-3 Specific example 193 194 AMP95

1-Cyclohexyl-3- [(propan-2-yl)oxy]- 1H-pyrazol-5-amine 436088- 86-7 E7 223 224 AMP96

1-(4-Fluorophenyl)- 3-[(propan-2- yl)oxy]-1H-pyrazol- 5-amine 1247169- 18-1 E7, Specific example 235 236 ¹(M-tBu + H)⁺ Method F: Synthesis of Aldehydes by SN—Ar

A is either CH or N LG is F, Cl, or Br

A solution of the aldehyde (1 equiv), the amine (1.3 to 2 equiv) and the base (DIPEA or K₂CO₃) (2 equiv) is prepared in acetonitrile, DMSO or DMA. This mixture is heated under thermal conditions or under microwave irradiations at a temperature ranging from 85° C. to 150° C. The reaction is worked up either by filtration of the base when needed or by diluting the reaction mixture with ethyl acetate or DCM and washing the organic phase with water and brine. In all cases, the organic phase is concentrated under reduced pressure, and the crude residue is used as such or purified either by flash column chromatography or precipitation to give the titled compound.

Illustrative Synthesis of ALD02: 5′-Formyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonitrile

A solution of 2-chloropyridine-5-carboxaldehyde (CAS: 23100-12-1, 25.1 g, 177.4 mmol), 4-cyanopiperidine (CAS: 4395-98-6, 25.4 g, 230.6 mmol) and DIPEA (62 mL, 354.7 mmol) in acetonitrile (250 mL) was refluxed for 20 hours. The reaction mixture was cooled to RT, and the mixture was concentrated under reduced pressure. The residue was dissolved in DCM (500 mL) and washed successively with a saturated aqueous solution of Na₂CO₃ (250 mL) and brine (250 mL). The organic phase was stirred for 2 minutes with 10 g of silica gel, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting mixture was dissolved in DCM (150 mL) and poured into a stirring solution of diisopropyl ether (1.5 L). The mixture was stirred vigorously for 4 hours. The precipitate was collected by filtration, washed with diisopropyl ether, and dried at 40° C. under reduced pressure to give the titled compound.

TABLE VI List of aldehydes Int. Structure Name SM method MW Mes ALD01

6-[(2-Methoxy- ethyl)-methyl- amino]-pyridine- 3-carbaldehyde 23100- 12-1 F 194 195 ALD02

5′-Formyl- 3,4,5,6- tetrahydro-2H- [1,2′]bipyridinyl 4-carbonitrile 23100- 12-1 F, Specific example 215 216 ALD03

6-[Methyl- (tetrahydro- pyran-4-yl)- amino]-pyridine- 3-carbaldehyde 23100- 12-1 F 220 221 ALD04

4-[(2-Methoxy- ethyl)-methyl- amino]- benzaldehyde 459- 57-4 F 193 194 ALD05

1-(4-Formyl- phenyl)- piperidine-4- carbonitrile 459- 57-4 F 214 215 ALD06

2-[Methyl- (tetrahydro- pyran-4-yl)- amino]- pyrimidine-5- carbaldehyde 933702- 55-7 F 221 222 ALD07

1-(5-Formyl- pyrimidin-2-yl)- piperidine-4- carbonitrile 933702- 55-7 F 216 217 ALD08

4-[Methyl- (tetrahydro- pyran-4-yl)- amino]- benzaldehyde 459-57-4 F 219 220 ALD09

2-[(2-Methoxy- ethyl)-methyl- amino]- pyrimidine-5- carbaldehyde 933702- 55-7 F 195 196 ALD10

6- Dimethylamino- pyridine-3- carbaldehyde 23100- 12-1 F 150 151 ALD11 1204- 86-0

4- Morpholino- benzaldehyde 191 ALD12

6-[bis(2- methoxyethyl) amino]pyridine-3- carbaldehyde 23100- 12-1 F 238 239 Methods G1-G3: Synthesis of Alkylidene Pyruvate Method G1: Synthesis of Alkylidene Pyruvate

A is either N or CH A′ is either R^(e) or L¹-G^(3C) as described in the Summary

A solution of potassium hydroxide (from 1.5 to 2 equiv) in water is added dropwise at 0° C. to a solution of aldehyde (1 equiv) and pyruvic acid (CAS 127-17-3, from 1 eq to 1.5 equiv) in methanol. The reaction is warmed up to RT and then heated at 40° C. for 1 h to several days. Then the reaction mixture undergoes one of the following processes:

-   -   Either the formed precipitate is collected by filtration,         suspended in an aqueous acidic solution, collected by filtration         again, and dried in vacuo to give the titled compound.     -   Or alternatively, methanol is removed in vacuo, and the         resulting suspension is filtered. The solid is taken up in water         and either ethyl acetate or dichloromethane and acidified to         pH=3-5 with either acetic acid or an aqueous solution of 2 M         HCl. The two phases are separated, and the aqueous phase is         extracted with either ethyl acetate or dichloromethane. The         combined organic phases are washed with water and brine, dried         over MgSO₄, filtered and concentrated in vacuo to afford the         titled compound which is used as such or further purified by         precipitation.

Illustrative Synthesis of ALP19: (E)-4-(4-Bromo-phenyl)-2-oxo-but-3-enoic Acid

A solution of potassium hydroxide (6.9 g, 121.6 mmol) in water (45 mL) was added at 0° C. to a stirring solution of 4-bromobenzaldehyde (CAS 1122-91-4, 15 g, 81.1 mmol) and pyruvic acid (CAS 127-17-3, 5.7 mL, 81.1 mmol) in methanol (105 mL) over a 5 minutes period. The reaction mixture was then heated at 40° C. for 4 hours, cooled down to RT and poured into ice/water (300 mL). The precipitate was stirred for 10 minutes, collected by filtration, washed with water and n-heptane, and air dried for 1 hour. The solid was suspended in aqueous 2 N HCl and stirred for 10 minutes. The precipitate was collected by filtration and dried at 40° C. under reduced pressure to afford the titled compound.

Method G2: Synthesis of Alkylidene Pyruvate

A is either N or CH A′ is either R^(e) or L¹-G^(3C) as described in the Summary

Triflic acid (CAS 1493-13-6, from 1.35 eq to 2.5 equiv) is added dropwise to a solution of aldehyde (1 equiv), triethyl orthoformate (CAS 122-51-0, from 1.1 eq to 1.3 equiv) and ethyl pyruvate (CAS 617-35-6, from 1.5 to 3.5 equiv) in chloroform. The solution is refluxed for 30 minutes to 24 h. The reaction mixture is cooled down to RT, diluted with dichloromethane, basified with a saturated aqueous solution of Na₂CO₃ or NaHCO₃. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are dried over sodium sulfate, filtered and concentrated under reduced pressure. This crude mixture is purified either by flash chromatography on silica gel or by precipitation to afford the titled compound.

Illustrative Synthesis of ALP09: Ethyl (E)-4-[6-(4-cyano-1-piperidyl)-3-pyridyl]-2-oxo-but-3-enoate

Triflic acid (CAS 1493-13-6, 26.7 mL, 301 mmol) was added dropwise to a solution of intermediate ALD02 (32.4 g, 150.5 mmol), triethyl orthoformate (CAS 122-51-0, 32.6 g, 195.7 mmol) and ethyl pyruvate (CAS 617-35-6, 41.7 mL, 376.3 mmol) in chloroform (180 mL). The solution was refluxed for 30 minutes and then cooled to RT. The reaction mixture was diluted with DCM (500 mL) and washed successively with a saturated aqueous solution of Na₂CO₃ (400 mL) and brine (400 mL). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude sample was purified by flash column chromatography on silica gel eluting with a gradient of n-heptane/ethyl acetate to yield the titled compound.

Method G3: Synthesis of Alkylidene Pyruvate

In a round bottom flask, under a nitrogen atmosphere, a suspension of 4-ethynylbenzene derivative (1 equiv.), 50% ethyl glyoxalate in toluene (2 equiv), morpholine ([110-91-8], 2 equiv), copper(I) bromide ([7787-70-4], 0.5 equiv) in dioxane is heated to 85° C. for 3 to 20 hours. The reaction mixture is cooled to RT, and the solvent was evaporated under reduced pressure. The residue is suspended in a mixture of DCM or DCM/2-propanol (95/5) and is washed twice with water. The organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude sample is purified by flash chromatography eluting with ethyl acetate/n-heptane/DCM.

Illustrative Synthesis of ALP36: Ethyl 4-(4-formylphenyl)-2-oxobut-3-enoate

In a round bottom flask, under a nitrogen atmosphere, a suspension of 4-ethynylbenzaldehyde ([63697-96-1], 5 g, 38.4 mmol), 50% ethyl glyoxalate in toluene ([924-44-7], 15.7 mL, 15.7 g, 76.8 mmol), morpholine ([110-91-8], 6.7 mL, 76.8 mmol), copper(I) bromide ([7787-70-4], 2.8 g, 19.2 mmol) in dioxane (50 mL) was heated to 85° C. for 3 hours. The reaction mixture was cooled to RT, and the volatiles were removed under reduced pressure. The residue was suspended in a mixture of DCM/2-propanol (200 mL, 95/5) and washed twice with water (50 mL). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate/n-heptane to yield the titled compound.

Synthesis of ALP38: 4-Cyano-4-[4-((E)-3-ethoxycarbonyl-3-oxo-propenyl)-phenyl]-piperidine-1-carboxylic Acid Tert-butyl Ester

Step 1: 4-Cyano-4-{4-[(triisopropylsilanyl)-ethynyl]-phenyl}-piperidine-1-carboxylic Acid Tert-butyl Ester

Nitrogen was bubbled for 5 minutes through a suspension of tert-butyl 4-(4-bromophenyl)-4-cyanopiperidine-1-carboxylate ([847615-14-9], 547 mg, 1.5 mmol), tetrakis(triphenylphosphine)palladium(0) ([14221-01-3], 90 mg, 77 μmol), copper(I) iodide ([7681-65-4], 8 mg, 42 μmol), lithium chloride ([7447-41-8], 8 mg, 189 μmol), and (triisopropylsilyl)acetylene ([89343-06-6], 670 μL, 3 mmol) in triethylamine (8 mL). The tube was sealed and heated at 100° C. for 6 hours. The mixture was then concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography eluting with ethyl acetate/n-heptane to give the titled compound.

Step 2: 4-Cyano-4-(4-ethynyl-phenyl)-piperidine-1-carboxylic Acid Tert-butyl Ester

The compound from Step 1 (700 mg, 1.5 mmol) was dissolved in anhydrous THF (10 mL) and 1 M tetra-n-butylammonium fluoride in THF (1.7 mL, 1.7 mmol) was added. The reaction mixture was stirred at RT for 2 hours and then concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography eluting with ethyl acetate/n-heptane to give the titled compound.

Step 3: 4-Cyano-4-[4-((E)-3-ethoxycarbonyl-3-oxo-propenyl)-phenyl]-piperidine-1-carboxylic Acid Tert-butyl Ester

In a round bottom flask, under a nitrogen atmosphere, a suspension of the compound from Step 2 (270 mg, 0.58 mmol), 50% ethyl glyoxalate in toluene ([924-44-7], 232 μL, 1.16 mmol), morpholine ([110-91-8], 101 μL, 1.16 mmol), and copper(I) bromide ([7787-70-4], 42 mg, 0.29 mmol) in dioxane (5 mL) was heated to 85° C. for 20 hours. The reaction mixture was cooled down to RT and 50% ethyl glyoxalate in toluene ([924-44-7], 232 μL, 1.16 mmol), morpholine ([110-91-8], 101 μL, 1.16 mmol), and copper(I) bromide ([7787-70-4], 42 mg, 0.29 mmol) were added again, and the sealed tube was heated at 100° C. for 1 hour. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was suspended in DCM (20 mL) and washed with water (15 mL). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate/n-heptane to yield the titled compound.

TABLE VII List of alkylidene pyruvates Int. Structure Name SM method MW Mes ALP01

(E)-4-(4- morpholino- phenyl)-2- oxo-but-3- enoic acid 1204-86-0 G1 261 262 ALP02

(E)-4-[4- (dimethylamino) phenyl]-2-oxo- but-3-enoic acid 100-10-7 G1 219 220 ALP03

(E)-4-[2- (dimethylamino) pyrimidin-5-yl]- 2-oxo-but-3- enoic acid 55551-49-0 G1 221 222 ALP04

(E)-4-[2- morpholino- pyrimidin-5-yl)- 2-oxo-but- 3-enoic acid 842974-69- 0 G1 263 264 ALP05

(E)-4-(6- morpholino-3- pyridyl)-2-oxo- but-3-enoic acid 173282-60- 5 G1 262 263 ALP06

(E)-4-(4- methoxyphenyl)- 2-oxo-but-3- enoic acid 123-11-5 G1 206 207 ALP07

(E)-4-(6-Chloro- pyridin-3-yl)-2- oxo-but-3-enoic acid 23100-12-1 G1 211- 213 212- 214 ALP08

ethyl (E)-4-[6- [2- methoxyethyl (methyl)amino]-3- pyridyl]-2-oxo- but-3-enoate ALD01 G2 291 292 ALP09

ethyl (E)-4-[6- (4-cyano-1- piperidyl)-3- pyridyl]-2-oxo- but-3-enoate ALD02 G2, Specific example 313 314 ALP10

ethyl (E)-4-[6- [methyl(tetra- hydropyran-4- yl)amino]-3- pyridyl]-2-oxo- but-3-enoate ALD03 G2 318 319 ALP11

ethyl (E)-4-[4- [2- methoxyethyl (methyl)amino] phenyl]-2-oxo-but- 3-enoate ALD04 G2 291 292 ALP12

ethyl (E)-4-[4- (4-cyano-1- piperidyl)phenyl]- 2-oxo-but-3- enoate ALD05 G2 312 313 ALP13

ethyl (E)-4-[2- [methyl(tetra- hydropyran-4- yl)amino] pyrimidin- 5-yl]-2-oxo- but-3-enoate ALD06 G2 319 320 ALP14

ethyl (E)-4-[2- (4-cyano-1- piperidyl) pyrimidin- 5-yl]-2-oxo- but-3-enoate ALD07 G2 314 315 ALP15

ethyl (E)-4-[4- [methyl(tetra- hydropyran-4- yl)amino]phenyl]- 2-oxo-but-3- enoate ALD08 G2 317 318 ALP16

ethyl (E)-4-[2- [2- methoxyethyl (methyl)amino] pyrimidin-5-yl]-2- oxo-but-3- enoate ALD09 G2 293 294 ALP17

ethyl (E)-4-(2,6- difluoro-4- methoxy- phenyl)-2-oxo- but-3-enoate 256417-10- 4 G2 270 271 ALP18

(E)-4-(4- Morpholin-4-yl- phenyl)-2-oxo- but-3-enoic acid ethyl ester ALD11, 1204-86-0 G2 289 290 ALP19

(E)-4-(4-Bromo- phenyl)-2-oxo- but-3-enoic acid 1122-91-4 G1, Specific example 254- 256 255- 257 ALP20

(E)-4-(6- Dimethylamino- pyridin-3-yl)-2- oxo-but-3-enoic acid ethyl ester ALD10 G2 248 249 ALP21

(E)-4-(6- Dimethylamino- pyridin-3-yl)-2- oxo-but-3-enoic acid ALD10 G1 220 221 ALP22

(E)-4-(2- Morpholin-4-yl- pyrimidin-5-yl)- 2-oxo-but-3- enoic acid ethyl ester 842974-69- 0 G2 291 292 ALP23

(E)-4-{6-[Bis- (2-methoxy- ethyl)-amino]- pyridin-3-yl}-2- oxo-but-3-enoic acid ethyl ester ALD12 G2 336 337 ALP24

(E)-4-(4- Acetylamino- phenyl)-2-oxo- but-3-enoic acid ethyl ester 122-85-0 G2 261 262 ALP25

(E)-4-(4- Dimethylamino- phenyl)-2-oxo- but-3-enoic acid ethyl ester 100-10-7 G2 247 248 ALP26

(E)-4-(6- Morpholin-4-yl- pyridin-3-yl)-2- oxo-but-3-enoic acid ethyl ester 173282-60- 5 G2 290 291 ALP36

ethyl 4-(4- formylphenyl)- 2-oxobut-3- enoate 63697-96-1 G3, Specific example 232 ALP38

4-Cyano-4-[4- ((E)-3- ethoxycarbonyl- 3-oxo- propenyl)- phenyl]- piperidine-1- carboxylic acid 847615-14- 9 Specific example 412 NA tert-butyl ester Methods H1-H3: Synthesis of Halogenated Pyrazolopyridine Method H1: Synthesis of Halogenated Pyrazolopyridine (Route 1)

Illustrative Synthesis of HP01: Ethyl 4-chloro-3-isopropyl-1-(m-tolyl)pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 6-Hydroxy-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid Ethyl Ester

5-Isopropyl-2-m-tolyl-2H-pyrazol-3-ylamine hydrochloride (AMP07, 14.97 g, 59.7 mmol) was dissolved in AcOH (100 mL). Diethyloxalacetate sodium salt (CAS: 40876-98-0, 15 g, 71.6 mmol, 1.2 equiv) was added, and the reaction mixture was refluxed overnight. The reaction mixture was cooled down to RT, poured into water (400 mL) and diluted with ethyl acetate. The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic layers were concentrated in vacuo, and the resulting residue was taken up twice with cyclohexane (2×200 mL) and concentrated in vacuo again. The residue was suspended in a mixture of ethanol/water (100 mL/20 mL), and the resulting precipitate was collected by filtration and washed with heptane. The solid was dried under vacuum to provide the titled compound.

Step 2: 3-Isopropyl-1-m-tolyl-6-trifluoromethanesulfonyloxy-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid Ethyl Ester

6-Hydroxy-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid ethyl ester (14.25 g, 42 mmol) was suspended in acetonitrile under nitrogen atmosphere. Pyridine (3.8 mL, 46.2 mmol, 1.1 equiv) was added. The reaction mixture was cooled to 0° C., and trifluoromethanesulfonic anhydride (CAS 358-23-6, 7.8 mL, 46.2 mmol, 1.1 equiv) was added dropwise over 20 min. The reaction mixture was then warmed up to RT over 20 min. Water was added (200 mL), and the suspension was filtered. The solid was washed successively with water and ethanol (40 mL) and then dried in vacuo to afford the titled compound.

Step 3: 6-Iodo-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid Ethyl Ester

3-Isopropyl-1-m-tolyl-6-trifluoromethanesulfonyloxy-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid ethyl ester (13.0 g, 27.6 mmol) was suspended in acetonitrile. Sodium iodide (20.7 g, 138 mmol, 5 equiv) was added. The reaction mixture was cooled to 0° C., trifluoromethanesulfonic acid (5.4 mL, 60.7 mmol, 2.2 equiv) was added dropwise. The reaction mixture was stirred at RT overnight. At this point, the reaction was not complete and additional trifluoromethanesulfonic acid (2 mL, 22.6 mmol, 0.8 equiv) was added and stirring was continued for 1 hour. Water was added to the reaction mixture, and the suspension was filtered. The solid was washed with ethanol (10 mL) and dried in vacuo to afford the titled compound.

Step 4: 6-Iodo-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid

6-Iodo-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid ethyl ester (8.73 g, 4.63 mmol) was suspended in ethanol (10 mL). An aqueous solution of 2 M sodium hydroxide (10 mL, 20 mmol, 4.3 equiv) was added, and the reaction mixture was stirred at 70° C. until complete conversion. Then the reaction mixture was cooled down to 0° C., and an aqueous solution of 2 M HCl was added until pH<2 was reached. The resulting suspension was filtered, and the solid was dried in vacuo to afford the titled compound.

Step 5: (6-Iodo-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic Acid Tert-butyl Ester

6-Iodo-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (8.12 g, 19.3 mmol) was suspended in toluene (43 mL). tert-Butanol (3.1 mL, 32.6 mmol, 2.0 equiv), triethylamine (4.54 mL, 32.6 mmol, 2.0 equiv) and diphenylphosphoryl azide (CAS 26386-88-9, 5 mL, 23.1 mmol, 1.2 equiv) were successively added. The reaction mixture was refluxed for 30 minutes. The reaction mixture was cooled down to RT and partitioned between ethyl acetate and water. The aqueous phase was further extracted with ethyl acetate. The combined organic phases were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was suspended in ethanol. The resulting precipitate was collected by filtration, washed with ethanol and dried under vacuum to provide the titled compound.

Step 6: (6-Cyano-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic Acid Tert-butyl Ester

(6-Iodo-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic acid tert-butyl ester (7.56 g, 15.4 mmol) was solubilized in dry dimethylformamide (20 mL) in a sealed vial. Zinc cyanide (CAS 557-21-1, 1.1 g, 9.2 mmol, 0.6 equiv) was added, and the reaction mixture was degassed with argon (bubbling) for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (CAS 14221-01-3, 0.9 g, 0.77 mmol, 0.05 equiv) was added, and the reaction mixture was degassed again with argon (bubbling) for 5 minutes. The vial was sealed, and the reaction mixture was stirred at 110° C. for 2 hour. The reaction mixture was cooled down to room temperature and diluted with water and ethyl acetate. The aqueous phase was further extracted with ethyl acetate. The combined organic phases were washed with brine, dried over Na₂SO₄, filtered and concentrated to a volume of 10 mL. Ethanol (10 mL) was added, and the suspension was stirred at 0° C. for 10 min. The resulting precipitate was collected by filtration, washed with ethanol and dried under vacuum to provide the titled compound.

Step 7: 4-Amino-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Hydrochloride Salt

(6-Cyano-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic acid tert-butyl ester (4.8 g, 12.26 mmol) was suspended in 6 M HCl (50 mL). The reaction mixture was refluxed for 24 h. The reaction mixture was cooled to 0° C., and the obtained suspension was filtered. The solid was washed with diisopropyl ether and dried in vacuo to yield the titled compound.

Step 8: 4-Amino-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

4-Amino-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid hydrochloride salt (4.23 g, 12.26 mmol) was solubilized in ethanol (150 mL). Thionyl chloride (CAS 7719-09-7, 1.34 mL, 18.39 mmol, 1.5 equiv) was carefully added. The reaction mixture was refluxed for 24 hours. The reaction mixture was cooled down to RT and concentrated in vacuo. The residue was taken up in ethanol (85 mL) and thionyl chloride (CAS 7719-09-7, 2.32 mL, 31.86 mmol, 2.6 equiv) was carefully added at RT. The mixture was refluxed for 6 hours. The reaction mixture was cooled down to RT and concentrated in vacuo. The crude mixture was diluted with ethyl acetate, basified with a saturated solution of sodium hydrogencarbonate. This mixture was filtered through a pad of Celpure® P65. Solids were washed with ethyl acetate. The two phases of the filtrate were separated, and the aqueous fraction was further extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 95/5 to 80/20) to afford the titled compound.

Step 9: 4-Chloro-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

Copper (II) chloride (CAS 7447-39-4, 1.045 g, 7.77 mmol, 1.0 equiv) was suspended in acetonitrile (33 mL). Isopentylnitrite (CAS 110-46-3, 1.57 mL, 11.65 mmol, 1.5 equiv) was added, and the reaction mixture was stirred at RT for 30 minutes. 4-Amino-3-isopropyl-1-m-tolyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid ethyl ester (2.63 g, 7.77 mmol, 1.0 equiv) was added. The reaction mixture was stirred at 75° C. for 2.5 h. The reaction mixture was cooled down to 0° C., and the resulting suspension was filtered. The solid was washed with cold acetonitrile and dried in vacuo to afford the titled compound. The filtrate was concentrated in vacuo and purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 98/2) to provide additional titled compound.

Method H1′: Alternative Conditions for Chlorination Route 1 Step 9

To the 4-amino intermediate (1 equiv) in acetonitrile at RT is added isopentylnitrite (CAS 110-46-3, from 3 to 6 eq) followed by copper(I) chloride (CAS 7758-89-6, from 3 to 6 equiv), and the reaction mixture is stirred at RT for 1 h to 24 h. The reaction mixture is diluted with dichloromethane and with a saturated solution of sodium hydrogencarbonate. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue is purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of HP03: Ethyl 4-chloro-1-[3-(dimethylamino)phenyl]-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To 4-amino-1-(3-dimethylamino-phenyl)-3-isopropyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid ethyl ester (1 g, 2.74 mmol, 1 equiv) in acetonitrile (10 mL) at RT was added isopentylnitrite (CAS 110-46-3, 1.1 mL, 8.21 mmol, 3 equiv) followed by copper(I) chloride (CAS 7758-89-6, 0.82 g, 8.21 mmol, 3 equiv), and the reaction mixture was stirred at RT for 1 h. The reaction mixture was diluted with dichloromethane and with a saturated solution of sodium hydrogencarbonate. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 90/10) to afford the titled compound.

Synthesis of HP13: Ethyl 4-chloro-3-methyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 6-Hydroxy-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid Ethyl Ester

5-Amino-3-methyl-1-phenylpyrazole (CAS: 1131-18-6, 6.83 g, 39.4 mmol) was dissolved in AcOH (70 mL). Diethyloxalacetate sodium salt (CAS: 40876-98-0, 9.12 g, 44.4 mmol, 1.1 equiv) was added, and the reaction mixture was refluxed until complete conversion. The reaction mixture was concentrated in vacuo, and the residue was taken up in cyclohexane (2×100 mL) and concentrated in vacuo again. The residue was suspended in a mixture of MeOH/water (150 mL/100 mL). The resulting precipitate was collected by filtration and washed with heptane. The solid was dried under vacuum to provide the titled compound.

Step 2: 6-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid Ethyl Ester

6-Hydroxy-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid ethyl ester (7.27 g, 24.5 mmol) was solubilized in anisole (30 mL). Phosphorous(V) oxybromide (CAS 7789-59-5, 8.23 g, 29.3 mmol, 1.2 equiv) was added, and the reaction mixture was refluxed at 140° C. for 1 h. The reaction mixture was cooled down to room temperature and basified with a saturated solution of sodium hydrogencarbonate. The reaction mixture was extracted twice with ethyl acetate, and the combined organic phases were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by filtration on a pad of silica gel (200 g), heptane/EtOAc 100/0 to 90/10) to give the titled compound.

Step 3: 6-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic Acid

6-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid ethyl ester (3.90 g, 10.8 mmol) was suspended in ethanol (20 mL). An aqueous solution of 1 M sodium hydroxide (20 mL, 20 mmol, 1.9 equiv) was added, and the reaction mixture was stirred at 70° C. for 30 min. The reaction mixture was then concentrated in vacuo. The residue was acidified with an aqueous solution of 2 M HCl and extracted with ethyl acetate. The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo to yield the titled compound.

Step 4: (6-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic Acid Tert-butyl Ester

6-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (3.50 g, 10.4 mmol) was suspended in toluene (35 mL). tert-Butanol (2 mL, 21.6 mmol, 2.1 equiv), triethylamine (4.4 mL, 31.2 mmol, 3.0 equiv) and diphenylphosphoryl azide (CAS 26386-88-9, 3.2 mL, 14.8 mmol, 1.4 equiv) were successively added. The reaction mixture was refluxed for 1.5 h. The reaction mixture was cooled down to RT and concentrated in vacuo, then partitioned between ethyl acetate and water. The aqueous phase was further extracted with ethyl acetate. The combined organic phases were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by filtration on a pad of silica gel (200 g, heptane/EtOAc 100/0 to 90/10) to give the titled compound.

Step 5: (6-Cyano-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic Acid Tert-butyl Ester

(6-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic acid tert-butyl ester (4.16 g, 10.3 mmol) was solubilized in dry dimethylformamide (20 mL) in a sealed vial. Zinc cyanide (CAS 557-21-1, 0.727 g, 6.2 mmol, 0.6 equiv) was added, and the reaction mixture was degassed with argon for 5 minutes. Tetrakis(triphenylphosphine) palladium(0) (CAS 14221-01-3, 0.595 g, 0.5 mmol, 0.05 equiv) was added, and the vial was sealed. The reaction mixture was stirred at 100° C. for 1 hour. The reaction was not complete. Additional tetrakis(triphenylphosphine)palladium(0) (CAS 14221-01-3, 0.595 g, 0.5 mmol, 0.05 equiv) and zinc cyanide (CAS 14221-01-3, 0.485 g, 4.1 mmol, 0.4 equiv) were added at RT, and the vial was sealed again. The reaction mixture was stirred at 100° C. for one hour and cooled down to room temperature. Water was added to the reaction mixture and precipitation occurred. The suspension was filtered, and the cake was washed with water. The solid residue was taken up with dichloromethane and with an aqueous solution of 0.5 M NaOH. The organic phase was separated, dried over Na₂SO₄, filtered and concentrated. The residue was purified by filtration on a pad of silica gel (150 g, heptane/EtOAc 100/0 to 60/40) to give the titled compound mixed with (6-cyano-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbonitrile. The mixture was engaged in the next step without further purification.

Step 6: 4-Amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Hydrochloride Salt

A mixture of (6-cyano-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbamic acid tert-butyl ester and (6-cyano-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-carbonitrile (3.5 g) was suspended in 6 M HCl (50 mL). The reaction mixture was refluxed for 18 h. The reaction mixture was cooled to 0° C. and the obtained suspension was filtered. The solid was washed with an aqueous solution of 0.1 M HCl. The filtrate was concentrated in vacuo and precipitation occurred. The solid was also collected by filtration. The combined solids were dried in vacuo to yield the titled compound.

Step 7: 4-Amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

4-Amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid hydrochloride salt (2.03 g, 7.6 mmol) was solubilized in ethanol (40 mL). Thionyl chloride (CAS 7719-09-7, 1.16 mL, 15.9 mmol, 2.1 equiv) was carefully added. The reaction mixture was refluxed for 24 hours. The reaction mixture was concentrated in vacuo and partitioned between ethyl acetate and aqueous saturated NaHCO₃. The aqueous phase was further extracted with ethyl acetate. The combined organic phases were dried over Na₂SO₄, filtered and concentrated in vacuo to give the titled compound.

Step 8: 4-Chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

Copper (II) chloride (CAS 7447-39-4, 0.908 g, 6.75 mmol, 1.0 equiv) was added to acetonitrile (50 mL). Isopentylnitrite (CAS 110-46-3, 1.4 mL, 10.1 mmol, 1.5 equiv) was added, and the reaction mixture was stirred at 75° C. for 5 minutes. 4-Amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid ethyl ester (2.0 g, 6.75 mmol, 1.0 equiv) dissolved in acetonitrile (50 mL) was added. The reaction mixture was stirred at 75° C. for 2.5 h. The reaction mixture was cooled down and concentrated in vacuo. Water was added to the residue, and the mixture was extracted with ethyl acetate. Copper salts prevented clean extraction. The suspension was filtered through diatomaceous earth. The organic phase was dried over Na₂SO₄, filtered and concentrated. The residue was suspended in ethanol (10 mL) and filtered. The solid was dried in vacuo to give the titled compound. The copper salts on the diatomaceous earth were washed with dichloromethane. The filtrate was concentrated to provide additional titled compound.

Method H2: Synthesis of Halogenated Pyrazolopyridine (Route 2)

Illustrative Synthesis of HP02: Methyl 4-chloro-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-4,6-diol

To a mixture of 3-cyclobutyl-1-phenyl-1H-pyrazol-5-amine (AMP29, 74.0 g, 347 mmol) in oxydibenzene (450.0 g, 2.64 mol) was added diethyl malonate (CAS 105-53-3, 139.0 g, 867 mmol). The system was heated at 130-150° C. for 40 h. By this time solid had precipitated and heating was stopped. Two more reactions were set up as described above. All three reaction mixtures were combined. The combined mixture was cooled to below 40° C. and diluted with about 1.8 L of diethyl ether, and the resulting suspension was stirred for 2 h and then filtered. The collected solids were rinsed with diethyl ether (1 L). The solids were dried on the filter to give the titled compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.28 (s, 1H), 8.18 (d, J=7.9 Hz, 2H), 7.58-7.39 (m, 2H), 7.21 (t, J=7.1 Hz, 1H), 5.85 (s, 1H), 3.88 (quin, J=8.4 Hz, 1H), 2.44-2.22 (m, 4H), 2.07-1.78 (m, 2H).

Step 2: 4,6-dichloro-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine

A mixture of 3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-4,6-diol (60.0 g, 213 mmol) in phenyl dichlorophosphate (CAS 770-12-7,135 g, 640 mmol) was stirred at 170° C. for 15 h. Two more reactions were set up as described above. All three reaction mixtures were combined and poured into ice water (5 L) keeping the internal temperature <10° C. The mixture was neutralized with concentrated NH₄OH (500 mL) to pH 6-7, then the suspension was stirred for 2 h. As the pH increased and with continued stirring, the semi-solid suspension becomes a flowing solid. The solid was collected by filtration. The wet solid was dissolved in dichloromethane (3 L) and filtered through a short path of silica gel (2 kg), eluting with dichloromethane (15 L). The filtrate was concentrated to a solid which was triturated with acetonitrile (1.5 L) and and collected by filtration to give the titled compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.20 (d, J=7.9 Hz, 2H), 7.51 (t, J=7.5 Hz, 2H), 7.35-7.27 (m, 1H), 7.16 (s, 1H), 4.15 (quin, J=8.4 Hz, 1H), 2.63-2.41 (m, 4H), 2.20-2.07 (m, 1H), 2.00 (s, 1H).

Step 3: Methyl 4-chloro-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To a mixture of 4,6-dichloro-3-cyclobutyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (50.0 g, 157 mmol) in methanol (700 mL) was added triethylamine (31.8 g, 314 mmol) and Pd(dppf)Cl₂.DCM (CAS 95464-05-4, 6.4 g, 7.86 mmol). The system was heated at 60° C. under CO (30 psi) for 40 h. Two more reactions were set up as described above. All three reaction mixtures were combined and concentrated to give a semisolid which was dissolved in dichloromethane (3 L) and filtered through a 2 kg plug of silica gel. After concentration, about 130 g of solid was obtained. This solid was taken up in 1.3 L of ethyl acetate with heating. This solution was stirred at room temperature. Solids came out over a couple of minutes, and then 1.3 L of hexane was added in a thin stream via addition funnel with stirring for 2 hours. The solids were collected by filtration to give the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.38-8.27 (m, 2H), 7.95 (s, 1H), 7.53 (t, J=7.9 Hz, 2H), 7.35-7.27 (m, 1H), 4.21 (q, J=8.6 Hz, 1H), 4.08-4.03 (m, 1H), 2.66-2.40 (m, 4H), 2.22-1.93 (m, 2H).

Illustrative Synthesis of HP19: Methyl 4-chloro-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 3-Cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-4,6-diol

A mixture of 3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazol-5-amine (AMP93, 5 g, 18.6 mmol) and diethyl malonate ([105-53-3], 8.5 mL, 55.8 mmol) was heated at 100° C. for 30 minutes and then at 170° C. for 3 hours. The reaction mixture was cooled down to RT and dissolved in dichloromethane (60 mL). The resultant solution was poured into a stirred solution of n-heptane (700 mL). The precipitate was collected by filtration, washed with n-heptane and dried at 40° C. under reduced pressure to give the titled compound.

Step 2: 4,6-Dichloro-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine

A three-neck round-bottom flask equipped with a Dean-Stark apparatus was charged with phenyl dichlorophosphate ([770-12-7], 854 g, 4.05 mol). 3-Cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-4,6-diol (404 g, 1.35 mol) was added in portions over a period of 5 minutes. The temperature was increased to 170° C. over a period of 1 hour, and the stirring at 170° C. was continued for 21 hours. The reaction mixture was cooled down to 50° C. and added slowly to a stirred aqueous 4 N NaOH (5 L) keeping the temperature below 20° C. The suspension was stirred for 1 hour at 10-15° C., and then cold water (3 L) was added. The precipitate was collected by filtration, washed with water and dried at 40° C. under reduced pressure to give the titled compound.

Step 3: Methyl 4-chloro-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A pressured vessel was charged with 4,6-dichloro-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine (5 g, 14.9 mmol), Pd(dppf)Cl₂.DCM (CAS 95464-05-4, 218 mg, 0.3 mmol), and sodium acetate (1.8 g, 22.3 mmol) in dioxane/methanol (1:1, 25 mL). The system was loaded with CO (4 bars) and heated at 40° C. for 2 hours. The vessel was cooled to RT, and the conversion was monitored by LCMS. The reaction vessel was charged again with CO (4 bars) and heated at 40° C. The sequence was repeated until full conversion was observed. The crude mixture was concentrated under reduced pressure and purified by flash column chromatography eluting with a mixture of n-heptane/dichloromethane (90/10 to 30/70) to give the titled compound.

Illustrative Synthesis of HP25: Methyl 4-chloro-3-cyclobutyl-1-cyclohexyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 3-cyclobutyl-1-cyclohexyl-4-hydroxy-3aH-pyrazolo[3,4-b]pyridin-6-one

A mixture of 5-cyclobutyl-2-cyclohexyl-2H-pyrazol-3-ylamine (AMP35, 10 g, 45.7 mmol) and diethyl malonate ([105-53-3], 27.7 mL, 183 mmol) in diphenylether (50 mL) was heated at 130° C. over approximately 60 hours. The reaction mixture was cooled down to RT and quenched with 0.5 M NaOH solution (100 mL, 50 mmol). Extraction with EtOAc gave an aqueous phase that was acidified with a 12 M HCl solution (4.3 mL, 51.6 mmol) giving rise to a suspension. This suspension was extracted with EtOAc. The obtained organic layer was dried and concentrated to give the titled compound that was used as such.

Step 2: 4,6-dichloro-3-cyclobutyl-1-cyclohexyl-pyrazolo[3,4-b]pyridine

The 3-cyclobutyl-1-cyclohexyl-4-hydroxy-3 aH-pyrazolo[3,4-b]pyridin-6-one (5.15 g, 17.9 mmol) was suspended in phenyl dichlorophosphate ([770-12-7], 8.01 mL, 53.8 mmol). The mixture was heated at 130° C. overnight. Next, the mixture was diluted in DCM and poured into ice water. After increasing the pH till 7-8 with a 20% NH₄OH solution, the biphasic mixture was stirred for 30 minutes. Subsequently, the organic phase was separated, dried and concentrated to give a residue. This residue was purified by chromatography using a petroleum ether/EtOAc gradient (100/0 to 90/10). This resulted in the titled compound that was used as such.

Step 3: Methyl 4-chloro-3-cyclobutyl-1-cyclohexyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

In a Parr apparatus, 4,6-dichloro-3-cyclobutyl-1-cyclohexyl-pyrazolo[3,4-b]pyridine (2.17 g, 6.72 mmol) was dissolved in MeOH (50 mL) together with Pd(dppf)Cl₂.DCM (CAS 95464-05-4, 275 mg, 0.33 mmol) and triethylamine (1.87 mL, 13.4 mmol). The system was loaded with CO (5 bar) and heated at 45° C. for 18 hours. After cooling down the mixture till RT, the mixture was concentrated, and the obtained residue was purified by chromatography using a petroleum ether/EtOAc gradient (100/0 till 95/5). This yielded the titled compound.

Method H3: Synthesis of Halogenated or Sulfonylated Pyrazolopyridine (Route 3)

Step 1: Diethyl But-2-Enedioate

To a suspension of aminopyrazole (1 equiv) in ethanol (150 mL) is added diethyl acetylenedicarboxylate (1.1 equiv). The reaction mixture is stirred at room temperature for 4 hours. The reaction mixture is concentrated. The crude residue is purified by silica gel column chromatography (heptane/EtOAc 100/0 to 70/30) to give the titled compound.

Step 2: Pyrazolopyridine Formation

The diethyl but-2-enedioate is heated under air atmosphere at 190-195° C. for one hour. The reaction mixture is cooled to room temperature and is partitioned between dichloromethane and water. The aqueous phase is separated and extracted two times with dichloromethane. The combined organic phases were dried, filtered and concentrated in vacuo. The crude residue can be purified by silica gel column chromatography to provide the pyrazolopyridine.

Step 3: Chlorination

A solution of the above pyrazolopyridine (1 equiv) in phosphorus(V) oxychloride (32 equiv) was stirred at 115° C. for 1 h. The reaction mixture is then cooled to room temperature and concentrated in vacuo. The residue is dissolved in ethyl acetate, and the reaction mixture is added dropwise to a solution of saturated of sodium hydrogencarbonate till total neutralization of phosphorus(V) oxychloride (pH 8). The aqueous phase is separated and extracted two times with ethyl acetate. The combined organic phases are washed with brine, dried, filtered and concentrated in vacuo. The crude residue can be purified by silica gel column chromatography to provide the chlorinated pyrazolopyridine from which the dimethoxybenzyl group has also been removed.

Illustrative Synthesis of HP08: 4-Chloro-3-isopropyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

Step 1: 2-[2-(2,4-Dimethoxy-benzyl)-5-isopropyl-2H-pyrazol-3-ylamino]-but-2-enedioic Acid Diethyl Ester

To a suspension of 2-(2,4-dimethoxy-benzyl)-5-isopropyl-2H-pyrazol-3-ylamine (AMP28, 18.14 g, 65.88 mmol) in ethanol (150 mL) was added diethyl acetylenedicarboxylate (CAS: 762-21-0, 11.60 mL, 72.47 mmol). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated. The crude residue was purified by silica gel column chromatography (heptane/EtOAc 100/0 to 70/30) to give the titled compound.

Step 2: Compound HP06: 1-(2,4-Dimethoxy-benzyl)-4-hydroxy-3-isopropyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

2-[2-(2,4-Dimethoxy-benzyl)-5-isopropyl-2H-pyrazol-3-ylamino]-but-2-enedioic acid diethyl ester (13.46 g, 30.21 mmol) was heated under air atmosphere at 190-195° C. for one hour. The reaction mixture cooled to room temperature and was partitioned between dichloromethane and water. The aqueous phase was separated and extracted two times with dichloromethane. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (heptane/EtOAc 100/0 to 60/40) to provide the titled compound.

Step 3: Compound HP08: 4-Chloro-3-isopropyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

A solution of 1-(2,4-dimethoxy-benzyl)-4-hydroxy-3-isopropyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid ethyl ester (HP06, 4.02 g, 10.06 mmol) in phosphorus(V) oxychloride (CAS 100025-87-3, 30 mL, 322 mmol) was stirred at 115° C. for 1 h. The reaction mixture was then cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate, and the reaction mixture was added dropwise to a solution of saturated of sodium hydrogencarbonate till total neutralization of phosphorus(V) oxychloride (pH 8). The aqueous phase was separated and extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (heptane/EtOAc 100/0 to 75/25) to provide the titled compound.

Illustrative Synthesis of HP20: Ethyl 1-tert-butyl-3-cyclobutyl-4-[(trifluoromethanesulfonyl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: Diethyl 2-[(1-tert-butyl-3-cyclobutyl-1H-pyrazol-5-yl)amino]but-2-enedioate

In an amber round bottom flask, diethyl acetylenedicarboxylate ([762-21-0], 14.8 mL, 87 mmol) was added to a suspension of AMP94 (15.2 g, 78.8 mmol) in ethanol (200 mL). The reaction mixture was stirred at room temperature for 20 hours, and the mixture was concentrated in vacuo. The crude residue was purified by silica gel column chromatography (heptane/dichloromethane 100/0 to 0/100) to give the titled compound.

Step 2: Ethyl 1-tert-butyl-3-cyclobutyl-4-hydroxy-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

In a sealed tube, a suspension of diethyl 2-[(1-tert-butyl-3-cyclobutyl-1H-pyrazol-5-yl)amino]but-2-enedioate (5 g, 13.8 mmol) in Dowtherm® A (5 mL) was heated at 185-190° C. for 24 hours. The reaction mixture was cooled to room temperature and was partitioned between n-heptane and acetonitrile. The acetonitrile phase was separated and evaporated under reduced pressure. The crude sample was purified by silica gel column chromatography (dichloromethane/n-heptane) to give the titled compound.

Step 3: Ethyl 1-tert-butyl-3-cyclobutyl-4-[(trifluoromethanesulfonyl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Trifluoromethanesulfonic anhydride ([358-23-6], 1.9 mL, 11.3 mmol) was added dropwise to a solution of ethyl 1-tert-butyl-3-cyclobutyl-4-hydroxy-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (2.5 g, 7.89 mmol) and pyridine (1.9 mL, 23.5 mmol) in acetonitrile (80 mL), maintaining the temperature around 20-25° C. The reaction mixture was stirred at RT for 20 hours. Then solid sodium hydrogencarbonate and few milliliters of water were added, and the reaction mixture was concentrated in vacuo. The residue was taken up in dichloromethane and water. The two phases were separated, and the aqueous phase was again extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (n-heptane/ethyl acetate) to yield the titled compound.

Synthesis of HP12: Methyl 4-chloro-1-cyclohexyl-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 1-cyclohexyl-3-isopropyl-pyrazolo[3,4-b]pyridine-4,6-diol

A mixture of AMP23 (5.0 g, 24.1 mmol) and diethylmalonate (CAS 105-53, 37.36 mL, 48.2 mmol, 2.0 equiv) was stirred at 190° C. for 2 hours. The reaction mixture was then cooled to RT, and diethyl ether was added. The obtained suspension was filtered; the solid was washed with pentane, and dried in vacuo to give the titled compound.

Step 2: [1-cyclohexyl-3-isopropyl-6-(trifuoromethylsulfonyloxy)pyrazolo[3,4-b]pyridin-4-yl]trifluoromethanesulfonate

Trifluoromethanesulfonic anhydride (CAS 358-23-6, 6.26 mL, 37.2 mmol, 1.75 equiv) was added dropwise at 0° C. to a solution of 1-cyclohexyl-3-isopropyl-pyrazolo[3,4-b]pyridine-4,6-diol (5.85 g, 21.2 mmol) and pyridine (4.3 mL, 53.1 mmol, 2.5 equiv) in acetonitrile (145 mL). The reaction mixture was stirred at RT for 16 hours. Dichloromethane and water were added to the reaction mixture. The two phases were separated, and the organic phase was washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was taken up in toluene and concentrated again in vacuo to give the titled compound.

Step 3: 4,6-dichloro-1-cyclohexyl-3-isopropyl-pyrazolo[3,4-b]pyridine

A mixture of [1-cyclohexyl-3-isopropyl-6-(trifluoromethylsulfonyloxy)pyrazolo[3,4-b]pyridin-4-yl]trifluoromethanesulfonate (10.86 g, 20.1 mmol) and 4 N HCl in dioxane (50 mL, 200 mmol, 10 equiv) was stirred at 100° C. for 16 hours in a sealed tube. The reaction mixture was cooled to RT and concentrated in vacuo. The residue was purified by chromatography on silica gel (heptane/dichloromethane 100/0 to 80/20) to yield the titled compound.

Step 4: HP12: Methyl 4-chloro-1-cyclohexyl-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Triethylamine (1.9 mL, 13.6 mmol, 2.0 equiv) and Pd(dppf)Cl₂ (CAS: 72287-26-4, 100 mg, 0.14 mmol, 0.02 equiv) were added to a solution of 4,6-dichloro-1-cyclohexyl-3-isopropyl-pyrazolo[3,4-b]pyridine (2.13 g, 6.82 mmol) in methanol (55 mL). The system was filled at RT with CO (40 psi) and heated at 100° C. for 1 hour. The reaction mixture was cooled down to RT and concentrated in vacuo. The residue was purified by chromatography on silica gel (heptane/ethyl acetate 100/0 to 90/10) to yield the titled compound.

Synthesis of HP14: Ethyl 3-cyclobutyl-1-[(2,4-dimethoxyphenyl)methyl]-4-(trifluoromethylsulfonyloxy)pyrazolo[3,4-b]pyridine-6-carboxylate

Trifluoromethanesulfonic anhydride (CAS 358-23-6, 92 HL, 0.56 mmol, 1.45 equiv) was added dropwise at RT to a solution of HP15 (160 mg, 0.39 mmol, 1 equiv) and pyridine (46 μL, 0.58 mmol, 1.5 equiv) in acetonitrile (4 mL). The reaction mixture was stirred at RT for 3 h. Then solid sodium hydrogencarbonate and few milliliters of water were added, and the reaction mixture was concentrated in vacuo. The residue was taken up in dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/dichloromethane gradient from 100/0 to 0/100) to yield the titled compound.

TABLE VIII List of halogenated pyrazolopyridine Int. Structure Name SM method MW Mes HP01

ethyl 4-chloro- 3-isopropyl-1- (m- tolyl)pyrazolo [3,4-b]pyridine- 6-carboxylate AMP07 H1 Specific example 357- 359 358- 360 HP02

methyl 4- chloro-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate AMP29 H2 Specific example 341- 343 342- 344 HP03

ethyl 4-chloro- 1-[3- (dimethylamino) phenyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate AMP06 H1(steps 1 to 8) and H1′ (step 9) Specific example 386- 388 387- 389 HP04

ethyl 4-chloro- 1-cyclohexyl- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate AMP23 H1(steps 1 to 8) and H1′ (step 9) 349- 351 350- 352 HP05

methyl 4- chloro-1-(4- fluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate AMP13 H2 347- 349 348- 350 HP06

ethyl 1-[(2,4- dimethoxyphenyl) methyl]-4- hydroxy-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate AMP28 H3 (steps 1 & 2 only) 399 400 HP07

4-chloro-1-[3- (dimethylamino) phenyl]-3- isopropyl- pyrazolo[3,4- 6]pyridine-6- carboxylic acid HP03 J1 358- 360 359- 361 HP08

ethyl 4-chloro- 3-isopropyl- 1H- pyrazolo[3,4- £]pyridine-6- carboxylate AMP28 H3 Specific example 267- 269 268 270 HP09

ethyl 4-chloro- 1-(4- fluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP08, 1765- 93-1 I4 361- 363 362- 364 HP10

4-chloro-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP02 J1 327- 329 328- 330 HP11

4-chloro-1-(4- fluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP05 J1 333- 335 334- 336 HP12

methyl 4- chloro-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate AMP23 Specific example 335- 337 336- 338 HP13

ethyl 4-chloro- 3-methyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate 1131- 18-6 Specific example 315- 317 316- 318 HP14

ethyl 3- cyclobutyl-1- [(2,4- dimethoxyphenyl) methyl]-4- (trifluoromethyl- sulfonyloxy) pyrazolo[3,4- b]pyridine-6- carboxylate HP15 Specific example 543 544 HP15

ethyl 3- cyclobutyl-1- [(2,4- dimethoxyphenyl) methyl]-4- hydroxy- pyrazolo[3,4- b]pyridine-6- carboxylate AMP36 H3 (steps 1 & 2 only)¹ 411 412 HP16

4-chloro-3- isopropyl-1- (m- tolyl)pyrazolo [3,4-6]pyridine- 6-carboxylic acid HP01 J1 329- 331 330- 332 HP19

methyl 4- chloro-3- cyclobutyl-1- (4- fluorophenyl)- 1H- pyrazolo[3,4- b]pyridine-6- carboxylate AMP93 Specific example 359- 361 360- 362 HP20

ethyl 1-tert- butyl-3- cyclobutyl-4- [(trifluoro- methanesulfonyl) oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate AMP94 Specific example 449 450 HP25

methyl 4- chloro-3- cyclobutyl-1- cyclohexyl- 1H- pyrazolo[3,4- b]pyridine-6- carboxylate AMP35 Specific example 347 348 HP26

4-chloro-3- cyclobutyl-1- (4- fluorophenyl)- 1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid AMP19 J1 345 346 ¹Step 2 performed in Dowtherm ™ at 160° C. for 48 h. Method I1-I34: Synthesis of Esters Method I1: Cyclization of Alkylidene Pyruvates and Aminopyrazoles

A is either N or CH A′ is either R^(e) or L¹-G^(3C) as described in the Summary

The alkylidene pyruvate (1 to 1.5 equiv) and the aminopyrazole (1 to 1.5 equiv) in acetic acid or DMF are stirred under air at temperatures ranging from RT to reflux for 1 h to several days. Alternatively, the reaction mixture is heated under microwave irradiation at 150° C. for 20 minutes to 2 h followed either by stirring under air in an opened flask at temperatures ranging from RT to 90° C. for 1 h to several days or by removal of the solvent in vacuo, dilution of the residue in ethanol and stirring at reflux for 1 h to several days. Then volatiles are removed in vacuo to afford the titled compound which is used as such or alternatively worked up by dilution with an organic solvent, washed successively with a basic aqueous solution and brine, dried over sodium sulfate, filtered and concentrated in vacuo and used as such or further purified either by precipitation, by preparative HPLC or by flash chromatography on silica gel.

Alternatively, the alkylidene pyruvate (1 equiv) and the aminopyrazole (1 equiv) in N-methylpyrrolidone can be heated at 80 to 100° C. over 8 to 24 hours. Next, the reaction mixture is cooled down to room temperature and a base such as Cs₂CO₃ (2-6 equiv) is added. The resulting mixture is stirred open to the air until full oxidation is observed.

Illustrative Synthesis of E018: 4-(4-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-3-cyclobutyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid Ethyl Ester

The alkylidene pyruvate ALP09 (47.1 g, 150.5 mmol) and the aminopyrazole AMP29 (30 g, 140.7 mmol) were dissolved in acetic acid (240 mL) in an opened round bottom flask equipped with a condenser. The solution was heated at 80° C. for 40 hours and then left cooling down to RT. The mixture was concentrated under reduced pressure, and the crude residue was diluted with DCM (400 mL). The organic phase was washed successively with a saturated aqueous solution of Na₂CO₃ and a saturated aqueous solution of NaCl, dried over sodium sulfate, filtered and concentrated in vacuo. The crude sample was purified by flash column chromatography eluting with dichloromethane/ethyl acetate. The solid was stirred for 10 minutes in methanol, filtered and dried at 40° C. under reduced pressure to give the titled compound.

Illustrative Synthesis of E425: Ethyl 1-cyclohexyl-4-(4-formylphenyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A solution of ALP36 (116 mg, 0.5 mmol) and AMP95 (112 mg, 0.5 mmol) in N-methylpyrrolidine (2 mL) was heated at 100° C. for 20 hours in a sealed tube. The volatiles were removed in vacuo, and the residue was purified by flash chromatography on silica gel eluted with ethyl acetate/n-heptane (0/1 to 1/0) to give the titled compound.

Illustrative Synthesis of E503: Methyl 4-(4-bromophenyl)-1-cyclohexyl-3-hydroxy-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

5-Amino-1-cyclohexyl-1H-pyrazol-3-ol ([436088-86-7], 5.54 g, 30.5 mmol,) and (E)-methyl-4-(4-bromophenyl)-2-oxobut-3-enoate ([608128-34-3], 8.22 g, 30.5 mmol,) in NMP (60 mL,) were heated overnight at 90° C. Next, the reaction mixture was cooled down to room temperature and Cs₂CO₃ (30 g, 91.6 mmol) was added. The resulting mixture was stirred open to the air until full oxidation to the titled compound was observed. The obtained solution was used as such for alkylation.

Method I2: Suzuki Coupling

Illustrative Synthesis of E197 and E198: Methyl 4-(1-tert-butoxycarbonyl-4-piperidyl)-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate and Methyl 4-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: Methyl 4-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate E198

A suspension of methyl 4-chloro-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate (HP05, 2.0 g, 5.75 mmol, 1.0 equiv), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (CAS 286961-14-6, 3.6 g, 11.5 mmol, 2.0 equiv), K₂CO₃ (2.4 g, 17.25 mmol, 3.0 equiv) and Pd(dppf)Cl₂ (CAS: 72287-26-4, 939 mg, 1.15 mmol, 0.2 equiv) in anhydrous DMF (15 mL) was degassed with nitrogen at room temperature for 2 minutes. The reaction mixture was heated at reflux overnight. The mixture was cooled to RT, and the mixture was poured into 150 mL of water and diluted with ethyl acetate. The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated. The crude residue was purified by silica gel chromatography (heptane/ethyl acetate: 100/0 to 80/20) to give E198.

Step 2: Methyl 4-(1-tert-butoxycarbonyl-4-piperidyl)-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of E198 (2.44 g, 4.93 mmol, 1.0 equiv) and platinum(IV) oxide (CAS 1314-15-4, 1.2 g) in AcOH was stirred at RT under hydrogen atmosphere (balloon) overnight. Then the reaction mixture was filtered over Celpure® P65. Solids were washed with ethyl acetate, and the filtrate was concentrated in vacuo. The crude residue was purified by silica gel chromatography (heptane/ethyl acetate: 100/0 to 80/20) to give the title compound.

Method I3: Nucleophilic Substitutions of Amines

A mixture of the chloride or triflate pyrazolopyridine intermediate (1.0 equiv), the amine as free base or hydrochloride salt (from 1 to 10 equiv) and DIPEA (from 1 to 15 equiv) in anhydrous acetonitrile and DMSO in a sealed tube or a round bottom flask is heated at a temperature ranging from 50 to 130° C. for 1 h to several days (up to 8 days). The reaction mixture is cooled to RT, and volatiles are removed in vacuo. The resulting residue is either purified by precipitation or by flash chromatography on silica gel to afford the titled compound or alternatively partitioned between either dichloromethane or ethyl acetate and water. The two phases are then separated, and the aqueous phase is extracted with either ethyl acetate or dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo and the resulting crude mixture is either used as such or purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of E092: Methyl 1-(4-fluorophenyl)-3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylate

A mixture of HP05 (6.71 g, 19.29 mmol, 1.0 equiv), 4-(methoxymethyl)piperidine hydrochloride (CAS 916317-00-5, 6.39 g, 38.58 mmol, 2 equiv) and DIPEA (10.1 mL, 57.88 mmol, 3 equiv) in anhydrous DMSO (65 mL) was heated at 100° C. for 20 h. The reaction mixture was cooled to RT, partitioned between ethyl acetate (300 mL) and a mixture of water and a saturated solution of NaCl 1:1 (300 mL). The two phases were separated, and the aqueous phase was extracted with ethyl acetate (150 mL). The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel eluting with n-heptane/ethyl acetate to afford the titled compound.

Illustrative Synthesis of E356: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(4-methoxy-1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of HP19 (8.11 gram, 22.6 mmol) in dry N-methylpyrrolidinone (100 mL) was added 4-methoxy-1,4′-bipiperidine (5.37 gram, 27.1 mmol, AMI10) and diisopropylethylamine (9.42 mL, 54.2 mmol). The reaction mixture was stirred at 100° C. for 24 hours and then cooled down to ambient temperature and diluted with water. A suspension formed upon cooling at 0° C. The suspension was filtered, and the obtained precipitate was washed with water. After drying, the titled compound was obtained.

Illustrative Synthesis of E357: Methyl 3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Methyl 4-chloro-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate (15 g, 43.9 mmol, HP02) and 4-(pyrrolidin-1-ylmethyl)piperidine (13.29 g, 79 mmol) were dissolved in a mixture of N-ethyl-N-isopropylpropan-2-amine (45.9 mL, 263 mmol) and N-methylpyrrolidinone (90 mL). The resulting solution was heated at 100° C. under nitrogen for two hours. After diluting with water (200 mL), the mixture was extracted with tert-butyl methyl ether (3×150 mL). The combined organic fractions were washed with 1 M aqueous NaOH (2×100 mL), water (2×50 mL), and saturated aqueous sodium chloride, then dried over sodium sulfate and concentrated under vacuum to approximately 100 mL followed by the addition of heptanes (200 mL). Volatiles were removed under vacuum, and the resulting thick slurry was stirred overnight at room temperature. The solid was collected by filtration, and then dried to constant weight under vacuum to give 18.39 g of the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.39-8.31 (m, 2H), 7.51 (dd, J=8.6, 7.4 Hz, 2H), 7.40 (s, 1H), 7.31-7.23 (m, 1H), 4.00 (m, 4H), 3.70-3.57 (m, 2H), 2.89 (td, J=12.2, 2.4 Hz, 2H), 2.63 (dq, J=11.7, 9.2 Hz, 2H), 2.56-2.49 (m, 4H), 2.47-2.38 (m, 4H), 2.05 (m, 4H), 1.86-1.78 (m, 4H), 1.73 (m, 1H), 1.53 (qd, J=12.1, 3.7 Hz, 2H); LC/MS (APCI) m/z 474.6 (M+H)⁺.

Method I4: Chan-Lam Coupling

To a solution of ethyl 1H-pyrazolo[3,4-b]pyridine-6-carboxylate intermediate (1.0 equiv) in dichloromethane at RT is added the aryl boronic acid (2.0 to 3.0 equiv), copper(II) acetate (CAS 142-71-2, 1.5 equiv) and pyridine (4.0 equiv). The reaction mixture is stirred at room temperature under air for 1 h to 48 h. Then the reaction mixture is filtered on a pad of diatomaceous earth. Solids are washed with dichloromethane, and the filtrate is concentrated in vacuo. The resulting residue is purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of E111: Ethyl 1-(2-fluoro-4-pyridyl)-3-isopropyl-4-(4-methoxy-1-piperidyl)pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of ethyl 3-isopropyl-4-(4-methoxy-1-piperidyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate E109 (70 mg, 0.20 mmol, 1.0 equiv) in dichloromethane (2 mL) at RT was added (2-fluoropyridin-4-yl)boronic acid (CAS: 401815-98-3, 56 mg, 0.40 mmol, 2.0 equiv), copper(II) acetate (CAS 142-71-2, 54 mg, 0.30 mmol, 1.5 equiv) and pyridine (64 μL, 0.80 mmol, 4.0 equiv). The reaction mixture was stirred at room temperature under air overnight. The reaction mixture was filtered on a pad of diatomaceous earth. Solids were washed with dichloromethane, and the filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate: 100/0 to 70/30) to give the titled compound.

Method I5: Nucleophilic Substitution

R² is isopropyl or cyclobutyl A is CH or N LG¹ and LG² are independently F, Cl or Br

To a solution of ethyl 3-substituted-1H-pyrazolo[3,4-b]pyridine-6-carboxylate intermediate (1.0 equiv) in anhydrous DMF or THF under nitrogen atmosphere at 0° C. is added sodium hydride (60% in mineral oil, from 1.2 equiv to 1.5 equiv), and the mixture is stirred 5 minutes at 0° C. Then an aromatic halide (2.0 equiv) is added, and the reaction mixture is warmed up to RT and stirred overnight. The reaction mixture is partitioned between water and ethyl acetate and acidified to pH 5 with AcOH. The two phases are separated. The organic phase is washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or purified by flash chromatography on silica gel.

Illustrative Synthesis of E133: Ethyl 1-(6-bromo-2-pyridyl)-3-isopropyl-4-(4-methoxy-1-piperidyl)pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of ethyl 3-isopropyl-4-(4-methoxy-1-piperidyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate E109 (245 mg, 0.71 mmol, 1.0 equiv) in anhydrous DMF (3 mL) under nitrogen atmosphere at 0° C. was added sodium hydride (60% in mineral oil, 34 mg, 0.85 mmol, 1.2 equiv), and the mixture was stirred 5 minutes at 0° C. then 2-bromo-6-fluoropyridine (CAS 144100-07-2, 250 mg, 1.42 mmol, 2.0 equiv) was added, and the reaction mixture was warmed up to RT and stirred overnight. The reaction mixture was partitioned between water and ethyl acetate and acidified to pH 5 with AcOH. The two phases were separated. The organic phase was washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which was used as such.

Method I6: Alkylation

To a suspension of ethyl 3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate E148 (1.0 equiv) in anhydrous DMF under nitrogen atmosphere is added potassium carbonate (1.2 equiv), then alkyl bromide (1.1 equiv). The reaction mixture is stirred at room temperature overnight. Then cesium carbonate (1.2 equiv) and potassium iodide (0.1 equiv) are added, and the reaction mixture is stirred at room temperature for 24 h. The mixture is partitioned between water and ethyl acetate. The aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture is purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of E154: Ethyl 1-(cyclobutylmethyl)-3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylate

To a suspension of ethyl 3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate E148 (100 mg, 0.28 mmol, 1.0 equiv) in anhydrous DMF (2 mL) under nitrogen atmosphere was added potassium carbonate (47 mg, 0.34 mmol, 1.2 equiv) and then (bromomethyl)cyclobutane (CAS: 17247-58-4, 35 μL, 0.31 mmol, 1.1 equiv). The reaction mixture was stirred at room temperature overnight. Then cesium carbonate (111 mg, 0.34 mmol, 1.2 equiv) and potassium iodide (5 mg, 0.028 mmol, 0.1 equiv) were added, and the reaction mixture was stirred at room temperature for 24 h. The mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 75/25) to afford the titled compound.

Method I7: Cross-Coupling to Pyrazole

Illustrative Synthesis of E157: Ethyl 3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]-1-(1-methyl-6-oxo-pyridazin-3-yl)pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of ethyl 3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate E148 (100 mg, 0.28 mmol, 1.0 equiv) in anhydrous toluene (1 mL) was degassed with nitrogen (bubbling) at room temperature for 5 minutes. Then to this suspension was added 6-bromo-2-methyl-pyridazin-3-one (CAS 1123169-25-4, 58 mg, 0.31 mmol, 1.1 equiv), cesium carbonate (365 mg, 1.12 mmol, 4.0 equiv), Xantphos (CAS 161265-03-8, 16 mg, 0.028 mmol, 0.1 equiv), and palladium(II) acetate (CAS 3375-31-3, 3 mg, 0.014 mmol, 0.05 equiv). The mixture was purged again with nitrogen at RT for 10 minutes, and then the mixture was stirred at reflux overnight. The reaction mixture was cooled down and concentrated in vacuo. The residue was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 0/100) to afford the titled compound.

Illustrative Synthesis of E510: Methyl 3-cyclobutyl-1-[3-(difluoromethoxy)phenyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A nitrogen-purged mixture of tris(dibenzylideneacetone)dipalladium(0) (0.0193 g, 0.021 mmol), and di-tert-butyl(2′,4′,6′-triisopropyl-3,4,5,6-tetramethyl-[1,1′-biphenyl]-2-yl)phosphine (0.0251 g, 0.052 mmol) in toluene (2.2 mL) was stirred for 20 minutes and then added to an nitrogen-purged mixture of methyl 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (0.1760 g, 0.441 mmol, E509), 1-bromo-3-(difluoromethoxy)benzene (0.1179 g, 0.529 mmol), and Cs₂CO₃ (0.2143 g, 0.658 mmol). The mixture was heated to 70° C. overnight, diluted with water, extracted with DCM (3×8 mL), dried (Na₂SO₄), and concentrated. The residue was chromatographed on silica (30-60% EtOAc/DCM to 4% MeOH/DCM) and re-chromatographed (2.5-4% iPrOH/DCM) to give the titled compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.28-8.16 (m, 2H), 7.58 (t, J=8.2 Hz, 1H), 7.51-7.03 (m, 3H), 3.95 (dq, J=18.1, 9.8, 8.5 Hz, 1H), 3.88 (s, 3H), 3.63-3.48 (m, 6H), 2.91 (t, J=11.9 Hz, 2H), 2.53-2.48 (m, 4H), 2.46-2.28 (m, 2H), 2.12-1.88 (m, 4H), 1.63 (td, J=13.1, 12.6, 6.4 Hz, 2H).

Method I8: Buchwald Coupling

A suspension of ethyl 1-(3-bromophenyl)-3-isopropyl-4-(4-morpholinophenyl)pyrazolo[3,4-b]pyridine-6-carboxylate E001 (1.0 equiv), XPhos Pd G1 (CAS 1028206-56-5, 0.1 equiv) and sodium tert-butoxide (CAS: 865-48-5, 1.3 equiv) in anhydrous toluene is degassed with argon (bubbling) at room temperature for 15 minutes. Amine (1.3 equiv) is added, and the mixture is purged with argon at RT for 2 minutes. The reaction mixture is stirred at 100° C. for 30 minutes to 24 h. The reaction mixture is concentrated in vacuo, and the residue is partitioned between water and dichloromethane and filtered on a pad of Celpure P65®. Solids were washed with dichloromethane and water, and the two phases of the filtrate are separated. The aqueous layer is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The titled compound is obtained from the crude mixture either by precipitation or by purification by flash chromatography on silica gel.

Illustrative Synthesis of E002: Ethyl 1-[3-(azetidin-1-yl)phenyl]-3-isopropyl-4-(4-morpholinophenyl)pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of ethyl 1-(3-bromophenyl)-3-isopropyl-4-(4-morpholinophenyl)pyrazolo[3,4-b]pyridine-6-carboxylate E001 (60 mg, 0.115 mmol, 1.0 equiv), XPhos Pd G1 (CAS 1028206-56-5, 9 mg, 0.011 mmol, 0.1 equiv), and sodium tert-butoxide (CAS: 865-48-5, 14 mg, 0.149 mmol, 1.3 equiv) in anhydrous toluene (1.2 mL) was degassed with argon (bubbling) at room temperature for 15 minutes. Azetidine (13 μL, 0.149 mmol, 1.3 equiv) was added, and the mixture was purged with argon at RT for 2 minutes. The reaction mixture was stirred at 100° C. for 1 hour. The reaction mixture was concentrated in vacuo; the residue was partitioned between water and dichloromethane, and then was filtered on a pad of Celpure P65®. Solids were washed with dichloromethane and water, and the two phases of the filtrate were separated. The aqueous layer was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluent system: dichloromethane/methanol gradient from 100/0 to 90/10). The obtained solid was suspended in ethanol, filtered, washed with diethyl ether and dried in vacuo to afford the titled compound.

Method I9: Esterification

To the acid (1 equiv) in either ethanol or methanol at RT is added concentrated sulfuric acid (catalytic amount). The reaction mixture is refluxed for 1 h to several days (up to 8 days). Then the reaction mixture is cooled down to RT. The resulting suspension is filtered; the solid is washed with either ethanol or methanol and then dried in vacuo. The crude solid is purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate) to give the titled compound.

Alternatively, if no suspension is formed when cooling down the reaction mixture, the solvent is removed in vacuo. The resulting residue is taken up in dichloromethane and basified with a saturated solution of NaHCO₃. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or further purified by flash chromatography on silica gel.

Illustrative Synthesis of E001 ethyl 1-(3-bromophenyl)-3-isopropyl-4-(4-morpholinophenyl)pyrazolo[3,4-b]pyridine-6-carboxylate

Concentrated sulfuric acid (0.23 mL) was added to a suspension of A242 (2.56 g, 4.9 mmol) in absolute ethanol (64 mL) at RT. The reaction mixture was refluxed for 5 hours. The reaction mixture was cooled down to RT, and the obtained suspension was filtered. The cake was washed with ethanol and dried in vacuo. The solid residue was purified by chromatography on silica gel (heptane/ethyl acetate 100/0 to 70/30) to give the titled compound.

Method I10: Buchwald Coupling on the Aryl Linker

To the amine (from 1.3 to 2 equiv), E010 (1 equiv) and sodium tert-butoxide (CAS: 865-48-5, from 1.3 to 3 equiv) is added degassed anhydrous toluene. The reaction mixture is purged with argon, XPhos Pd G1 (CAS 1028206-56-5, 0.1 equiv) is added, and the mixture is purged again with argon. The reaction mixture is stirred at a temperature ranging from 90° C. to 110° C. for 1 h to 24 h. The reaction mixture is cooled down and filtered on a pad of diatomaceous earth. Solids are washed with organic solvents, and the combined filtrates are concentrated in vacuo. The resulting residue is purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of E011: Ethyl 4-[4-[3-(dimethylamino)azetidin-1-yl]phenyl]-3-methyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To N,N-dimethylazetidin-3-amine hydrochloride (CAS: 935670-07-8, 40 mg, 0.194 mmol, 1.3 equiv), E010 (100 mg, 0.23 mmol, 1 equiv) and sodium tert-butoxide (CAS: 865-48-5, 57 mg, 0.598 mmol, 2.6 equiv) was added degassed toluene (2 mL). The reaction mixture was purged with argon, XPhos Pd G1 (CAS 1028206-56-5, 17 mg, 0.023 mmol, 0.1 equiv) was added and the mixture was purged again with argon. The reaction mixture was stirred at 100° C. for 1 hour. The reaction mixture was cooled down and filtered on a pad of diatomaceous earth. Solids were washed with toluene, ethyl acetate and dichloromethane, and the combined filtrates were concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane/methanol 98/2) to afford the titled compound.

Method I11: Acylation of Amine

Synthesis of E176: Methyl 4-[(1-acetyl-4-piperidyl)methoxy]-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To E177 (0.1 g, 0.23 mmol, 1 equiv) in anhydrous dichloromethane (2 mL) at RT was added acetyl chloride (CAS 75-36-5, 19 μL, 0.28 mmol, 1.2 equiv) followed by triethylamine (47 μL, 0.345 mmol, 1.5 equiv). The reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 0/100) to afford the titled compound.

Synthesis of E178: Methyl 1-(4-fluorophenyl)-3-isopropyl-4-[(1-methoxycarbonyl-4-piperidyl)methoxy]pyrazolo[3,4-b]pyridine-6-carboxylate

To E177 (0.1 g, 0.23 mmol, 1 equiv) in anhydrous dichloromethane (2 mL) at RT was added methyl chloroformate (CAS: 79-22-1, 19 μL, 0.28 mmol, 1.2 equiv) followed by triethylamine (47 μL, 0.345 mmol, 1.5 equiv). The reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: heptane/ethyl acetate gradient from 100/0 to 50/50) to afford the titled compound.

Synthesis of E042: Ethyl 4-(4-acetamidophenyl)-1-(3,5-difluorophenyl)-3-(1-methoxycarbonylazetidin-3-yl)pyrazolo[3,4-b]pyridine-6-carboxylate

Diisopropylethylamine (0.045 mL, 0.26 mmol, 2.0 equiv) and 4-(dimethylamino)pyridine (CAS 1122-58-3, 3 mg, 0.026, 0.2 equiv) were added to a solution of E043 (65 mg, 0.13 mmol, 1 equiv) in dichloromethane (1 mL) at RT. The reaction mixture was cooled to 0° C. and methyl chloroformate (CAS: 79-22-1, 0.010 mL, 0.13 mmol, 1.0 equiv) was added. The reaction mixture was stirred at RT for 45 min then partitioned between dichloromethane and water. The organic phase was separated, washed with water, dried over MgSO₄, filtered and concentrated. The residue was purified by silica gel chromatography (DCM/MeOH: 100/0 to 93/7) to give the titled compound.

Synthesis of E129: Methyl 3-cyclobutyl-4-(1-methoxycarbonyl-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-5-yl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To E130 (31 mg, 0.073 mmol, 1 equiv) in anhydrous dichloromethane (0.5 mL) at 0° C. was added triethylamine (31 μL, 0.219 mmol, 3 equiv) followed by methyl chloroformate (CAS: 79-22-1, 7 μL, 0.088 mmol, 1.2 equiv). The reaction mixture was stirred at RT for 1.5 h. The reaction mixture was diluted with dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: dichloromethane/methanol, gradient from 100/0 to 98/2) to afford the titled compound.

Synthesis of E132: Methyl 4-(1-acetyl-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-5-yl)-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To E130 (31 mg, 0.073 mmol, 1 equiv) in anhydrous dichloromethane (2 mL) at 0° C. was added (31 μL, 0.219 mmol, 3 equiv) followed by acetyl chloride (CAS 75-36-5, 5 μL, 0.088 mmol, 1.2 equiv). The reaction mixture was stirred at RT for 1.5 h. The reaction mixture was diluted with dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: dichloromethane/methanol, gradient from 100/0 to 96/4) to afford the titled compound.

Method I12: Nucleophilic Substitution

To a solution of the intermediate ester (1.0 equiv) in anhydrous DMSO, are added the amine (from 2.0 to 3.0 equiv) and K₂CO₃ (3.0 equiv). The reaction mixture is stirred at 100° C. overnight. The reaction mixture is cooled down to RT, poured into water and extracted with ethyl acetate. The combined organic layers are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue is purified by silica gel chromatography to afford the titled compound.

Illustrative Synthesis of E110: Ethyl 3-isopropyl-4-(4-methoxy-1-piperidyl)-1-(2-pyrrolidin-1-yl-4-pyridyl)pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of ethyl 1-(2-fluoro-4-pyridyl)-3-isopropyl-4-(4-methoxy-1-piperidyl)pyrazolo[3,4-b]pyridine-6-carboxylate E111 (50 mg, 0.11 mmol, 1.0 equiv) in anhydrous DMSO (1 mL), were added pyrrolidine (18 μL, 0.22 mmol, 2.0 equiv) and K₂CO₃ (46 mg, 0.33 mmol, 3.0 equiv). The reaction mixture was stirred at 100° C. overnight. The reaction mixture was cooled down to RT, poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography (heptane/ethyl acetate: 100/0 to 40/60) to afford the titled compound.

Method I13: O-Alkylation of the Pyrazole

Intermediate E153 (1.0 equiv), the alkyl iodide (from 3 to 5.7 equiv) and cesium carbonate (from 3 to 5.7 equiv) are charged in a sealed vial. NMP is added, and the vial is sealed. The reaction mixture is stirred at 130° C. for 1 hour. The reaction mixture is cooled down to RT and partitioned between water and ethyl acetate. The phases are separated, and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or purified by flash chromatography on silica gel.

Illustrative Synthesis of E152: Ethyl 3-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-4-[6-(4-cyano-1-piperidyl)-3-pyridyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Intermediate E153 (110 mg, 0.23 mmol), N-Boc-4-iodo-piperidine (CAS: 301673-14-3, 410 mg, 1.32 mmol, 5.7 equiv) and cesium carbonate (430 mg, 1.32 mmol, 5.7 equiv) were charged in a sealed vial. NMP (2.9 mL) was added, and the vial was sealed. The reaction mixture was stirred at 130° C. for 1 hour. The reaction mixture was cooled down to RT and partitioned between water and ethyl acetate. The phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (heptane/ethyl acetate: gradient from 100/0 to 2:1) to give the titled compound.

Method I14: Mitsunobu Reaction

Diisopropyl azodicarboxylate (CAS: 2446-83-5, 0.606 mL, 3.075 mmol, 1.5 equiv) is added dropwise to a stirred solution of the intermediate phenol HP (1 equiv), tetrahydropyran-4-methanol (CAS: 14774-37-9, from 1.5 to 2.0 equiv) and triphenylphosphine (CAS: 603-35-0, 1.5 equiv) in tetrahydrofuran under nitrogen atmosphere. The reaction mixture is stirred at RT for 1 to 3 h. The solvent is removed under reduced pressure, and the resulting crude sample is purified by flash column chromatography on silica gel (eluent system: heptane/ethyl acetate) to yield the titled compound.

Illustrative Synthesis of E183 ethyl 1-[(2,4-dimethoxyphenyl)methyl]-3-isopropyl-4-(tetrahydropyran-4-ylmethoxy)pyrazolo[3,4-b]pyridine-6-carboxylate

Diisopropyl azodicarboxylate (CAS: 2446-83-5, 0.606 mL, 3.075 mmol, 1.5 equiv) was added dropwise to a stirred solution of HP06 (820 mg, 2.05 mmol), tetrahydropyran-4-methanol (CAS: 14774-37-9, 477 mg, 4.1 mmol, 2.0 equiv) and triphenylphosphine (CAS: 603-35-0, 806 mg, 3.075 mmol, 1.5 equiv) in tetrahydrofuran (20 mL) under nitrogen atmosphere. The reaction mixture was stirred at RT for 1 hour. The volatiles were removed under reduced pressure, and the crude sample was purified by flash column chromatography on silica gel eluting with n-heptane/ethyl acetate from 90/10 to 1/1 to yield the titled compound.

Method I15: Dimethoxybenzyl Group Removal

Trifluoroacetic acid or a mixture of dichloromethane and trifluoroacetic acid is added to the (2,4-dimethoxyphenyl)methyl]pyrazolo[3,4-b]pyridine compound. The reaction mixture is stirred at RT for several hours. Then the titled compound is isolated by precipitation in diethyl ether directly from the reaction mixture or after removal of volatiles and is used as such or is taken up in dichloromethane and basified with a saturated solution of sodium hydrogencarbonate. The phases are separated and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or further purified by silica gel chromatography.

Alternatively the reaction mixture is concentrated in vacuo. The residue is taken up in dichloromethane and basified with a saturated solution of sodium hydrogencarbonate. The phases are separated and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo which was used as such or purified by precipitation or by flash chromatography on silica gel.

Illustrative Synthesis of compound E055: Ethyl 3-isopropyl-4-(4-morpholinophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Trifluoroacetic acid (4.24 mL, 55.4 mmol, 71 equiv) was added to compound E056 (424 mg, 0.78 mmol). The reaction mixture was stirred at RT for 3 hours. Diethyl ether (20 mL) was added to the reaction mixture which was vigorously stirred for 5 minutes. The resulting suspension was filtered, and the cake was washed with diethyl ether. The solid was partitioned between dichloromethane and a saturated solution of sodium hydrogencarbonate and vigorously stirred. The suspension was filtered, and the solids were washed with dichloromethane. The two phases of the filtrate were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo to yield the titled compound which was used without further purification.

Method I16: Ullmann Coupling

Synthesis of E171: Ethyl 3-cyclobutyl-1-(4-fluorophenyl)-4-(tetrahydropyran-4-ylmethoxy)pyrazolo[3,4-b]pyridine-6-carboxylate

A degassed solution of trans-N,N′-dimethyl-1,2-cyclohexane (CAS: 67579-81-1, 0.002 mL, 0.01 mmol, 0.15 equiv) and 1-fluoro-4-iodobenzene (CAS: 352-34-1, 0.007 mL, 0.06 mmol, 0.7 equiv) in toluene (2 mL) was added to a mixture of E172 (30 mg, 0.08 mmol), K₃PO₄ (35 mg, 0.167 mmol, 2.0 equiv) and CuI (1 mg, 0.005 mmol, 0.07 equiv). The vial was sealed and the reaction mixture was stirred at 110° C. for 16 hours. The reaction mixture was cooled down to RT and partitioned between water and ethyl acetate. The organic phase was separated, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane/heptane/ethyl acetate: 100/0/0 to 0/70/30) to give the titled compound.

Method I17: O-Alkylation of Pyrazole

Synthesis of Compound E090: Isopropyl 3-isopropoxy-4-(4-morpholinophenyl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of A256 (330 mg, 0.79 mmol) and 2-iodopropane (CAS 75-30-9, 0.19 mL, 1.90 mmol, 2.4 equiv) in anhydrous NMP (4 mL) was added cesium carbonate (775 mg, 2.38 mmol, 3.0 equiv), and the reaction mixture was stirred at 130° C. for 16 hours. The reaction mixture was cooled down to RT and partitioned between dichloromethane and a saturated solution of sodium hydrogencarbonate. The organic phase was separated, washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate: 80/20 to 70/30) to give the titled compound.

Synthesis of Intermediate E504: Methyl 4-(4-bromophenyl)-1-cyclohexyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution containing methyl 4-(4-bromophenyl)-1-cyclohexyl-3-hydroxy-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (30.5 mmol, E503) was added isopropyl bromide ([75-26-3], 5.73 mL, 61.1 mmol) and cesium carbonate (2.70 g, 8.28 mmol), and the resulting mixture stirred under N₂ at 60° C. for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine (2×) and concentrated. The obtained residue was purified by column chromatography using a petroleum ether/EtOAc gradient (95/5 till 90/10) to afford the titled compound.

Synthesis of Intermediate E505: Methyl 4-(4-bromophenyl)-3-(cyclobutyloxy)-1-cyclohexyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution containing methyl 4-(4-bromophenyl)-1-cyclohexyl-3-hydroxy-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (5.52 mmol, E503) was added cyclobutyl bromide ([4399-47-7], 1.04 mL, 11.0 mmol) and cesium carbonate (5.40 g, 11.0 mmol), and the resulting mixture stirred under N₂ at 60° C. for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine (2×) and concentrated. The obtained residue was purified by column chromatography using a petroleum ether/EtOAc gradient (95/5 till 90/10) to afford the titled compound.

Method I18: General Method for Reductive Amination

A suspension of ketone (1 eq), amine (1.5 to 3 eq) and triethylamine (1 to 2 eq) in dichloromethane is stirred at RT for 5 minutes. Acetic acid (1 to 2 eq) is added, and the stirring at RT is continued for 30 minutes. Sodium triacetoxyborohydride (1 to 3 eq) is then added, and the stirring is continued for 20 hours. The reaction mixture is diluted with dichloromethane and washed with a saturated aqueous solution of NaHCO₃. The organic phase is separated, dried over sodium sulfate and concentrated under reduced pressure. The crude sample is used as such or purified by flash column chromatography.

Illustrative Synthesis of E354: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-{4-[2-(methoxymethyl)morpholin-4-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of E353 (0.1 g, 0.24 mmol), 2-(methoxymethyl)morpholine ([156121-15-2], 63 mg, 0.47 mmol) and triethylamine (33 μL, 0.24 mmol) in dichloromethane (2 mL) was stirred at RT for 5 minutes. Acetic acid (21 μL, 0.35 mmol) was added, and the stirring at RT was continued for 30 minutes. Sodium triacetoxyborohydride (76 mg, 0.35 mmol) was then added, and the stirring was continued for 20 hours. The reaction mixture was diluted with dichloromethane (3 mL) and washed with a saturated aqueous solution of NaHCO₃ (2 mL). The organic phase was separated using a phase separator and concentrated in vacuo to give the titled compound.

Method I19: General Method for the Reductive Removal of Benzyloxycarbonyl

A solution of the benzyloxycarbonyl-protected amine (1 eq) in methanol is flushed with N₂. Next, 10% Pd/C (0.1 eq) is added and the mixture is put under hydrogen pressure with a balloon. After stirring overnight at ambient temperature, the mixture is filtered through diatomaceous earth, and the filtrate is concentrated. The residue is used as such or purified by flash column chromatography.

Method I23: General Method for Oxidation

Dess Martin's periodinane (1 to 2 eq) is added at RT to a stirred solution of alcohol (1 eq) in dichloromethane. After 0.5 to 2 hours, the reaction mixture is diluted with dichloromethane. A solution of 20% Na₂S₂O₃ in water and a saturated aqueous solution of NaHCO₃ (1:1) is added and the stirring is continued for 30 minutes. The organic phase is separated, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound. The compound can be used as such or purified by flash column chromatography.

Synthesis of Compound E353: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-(4-oxopiperidin-1-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Dess-Martin periodinane (4 g, 9.4 mmol) was added at RT to a stirred solution of E352 (3.6 g, 8.6 mmol) in dichloromethane (40 mL). After 30 minutes, the reaction mixture was diluted with dichloromethane (50 mL). A solution of 20% aqueous Na₂S₂O₃ 20% and a saturated aqueous solution of NaHCO₃ (1:1, 50 mL) were added, and the stirring was continued for 30 minutes. The organic phase was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound.

Method I24: Coupling of Amines

EDC.HCl ([25952-538], 1.2 equiv) is added at RT to a stirring solution of carboxylic acid (1 equiv), amine (4 equiv) and 4-(dimethylamino) pyridine ([1122-58-3], 2 equiv) in dichloromethane. The reaction mixture is stirred at RT for 20 hours. The solvent is evaporated under reduced pressure. The residue is purified flash column chromatography eluting with ethyl acetate/n-heptane and/or DCM/MeOH to yield the desired compound.

Illustrative Synthesis of E439: Ethyl 4-{4-[5-(tert-butoxycarbonyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carbonyl]phenyl}-1-cyclohexyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

EDC.HCl ([25952-538], 18 mg, 74 μmol) was added at RT to a stirred solution of E438 (30 mg, 62 μmol), tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate ([141449-85-6], 52 mg, 248 μmol) and 4-(dimethylamino) pyridine ([1122-58-3], 17 mg, 124 μmol) in dichloromethane (5 mL). The reaction mixture was stirred at RT for 20 hours. The mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with ethyl acetate/n-heptane to yield the titled compound.

Illustrative Synthesis of E441: Ethyl 1-cyclohexyl-4-{4-[3-(dimethylamino)azetidine-1-carbonyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

EDC.HCl ([25952-538], 24 mg, 125 μmol) was added at RT to a stirred solution of E438 (40 mg, 89 μmol), N,N-dimethylazetidin-3-amine hydrochloride ([935670-07-8], 49 mg, 358 μmol), triethylamine (50 μL, 358 μmol) and 4-(dimethylamino)pyridine ([1122-58-3], 24 mg, 196 μmol) in dichloromethane (15 mL). The reaction mixture was stirred at RT for 20 hours. The mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with ethyl acetate/DCM/MeOH (100/0/0 to 0/90/10) to yield the titled compound.

Method I25: Tert-Butoxycarbonyl (Boc) Deprotection

To a solution of the Boc-protected amine (1 eq) in dichloromethane at 0° C., TFA (76-05-1, 5-20 eq) is added. The resulting mixture is stirred at room temperature until deprotection is complete. The mixture can be worked up by diluting the reaction mixture with DCM followed by washing with a saturated aqueous NaHCO₃ solution. The organic fraction is dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the titled compound. Alternatively, the reaction mixture can be concentrated under reduced pressure, and the crude titled compound can be used as such without further purification.

Illustrative Synthesis of Compound E043: Ethyl 4-(4-acetamidophenyl)-3-(azetidin-3-yl)-1-(3,5-difluorophenyl)pyrazolo[3,4-b]pyridine-6-carboxylate

Trifluoroacetic acid (1.0 mL, 13.0 mmol, 33 equiv) was added at 0° C. to a solution of E044 (230 mg, 0.39 mmol) in dichloromethane (5.0 mL). The reaction mixture was stirred at RT for 1 hour. The reaction mixture was partitioned between dichloromethane and a saturated solution of sodium hydrogencarbonate. The organic phase was separated, dried over Na₂SO₄, filtered and concentrated to give the titled compound.

Illustrative Synthesis of Compound E130: Methyl 4-(1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridin-5-yl)-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylate

A solution of 4 M HCl in dioxane (0.245 mL, 0.98 mmol, 4.0 equiv) was added at RT to a solution of E131 (130 mg, 0.24 mmol) in dioxane (2.0 mL). The reaction mixture was stirred at RT for 16 hours. Additional 4 M HCl in dioxane (0.1 mL, 0.4 mmol, 1.7 equiv) was added, and the reaction mixture was stirred at RT for 48 hours. The reaction mixture was concentrated in vacuo and partitioned between dichloromethane and a saturated solution of sodium hydrogencarbonate. The organic phase was separated, dried over Na₂SO₄, filtered and concentrated in vacuo to give the titled compound.

Method I26: Reductive Amination to Install a Cyclopropyl Group

The amine (1 eq) is mixed with (1-ethoxycyclopropoxy)trimethylsilane ([27374-25-0], 2 eq), AcOH (1.6 eq) and NaBH₃CN (1.5 eq) in a mixture of THF/MeOH (1/1). The resulting mixture is stirred overnight at 50° C. After cooling the mixture down to room temperature, the reaction is quenched by the addition of water. Next, 1 M NaOH solution is added, and the mixture is stirred for another 15 minutes. After dilution with DCM, the organic layer is separated, dried and concentrated to give the titled compound.

Illustrative Synthesis of Compound E465: Methyl 3-cyclobutyl-4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(piperazin-1-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (200 mg, 0.41 mmol, E498) was mixed with (1-ethoxycyclopropoxy)trimethylsilane ([27374-25-0], 163 μL, 0.81 mmol), AcOH (26 μL, 0.65 mmol) and sodium cyanoborohydride ([25895-60-7], 38 mg, 0.61 mmol) in a mixture of THF/MeOH (1/1, 1 mL). The resulting mixture was stirred overnight at 50° C. After cooling the mixture down to room temperature, the reaction was quenched by the addition of water. Next, 1 M NaOH solution was added, and the mixture was stirred for another 15 minutes. After dilution with DCM, the organic layer was separated, dried and concentrated to give the titled compound.

Method I27: Alkylation Amine

The amine (1 eq) is mixed with 1-bromo-2-methoxyethane ([6482-24-2], 1.1 eq) and K₂CO₃ (2 eq) in MeCN. The resulting mixture is heated at reflux overnight at 50° C. After cooling down, the mixture is used as such in the next step.

Method I28: Amino-Carbonylation

A is CH or N

In a Parr reactor, the arylbromide (1 eq) is mixed with an amine (2 eq), Et₃N (4 eq) and Xantphos Pd G3 (0.03 eq) in dioxane. A CO pressure of 5 bars is applied and the mixture is heated at 100° C. overnight. Concentration gives a residue that is re-dissolved in DCM. Extraction with water gives an organic phase that is concentrated to give a residue that is used as such in the next step.

Illustrative Synthesis of Compound E474: Methyl 1-cyclohexyl-4-[4-(4-methylpiperazine-1-carbonyl)phenyl]-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A Parr reactor was loaded with E504 (0.50 mmol, 250 mg), 1-methylpiperazine dihydrochloride ([34352-59-5], 1.0 mmol, 173 mg) and [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate] (0.015 mmol, 14 mg). The reactor was evacuated and back-filled with N₂, Et₃N (4.0 equiv, 2.0 mmol, 279 μL) and 1,4-dioxane (dry, 8 mL/mmol, 4 mL) were added, and the reaction mixture was heated to 100° C. under a CO atmosphere (5 bar) overnight. The reaction mixture was concentrated in vacuo, and the residue was partitioned between H₂O and dichloromethane. The organic phase was dried and concentrated in vacuo to give the titled compound which was used as such in the next step.

Method I29: Alternative Buchwald Coupling on the Aryl Linker

A tube is loaded with the arylbromide (1 eq). The amine (1.2 eq) is added together with (RuPhos) palladium(II) phenethylamine chloride (1:1 MTBE solvate, 0.1 eq), NaOtBu (1.2 eq) in dioxane. The resulting suspension is put under a N₂ atmosphere and stirred at 100° C. Next, the mixture is diluted with water and acidified with a 1 N citric acid solution till pH 3-4. Extraction with DCM gives the crude product that is either used as such or purified by chromatography. During this method, it is possible that partial hydrolysis of the ester to the corresponding acid occurs.

Illustrative Synthesis of Compound E502: Methyl 1-cyclohexyl-4-[4-(4-methylpiperazin-1-yl)phenyl]-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A tube was loaded with the E504 (100 mg, 0.21 mmol). 1-Methylpiperazine ([109-01-3], 28 μL, 0.25 mmol) was added together with (RuPhos) palladium(II) phenethylamine chloride (1:1 MTBE solvate, 17 mg, 0.02 mmol), and NaOtBu (25 mg, 0.25 mmol) in dioxane (1 mL). The resulting suspension was put under a N₂ atmosphere and stirred at 100° C. Next, the mixture was diluted with water and acidified with a 1 N citric acid solution till pH 3-4. Extraction with DCM gave the titled compound that was used as such. Partial hydrolysis of the ester to the corresponding acid was observed.

Method I30: Alternative Reductive Amination

A solution of the amine (1 eq), the ketone (2 eq) and AcOH (1.5 eq) in DCM is cooled to 0° C. Next, sodium triacetoxyborohydride ([56553-60-7], 2 eq) is added portionwise, and the reaction is stirred overnight at ambient temperature. Subsequently, the mixture is diluted with saturated NaHCO₃ solution and extracted with DCM. The organic phase is concentrated to give the alkylated amine that is used as such or purified by chromatography.

Illustrative Example of Compound E469: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-[9-(oxetan-3-yl)-3,9-diazaspiro[5.5]undecan-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A solution of the methyl 3-cyclobutyl-4-(3,9-diazaspiro[5.5]undecan-3-yl)-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (200 mg, 0.42 mmol, E500), 3-oxetanone ([6704-31-0], 54 μL, 0.84 mmol) and AcOH (36 μL) in DCM (3 mL) was cooled at 0° C. Next, sodium triacetoxyborohydride ([56553-60-7], 178 mg, 0.84 mmol) was added portion wise and the reaction was stirred overnight at ambient temperature. Subsequently, the mixture was diluted with sat. NaHCO₃ solution and extracted with DCM. The organic phase was evaporated to give the titled compound.

Method I31: Carbamate Synthesis

To a solution of the amine (1 eq) in DCM is added trimethylamine (2 eq) and then methyl chloroformate ([79-22-1], 2 eq). The mixture is stirred at RT overnight. Next, the reaction mixture is diluted with saturated NaHCO₃ solution and extracted with DCM. After concentration, the carbamate is obtained that is used as such or purified by chromatography.

Illustrative Example of Compound E486: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-{4-[4-(methoxycarbonyl)piperazin-1-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of the E498 (118 mg, 0.239 mmol) in DCM (1 mL) was added triethylamine (67 μL, 0.478 mmol) and then methyl chloroformate (37 μL, 0.478 mmol). The mixture was stirred at RT overnight. Next, the reaction mixture was diluted with saturated NaHCO₃ solution and extracted with DCM. After concentration, the titled compound was obtained that was used as such.

Method I32: Amide Synthesis Using Acetyl Chloride

To a solution of the amine (1 eq) in DCM is added trimethylamine (2 eq) and then acetyl chloride ([75-36-5], 2 eq). The mixture is stirred at RT overnight. Next, the reaction mixture is diluted with saturated NaHCO₃ solution extracted with DCM. After concentration, the amide is obtained that is used as such or purified by chromatography.

Illustrative Example of Compound E487: Methyl 4-[4-(4-acetylpiperazin-1-yl)piperidin-1-yl]-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of the E498 (118 mg, 0.239 mmol) in DCM (1 mL) was added triethylamine (67 μL, 0.478 mmol) and then acetyl chloride ([75-36-5], 0.478 mmol). The mixture was stirred at RT overnight. Next, the reaction was diluted with saturated NaHCO₃ solution and extracted with DCM. After concentration, the titled compound was obtained that was used as such.

Method I34: Reductive Amination on Aldehydes

A is —O—C₁-C₆ alkyl or —NHS(O)₂R⁵

A suspension of amine hydrochloride or free base (1 to 2 equiv) and triethylamine (from 1 to 2 equiv) in 1,2-dichloroethane is stirred at RT for 10 minutes. Aldehyde (1 equiv), sodium triacetoxyborohydride (2 equiv), and acetic acid (0.6 to 4 equiv) are successively added, and the stirring at RT is continued for 20 hours. Starting reagents can be added until full conversion is observed. The reaction mixture is diluted with DCM, washed with a saturated aqueous solution of NaHCO₃ and/or a saturated aqueous solution of NH₄Cl and a phosphate buffer (pH 6.2). The organic phase is dried over sodium sulfate and concentrated under reduced pressure. The residue is used as such or purified by flash column chromatography to yield the reductively aminated compound.

Illustrative Synthesis of E426: Ethyl 1-cyclohexyl-4-(4-{[3-(dimethylamino)azetidin-1-yl]methyl}phenyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of 3-(dimethylamino)azetidine dihydrochloride ([124668-49-1], 17 mg, 124 μmol) and triethylamine (35 μL, 248 μmol) in 1,2-dichloroethane (2 mL) was stirred at RT for 10 minutes. Aldehyde E425 (54 mg, 124 μmol), sodium triacetoxyborohydride (53 mg, 248 mol), and acetic acid (29 μL, 496 μmol) were successively added, and the stirring at RT was continued for 20 hours. The reaction mixture was diluted with DCM and washed with a saturated aqueous solution of NaHCO₃. The organic phase was separated, dried over sodium sulfate and concentrated under reduced pressure. The residue was used as such or purified by flash column chromatography eluted with ethyl acetate/n-heptane to yield the titled compound.

Synthesis of E199: Methyl 4-(4-azidophenyl)-1-[3-(dimethylamino)phenyl]-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylate

Intermediate E074 (0.5 g, 1.013 mmol, 1.0 equiv) and sodium azide (CAS 26628-22-8, 132 mg, 2.026 mmol, 2 equiv) were put in a sealed vial. A 2:1 mixture of ethanol and water (2 mL) was added, and the vial was purged with nitrogen. Then copper(I) iodide (CAS 7681-65-4, 20 mg, 0.101 mmol, 0.1 equiv), sodium ascorbate (CAS 134-03-2, 11 mg, 0.051 mmol, 0.05 equiv) and N,N-dimethylethylenediamine (CAS 110-70-3, 45 μL, 0.405 mmol, 0.2 equiv) were added, and the vial was sealed. The reaction mixture was heated under microwave irradiation at 80° C. for 45 minutes. Volatiles were removed in vacuo. The resulting aqueous residue was diluted with ethyl acetate. The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which was used as such.

Synthesis of E390: Ethyl 3-cyclobutyl-1-[2-(3,6-dihydro-2H-pyran-4-yl)pyridin-4-yl]-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate and E391: Ethyl 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: E390: Ethyl 3-cyclobutyl-1-[2-(3,6-dihydro-2H-pyran-4-yl)pyridin-4-yl]-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

In a sealed tube, a suspension of E389 (110 mg, 0.23 mmol), 3,6-dihydro-2H-pyran-4-boronic pinacol ester (72 mg, 0.34 mmol), K₃PO₄ (146 mg, 0.69 mmol) and Pd(Amphos)Cl₂ ([887919-35-9], 16 mg, 23 μmol) in dioxane (3 mL) and water (0.5 mL) was degassed with N₂ at room temperature for 2 minutes. The reaction mixture was heated at 100° C. for 3 hours. The mixture was cooled to RT and then concentrated under reduced pressure. The crude sample was purified by flash column chromatography eluted with ethyl acetate/n-heptane to give the titled compound E390.

Step 2: E391: Ethyl 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of E390 (60 mg, 0.11 mmol) and palladium hydroxide on carbon (20 mg) in ethanol was hydrogenated for 6 hours. The reaction mixture was filtered over Celpure® and washed with ethyl acetate. The filtrate was concentrated in vacuo, and the residue was purified by silica gel chromatography eluted with ethyl acetate/n-heptane to give the titled compound E391.

Synthesis of E393: Ethyl 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Trifluoromethanesulfonic acid (860 μL, 10 mmol) was added dropwise at RT to a solution of E392 (1 g, 2 mmol) in dichloromethane (10 mL). The reaction mixture was stirred for 4 hours and poured into a mixture of saturated aqueous NaHCO₃ and water (1:1, 10 mL). The aqueous phase was extracted twice with dichloromethane/isopropanol (95/5, 20 mL). The combined organic phases were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound as a colorless solid.

Synthesis of E402: Ethyl 3-cyclobutyl-1-(2-hydroxypyridin-4-yl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of E401 (75 mg, 0.12 mmol) and palladium hydroxide on carbon (10 mg) in THF was hydrogenated for 20 hours. The reaction mixture was filtered over Celpure® that was washed with dichloromethane/methanol. The filtrate was concentrated in vacuo to give the titled compound E402.

Synthesis of E407: Ethyl 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: Ethyl 3-cyclobutyl-1-[2-(3,6-dihydro-2H-pyran-4-yl)pyridin-4-yl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

In a sealed tube, a suspension of E406 (110 mg, 0.21 mmol), 3,6-dihydro-2H-pyran-4-boronic pinacol ester (72 mg, 0.34 mmol), K₃PO₄ (146 mg, 0.69 mmol) and Pd(Amphos)Cl₂ ([887919-35-9], 16 mg, 23 μmol) in dioxane (3 mL) and water (0.5 mL) was degassed with N₂ at room temperature for 2 minutes. The reaction mixture was heated at 100° C. for 20 hours. The mixture was cooled to RT, and the mixture was concentrated under reduced pressure. The crude sample was purified by flash column chromatography eluted with ethyl acetate/n-heptane to give the titled compound.

Step 2: Ethyl 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-[2-(oxan-4-yl)pyridin-4-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of ethyl 3-cyclobutyl-1-[2-(3,6-dihydro-2H-pyran-4-yl)pyridin-4-yl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (54 mg, 0.94 mmol) and palladium hydroxide on carbon (15 mg) in ethanol/THF (1:1, 10 mL) was hydrogenated for 6 hours. The reaction mixture was filtered over Celpure® that was washed with ethyl acetate, and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography eluted with ethyl acetate/n-heptane to give the titled compound, E407.

Synthesis of E413: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: Methyl 4-[1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of methyl 4-chloro-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (HP19, 2.0 g, 5.75 mmol, 1.0 equiv), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (CAS 286961-14-6, 3.6 g, 11.5 mmol, 2.0 equiv), K₂CO₃ (2.4 g, 17.25 mmol, 3.0 equiv) and Pd(dppf)Cl₂ (CAS: 72287-26-4, 939 mg, 1.15 mmol, 0.2 equiv) in anhydrous DMF (15 mL) was degassed with nitrogen at room temperature for 2 minutes. The reaction mixture was refluxed for 20 hours. The mixture was cooled to RT, poured into 150 mL of iced water and diluted with ethyl acetate. The two phases were separated, and the aqueous phase was extracted again with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude residue was purified by silica gel chromatography (heptane/ethyl acetate: 100/0 to 80/20) to give the titled compound.

Step 2: Methyl 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of compound from Step 1 (2.44 g, 4.93 mmol, 1.0 equiv) and platinum (IV) oxide (CAS 1314-15-4, 1.2 g) in acetic acid (240 mL) was stirred at RT under a hydrogen atmosphere (balloon) for 20 hours. The reaction mixture was filtered over Celpure® P65. Solids were washed with ethyl acetate, and the filtrate was concentrated in vacuo. The crude residue was purified by silica gel chromatography (heptane/ethyl acetate: 100/0 to 80/20) to give the title compound.

Step 3: Methyl 3-cyclobutyl-1-(4-fluorophenyl)-4-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Methyl 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3-cyclobutyl-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (2.75 g, 5.4 mmol, 1 equiv) was dissolved in 4 M HCl in dioxane (40 mL, 162.2 mmol, 30 equiv), and the solution was stirred at RT for 2 hours. The solvent was concentrated under reduced pressure. The residue was dissolved in a minimum of methanol and poured into diethyl ether (500 mL). The precipitate was filtered, washed with diethyl ether and dried at 40° C. under reduced pressure to give the titled compound, E413.

Synthesis of E430: Methyl 3-cyclobutyl-4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

In a sealed tube, a suspension of HP02 (1 g, 2.92 mmol), 1,4-dioxa-spiro[4,5]dec-7-en-8-boronic acid, pinacol ester ([680596-79-6], 1.01 g, 3.8 mmol), K₃PO₄ (1.86 g, 8.77 mmol), Pd(OAc)₂ ([3375-31-3], 330 mg, 0.14 mmol), and SPhos ([657408-07-6], 150 mg, 0.365 mmol) in toluene (22 mL) and water (6 mL) was degassed with N₂ at room temperature for 5 minutes. The reaction mixture was stirred at RT for 2 hours. Additional Pd(OAc)₂ ([3375-31-3], 330 mg, 0.14 mmol) and SPhos ([657408-07-6], 150 mg, 0.365 mmol) were added. The stirring at RT was continued for 20 hours. Pd(OAc)₂ ([3375-31-3], 165 mg, 0.07 mmol) and SPhos ([657408-07-6], 75 mg, 0.18 mmol) were again added, and the reaction mixture was heated at 100° C. for 1 hour. The reaction mixture was cooled to RT, diluted with ethyl acetate and filtered. The filtrate was washed successively with water and a saturated aqueous solution of NaCl. The organic phase was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash column chromatography on silica gel eluting with ethyl acetate/n-heptane to give the titled compound.

Synthesis of E431: Methyl 3-cyclobutyl-4-(1,4-dioxaspiro[4.5]decan-8-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A suspension of E430 (823 mg, 1.85 mmol) and palladium hydroxide on carbon ([12135-22-7], 280 mg) in THF/MeOH (25 mL, 2/1) was hydrogenated for 20 hours. The reaction mixture was filtered over Celpure® which was washed with DCM. The filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography eluting with ethyl acetate/n-heptane to give the titled compound E431.

Synthesis of E432: Methyl 3-cyclobutyl-1-[(3E,5Z)-hepta-1,3,5-trien-4-yl]-4-(4-oxocyclohexyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

The ester, E431 (732 mg, 1.64 mmol), was dissolved in DCM and TFA (2.2 mL, 3 volumes) was added dropwise at RT. The solution was stirred for 48 hours and then diluted with DCM. The mixture was washed with a saturated aqueous solution of NaHCO₃. The organic phase was separated, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with ethyl acetate/n-heptane to give the titled compound E432.

Synthesis of E438: 4-{1-cyclohexyl-6-(ethoxycarbonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridin-4-yl}benzoic Acid

A mixture of aldehyde E425 (27 mg, 62 μmol), sulfamic acid ([226-18-8], 17 mg, 168 μmol), and sodium chlorite ([7758-19-2], 17 mg, 188 μmol) in THF/water (3.3 mL, 10/1) was stirred at RT for 1 hour. The reaction mixture was diluted with DCM (20 mL) and washed with water (20 mL). The organic phase was dried over sodium sulfate, filtered and evaporated under reduced pressure. The titled compound was used as such in the next step.

Synthesis of E444: Ethyl 1-cyclohexyl-4-{4-[(8-methyl-2-oxa-5,8-diazaspiro[3.5]nonan-5-yl)methyl]phenyl}-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Iodomethane (3 μL, 48 μmol) was added at RT to a stirred suspension of E443 (22 mg, 40 μmol) and cesium carbonate (33 mg, 100 μmol) in DMF (2 mL). The reaction mixture was stirred for 20 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with ethyl acetate/DCM/MeOH (100/0/0 to 0/90/10) to give the titled compound.

Synthesis of E445: Ethyl 4-[4-(4-cyano-1-methylpiperidin-4-yl)phenyl]-1-cyclohexyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: Ethyl 4-{4-[1-(tert-butoxycarbonyl)-4-cyanopiperidin-4-yl]phenyl}-1-cyclohexyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A solution of ALP38 (305 mg, 0.74 mmol) and AMP95 (575 mg, 0.77 mmol) in N-methylpyrrolidine (4 mL) was heated at 110° C. for 24 hours in an opened vessel. The reaction mixture was cooled to RT, and the mixture was concentrated in vacuo. The residue was partitioned between ethyl acetate and water. The organic phase was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate/n-heptane to give the titled compound.

Step 2: Ethyl 4-[4-(4-cyanopiperidin-4-yl)phenyl]-1-cyclohexyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Trifluoroacetic acid (1 mL) was added to a solution of the tert-butoxycarbonyl protected compound from Step 1 (230 mg, 0.37 mmol) in DCM (10 mL). The solution was stirred at RT for 2 hours. The reaction mixture was diluted with toluene (5 mL) and then concentrated under reduced pressure. The residue was partitioned between ethyl acetate, water, and a phosphate buffer solution (pH 6.2). The organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel eluting with ethyl acetate/n-heptane to give the titled compound.

Step 3: Ethyl 4-[4-(4-cyano-1-methylpiperidin-4-yl)phenyl]-1-cyclohexyl-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Iodomethane (2 μL, 32 μmol) was added at RT to a stirred suspension of the compound from Step 2 (15 mg, 29 μmol) and cesium carbonate (33 mg, 100 μmol) in DMF (2 mL). The reaction mixture was stirred for 2 hours. The reaction mixture was partitioned between water and DCM. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with ethyl acetate/DCM/MeOH (100/0/0 to 0/90/10) to give the titled compound.

Synthesis of E509: Methyl 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 4-[1-(2,6-dichloropyridin-4-yl)piperidin-4-yl]morpholine

N-Ethyl-N-isopropylpropan-2-amine (22.91 mL, 132 mmol) was added to a suspension of 2,4,6-trichloropyridine (12 g, 65.8 mmol) and 4-(piperidin-4-yl)morpholine (13.44 g, 79 mmol) in acetonitrile (120 mL). The reaction mixture was heated to 60° C. and stirred for 16 hours. Upon cooling to room temperature, the precipitate was collected by filtration. The crude solid was then precipitated from EtOAc to give the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 6.59 (s, 2H), 3.89-3.79 (m, 2H), 3.77-3.69 (m, 4H), 2.96 (ddd, J=13.3, 11.8, 2.8 Hz, 2H), 2.60-2.52 (m, 4H), 2.45 (tt, J=10.8, 3.7 Hz, 1H), 1.95 (ddd, J=12.9, 3.9, 1.9 Hz, 2H), 1.61-1.48 (m, 2H); MS (APCI+) m/z 316.2 (M+H)⁺.

Step 2: Cyclobutyl{2,6-dichloro-4-[4-(morpholin-4-yl)piperidin-1-yl]pyridin-3-yl}methanone

n-Butyllithium (19.2 mL, 26.9 mmol) was added in 5 mL portions to a stirred solution of 4-[1-(2,6-dichloropyridin-4-yl)piperidin-4-yl]morpholine (7.95 g, 25.1 mmol) in THF (160 mL) at −78° C. After stirring at this temperature for 1.5 hours, cyclobutanecarbonyl chloride (1.42 g, 11.9 mmol) was added rapidly, and the reaction mixture was stirred for 10 minutes. To obtain higher conversion, sequential additions of n-butyllithium and cyclobutanecarbonyl chloride were performed in the same manner. Addition 1: n-butyllithium (13.0 mL, 18.2 mmol) and cyclobutanecarbonyl chloride (0.97 g, 8.1 mmol); Addition 2: n-butyllithium (9.2 mL, 12.9 mmol) and cyclobutanecarbonyl chloride (0.68 g, 5.6 mmol); Addition 3: n-butyllithium (6.9 mL, 9.7 mmol) and cyclobutanecarbonyl chloride (0.51 g, 4.2 mmol); Addition 4: n-butyllithium (5.7 mL, 8.0 mmol) and cyclobutanecarbonyl chloride (0.41 g, 3.4 mmol). Upon completion of the last addition, the excess n-butyl lithium was quenched with water (200 mL), and the mixture was extracted with ethyl acetate (3×100 mL). The combined organic fractions were washed with brine (100 mL), dried over sodium sulfate, and concentrated in vacuo. The residue was purified by column chromatography (0-5% 95/5 MeOH/30% aqueous NH₃ in DCM) to give the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 6.76 (s, 1H), 3.80-3.65 (m, 5H), 3.50-3.40 (m, 2H), 2.98-2.76 (m, 2H), 2.62-2.50 (m, 4H), 2.50-2.37 (m, 2H), 2.29 (tt, J=11.0, 3.8 Hz, 1H), 2.22-2.08 (m, 2H), 2.08-1.93 (m, 2H), 1.93-1.83 (m, 2H), 1.52 (dddd, J=14.8, 12.8, 7.5, 3.8 Hz, 2H); MS (APCI+) m/z 398.2 (M+H)⁺.

Step 3: 6-chloro-3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine

Hydrazine (35% in water, 3.10 mL, 33.9 mmol) was added to cyclobutyl{2,6-dichloro-4-[4-(morpholin-4-yl)piperidin-1-yl]pyridin-3-yl}methanone (4.5 g, 11.30 mmol) in EtOH (32 mL). The reaction mixture was heated to reflux for 14 hours. Upon cooling to −5° C., the precipitate was isolated by filtration. The filter cake was rinsed with cold EtOH to give the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 10.21 (br s, 1H), 6.45 (s, 1H), 3.94-3.76 (m, 5H), 3.63 (d, J=12.4 Hz, 2H), 2.84 (td, J=12.4, 2.3 Hz, 2H), 2.71-2.59 (m, 4H), 2.58-2.44 (m, 2H), 2.44-2.31 (m, 3H), 2.14-1.97 (m, 4H), 1.85-1.70 (m, 2H); MS (APCI+) m/z 376.2 (M+H)⁺.

Step 4: Methyl 3-cyclobutyl-4-(4-morpholinopiperidin-1-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Into a 600 mL Parr reactor was charged 6-chloro-3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine (3.4 g, 9.05 mmol), followed by THF (170 mL) and MeOH (170 mL). 1,1′-Bis(diphenylphosphino)ferrocene-palladium (II) dichloride dichloromethane complex (0.739 g, 0.905 mmol), and triethylamine (2.52 mL, 18.09 mmol) were added to give a suspension. The reaction vessel was purged with argon followed by CO, pressurized to 100 psig with CO, and heated to 80° C. After 8 hours, the reaction mixture was cooled to room temperature, diluted with CH₂Cl₂ (800 mL), and filtered. The filtrate was concentrated in vacuo, and the residue was dissolved in CH₂Cl₂ (800 mL). The organic mixture was washed with saturated aqueous NaHCO₃ (300 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude residue was slurried in EtOAc to give the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 10.98 (br s, 1H), 7.37 (s, 1H), 4.08 (s, 3H), 3.96 (p, J=8.4 Hz, 1H), 3.83-3.76 (m, 4H), 3.70 (d, J=12.3 Hz, 2H), 2.92 (t, J=11.8 Hz, 2H), 2.66 (t, J=4.7 Hz, 4H), 2.55 (dq, J=11.3, 9.0 Hz, 2H), 2.44-2.31 (m, 3H), 2.15-2.00 (m, 4H), 1.88-1.74 (m, 2H); MS (APCI+) m/z 400.3 (M+H)⁺.

Synthesis of E511: Methyl 1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Step 1: 1-(4-fluorophenyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-4,6-diol

In a sealed tube, a suspension of AMP96 (215 mg, 0.91 mmol) and diethyl malonate ([105-53-3], 418 μL, 2.75 mmol) in Dowtherm® A was heated at 200° C. 4 hours. The reaction mixture was cooled down to 70-80° C. and poured onto a stirring solution of n-heptane (200 mL). The precipitate was collected by filtration, washed with n-heptane and dried at 40° C. under reduced pressure to give the titled compound.

Step 2: 1-(4-fluorophenyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-4,6-diyl Bis(trifluoromethanesulfonate)

Trifluoromethanesulfonic anhydride ([358-23-6], 302 μL, 1.8 mmol) was added dropwise to a solution of 1-(4-fluorophenyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-4,6-diol (270 mg, 0.9 mmol, Step 1) and pyridine (220 μL, 2.25 mmol) in acetonitrile (5 mL), maintaining the temperature around 20-25° C. The reaction mixture was stirred at RT for 20 hours. The reaction mixture was diluted with DCM and extracted twice with a saturated aqueous solution of NaHCO₃. The organic phase was separated, dried over MgSO₄, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (n-heptane/ethyl acetate, 1/0 to 0/1) to yield the titled compound.

Step 3: 1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridin-6-yl Trifluoromethanesulfonate

A mixture of 1-(4-fluorophenyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-4,6-diyl bis(trifluoromethanesulfonate) (29 mg, 50 μmol, Step 2), 4-methoxy-1-piperidin-4-ylpiperidine hydrochloride ([930603-98-8], 14 mg, 50 μmol) and DIPEA (35 μL, 200 μmol) in anhydrous DMSO (1 mL) was heated at 100° C. for 2 hours. The reaction mixture was cooled to RT and partitioned between ethyl acetate (50 mL) and water (30 mL). The organic phase was separated, dried over MgSO₄, filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography on silica gel eluting with n-heptane/ethyl acetate (1/0 to 0/1) and ethyl acetate/(DCM/MeOH, 9/1) (1/0 to 0/1) to afford the titled compound.

Step 4: Methyl 1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A pressured vessel was charged with 1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridin-6-yl trifluoromethanesulfonate (145 mg, 240 μmol, Step 3), Pd(dppf)Cl₂.DCM ([95464-05-4], 4 mg, 4.8 μmol), and triethylamine (66 μL, 500 μmol) in MeOH (5 mL). The system was loaded with CO (6 bars) and heated at 100° C. for 1 hour. The vessel was cooled down to RT, and the mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with a mixture of ethyl acetate/(DCM/MeOH, 9/1) (1/0 to 0/1) to give the titled compound.

Synthesis of AMI01: 4-(methoxymethyl)piperidin-4-ol Hydrochloride

Step 1: 4-Hydroxy-4-methoxymethyl-piperidine-1-carboxylic Acid Tert-butyl Ester

A suspension of tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (CAS: 147804-30-6, 200 mg, 0.94 mmol) and sodium methoxide (61 mg, 1.13 mmol) in methanol (2 mL) was placed in a sealed tube and was heated at 100° C. for 20 hours. The reaction mixture was cooled to RT, acidified with acetic acid to pH 5-6, diluted with DCM and washed with water. The organic phase was separated using a phase separator and concentrated in vacuo. The titled compound was used as such in the next step without any further purification.

Step 2: 4-Methoxymethyl-piperidin-4-ol Hydrochloride

4-Hydroxy-4-methoxymethyl-piperidine-1-carboxylic acid tert-butyl ester (206 mg, 0.84 mmol) was dissolved in dioxane (2 mL). 4 M HCl in dioxane (1.05 mL, 4.2 mmol) was added, and the solution was stirred at RT for 20 hours. The volatiles were removed under reduced pressure. The titled compound was used as such in the next step without any further purification.

Synthesis of AMI02: 4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]piperidin-4-ol Hydrochloride

Step 1: Tert-butyl 4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-4-hydroxy-piperidine-1-carboxylate

A solution of tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (CAS: 147804-30-6, 150 mg, 0.7 mmol) and thiomorpholine 1,1-dioxide (CAS: 39093-93-1, 380 mg, 2.8 mmol) in ethanol (2 mL) was placed in a sealed tube and was heated at 75° C. for 20 hours. The reaction mixture was cooled to RT, diluted with DCM and washed with water. The organic phase was separated using a phase separator and concentrated in vacuo. The titled compound was obtained by flash column chromatography eluting with DCM/MeOH.

Step 2: 4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]piperidin-4-ol Hydrochloride

tert-Butyl 4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-4-hydroxy-piperidine-1-carboxylate (215 mg, 0.62 mmol) was dissolved in dioxane (2 mL). 4 M HCl in dioxane (0.89 mL, 3.6 mmol) was added, and the solution was stirred at RT for 20 hours. The volatiles were removed under reduced pressure. The titled compound was used as such in the next step without any further purification.

Synthesis of AMI03: (2S)-2-fluoro-N,N-dimethyl-2-(4-piperidyl)ethanamine Hydrochloride

Step 1: (S)-tert-butyl 4-(1-fluoro-2-oxoethyl)piperidine-1-carboxylate

To a suspension of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide ((CAS 133745-75-2, 347 g, 1100 mmol) and (5R)-(+)-2,2,3-trimethyl-5-benzyl-4-imidazolidinone dichloroacetic acid (CAS 857303-87-8, 76 g, 220 mmol) in THF and isopropyl alcohol at −20° C. was added a solution of tert-butyl 4-(2-oxoethyl)piperidine-1-carboxylate (250 g, 1100 mmol, CAS: 142374-19-4) in THF. The mixture was stirred at 10° C. for 16 h, diluted with hexane at −78° C. and filtered through silica, washed with hexane, then with saturated aqueous NaHCO₃, dried, filtered, and concentrated to give (S)-tert-butyl 4-(1-fluoro-2-oxoethyl)piperidine-1-carboxylate.

Step 2: (S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate

A solution of (S)-tert-butyl 4-(1-fluoro-2-oxoethyl)piperidine-1-carboxylate (10 g, 40.8 mmol) in dichloromethane (280 mL) and ethanol (220 mL) was stirred at 10° C. Then, sodium borohydride (CAS 16940-66-2, 4.0 g, 105.7 mmol, 2.6 equiv) was added. The mixture was stirred at 10° C. for 1 hour, was diluted with water and extracted with dichloromethane. The organic layer was dried, filtered and concentrated, and the residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate) to give (S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate.

Step 3: (S)-tert-butyl 4-(2-(benzylamino)-1-fluoroethyl)piperidine-1-carboxylate

Trifluoromethanesulfonic anhydride (CAS 358-23-6, 5.70 g, 20.22 mmol, 1.0 equiv) was added to a solution of (S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate (5 g, 20.22 mmol) and 2,6-dimethylpyridine (CAS 108-48-5, 2.166 g, 20.22 mmol, 1.0 equiv) in dichloromethane at 0° C. The mixture was stirred at 0° C. for 0.5 h. A separated round bottom flask was charged with benzylamine (2.166 g, 20.22 mmol, 1.0 equiv) in dichloromethane at 0° C. The solution of the triflate was then added slowly at 0° C. The reaction mixture was stirred at 25° C. for 12 hours, quenched with a saturated aqueous solution of sodium hydrogencarbonate, and extracted with dichloromethane. The organic fraction was concentrated. The residue was purified on silica gel chromatography, eluting with acetone/dichloromethane to give (S)-tert-butyl 4-(2-(benzylamino)-1-fluoroethyl)piperidine-1-carboxylate.

Step 4: (S)-tert-butyl 4-(2-amino-1-fluoroethyl)piperidine-1-carboxylate

To a solution of (S)-tert-butyl 4-(2-(benzylamino)-1-fluoroethyl)piperidine-1-carboxylate (4.5 g, 13.38 mmol) in methanol was added Pd/C, then the solution was stirred at 35° C. under hydrogen atmosphere (45 psi) for 12 hours. The mixture was filtered and concentrated to give (S)-tert-butyl 4-(2-amino-1-fluoroethyl)piperidine-1-carboxylate.

Step 5: (S)-tert-butyl 4-(2-(dimethylamino)-1-fluoroethyl)piperidine-1-carboxylate

To a mixture of (S)-tert-butyl 4-(2-amino-1-fluoroethyl)piperidine-1-carboxylate (3.0 g, 12.18 mmol) in methanol was added paraformaldehyde (CAS 30525-89-4, 1.828 g, 60.9 mmol, 5.0 equiv) followed by three drops of acetic acid. The reaction mixture stirred for 1 hour. Then sodium cyanoborohydride (CAS 25895-60-7, 1.148 g, 18.27 mmol, 1.5 equiv) was added, and the mixture was stirred for 12 hours. The reaction mixture was filtered and concentrated, and the residue was purified by column chromatography on silica gel (DCM/MeOH) to afford (S)-tert-butyl 4-(2-(dimethylamino)-1-fluoroethyl)piperidine-1-carboxylate

Step 6: (S)-2-fluoro-N,N-dimethyl-2-(piperidin-4-yl)ethanamine hydrochloride

To a solution of (S)-tert-butyl 4-(2-(dimethylamino)-1-fluoroethyl)piperidine-1-carboxylate (2 g, 7.29 mmol) in MeOH was added 4 N hydrogen chloride in methanol (10 mL, 40 mmol, 5.5 equiv), and the mixture was stirred at RT for 2 hours. Then the solution was concentrated to give (S)-2-fluoro-N,N-dimethyl-2-(piperidin-4-yl)ethanamine hydrochloride.

Synthesis of AMI04: 4-(ethoxymethyl)-4-fluoro-piperidine

Step 1: 1-tert-butyl 4-ethyl 4-fluoropiperidine-1,4-dicarboxylate

In a 100 mL round-bottomed flask was combined 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate (1 g, 3.89 mmol) and THF (10 mL). The solution was cooled to −78° C., and sodium hexamethyldisilazide (6 mL of 1 M THF solution, 6.00 mmol) was added slowly via syringe. After 60 min, N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (2 g, 6.34 mmol) in THF (3 mL) was added. After 2 h, dichloromethane/water (1:1, 40 mL) was added. The aqueous layer was extracted with dichloromethane, and the combined organic fractions were dried over Na₂SO₄, filtered, and concentrated in vacuo.

Step 2: Tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate

A solution of 1-tert-butyl 4-ethyl 4-fluoropiperidine-1,4-dicarboxylate (1.5 g, 5.45 mmol) in THF (5 mL) was cooled to 0° C., and then 1 M LiAlH₄ in THF (3.81 mL, 3.81 mmol) was added dropwise. The reaction mixture was warmed up to RT and stirred for 2 h. Water (0.9 mL) was added to the reaction mixture dropwise followed by 2 N NaOH (0.3 mL). The mixture was stirred for another 30 minutes, and then solid removed by filtration through diatomaceous earth and washed with EtOAc. The filtrate was washed with brine, dried over Na₂SO₄, and concentrated from acetonitrile under vacuum several time to remove the water to afford tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate.

Step 3: Tert-butyl 4-(ethoxymethyl)-4-fluoropiperidine-1-carboxylate

tert-Butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (30 g, 129 mmol) was first treated with sodium hydride (6.17 g, 154 mmol) DMF (500 mL), and then iodoethane (24.07 g, 154 mmol) was added at room temperature. The reaction mixture was stirred at 25° C. for 12 h. The mixture was washed with H₂O and extracted with EtOAc, and then the combined organic phases were washed with H₂O, and brine. The organic fraction was dried Na₂SO₄, filtered and concentrated to give tert-butyl 4-(ethoxymethyl)-4-fluoropiperidine-1-carboxylate (26.9 g, 103 mmol, 80% purity).

Step 4: 4-(ethoxymethyl)-4-fluoro-piperidine

A mixture of tert-butyl 4-(ethoxymethyl)-4-fluoropiperidine-1-carboxylate 26.9 g, 103 mmol) in ethyl acetate (200 mL) was made acidic by addition of HCl in ethyl acetate solution at 0° C. Then the mixture was allowed to warm to 15° C. and stirred at 15° C. for 3 h. The reaction mixture was concentrated under vacuum to yield 4-(ethoxymethyl)-4-fluoropiperidine as a hydrochloride salt (15.27 g, 95 mmol, 92% yield).

Synthesis of AMI05: 4-fluoro-4-(2-methoxyethoxymethyl)piperidine

Step 1: Tert-butyl 4-fluoro-4-((2-methoxyethoxy)methyl)piperidine-1-carboxylate

To a mixture of tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (30 g, 129 mmol, prepared as described in the synthesis of AMI04) in DMF (400 mL) was added sodium hydride (6.43 g, 161 mmol) at 0° C. After 15 minutes, 1-bromo-2-methoxyethane (35.7 g, 257 mmol) was added at 0° C., and the mixture was stirred at 25° C. for 12 h. The mixture was quenched with 200 mL of aqueous NH₄Cl at 5° C. The organic layer was separated, washed with water and brine, dried over Na₂SO₄, and concentrated. After column chromatography on silica gel (petroleum ether/EtOAc=10:1 to petroleum ether/EtOAc=2:1), tert-butyl 4-fluoro-4-((2-methoxyethoxy)methyl)piperidine-1-carboxylate (20.5 g, 70.4 mmol, 54.% yield) was obtained.

Step 2: 4-fluoro-4-(2-methoxyethoxymethyl)piperidine

A solution of tert-butyl 4-fluoro-4-((2-methoxyethoxy)methyl)piperidine-1-carboxylate (20 g, 68.6 mmol) in 200 mL EtOAc was made acidic with HCl in EtOAc at room temperature. After TLC on silica gel (petroleum ether/EtOAc=1:1) showed that the reaction was complete, the mixture was concentrated to afford the titled compound as a hydrochloride salt (15 g, 65.9 mmol, 96% yield).

Synthesis of AMI07: 4-fluoro-4-(methoxymethyl)piperidine

Step 1: Tert-butyl 4-fluoro-4-(methoxymethyl)piperidine-1-carboxylate

To a mixture of tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (30 g, 129 mmol, prepared as described in the synthesis of AMI04) and NaH (3.09 g, 129 mmol) in THF (500 mL) was added iodomethane (41.9 g, 295 mmol) at room temperature, and then the mixture was stirred at 25° C. for 12 h, The reaction mixture was diluted with water and extracted with EtOAc. The combined organic phases were washed with water and brine. The organic fraction was dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluted with petroleum ether/EtOAc=2:1 to give tert-butyl 4-fluoro-4-(methoxymethyl)piperidine-1-carboxylate (25 g, 101 mmol, 79% yield).

Step 2: 4-fluoro-4-(methoxymethyl)piperidine

A mixture of tert-butyl 4-fluoro-4-(methoxymethyl)piperidine-1-carboxylate (25 g, 101 mmol) in EtOAc (300 mL) was made acidic with HCl in EtOAc at 0° C., and the mixture was allowed to warm to 15° C. and stirred at 15° C. for 3 h. The reaction mixture was concentrated under vacuum to yield the titled compound as a hydrochloride salt (13 g, 70.8 mmol, 70.0% yield).

Synthesis of AMI08: 3-fluoro-3-(2-methoxyethoxymethyl)piperidine

Step 1: Tert-butyl 3-fluoro-3-((2-methoxyethoxy)methyl)piperidine-1-carboxylate

To a mixture of tert-butyl 3-fluoro-3-(hydroxymethyl)piperidine-1-carboxylate (25 g, 107 mmol) in THF (300 mL) was added NaH (2.57 g, 107 mmol) at 0° C. After 15 minutes, 1-bromo-2-methoxyethane (29.8 g, 214 mmol) was added at 0° C. The mixture was stirred at 25° C. for 12 h, and then the reaction was quenched by the addition of saturated aqueous NH₄Cl and extracted with EtOAc. The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuum. The residue was added to a silica gel column eluted with hexanes:ethyl acetate (2:1) to give tert-butyl 3-fluoro-3-((2-methoxyethoxy)methyl)piperidine-1-carboxylate (22 g, 76 mmol, 70.5% yield).

Step 2: 3-fluoro-3-(2-methoxyethoxymethyl)piperidine

A mixture of tert-butyl 3-fluoro-3-((2-methoxyethoxy)methyl)piperidine-1-carboxylate (25 g, 86 mmol) in EtOAc (200 mL) was made acidic with HCl in EtOAc at 0° C. The mixture was allowed to warm to 15° C. and stirred at 15° C. for 3 h. The reaction mixture was concentrated under vacuum to the titled compound as a hydrochloride salt (15 g, 65.9 mmol, 77% yield).

Synthesis of AMI09: 2-(4-hydroxy-4-piperidyl)acetonitrile Hydrochloride

Step 1: Tert-butyl 4-(cyanomethyl)-4-hydroxy-piperidine-1-carboxylate

A flame-dried round bottom flask was cooled down to RT under argon. A solution of 1 M LiHMDS in THF (1.51 mL, 3.02 mmol, 2.0 equiv) was introduced into the flask and cooled down to −78° C. (acetone/dry ice bath). Dry MeCN (157 μL, 3.02 mmol, 2.0 equiv) in anhydrous THF (5 mL) was then added dropwise under argon, and the reaction mixture was stirred for 45 minutes at −78° C. At this point, a solution of 1-(tert-butoxycarbonyl)-4-piperidone (300 mg, 1.51 mmol, 1.0 equiv) in dry THF (5 mL) was added dropwise, and the reaction mixture was stirred at −78° C. for 1 h. The reaction mixture was quenched with an aqueous saturated solution of ammonium chloride and diluted with ethyl acetate. The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford tert-butyl 4-(cyanomethyl)-4-hydroxypiperidine-1-carboxylate which was used as such in the next step.

Step 2: 2-(4-hydroxy-4-piperidyl)acetonitrile Hydrochloride

tert-Butyl 4-(cyanomethyl)-4-hydroxypiperidine-1-carboxylate (226 mg, 0.94 mmol, 1 equiv) was dissolved in dioxane (2.5 mL). 4 M HCl in dioxane (1.41 mL, 1.88 mmol, 6 equiv) was added, and the solution was stirred at RT for 5 days. The reaction mixture was concentrated under reduced pressure. The titled compound was used as such without any further purification.

Synthesis of AMI10: 4-methoxy-1,4′-bipiperidine

Step 1: Benzyl 4-methoxy-[1,4′-bipiperidine]-1′-carboxylate

To a solution of benzyl 4-oxopiperidine-1-carboxylate ([19099-93-5], 40 gram, 171 mmol) and 4-methoxypiperidine ([4045-24-3], 24.6 gram) in dichloromethane (800 mL) was added acetic acid (10.8 mL, 189 mmol) and sodium triacetoxyborohydride (54.5 gram, 257 mmol). The mixture was stirred at 0° C. for 120 minutes. Next, the mixture was washed with a saturated aqueous K₂CO₃ solution. The organic phase was separated and concentrated to give a residue that was purified by chromatography on silica gel using a gradient elution with CH₂Cl₂ to CH₂Cl₂/CH₃OH (100/0 to 97/2.5) to give the titled compound.

Step 2: 4-methoxy-1,4′-bipiperidine

Benzyl 4-methoxy-[1,4′-bipiperidine]-1′-carboxylate (23 gram, 69 mmol) was dissolved in CH₃OH (350 mL). The solution was flushed with N₂ and 10% Pd/C (7.3 gram, 6.9 mmol) was added. After applying a balloon with H₂, the mixture was stirred at ambient temperature overnight. Next, the mixture was filtered through diatomaceous earth, and the resulting filtrate was concentrated to give the titled compound.

Synthesis of AMI11: 1-piperidin-1-ium-4-ylpiperidine-4-carbonitrile Chloride

Step 1: Tert-butyl 4-(4-cyano-1-piperidyl)piperidine-1-carboxylate

A suspension of 4-cyanopiperidine ([4395-98-6], 500 mg, 4.5 mmol), tert-butyl 4-oxopiperidine-1-carboxylate ([79099-07-3], 900 mg, 4.5 mmol) and AcOH (0.27 mL) in DCM (66 mL) was cooled at 0° C. Next, sodium triacetoxyborohydride ([56553-60-7], 955 mg, 4.5 mmol) was added portion wise. After overnight stirring, the reaction was diluted with 60 mL of water together with a 1 N citric acid solution to bring down the pH till 3-4. The organic layer was separated and discarded. Next, the aqueous layer was brought to neutral pH with a saturated aqueous NaHCO₃ solution. After extraction with DCM, the organic phase was concentrated to give the titled compound.

Step 2: 1-piperidin-1-ium-4-ylpiperidine-4-carbonitrile Chloride

tert-Butyl 4-(4-cyano-1-piperidyl)piperidine-1-carboxylate (662 mg, 2.26 mmol) was dissolved in DCM and trifluoroacetic acid ([76-05-1], 0.93 mL) was added. After overnight stirring, the mixture was concentrated to dryness. The obtained residue was suspended in 4 N HCl in dioxane. The addition of ethanol gave a suspension which was filtered to give the titled compound as a precipitate.

Synthesis of ALC02: (2R)-2-fluoro-2-tetrahydropyran-4-yl-ethanol

Step 1: (2R)-2-fluoro-2-tetrahydropyran-4-yl-acetaldehyde

To a mixture of (R)-5-benzyl-2,2,3-trimethylimidazolidin-4-one dichloroacetic acid salt (CAS 857303-87-8, 2.71 g, 7.80 mmol, 0.2 equiv) and N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (CAS 133745-75-2, 12.30 g, 39 mmol, 1.0 equiv) in THF (200 mL) and isopropyl alcohol (25 mL) was slowly added at −20° C. a solution 2-(tetrahydro-2H-pyran-4-yl)acetaldehyde (5 g, 39 mmol, CAS 65626-23-5) in THF (25 mL). The mixture was stirred at −20° C. for 12 hours, then diluted with hexane (800 mL) cooled to −78° C. and filtered through silica, washed with hexane. The filtrate was concentrated to give (R)-2-fluoro-2-(tetrahydro-2H-pyran-4-yl)acetaldehyde.

Step 2: (2R)-2-fluoro-2-tetrahydropyran-4-yl-ethanol

To a solution of (R)-2-fluoro-2-(tetrahydro-2H-pyran-4-yl)acetaldehyde (4 g, 27.4 mmol) in dichloromethane (48 mL) and ethanol (40 mL) was added sodium borohydride (CAS 16940-66-2, 2.59 g, 68.4 mmol, 2.5 equiv). The mixture was stirred at 25° C. for 12 hours, then diluted with water and extracted with dichloromethane. The organic layer was dried, filtered, concentrated and purified by chromatography (petroleum ether, ethylate) to give (2R)-2-fluoro-2-tetrahydropyran-4-yl-ethanol.

Synthesis of ALC03: 1-[4-fluoro-4-(hydroxymethyl)-1-piperidyl]ethanone

Step 1: Tert-butyl 4-(bromomethyl)-4-fluoropiperidine-1-carboxylate

To a mixture of tert-butyl 4-methylenepiperidine-1-carboxylate (159635-49-1, 50 g, 253 mmol) and triethylamine trihydrofluoride (102 g, 634 mmol) in dichloromethane (1 L) was added 1-bromopyrrolidine-2,5-dione (67.7 g, 380 mmol) at 0° C. After 15 min, stirring was continued at 20° C. for 3 h. Then the mixture was poured into ice-water, neutralized with aqueous 28% ammonia and extracted with dichloromethane. The combined extracts were washed with ˜0.1 N HCl and with 5% aqueous sodium hydrogencarbonate solution, dried with sodium sulfate, filtered and concentrated. The residue was purified by column chromatography to provide tert-butyl 4-(bromomethyl)-4-fluoropiperidine-1-carboxylate (60.1 g, 203 mmol, 80% yield).

Step 2: Tert-butyl 4-(acetoxymethyl)-4-fluoropiperidine-1-carboxylate

To a mixture of tert-butyl 4-(bromomethyl)-4-fluoropiperidine-1-carboxylate (50 g, 169 mmol) and potassium iodide (7.01 g, 42.2 mmol) in dimethyl formamide (1.5 L) was added potassium acetate (249 g, 2532 mmol) at room temperature. The mixture was stirred at 120-140° C. for 12 h, then cooled, diluted with water, and extracted with ethyl acetate. The combined organic phases were washed with water and brine. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by chromatography on a silica gel column eluted with hexanes:ethyl acetate to give tert-butyl 4-(acetoxymethyl)-4-fluoropiperidine-1-carboxylate (42 g, 153 mmol, 90% yield).

Step 3: (4-fluoropiperidin-4-yl)methyl Acetate Hydrochloride

To a mixture of tert-butyl 4-(acetoxymethyl)-4-fluoropiperidine-1-carboxylate (50 g, 182 mmol) in ethyl acetate (400 mL) was added a solution of HCl (1 L) at 0° C. The mixture was allowed to warm to 15° C. and stirred at 15° C. overnight. The reaction mixture was concentrated under vacuum, and the residue washed with dichloromethane. Then the precipitate was collected by filtration to obtain (4-fluoropiperidin-4-yl)methyl acetate hydrochloride (33 g, 156 mmol, 86% yield).

Step 4: (1-acetyl-4-fluoropiperidin-4-yl)methyl Acetate

To a solution of (4-fluoropiperidin-4-yl)methyl acetate hydrochloride (30 g, 142 mmol) and triethylamine (59.3 mL, 425 mmol) in dichloromethane (300 mL) was added acetyl chloride (16.69 g, 213 mmol) at 0° C. The mixture was stirred overnight at 20° C., then diluted with dichloromethane and washed with water. The dichloromethane layer was concentrated to give crude (1-acetyl-4-fluoropiperidin-4-yl)methyl acetate (21 g, 97 mmol, 68.2% yield).

Step 5: 1-[4-fluoro-4-(hydroxymethyl)-1-piperidyl]ethanone

(1-Acetyl-4-fluoropiperidin-4-yl)methyl acetate (30.8 g, 142 mmol) was dissolved in 3:1 THF:water (400 mL) at 0° C., and then lithium hydroxide (6.80 g, 284 mmol) was added in one portion. The reaction mixture was stirred for 1 hour at 0° C. The mixture was poured into ethyl acetate and water, shaken, and the layers separated. The aqueous layer was extracted with ethyl acetate. The ethyl acetate extracts were combined, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was titrated with CH₂Cl₂ and cyclohexane to afford 1-[4-fluoro-4-(hydroxymethyl)-1-piperidyl]ethanone (19 g, 108 mmol, 76% yield). Alternatively, 1-[4-fluoro-4-(hydroxymethyl)-1-piperidyl]ethanone is available by treatment of commercially available (4-fluoropiperidin-4-yl)methanol (CAS: 949100-11-2) with acetic anhydride.

Synthesis of ALC04: 2-[isopropyl(oxetan-3-yl)amino]ethanol

2-[Isopropyl(oxetan-3-yl)amino]ethanol is available by the reaction of (isopropylamino)ethanol (CAS: 109-56-8) with 1 equivalent of 3-oxetanone (CAS: 6704-31-0) in a solvent such as isopropanol or THF with a reducing agent such as sodium borohydride or sodium triacetoxyborohydride, followed by distillation.

Synthesis of ALC05: 2-(oxetan-3-yloxy)ethanol

Step 1: 3-(2-benzyloxyethoxy)oxetane

1.0 M Lithium bis(trimethylsilyl)amide in THF (31.1 mL, 31.1 mmol, 1.2 equiv) was added dropwise at RT to a solution of oxetan-3-ol (1.92 g, 25.9 mmol) and ((2-bromoethoxy)methyl)benzene (6.13 g, 28.5 mmol, 1.1 equiv) in dioxane (15 mL). The mixture was stirred at ambient temperature for 2 hours. DMF (20 mL) was added along with sodium iodide, and the reaction mixture was stirred at ambient temperature overnight, then stirred at 70° C. for 20 hours. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and aqueous citric acid. The organic layer was washed twice with brine, then dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (dichloromethane and ethyl acetate) to give 3-(2-(benzyloxy)ethoxy)oxetane.

Step 2: 2-(oxetan-3-yloxy)ethanol

To a solution of 3-(2-(benzyloxy)ethoxy)oxetane (1.40 g, 6.72 mmol) in THF (28 mL) was added 20% palladium hydroxide on carbon (0.178 g, 0.645 mmol) in a 50 mL pressure bottle, and the mixture was stirred for 4 h under a hydrogen atmosphere. The reaction mixture was filtered free of catalyst and solids, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a mixture of ethyl acetate and dichloromethane to give the titled compound.

Synthesis of Intermediate BF01: Potassium Trifluorido{[4-(methoxymethyl)piperidin-1-yl]methyl}borate

4-(Methoxymethyl)piperidine hydrochloride ([916317-00-5], 1.0 g, 6.03 mmol,), potassium bromomethyl trifluoroborate (1.21 g, 6.03 mmol), KHCO₃ (1.2 g, 12.1 mmol) and KI (100 mg, 0.6 mmol) were stirred under N₂ in dry THF (8 mL) at 80° C. for 4 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was suspended in dry acetone and filtered. The filtrate was treated with diethyl ether, and the resulting precipitate was collected by filtration and dried to afford the titled compound, which was used as such in the next step.

TABLE IX List of amines Int. Structure Name SM method MW Mes AMI01

4- (methoxymethyl) piperidin-4- ol hydrochloride 147804- 30-6 Specific example 181 AMI02

4-[(1,1-dioxo- 1,4-thiazinan- 4- yl)methyl] piperidin-4-ol hydrochloride 147804- 30-6 Specific example 284 AMI03

(2S)-2-fluoro- N,N-dimethyl- 2-(4- piperidyl)ethan amine hydrochloride 142374- 19-4 Specific example 210 AMI04

4- (ethoxymethyl)- 4-fluoro- piperidine 142851- 03-4 Specific example 161 AMI05

4-fluoro-4-(2- methoxyethoxy methyl)piperidine 614730- 97-1 Specific example 191 AMI06 955082- 95-8 or 955028- 84-9 (HCl salt)

(3R,4R)-3- fluoropiperidin- 4-ol 119 AMI07

4-fluoro-4- (methoxymethyl) piperidine 614730- 97-1 Specific example 147 AMI08

3-fluoro-3-(2- methoxyethoxy methyl)piperidine 1209781- 11-2 Specific example 191 AMI09

2-(4-hydroxy- 4- piperidyl) acetonitrile hydrochloride 79099- 07-3 Specific example 140 AMI10

4-methoxy- 1,4′- bipiperidine 19099- 93-5 and 4045- Specific example 198 24-3 AMI11

1-piperidin- 1-ium-4- ylpiperidine- 4- carbonitrile chloride 79099- 07-3 and 4395- 98-6 Specific example 249

TABLE X List of alcohols Int. Structure Name SM method MW Mes ALC01

(2S)-2-fluoro-2- 2- tetrahydro- pyran-4-yl- ethanol Analogous to ALC02 148 ALC02

(2R)-2-fluoro- 2- tetrahydropyran- 4-yl-ethanol 65626- 23-5 Specific example 148 ALC03

1-[4-fluoro-4- (hydroxymethyl)- 1-piperidyl] ethanone 159635- 49-1 Specific example 175 ALC04

2- [isopropyl(oxetan- 3- yl)amino]ethanol Specific example 159 ALC05

2-(oxetan-3- yloxy)ethanol Specific example 118 ALC06

(1- cyclobutyl- 4- piperidyl) 6457- 49-4 and 1191- 118 169 170 methanol 95-3 ALC07

(1- cyclohexyl- 4- piperidyl) 6457- 49-4 and 108- 118 197 198 methanol 94-1 ALC08

(1- tetrahydro- pyran-4-yl-4- piperidyl) methanol 6457- 49-4 and 29943- 42-8 118 199 200 ALC09

(1- cyclopropyl- 4- piperidyl) 6457- 49-4 and 27374- 126 155 156 methanol 25-0

TABLE XI List of BF₃ salts Int. Structure Name SM method MW Mes BF01

potassium trifluorido{[4- (methoxymethyl) piperidin-1- yl]methyl}borate 916317- 00-5 and 888711- 44-2 Specific example 249 NA

TABLE XII List of esters Int. Structure Name SM method MW Mes E001

ethyl 1-(3- bromophenyl)-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4-b] pyridine- 6-carboxylate A242 I9, Specific example 548- 550 549- 551 E002

ethyl 1-[3-(azetidin-1- yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4-b] pyridine- 6-carboxylate E001, 935670- 07-8 I8, Specific example 525 526 E003

ethyl 1-cyclohexyl-3- isopropyl-4-(2- morpholinopyrimidin- 5-yl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP22, AMP23 I1 478 479 E004

ethyl 3-methyl-1- phenyl-4-(1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP13, 98-77-1 I3 364 365 E005

ethyl 3-isopropyl-4- (4- morpholinophenyl)-1- (3-pyrrolidin-1- ylphenyl)pyrazolo[3,4- b]pyridine-6- carboxylate E001 I8 539 540 E006

ethyl 4-[4- (dimethylamino) phenyl]-3-methyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP25, 1131- 18-6 I1 400 401 E007

ethyl 3-isopropyl-4- (6-morpholino-3- pyridyl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP26, AMP04 I1 471 472 E008

ethyl 3-isopropyl-1- [3-(3- methoxyazetidin-1- yl)phenyl]-4-(4- morpholinophenyl) pyrazolo[3,4-b] pyridine- 6-carboxylate E001, 110925- 17-2 I8, Specific example 555 556 E009

ethyl 3-methyl-4-(6- morpholino-3- pyridyl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP26, 1131- 18-6 I1 443 444 E010

ethyl 4-(4- bromophenyl)-3- methyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate A246 I9 435- 437 436- 438 E011

ethyl 4-[4-[3- (dimethylamino) azetidin-1-yl] phenyl]-3- methyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate E010, 138022- 85-2 I10 Specific example 455 456 E012

ethyl 1-[3-(3,3- dimethylazetidin-1- yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4-b] pyridine- 6-carboxylate E001, 19816- 92-3 I8 553 554 E013

ethyl 1-[3-(3- fluoropyrrolidin-1- yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4-b] pyridine- 6-carboxylate E001- 116574- 74-4 I8 553 558 E014

ethyl 1-cyclohexyl-3- isopropyl-4-[6- [methyl(tetrahydro- pyran-4-yl)amino]-3- pyridyl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP10, AMP23 I1 505 506 E015

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-(6- morpholino-3- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP26, AMP06 I1 514 515 E016

ethyl 1-[3- (dimethylamino) phenyl]-3-isopropyl- 4-(2- morpholinopyrimidin- 5-yl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP22, AMP06 I1 515 516 E017

ethyl 3-cyclobutyl-4- [6-[2- methoxyethyl(methyl) amino]-3-pyridyl]-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP08, AMP29 I1 485 486 E018

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP29 I1 506 507 E019

ethyl 3-cyclobutyl-4- [6- [methyl(tetrahydro- pyran-4-yl)amino]-3- pyridyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP10, AMP29 I1 511 512 E020

ethyl 3-cyclobutyl-4- [4-[2- methoxyethyl(methyl) amino]phenyl]-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP11, AMP29 I1 484 485 E021

ethyl 4-(4- acetamidophenyl)-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP24, AMP23 I1 448 449 E022

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP23 I1 499 500 E023

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-1- [3- (dimethylamino) phenyl]-3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP06 I1 536 537 E024

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-[4- [2- methoxyethyl(methyl) amino]phenyl]pyrazolo [3,4-b]pyridine-6- carboxylate ALP11, AMP06 I1 515 516 E025

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 1-[3- (dimethylamino) phenyl]-3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP06 I1 537 538 E026

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-[6- [2- methoxyethyl(methyl) amino]-3- pyridyl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP08, AMP06 I1 516 517 E027

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-isopropyl-1-(3- morpholinophenyl) pyrazolo[3,4-b] pyridine- 6-carboxylate ALP09, AMP10 I1 579 580 E028

ethyl 3-isopropyl-4- [6-[2- methoxyethyl(methyl) amino]-3-pyridyl]-1- (3- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate ALP08, AMP10 I1 558 559 E029

ethyl 3-isopropyl-4- [6- [methyl(tetrahydropyran- 4-yl)amino]-3- pyridyl]-1-(3- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate ALP10, AMP10 I1 584 585 E030

ethyl 3-isopropyl-4- [4-[2- methoxyethyl(methyl) amino]phenyl]-1-(3- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate ALP11, AMP10 I1 557 558 E031

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-[6- [methyl(tetrahydropyran- 4-yl)amino]-3- pyridyl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP10, AMP06 I1 542 543 E032

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-[2- [methyl(tetrahydropyran- 4- yl)amino]pyrimidin-5- yl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP13, AMP06 I1 543 544 E033

ethyl 1-cyclohexyl-3- cyclopropyl-4-[6- (dimethylamino)-3- pyridyl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP20, AMP39 I1 433 434 E034

ethyl 4-[2-(4-cyano-1- piperidyl)pyrimidin-5- yl]-1-[3- (dimethylamino)phenyl]- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP14, AMP06 I1 538 539 E035

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-[4- [methyl(tetrahydro- pyran-4- yl)amino]phenyl] pyrazolo[3,4-b]pyridine- 6-carboxylate ALP15, AMP06 I1 541 542 E036

ethyl 3-isopropyl-4- [4- [methyl(tetrahydro- pyran-4- yl)amino]phenyl]-1- (3- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate ALP15, AMP10 I1 583 584 E037

ethyl 4-[2-(4-cyano-1- piperidyl)pyrimidin-5- yl]-3-isopropyl-1-(3- morpholinophenyl) pyrazolo[3,4-6]pyridine- 6-carboxylate ALP14, AMP10 I1 580 581 E038

ethyl 4-[4-[3- (dimethylamino) pyrrolidin-1-yl]phenyl]- 3-methyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate E010, 69478- 75-7 I10 469 470 E039

ethyl 3-isopropyl-1- (m-tolyl)-4-(1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate Hp01, 98-77-1 I3 406 407 E040

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-3- cyclobutyl-1- cyclohexyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP35 I1 511 512 E041

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-cyclobutyl-1- cyclohexyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP35 I1 512 513 E042

ethyl 4-(4- acetamidophenyl)-1- (3,5-difluorophenyl)- 3-(1- methoxycarbonyl- azetidin-3-yl) pyrazolo[3,4- b]pyridine-6- carboxylate E043 I11 Specific example 549 550 E043

ethyl 4-(4- acetamidophenyl)-3- (azetidin-3-yl)-1-(3,5- difluorophenyl)pyrazolo [3,4-b]pyridine-6- carboxylate E044 Specific example 491 492 E044

ethyl 4-(4- acetamidophenyl)-3- (1-tert- butoxycarbonylazetidin- 3-yl)-1-(3,5- difluorophenyl)pyrazolo [3,4-b]pyridine-6- carboxylate ALP24, AMP40 I1 591 592 E045

ethyl 3-isopropyl-4- [4-[2- methoxyethyl(methyl) amino]phenyl]-1-(3- pyrrolidin-1- ylphenyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP11, AMP11 I1 541 542 E046

ethyl 3-isopropyl-4- [4- [methyl(tetrahydropyran- 4- yl)amino]phenyl]-1- (3-pyrrolidin-1- ylphenyl)pyrazolo[3,4- 6]pyridine-6- carboxylate ALP15, AMP11 I1 567 568 E047

ethyl 3-cyclobutyl-4- [4- [methyl(tetrahydropyran- 4- yl)amino]phenyl]-1- (3-pyrrolidin-1- ylphenyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP15, AMP31 I1 580 581 E048

ethyl 3-isopropyl-4- (4-methoxy-1- piperidyl)-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01, 4045- 24-3 I3 436 437 E049

ethyl 4-[2-(4-cyano-1- piperidyl)pyrimidin-5- yl]-1-cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP14, AMP23 I1 501 502 E050

ethyl 1-cyclohexyl-3- isopropyl-4-[2-[2- methoxyethyl(methyl) amino]pyrimidin-5- yl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP16, AMP23 I1 480 481 E051

ethyl 1-cyclohexyl-3- isopropyl-4-[2- [methyl(tetrahydropyran- 4- yl)amino]pyrimidin-5- yl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP13, AMP23 I1 506 507 E052

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-isopropyl-1-[3- (trifluoromethyl)phenyl] pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP08 I1 562 563 E053

ethyl 1-[6- (dimethylamino)-2- pyridyl]-3-isopropyl- 4-(4- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate ALP18, AMP18 I1 514 515 E054

ethyl 3-isopropyl-4- (4- morpholinophenyl)-1- [3- (trifluoromethoxy)phenyl] pyrazolo[3,4- b]pyridine-6- carboxylate E055, 179113-90-7 I4 554 555 E055

ethyl 3-isopropyl-4- (4- morpholinophenyl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E056 I15, Specific example 394 395 E056

ethyl 1-[(2,4- dimethoxyphenyl)methyl]- 3-isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate ALP18, AMP28 I1 544 545 E057

ethyl 1-(3,4- difluorophenyl)-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4-b]pyridine- 6-carboxylate E055 I4 506 507 E058

ethyl 3-isopropyl-4- (4- morpholinophenyl)-1- (6-morpholino-2- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP18, AMP19 I1 556 557 E059

ethyl 4-(2,6-difluoro- 4-methoxy-phenyl)-1- (3-fluoro-5-methoxy- phenyl)-3-methyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP17, AMP03 I1 471 472 E060

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-1- (3,5-difluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP09 I1 529 530 E061

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-1- (3-fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP12 I1 511 512 E062

ethyl 3-isopropyl-4- [4-[2- methoxyethyl(methyl) amino]phenyl]-1-[3- (trifluoromethyl) phenyl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP11, AMP08 I1 540 541 E063

ethyl 3-isopropyl-4- [6- [methyl(tetrahydropyran- 4-yl)amino]-3- pyridyl]-1-[3- (trifluoromethyl)phenyl] pyrazolo[3,4- b]pyridine-6- carboxylate ALP10, AMP08 I1 567 568 E064

ethyl 1-(4- fluorophenyl)-3- isopropyl-4-[2- [methyl(tetrahydropyran- 4- yl)amino]pyrimidin-5- yl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP13, AMP13 I1 518 519 E065

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-3- isopropyl-1-[3- (trifluoromethyl)phenyl] pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP08 I1 561 562 E066

ethyl 3-isopropyl-4- (4- morpholinophenyl)-1- (2-morpholino-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP18, AMP21 I1 556 557 E067

ethyl 3-(1- methylcyclobutyl)-4- (4- morpholinophenyl)-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP18, AMP41 I1 496 497 E068

ethyl 4-[2-(4-cyano-1- piperidyl)pyrimidin-5- yl]-1-(2,4- difluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP14, AMP14 I1 531 532 E069

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 1-(2,4- difluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP14 I1 530 531 E070

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-1- (2,4-difluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP14 I1 529 530 E071

methyl 3-cyclobutyl- 4-(4-methoxy-1- piperidyl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 420 421 E072

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP03 I3 479 480 E073

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-isopropyl-1- tetrahydropyran-3-yl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP25 I1 502 503 E074

methyl 4-(4- bromophenyl)-1-[3- (dimethylamino)phenyl]- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate 308128- 34-3, AMP06 I1 492- 494 493- 495 E075

ethyl 4-(2,2-difluoro- 5-azaspiro[2.4]heptan- 5-yl)-3-isopropyl-1- (m-tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I3 454 455 E076

ethyl 1-cyclohexyl-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP04 I3 428 429 E077

methyl 3-cyclobutyl- 4-(4-isopropoxy-1- piperidyl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 448 449 E078

methyl 3-cyclobutyl- 1-phenyl-4-(4- propoxy-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 448 449 E079

methyl 3-cyclobutyl- 4-[3- (methoxymethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 434 435 E080

methyl 3-cyclobutyl- 4-[4-(2-oxo-2- pyrrolidin-1-yl- ethoxy)-1-piperidyl]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 517 518 E081

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo[3,4- 6]pyridine-6- carboxylate HP03 I3 465 466 E082

ethyl 3-isopropyl-4- [4-(methoxymethyl)- 1-piperidyl]-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I3 450 451 E083

ethyl 1-[3- (dimethylamino)phenyl]- 3-isopropyl-4-(1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP03 I3 435 436 E084

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-isopropyl-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP22 I1 564 565 E085

methyl 3-cyclobutyl- 4-(1-oxa-7- azaspiro[3.5]nonan-7- yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 432 433 E086

ethyl 4-(4-cyano-1- piperidyl)-1-[3- (dimethylamino)phenyl]- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP03 I3 460 461 E087

ethyl 3-isopropyl-4- [4-(2-methoxyethyl)- 1-piperidyl]-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I3 464 465 E088

ethyl 3-isopropyl-4- (3-methoxy-1- piperidyl)-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I3 436 437 E089

ethyl 3-isopropyl-4- (4-methylsulfonyl-1- piperidyl)-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I3 484 485 E090

isopropyl 3- isopropoxy-4-(4- morpholinophenyl)-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate A256 I17, Specific example 500 501 E091

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 426 427 E092

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3, Specific example 440 441 E093

ethyl 4-[4-(4-cyano-1- piperidyl)phenyl]-3- isopropyl-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP12, AMP22 I1 563 564 E094

ethyl 3-isopropyl-4- [2- methoxyethyl(methyl) amino]-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I1 410 411 E095

ethyl 3-isopropyl-1- (m-tolyl)-4-(8-oxa-2- azaspiro[4.5]decan-2- yl)pyrazolo[3,4- b]pyridine-6- carboxylate HP01 I3 462 463 E096

methyl 4-(4-butoxy-1- piperidyl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 468 467 E097

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(4- methoxy-4-methyl-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 440 441 E098

methyl 1-(4- fluorophenyl)-4-(4- isobutoxy-1- piperidyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 468 469 E099

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(1-oxa-7- azaspiro[3.5]nonan-7- yl)pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 438 439 E100

methyl 4-[3- (difluoromethyl)-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 446 447 E101

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(6-oxa-2- azaspiro[3.5]nonan-2- yl)pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 438 439 E102

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(1-oxa-8- azaspiro[4.5]decan-8- yl)pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 452 453 E103

methyl 3-cyclobutyl- 1-phenyl-4-(1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 390 391 E104

methyl 3-cyclobutyl- 4-[4-(2- methoxyethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 448 449 E105

methyl 4-(2- azaspiro[3.4]octan-2- yl)-3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 416 417 E106

methyl 3-cyclobutyl- 4-[4- (methoxymethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 434 435 E107

methyl 4-(3- azabicyclo[3.1.0]hexan- 3-yl)-3-cyclobutyl- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 388 389 E108

ethyl 1-(2-bromo-4- pyridyl)-3-isopropyl- 4-(4-methoxy-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate HP09 I4 501- 503 502- 504 E109

ethyl 3-isopropyl-4- (4-methoxy-1- piperidyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP08 I3 346 347 E110

ethyl 3-isopropyl-4- (4-methoxy-1- piperidyl)-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate E111 I12, Specific example 492 493 E111

ethyl 1-(2-fluoro-4- pyridyl)-3-isopropyl- 4-(4-methoxy-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate E109 I4, Specific example 441 442 E112

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-cyclobutyl-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP34 I1 576 577 E113

methyl 3-cyclobutyl- 4-(4-methylsulfonyl- 1-piperidyl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 468 469 E114

methyl 4-(4-cyano-1- piperidyl)-3- cyclobutyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 415 416 E115

methyl 4-(2- azaspiro[3.5]nonan-2- yl)-3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 430 431 E116

methyl 3-cyclobutyl- 4-[3- (methoxymethyl)azetidin- 1-yl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 406 407 E117

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-(3- methoxycyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP42 I1 536 537 E118

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-(3,3- difluorocyclobutyl)-1- phenyl-pyrazolo[3,4- 6]pyridine-6- carboxylate ALP09, AMP43 I1 542 543 E119

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-(3,3- dimethylcyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP44 I1 534 535 E120

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-(3- fluorocyclobutyl)-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP45 I1 524 525 E121

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-cyclobutyl-1-(2- morpholino-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP33 I1 592 593 E122

methyl 3-cyclobutyl- 4-(2,2-difluoro-5- azaspiro[2.4]heptan-5- yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 438 439 E123

methyl 3-cyclobutyl- 4-(5-oxa-2- azaspiro[3.5]nonan-2- yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 432 433 E124

methyl 3-cyclobutyl- 4-(7-oxa-2- azaspiro[3.5]nonan-2- yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 432 433 E125

methyl 4-(5- azaspiro[2.5]octan-5- yl)-3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 416 417 E126

methyl 3-cyclobutyl- 4-[2- methoxyethyl(methyl) amino]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 394 395 E127

methyl 4-[4- (benzyloxymethyl)-1- piperidyl]-3- cyclobutyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 510 511 E128

methyl 4-(2- azaspiro[3.3]heptan-2- yl)-3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 402 403 E129

methyl 3-cyclobutyl- 4-(1- methoxycarbonyl- 3,3a,4,6,7,7a- hexahydro-2H- pyrrolo[3,2-c]pyridin- 5-yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate E130 I11, Specific example 489 490 E130

methyl 4- (1,2,3,3a,4,6,7,7a- octahydropyrrolo[3,2- c]pyridin-5-yl)-3- cyclobutyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate E131 Specific example 431 432 E131

methyl 4-(1-tert- butoxycarbonyl- 3,3a,4,6,7,7a- hexahydro-2H- pyrrolo[3,2-c]pyridin- 5-yl)-3-cyclobutyl-1- phenyl-pyrazolo[3,4- 6]pyridine-6- carboxylate HP02 I3 531 532 E132

methyl 4-(1-acetyl- 3,3a,4,6,7,7a- hexahydro-2H- pyrrolo[3,2-c]pyridin- 5-yl)-3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate E130 I11, Specific exampl 473 474 E133

ethyl 1-(6-bromo-2- pyridyl)-3-isopropyl- 4-(4-methoxy-1- piperidyl)pyrazolo[3,4- b]pyridine-6- carboxylate E109 I5, Specific example 501- 503 502- 504 E134

methyl 1-cyclohexyl- 4-[4-(hydroxymethyl)- 1-piperidyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP12 I3 414 415 E135

methyl 3-cyclobutyl- 4-[4-[(1S)-2- (dimethylamino)-1- fluoro-ethyl]-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI03 I3 479 480 E136

methyl 1-(4- fluorophenyl)-4-[4-(1- hydroxy-1-methyl- ethyl)-1-piperidyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 454 455 E137

ethyl 1-(3- fluorophenyl)-3- isopropyl-4-[6- [methyl(tetrahydropyran- 4-yl)amino]-3- pyridyl]pyrazolo[3,4- b]pyridine-6- carboxylate ALP10, AMP12 I1 517 518 E138

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-isopropyl-1-(2- morpholino-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP21 I1 580 581 E139

methyl 3-cyclobutyl- 4-[4-(cyclopentoxy)- 1-piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 474 475 E140

methyl 3-cyclobutyl- 4-[4-(cyclohexoxy)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 488 489 E141

methyl 3-cyclobutyl- 4-[4- (cyclopropylmethoxy)- 1-piperidyl]-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 460 461 E142

ethyl 4-(4-cyano-1- piperidyl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP09 I3 435 436 E143

methyl 3-cyclobutyl- 4-[4-(1- hydroxyethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 434 435 E144

methyl 3-cyclobutyl- 1-phenyl-4-[4-(2,2,2- trifluoro-1-hydroxy-1- methyl-ethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 502 503 E145

ethyl 4-[6-[bis(2- methoxyethyl)amino]- 3-pyridyl]-3- cyclobutyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate ALP23, AMP29 I1 529 530 E146

methyl 3-cyclobutyl- 4-[4-hydroxy-4- (methoxymethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI01 I3 450 451 E147

ethyl 1-(2-fluoro-4- pyridyl)-3-isopropyl- 4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate E148 I4 455 456 E148

ethyl 3-isopropyl-4- [4-(methoxymethyl)- 1-piperidyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP08 I3 360 361 E149

ethyl 4-[6-[bis(2- methoxyethyl)amino]- 3-pyridyl]-3- isopropyl-1-(2- morpholino-4- pyridyl)pyrazolo[3,4- b]pyridine-6- carboxylate ALP23, AMP21 I1 603 604 E150

methyl 3-cyclobutyl- 4-[4-[(1,1-dioxo-1,4- thiazinan-4- yl)methyl]-4-hydroxy- 1-piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI02 I3 553 554 E151

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-(3- methylcyclobutyl)-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, AMP46 I1 520 521 E152

ethyl 3-[(1-tert- butoxycarbonyl-4- piperidyl)oxy]-4-[6- (4-cyano-1-piperidyl)- 3-pyridyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate E153 I13, Specific example 651 E153

ethyl 4-[6-(4-cyanol-1- piperidyl)-3-pyridyl]- 3-oxo-1-phenyl-2H- pyrazolo[3,4- b]pyridine-6- carboxylate ALP09, 70373- 98-7 I1 468 469 E154

ethyl 1- (cyclobutylmethyl)-3- isopropyl-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate E148 I6, Specific example 428 429 E155

ethyl 1-isobutyl-3- isopropyl-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate E148 I6 416 417 E156

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[4-(2,2,2- trifluoroethyl)piperazin- 1-yl]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 479 480 E157

ethyl 3-isopropyl-4- [4-(methoxymethyl)- 1-piperidyl]-1-(1- methyl-6-oxo- pyridazin-3- yl)pyrazolo[3,4- b]pyridine-6- carboxylate E148 I7 468 469 E158

methyl 3-cyclobutyl- 4-(4- isopropylpiperazin-1- yl)-1-phenyl- pyrazolo[3,4- 6]pyridine-6- carboxylate HP02 I3 433 434 E159

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 1-phenyl-3- tetrahydrofuran-3- yloxy-pyrazolo[3,4- b]pyridine-6- carboxylate E153 I13 538 539 E160

ethyl 3-isopropyl-4- [4-(methoxymethyl)- 1-piperidyl]-1-(2- morpholinopyrimidin- 4-yl)pyrazolo[3,4- b]pyridine-6- carboxylate E161 I12 523 524 E161

ethyl 1-(2- chloropyrimidin-4-yl)- 3-isopropyl-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate E148 I5 472- 474 476- 475 E162

methyl 4-(4- cyclobutylpiperazin-1- yl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 451 452 E163

methyl 3-cyclobutyl- 4-[4-(1-hydroxy-1- methyl-ethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 448 449 E164

ethyl 4-[6-(4-cyano-1- piperidyl)-3-pyridyl]- 3-(oxetan-3-yloxy)-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate E153 I13 524 525 E165

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[2- methoxyethyl(methyl) amino]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 400 401 E166

methyl 1-(4- fluorophenyl)-4-[4-(1- hydroxy-1-methyl- ethyl)-1-piperidyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 454 455 E167

ethyl 3-cyclobutyl-1- (4-fluorophenyl)-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- 6]pyridine-6- carboxylate E168 I4 466 467 E168

ethyl 3-cyclobutyl-4- [4-(methoxymethyl)- 1-piperidyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E169 I15 372 373 E169

ethyl 3-cyclobutyl-1- [(2,4- dimethoxyphenyl) methyl]-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP14 I3 522 523 E170

methyl 3-cyclobutyl- 4-[4-(1-hydroxy-1- methyl-ethyl)-1- piperidyl]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 448 449 E171

ethyl 3-cyclobutyl-1- (4-fluorophenyl)-4- (tetrahydropyran-4- ylmethoxy)pyrazolo [3,4-b]pyridine-6- carboxylate E172 I16, Specific example 453 454 E172

ethyl 3-cyclobutyl-4- (tetrahydropyran-4- ylmethoxy)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E173 I15 359 360 E173

ethyl 3-cyclobutyl-1- [(2,4- dimethoxyphenyl) methyl]-4- (tetrahydropyran-4- ylmethoxy)pyrazolo [3,4-b]pyridine-6- carboxylate HP15 I14 509 510 E174

methyl 4-[4- (dimethylamino)-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 439 440 E175

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[4-(1- methyl-4-piperidyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 493 494 E176

methyl 4-[(1-acetyl-4- piperidyl)methoxy]-1- (4-fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate E177 I11, Specific example 468 469 E177

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(4- piperidylmethoxy) pyrazolo[3,4-b]pyridine- 6-carboxylate A263 I9 426 427 E178

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[(1- methoxycarbonyl-4- piperidyl)methoxy] pyrazolo[3,4-b]pyridine- 6-carboxylate E177 I11, Specific example 484 485 E179

methyl 4-[4- (cyanomethyl)-4- hydroxy-1-piperidyl]- 3-cyclobutyl-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI09 I3 445 446 E180

methyl 3-cyclobutyl- 1-phenyl-4-[4-(2,2,2- trifluoroethyl)piperazin- 1-yl]pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 473 474 E181

ethyl 1-(2-fluoro-4- pyridyl)-3-isopropyl- 4-(tetrahydropyran-4- ylmethoxy)pyrazolo [3,4-b]pyridine-6- carboxylate E182 I4 442 443 E182

ethyl 3-isopropyl-4- (tetrahydropyran-4- ylmethoxy)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E183 I15 347 348 E183

ethyl 1-[(2,4- dimethoxyphenyl) methyl]-3-isopropyl-4- (tetrahydropyran-4- ylmethoxy)pyrazolo [3,4-b]pyridine-6- carboxylate HP06 I14, Specific example 497 498 E184

methyl 4-(4- ethoxycarbonylpiperazin- 1-yl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 469 470 E185

methyl 1-(4- fluorophenyl)-3- isopropyl-4-(3- methyl-2-oxo-1-oxa- 3,8- diazaspiro[4.5]decan- 8-yl)pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 481 482 E186

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[3- (trifluoromethyl) piperazin-1- yl]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 465 466 E187

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[4-(2- methoxyethyl)piperazin- 1-yl]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 455 456 E188

methyl 4-(2,4-dioxo- 1,3,8- triazaspiro[4.5]decan- 8-yl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 480 481 E189

methyl 4-[4- (ethoxymethyl)-4- fluoro-1-piperidyl]-1- (4-fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05, AMI04 I3 472 473 E190

methyl 4-[4-fluoro-4- (2- methoxyethoxymethyl)- 1-piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05, AMI05 I3 502 503 E191

methyl 4-[(3R,4R)-3 fluoro-4-hydroxy-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05, AMI06 I3 430 431 E192

methyl 4-[4-fluoro-4 (methoxymethyl)-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05, AMI07 I3 458 459 E193

methyl 4-[3-fluoro-3- (2- methoxyethoxymethyl)- 1-piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05, AMI08 I3 502 503 E194

methyl 1-(4- fluorophenyl)-3- isopropyl-4-[4-(1- piperidyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I3 479 480 E195

ethyl 1-(2,6-dimethyl- 4-pyridyl)-3- isopropyl-4-[4- (methoxymethyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate E148 I4 465 466 E196

methyl 3-cyclobutyl- 4-(1,1-dioxo-1,4- thiazinan-4-yl)-1- phenyl-pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 440 441 E197

methyl 4-(1-tert- butoxycarbonyl-4- piperidyl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate E198 Specific example 496 497 E198

methyl 4-(1-tert- butoxycarbonyl-3,6- dihydro-2H-pyridin-4- yl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate HP05 I2, Specific example 494 495 E199

methyl 4-(4- azidophenyl)-1-[3- (dimethylamino)phenyl]- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylate E074 Specific example 455 456 E352

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (4-hydroxypiperidin- 1-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19 I3 424 425 E353

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (4-oxopiperidin-1-yl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E352 Specific example 422 423 E354

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[2- (methoxymethyl) morpholin-4-yl] piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E353 Specific example 537 538 E355

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(4- isopropylpiperazin-1- yl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 202991- 78-4 I3 534 535 E356

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(4-methoxy-1- piperidyl)-1- piperidyl]pyrazolo[3,4- b]pyridine-6- carboxylate HP19, AMI10 I3, Specific example 522 523 E357

methyl 3-cyclobutyl- 1-phenyl-4-{4- [(pyrrolidin-1- yl)methyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP02, 683772- 11-4 I3, Specific example 473 474 E358

methyl 3-cyclobutyl- 4-(4,4-difluoro[1,4′- bipiperidin]-1′-yl)-1- (4-fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 527 528 E359

methyl 4-[4-(2- cyanomorpholin-4- yl)piperidin-1-yl]-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 518 519 E360

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(2-oxa-5- azabicyclo[2.2.1]heptan- 5-yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 505 506 E361

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[methyl(oxan-4- yl)amino]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 521 522 E362

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[3- (trifluoromethyl) pyrrolidin- 1-yl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 545 546 E363

methyl 4-[4-(3- cyanopyrrolidin-1- yl)piperidin-1-yl]-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 502 503 E364

methyl 4-(3- cyano[1,4′- bipiperidin]-1′-yl)-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 516 517 E365

methyl 3-cyclobutyl- 4-(3-fluoro[1,4′- bipiperidin]-1′-yl)-1- (4-fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 509 510 E366

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(3- methoxyazetidin-1- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 493 494 E367

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [3- (trifluoromethyl)[1,4′- bipiperidin]-1′-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 559 560 E368

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (3-methoxy[1,4′- bipiperidin]-1′-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 521 522 E369

methyl 3-cyclobutyl- 4-[4-(2,2- dimethylmorpholin-4- yl)piperidin-1-yl]-1- (4-fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 521 522 E370

methyl 3-cyclobutyl- 4-{4-[4- (ethoxycarbonyl) piperazin- 1-yl]piperidin-1- yl}-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 564 565 E371

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [1-(propan-2- yl)octahydro-5H- pyrrolo[3,2-c]pyridin- 5-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E514 I33 491 492 E372

methyl 3-cyclobutyl- 4-(1- cyclobutyloctahydro- 5H-pyrrolo[3,2- c]pyridin-5-yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E514 I33 503 504 E373

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [1-(oxetan-3- yl)octahydro-5H- pyrrolo[3,2-c]pyridin- 5-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E514 I33 505 506 E374

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [1-(oxan-4- yl)octahydro-5H- pyrrolo[3,2-c]pyridin- 5-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E514 I33 533 534 E375

methyl 3-cyclobutyl- 4-(4-fluoro[1,4′- bipiperidin]-1′-yl)-1- (4-fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 509 510 E376

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[(2- methoxyethyl)(methyl) amino]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 495 496 E377

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19 I3 493 494 E378

methyl 4-([1,4′- bipiperidin]-1′-yl)-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19 I3 491 492 E379

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (3-hydroxy-1-oxa-8- azaspiro[4.5]decan-8- yl)-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19 I3 480 481 E380

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (3-oxo-1-oxa-8- azaspiro[4.5]decan-8- yl)-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E379 I23 478 479 E381

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [3-(morpholin-4-yl)-1- oxa-8- azaspiro[4.5]decan-8- yl]-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E380 I18 533 534 E382

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[2-(morpholin-4- yl)ethyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19 I3 521 522 E383

methyl 3-cyclobutyl- 4-{4-[2-(4- methylpiperidin-1- yl)ethyl]piperidin-1- yl}-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 515 516 E384

methyl 3-cyclobutyl- 4-[4-(4- cyclopropylpiperazin- 1-yl)piperidin-1-yl]-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 514 515 E385

methyl 3-cyclobutyl- 1-phenyl-4-[4- (propan-2- yl)piperazin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 433 434 E388

ethyl 3-cyclobutyl-4- [4- (methoxymethyl) piperidin-1-yl]-1-(2- methoxypyridin-4-yl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E168 I4 479 480 E389

ethyl 1-(2- chloropyridin-4-yl)-3- cyclobutyl-4-[4- (methoxymethyl) piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E-168 I4 484- 486 485- 487 E390

ethyl 3-cyclobutyl-1- [2-(3,6-dihydro-2H- pyran-4-yl)pyridin-4- yl]-4-[4- (methoxymethyl) piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E389 Specific example 531 532 E391

ethyl 3-cyclobutyl-4- [4- (methoxymethyl) piperidin-1-yl]- 1-[2-(oxan- 4-yl)pyridin-4-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E390 Specific example 533 534 E392

ethyl 1-tert-butyl-3- cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP20 I3 469 470 E393

ethyl 3-cyclobutyl-4- [4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E392 Specific example 413 414 E394

ethyl 3-cyclobutyl-1- (2-methoxypyridin-4- yl)-4-[4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 520 521 E395

ethyl 3-cyclobutyl-1- (3-methylphenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 503 504 E396

ethyl 3-cyclobutyl-1- (3-methoxyphenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 519 520 E397

ethyl 3-cyclobutyl-4- [4-(morpholin-4- yl)piperidin-1-yl]-1- [4- (trifluoromethyl) phenyl]-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 557 558 E398

ethyl 3-cyclobutyl-1- (4-fluoro-3- methylphenyl)-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 521 522 E399

ethyl 3-cyclobutyl-4- [4-(morpholin-4- yl)piperidin-1-yl]-1- [3- (trifluoromethyl) phenyl]-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 557 558 E400

ethyl 3-cyclobutyl-4- [4-(morpholin-4- yl)piperidin-1-yl]-1- {2-[(propan-2- yl)oxy]pyridin-4-yl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 548 549 E401

ethyl 1-[2- (benzyloxy)pyridin-4- yl]-3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 596 597 E402

ethyl 3-cyclobutyl-1- (2-hydroxypyridin-4- yl)-4-[4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E401 Specific example 506 507 E403

ethyl 3-cyclobutyl-1- [2- (difluoromethoxy) pyridin-4-yl]-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 556 557 E404

ethyl 3-cyclobutyl-1- (3-fluorophenyl)-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 507 508 E405

ethyl 3-cyclobutyl-1- (2,2-difluoro-2H-1,3- benzodioxol-5-yl)-4- [4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 569 570 E406

ethyl 1-(2- chloropyridin-4-yl)-3- cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I4 525- 527 526- 528 E407

ethyl 3-cyclobutyl-4- [4-(morpholin-4- yl)piperidin-1-yl]-1- [2-(oxan-4-yl)pyridin- 4-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E406 Specific example 574 575 E408

methyl 3-cyclobutyl- 4-[4-(ethoxymethyl)- 4-fluoropiperidin-1- yl]-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI04 I3 466 467 E409

methyl 3-cyclobutyl- 4-{4-fluoro-4-[(2- methoxyethoxy)methyl] piperidin-1-yl}-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI05 I3 496 497 E410

methyl 3-cyclobutyl- 4-{3-fluoro-3-[(2- methoxyethoxy)methyl] piperidin-1-yl}-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI08 I3 496 497 E411

methyl 3-cyclobutyl- 4-[4-fluoro-4- (methoxymethyl) piperidin-1- yl]-1-phenyl- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP02, AMI07 I3 452 453 E412

methyl 3-cyclobutyl- 4-{4-[2-(4- methylpiperidin-1- yl)ethyl]piperidin-1- yl}-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 I3 515 516 E413

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (piperidin-4-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19 Specific example 408 409 E414

methyl 3-cyclobutyl- 4-[1-(4,4- difluorocyclohexyl) piperidin-4-yl]-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 526 527 E415

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [1-(propan-2- yl)piperidin-4-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 450 451 E416

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [1-(oxan-4- yl)piperidin-4-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 492 493 E417

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {1-[(oxan-4- yl)methyl]piperidin-4- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 506 507 E418

methyl 3-cyclobutyl- 4-{1-[(2,5- dimethoxyoxolan-3- yl)methyl]piperidin-4- yl}-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 552 553 E419

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [1-(3,3,3- trifluoropropyl) piperidin- 4-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 504 505 E421

methyl 3-cyclobutyl- 4-[1- (cyclopropylmethyl) piperidin-4-yl]-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E413 I18 462 463 E422

ethyl 1-(2- chloropyrimidin-4-yl)- 3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E393 I5 525 526 E424

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (4-methoxy[1,4′- bipiperidin]-1′-yl)- 1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19 I3 521 522 E425

ethyl 1-cyclohexyl-4- (4-formylphenyl)-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate ALP36, AMP95 Specific example 435 436 E426

ethyl 1-cyclohexyl-4- (4-{[3- (dimethylamino) azetidin-1- yl]methyl}phenyl)-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E425 I34, Specific example 519 520 E427

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(3-fluoropyrrolidin- 1-yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 495 496 E428

methyl 4-[4-(3- cyanoazetidin-1- yl)piperidin-1-yl]-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 488 489 E429

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(3- methoxypyrrolidin-1- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 507 508 E430

methyl 3-cyclobutyl- 4-(1,4- dioxaspiro[4.5]dec-7- en-8-yl)-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP02 Specific example 445 446 E431

methyl 3-cyclobutyl- 4-(1,4- dioxaspiro[4.5]decan- 8-yl)-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E430 Specific example 447 448 E432

methyl 3-cyclobutyl- 4-(4-oxocyclohexyl)- 1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E431 Specific example 403 404 E433

methyl 3-cyclobutyl- 4-[4-(morpholin-4- yl)cyclohexyl]-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E432 I18 474 475 E434

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[4-(propan-2- yl)piperazin-1- yl]piperidin-1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E353 I18 534 535 E435

ethyl 1-cyclohexyl-3- [(propan-2-yl)oxy]-4- (4-{[4-(propan-2- yl)piperazin-1- yl]methyl}phenyl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E425 I34 547 548 E436

ethyl 1-cyclohexyl-4- (4-[(4- methoxypiperidin-1- yl)methyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E425 I34 534 535 E437

ethyl 1-cyclohexyl-4- {4-[(5- methylhexahydropyrrolo [3,4-c]pyrrol- 2(1H)- yl)methyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E425 I34 545 546 E438

4-{1-cyclohexyl-6- (ethoxycarbonyl)-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridin-4- yl}benzoic acid E425 Specific example 451 452 E439

ethyl 4-{4-[5-(tert- butoxycarbonyl)hexa- hydropyrrolo[3,4- c]pyrrole-2(1H)- carbonyl]phenyl}-1- cyclohexyl-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E438 I24, Specific example 645 646 E440

ethyl 1-cyclohexyl-4- [4-(5- methylhexahydro- pyrrolo[3,4-c]pyrrole- 2(1H)- carbonyl)phenyl]-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E438 I24 559 560 E441

ethyl 1-cyclohexyl-4- {4-[3- (dimethylamino) azetidine-1- carbonyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E438 I24, Specific example 533 534 E442

ethyl 4-(4-{[8-(tert- butoxycarbonyl)-2- oxa-5,8- diazaspiro[3.5]nonan- 5-yl]methyl}phenyl)- 1-cyclohexyl-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E425 I34 647 648 E443

ethyl 1-cyclohexyl-4- {4-[(2-oxa-5,8- diazaspiro[3.5]nonan- 5-yl)methyl]phenyl}- 3-[(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E442 I25 547 548 E444

ethyl 1-cyclohexyl-4- (4-[(8-methyl-2-oxa- 5,8- diazaspiro[3.5]nonan- 5-yl)methyl]phenyl}- 3-[(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E443 Specific example 561 562 E445

ethyl 4-[4-(4-cyano-1- methylpiperidin-4- yl)phenyl]-1- cyclohexyl-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate ALP38, AMP95 Specific example 529 530 E460

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[1-(morpholin-4- yl)ethyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 436852- 25-4 I3 521 522 E461

methyl 3-cyclobutyl- 1-cyclohexyl-4-[4-(2- methylpyridin-4- yl)piperazin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 98010- 38-9 I3 488 489 E462

methyl 3-cyclobutyl- 1-cyclohexyl-4-{4-[4- (propan-2- yl)piperazin-1- yl]piperidin-1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 202991, 202991- 78-4 I3 522 523 E463

methyl 4-[(3,S)-4- benzyl-3- methylpiperazin-1-yl]- 3-cyclobutyl-1- cyclohexyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 511254- 95-57 I3 501 502 E464

methyl 4-[(3R)-4- benzyl-3- methylpiperazin-1-yl]- 3-cyclobutyl-1- cyclohexyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 1588480- 39-0 I3 501 502 E465

methyl 3-cyclobutyl- 4-[4-(4- cyclopropylpiperazin- 1-yl)piperidin-1-yl]-1- (4-fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E498 I26, Specific example 517 518 E466

methyl 3-cyclobutyl- 4-(9-cyclopropyl-3,9- diazaspiro[5.5]undecan- 3-yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E500 I26 517 518 E467

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[(pyrrolidin-1- yl)methyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 683772- 11-5 I3 491 492 E468

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[4-(2- methoxyethyl)piperazin- 1-yl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate E498, 6482- 24-2 I27 550 551 E469

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [9-(oxetan-3-yl)-3,9- diazaspiro[5.5]undecan- 3-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E500, 6704- 31-0 I30, Specific example 533 534 E470

methyl 3-cyclobutyl- 1-(4-fIuorophenyl)-4- {4-[4-(oxetan-3- yl)piperazin-1- yl]piperidin-1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E498, 6704- 31-0 I30 548 549 E471

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [(morpholin-4- yl)methyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 936329- 94-1 J13 424 425 E472

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [(4-methylpiperazin- 1-yl)methyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 1015484- 22-6 J13 438 439 E473

methyl 1-cyclohexyl- 4-{4-[(morpholin-4- yl)methyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 1268340- 94-8 J13 493 493 E474

methyl 1-cyclohexyl- 4-[4-(4- methylpiperazine-1- carbonyl)phenyl]-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 34352- 59-5 I28, Specific example 519 520 E475

methyl 3-cyclobutyl- 1-cyclohexyl-4-[4- (pyridin-4- yl)piperazin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 1008- 91-9 I3 474 475 E476

methyl 3- (cyclobutyloxy)-1- cyclohexyl-4-{4- [(morpholin-4- yl)methyl]phenyl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E505, 1268340- 94-8 J13 504 505 E477

methyl 1-cyclohexyl- 4-{4-[4- (dimethylamino) piperidine-1- carbonyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504- 4318- 42-7 I28 548 549 E478

methyl 1-cyclohexyl- 4-{4-[(piperidin-1- yl)methyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 1268340- 93-7 J13 491 492 E479

methyl 1-cyclohexyl- 4-{4-[(4- methylpiperazin-1- yl)methyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 1015484- 22-6 J13 506 507 E480

methyl 1-cyclohexyl- 3-[(propan-2-yl)oxy]- 4-{4-[(pyrrolidin-1- yl)methyl]phenyl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 888711- 53-3 J13 477 477 E481

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {[4- (methoxymethyl) piperidin-1-yl]methyl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19, BF01 J13 466 467 E482

methyl 1-cyclohexyl- 4-{4-[(4- cyclopropylpiperazin- 1-yl)methyl]phenyl}- 3-[(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E494 I26 531 532 E483

methyl 1-cyclohexyl- 3-[(propan-2-yl)oxy]- 4-{4-[4-(propan-2- yl)piperazin-1- yl]phenyl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E504, 4318- 42-7 I29 519 520 E484

methyl 1-cyclohexyl- 4-[4-(4- cyclopropylpiperazin- 1-yl)phenyl]-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 20327- 23-5 I29 517 518 E485

methyl 4-(4- cyano[1,4′- bipiperidin]-1′-yl)-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, AMI11 I3 516 517 E486

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[4- (methoxycarbonyl) piperazin-1-yl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E498 I31, Specific example 550 551 E487

methyl 4-[4-(4- acetylpiperazin-1- yl)piperidin-1-yl]-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E498 I32, Specific example 534 535 E488

methyl 3-cyclobutyl 1-cyclohexyl-4-{4- [(morpholin-4- yl)methyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 81310- 62-5 I3 495 496 E489

methyl 3-cyclobutyl- 1-cyclohexyl-4-{4-[2 (morpholin-4- yl)ethyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 500357- 64-2 I3 509 510 E490

methyl 3-cyclobutyl- 1-cyclohexyl-4-[4- (morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP25, 53617- 35-9 I3 481 482 E491

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- {4-[(morpholin-4- yl)methyl]piperidin-1- yl}-1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 202991- 78-4 I3 507 508 E492

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (4-hydroxy[1,4′- bipiperidin]-1′-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 202991- 78-4 I3 507 508 E493

methyl 4-([1,4′- bipiperidin]-1′-yl)-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 202991- 78-4 I3 491 492 E494

methyl 1-cyclohexyl- 4-{4-[(piperazin-1- yl)methyl]phenyl}-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E495 I25 491 492 E495

methyl 4-(4-{[4-(tert- butoxycarbonyl) piperazin-1- yl]methyl}phenyl)-1- cyclohexyl-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E504, 936329- 97-4 J13 591 592 E498

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- [4-(piperazin-1- yl)piperidin-1-yl]-1H- pyrazolo[3,4- 6]pyridine-6- carboxylate E499 I25 492 493 E499

methyl 4-{4-[4-(tert- butoxycarbonyl)piperazin- 1-yl]piperidin-1- yl}-3-cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 205059- 24-1 I3 592 593 E500

methyl 3-cyclobutyl- 4-(3,9- diazaspiro[5.5]undecan- 3-yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E501 I25 477 478 E501

tert-butyl 9-[3- cyclobutyl-1-(4- fluorophenyl)-6- (methoxycarbonyl)- 1H-pyrazolo[3,4- b]pyridin-4-yl]-3,9- diazaspiro[5.5]undecane- 3-carboxylate HP19 173405- 78-2 I3 577 578 E502

methyl 1-cyclohexyl- 4-[4-(4- methylpiperazin-1- yl)phenyl]-3-[(propan- 2-yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E504, 109-01- 3 I29, Specific example 491 492 E503

methyl 4-(4- bromophenyl)-1- cyclohexyl-3- hydroxy-1H- pyrazolo[3,4- b]pyridine-6- carboxylate 436088- 86-7 and 608128- 34-3 I1, Specific example 430 431 E504

methyl 4-(4- bromophenyl)-1- cyclohexyl-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E503 I17, Specific example 472 472 E505

methyl 4-(4- bromophenyl)-3- (cyclobutyloxy)-1- cyclohexyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E503 I17, Specific example 504 505 E509

methyl 3-cyclobutyl- 4-[4-(morpholin-4- yl)piperidin-1-yl]-1H- pyrazolo[3,4- 6]pyridine-6- carboxylate 53617- 35-9, 16063- 69-7, 5006- 22-4, 301-01- 2, 630-08- 0 Specific example 399 400 E510

methyl 3-cyclobutyl- 1-[3- (difluoromethoxy) phenyl]-4-[4-(morpholin- 4-yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate E509 I7, Specific example 541 542 E511

methyl 1-(4- fluorophenyl)-4-(4- methoxy[1,4′- bipiperidin]-1′-yl)-3- [(propan-2-yl)oxy]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate AMP96 Specific example 525 526 E513

methyl 4-[1-(tert- butoxycarbonyl)octa- hydro-5H-pyrrolo[3,2- c]pyridin-5-yl]-3- cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylatee HP19 I3 549 550 E514

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (octahydro-5H- pyrrolo[3,2-c]pyridin- 5-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate E513 I21A 449 450 E515

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (9-methyl-3,9- diazaspiro[5.5]undecan- 3-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 13323- 45-0 I3 491 492 E516

methyl 3-cyclobutyl- 4-[4- (ethoxycarbonyl) piperazin-1-yl]-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 120-43- 4 I3 481 482 E517

methyl 3-cyclobutyl- 1-(4-fluorophenyl)-4- (4-[(2- methylpropoxy) carbonyl]piperazin- 1-yl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylate HP19, 23672- 96-0 I3 509 510 Method J1: Synthesis of Carboxylic Acids by Saponification of Ester

To the intermediate ester (1 equiv) in THF or in a mixture of THF/methanol or in dioxane/water or in THF/methanol/water at RT is added either aqueous 1 to 2 N sodium hydroxide or lithium hydroxide monohydrate (from 1 to 5 equiv). The reaction mixture is stirred at a temperature ranging from RT to 60° C. for 20 minutes to several days (up to 8 days). The volatiles are removed under reduced pressure, and the resulting mixture is acidified with either aqueous 2-6 N HCl or acetic acid. If a filterable suspension is obtained, the precipitate is collected by filtration, washed with water and dried in vacuo to afford the titled compound which is used as such or further purified either by preparative HPLC or flash chromatography on silica gel. In other cases, the mixture is partitioned between water and either dichloromethane or ethyl acetate. The two phases are separated, and the aqueous phase is optionally neutralized and then extracted either with dichloromethane or ethyl acetate. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or further purified either by preparative HPLC or flash chromatography on silica gel.

Illustrative Synthesis of Intermediate A056: 4-(4-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-3-cyclobutyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Intermediate E018 (30.7 g, 60.3 mmol) was dissolved in a mixture of THF/methanol (1/1; 1 L) and 2 N sodium hydroxide (109 mL, 218 mmol) in water was added at RT. The solution was stirred for 1 hour. The volatiles were removed under reduced pressure, and the resulting mixture was diluted with water (300 mL). The aqueous phase was acidified with aqueous 2 N HCl (110 mL), and the precipitate was filtered, washed with water and dried at 40° C. under reduced pressure to give the titled compound.

Illustrative Synthesis of Intermediate A285: 3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Methyl 3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl})-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (18.39 g, 38.8 mmol, E357) was dissolved in a mixture of tetrahydrofuran (100 mL), methanol (50 mL), and water (100 mL). To this mixture was added lithium hydroxide hydrate (4.89 g, 116 mmol). The resulting suspension was heated at 50° C. for 30 minutes. The reaction mixture was cooled to room temperature and neutralized with 6 M aqueous HCl (6 mL) to a pH of 7. To this was then added water in 10 mL portions. After a total of 200 mL of water had been added, a solid formed. The solid was collected by filtration and dried to constant weight in a vacuum oven at 50° C. over 72 hours to give 14.98 g of the titled compound. ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.89 (d, J=8.0 Hz, 2H), 7.84 (s, 1H), 7.52 (t, J=7.9 Hz, 2H), 7.25 (t, J=7.5 Hz, 1H), 4.14 (p, J=8.4 Hz, 1H), 3.56 (dd, J=12.2, 3.7 Hz, 2H), 2.86-2.67 (m, 4H), 2.63 (br s, 4H), 2.53-2.42 (m, 4H), 2.10-1.98 (m, 4H), 1.83-1.68 (m, 5H), 1.63-1.48 (m, 2H); MS (ESI+) m/z 460.2 (M+H)⁺.

Method J1A: Synthesis of Carboxylic Acids by Saponification of Ester

To the ester intermediate (1 equiv) in THF or ethanol or methanol or a mixture of the cited solvents at RT is added either aqueous 1 N or 2 N sodium hydroxide 1 (from 1 to 10 equiv). The reaction mixture is stirred at RT until complete conversion is observed. Sodium hydroxide can be added to allow the full conversion of the starting ester. The volatiles are removed under reduced pressure, and the resulting mixture is acidified with either aqueous 1 N or 2 N HCl. If a filterable suspension is obtained, the precipitate is collected by filtration, washed with water and dried in vacuo to afford the titled compound which is used as such or further purified either by preparative HPLC or flash chromatography on silica gel. In other cases, the mixture is partitioned between a phosphate buffer (pH 6.2) and either dichloromethane or chloroform or a mixture of dichloromethane/isopropanol. The organic phases are separated, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or further purified either by preparative HPLC or flash chromatography on silica gel.

Illustrative Synthesis of A318a: 3-cyclobutyl-1-(3-methylphenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Ester E395 (40 mg, 80 μmol) was dissolved in a mixture of THF/ethanol (1/1; 6 mL) and 1 N sodium hydroxide (0.5 mL, 500 μmol) in water was added at RT. The solution was stirred for 4 hours. Aqueous 1 N HCl (0.5 mL, 500 μmol) and a phosphate buffer were added (pH 6.2). The solvent was partially removed under reduced pressure, and the resulting mixture was extracted twice with chloroform. The combined organic phases were dried over magnesium sulfate, filtered and evaporated under reduced pressure to give the titled compound.

Method J2: Synthesis of Acids

A is either N or CH A′ is either R^(e) or L¹-G^(3C) as described in the Summary

The alkylidene pyruvate (1 to 1.5 equiv) and the aminopyrazole (1 to 1.5 equiv) in acetic acid are stirred under air at temperatures ranging from RT to reflux for 1 h to several days. Alternatively, the alkylidene pyruvate (1 to 1.5 equiv) and the aminopyrazole (1 to 1.5 equiv) in DMF or acetic acid are heated under microwave irradiation at 150° C. for 20 minutes to 2 h followed by stirring under air in an opened flask at temperatures ranging from RT to 90° C. for 1 h to several days with or without dilution of the reaction mixture with a large amount of ethanol or methanol. Then the reaction mixture is filtered, and the solid is washed with solvents, and dried in vacuo to afford the titled compound which is used as such or purified by precipitation, by preparative HPLC or by flash chromatography on silica gel. Alternatively, the reaction mixture is concentrated in vacuo to afford a crude mixture which is used as such or further purified either by precipitation, by preparative HPLC or by flash chromatography on silica gel.

Illustrative Synthesis of Intermediate A002: 3-methyl-4-(4-morpholinophenyl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

ALP01 (261 mg, 1 mmol, 1 equiv) and 3-methyl-1-phenyl-1H-pyrazol-5-amine (CAS 1131-18-6, 173 mg, 1 mmol, 1 equiv) were introduced in a sealed tube. DMF (2 mL) was added, and the vial was sealed. The reaction mixture was heated under microwave irradiation at 150° C. for 1 h. Then after cooling down to RT, the vial was opened, diluted with a large amount of ethanol, and stirred vigorously under air at RT overnight. The resulting suspension was filtered. The solid was washed with ethanol, and dried in vacuo to afford the titled compound.

Method J3: Nucleophilic Substitution on the Central Core with Alcohols

To a solution of alcohol (3.0 equiv) in anhydrous THF under nitrogen atmosphere at RT is added 60% sodium hydride in mineral oil (6.0 equiv), and the mixture is stirred at room temperature for 30 minutes. Then the aryl chloride intermediate HP (1.0 equiv) is added, the reaction mixture is stirred at room temperature for 5 minutes, and then heated at reflux for 1 h to 24 h. The reaction mixture is cooled to 0° C., diluted with heptane, quenched with water and acidified with 2 N HCl (6.0 equiv). Volatiles are removed in vacuo. The resulting aqueous residue is filtered, and the solid is washed with water and with a mixture heptane/Et₂O 1/1, and dried in vacuo to afford the titled compound which is used as such or purified by silica gel chromatography. Alternatively, the aqueous residue is diluted with dichloromethane. The two phases are separated and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or purified by silica gel chromatography.

Alternatively, to a solution of alcohol (2.0 equiv) in anhydrous DMF is added 1 M potassium tert-butoxide (3-4 equiv), and the mixture is stirred at room temperature for several minutes. Then the aryl chloride intermediate HP (1.0 equiv) is added, and then the reaction mixture is heated at 40-60° C. for 1 h to 24 h. After cooling to ambient temperature, the product can be precipitated from an appropriate solvent or purified chromatographically.

Illustrative Synthesis of Intermediate A148: 3-cyclobutyl-1-phenyl-4-(tetrahydropyran-4-ylmethoxy)pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To a solution of tetrahydropyran-4-ylmethanol (CAS: 14774-37-9, 54 mg, 0.457 mmol, 3.0 equiv) in anhydrous THF (1 mL) under nitrogen atmosphere was added 60% sodium hydride in mineral oil (37 mg, 0.915 mmol, 6.0 equiv), and the mixture was stirred at room temperature for 30 minutes. HP10 (50 mg, 0.152 mmol, 1.0 equiv) was added; the reaction mixture was stirred at room temperature for 5 minutes and then heated at reflux for 3 hours. The reaction mixture was cooled to 0° C., diluted with heptane (1 mL), quenched with water (1 mL) and acidified with 2 N HCl (0.46 mL, 6.0 equiv). Volatiles were removed in vacuo. The resulting aqueous suspension was diluted with a mixture heptane/Et₂O: 1/1 (1 mL) and filtered. The solid was washed with water and with a mixture heptane/Et₂O 1/1 and dried in vacuo. The crude solid was purified by silica gel chromatography (eluent system: DCM/(DCM/MeOH/AcOH/H₂O: 90/10/1/1) gradient from 100/0 to 90/10) to give the titled compound.

Illustrative Synthesis of Intermediate A173: 3-cyclobutyl-4-(3-morpholinopropoxy)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

3-Morpholinopropan-1-ol (73 mg, 0.50 mmol) was dissolved into anhydrous DMF (830 μL), treated with 1 M KOtBu in THF (830 μL, 0.83 mmol), stirred three minutes, treated further with intermediate HP10 (82 mg, 0.25 mmol), and heated at 50° C. for about an hour. More DMF (570 μL) was added and heating was continued overnight. The mixture was brought to room temperature, diluted with MeCN and filtered with a MeCN rinse. The collected solids were mixed with acetic acid into DMSO, and diluted with water to precipitate solids which were collected by filtration, rinsed with water and dried under vacuum to give the titled compound (65 mg). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.38-8.28 (m, 2H), 7.61-7.52 (m, 2H), 7.41 (s, 1H), 7.36-7.29 (m, 1H), 4.43-4.34 (m, 2H), 4.08-3.98 (m, 1H), 3.62-3.58 (m, 4H), 2.57-2.35 (m, 10H), 2.15-1.89 (m, 4H).

Method J4: Buchwald Coupling on the Central Core

To a degassed solution of the aryl chloride intermediate HP (1.0 equiv) and the amine as free base or hydrochloride salt (1.5 equiv) in anhydrous THF at RT under nitrogen atmosphere in a sealed vial is added XPhos Pd G1 (CAS 1028206-56-5, 0.1 equiv) followed by 1 N LiHMDS in THF (from 3 to 5 equiv). The reaction mixture is purged with nitrogen and the vial is sealed. The reaction mixture is stirred at 100° C. for 1 h to 24 h. Then the reaction mixture is cooled down and volatiles are removed in vacuo. The resulting residue is taken up in dichloromethane and water and acidified with acetic acid. The two phases are separated and the aqueous phase is extracted with dichloromethane. The combined organic layers are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue is purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of Intermediate A216: 3-cyclobutyl-4-[4-(fluoromethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To a degassed solution of HP10 (64 mg, 0.194 mmol, 1.0 equiv) and 4-(fluoromethyl)piperidine hydrochloride (CAS 259143-04-9, 45 mg, 0.292 mmol, 1.5 equiv) in anhydrous THF (2 mL) at RT under nitrogen atmosphere in a sealed vial was added XPhos Pd G1 (CAS 1028206-56-5, 14 mg, 0.019 mmol, 0.1 equiv) followed by 1 N LiHMDS in THF (0.97 mL, 0.97 mmol, 5.0 equiv). The reaction mixture was purged with nitrogen, and the vial was sealed. The reaction mixture was stirred at 100° C. overnight. Then the reaction mixture was cooled down and volatiles were removed in vacuo. The resulting residue was taken up in dichloromethane and water and acidified with acetic acid. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: dichloromethane/methanol gradient from 100/0 to 95/5) to afford the titled compound.

Method J5: Buchwald Coupling on the Aryl Linker

To a degassed solution of pyridyl chloride (1.0 equiv) and amine (1.5 equiv) in anhydrous THF at RT under nitrogen atmosphere is added 1 N LiHMDS in THF (from 3 to 4.5 equiv) followed by XPhos Pd G1 (CAS 1028206-56-5, 0.1 equiv). The reaction mixture is stirred at room temperature for 1 h to 24 h. The mixture is quenched with acetic acid and diluted with water and dichloromethane. The organic layer is separated, washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or further purified by preparative HPLC or by flash chromatography on silica gel. The cross-coupling reaction can be performed on either a carboxylic acid or ester. In some instances, an ester starting material is concomitantly hydrolyzed to the corresponding carboxylic acid product under the reaction conditions.

Illustrative Synthesis of Intermediate A065: 1-cyclohexyl-4-[6-(2,6-dimethylmorpholin-4-yl)-3-pyridyl]-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To a degassed solution of A250 (75 mg, 0.188 mmol, 1.0 equiv) and 2,6-dimethylmorpholine (CAS 141-91-3, 32 μL, 0.26 mmol, 1.5 equiv) in anhydrous THF (0.7 mL) at RT under nitrogen atmosphere was added 1 N LiHMDS in THF (765 μL, 0.765 mmol, 4.5 equiv) followed by XPhos Pd G1 (CAS 1028206-56-5, 12.5 mg, 0.017 mmol, 0.1 equiv). The reaction mixture was stirred at room temperature for 1 h. The mixture was quenched with AcOH and diluted with water and dichloromethane. The organic layer was separated, washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (eluent system: dichloromethane/methanol, gradient from 100/0 to 95/5) to afford the titled compound.

Method J6: Nucleophilic Substitution on the R¹ Part

To the intermediate fluoropyridine (1.0 equiv) in anhydrous DMSO is added the amine (from 2.0 to 10.0 equiv) and K₂CO₃ (from 3.0 to 10 equiv). The reaction mixture is stirred at 100° C. overnight. If the reaction is not complete, additional amine (from 2.0 to 10 equiv) and K₂CO₃ (from 0 to 10 equiv) are added, and the reaction mixture is stirred at 100° C. until the reaction is finished. Then the reaction mixture is cooled down to RT, diluted with water and extracted with ethyl acetate. The combined organic layers are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which is used as such or purified by flash chromatography on silica gel.

Illustrative Synthesis of Intermediate A179: 3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]-1-(2-morpholino-4-pyridyl)pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To E147 (144 mg, 0.32 mmol, 1.0 equiv) in anhydrous DMSO (1.5 mL) was added morpholine (56 μL, 0.64 mmol, 2.0 equiv) and K₂CO₃ (133 mg, 0.96 mmol, 3.0 equiv). The reaction mixture was stirred at 100° C. overnight. Additional morpholine (56 μL, 0.64 mmol, 2.0 equiv) and K₂CO₃ (133 mg, 0.96 mmol, 3.0 equiv) were added, and the reaction mixture was stirred at 100° C. for 24 h. Then additional morpholine (56 μL, 0.64 mmol, 2.0 equiv) was added again, and the reaction mixture was stirred at 100° C. for 5 days. Then the reaction mixture was cooled down to RT, diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (eluent system: dichloromethane/methanol, gradient 100/0 to 95/5 with 0.1% AcOH) to afford the titled compound.

Method J7: Buchwald Coupling on the Phenyl or Heteroaryl Halogen

To a degassed solution of the aromatic bromide intermediate (1.0 equiv) and the amine as free base or hydrochloride salt (from 1.5 to 2 equiv) in anhydrous THF at RT under nitrogen atmosphere in a sealed vial is added XPhos Pd G1 (CAS 1028206-56-5, 0.1 equiv) followed by 1 N LiHMDS in THF (from 3 to 5 equiv). The reaction mixture is purged with nitrogen, and the vial is sealed. The reaction mixture is stirred at a temperature ranging from RT to 100° C. for 1 h to 3 h. If the reaction is not complete, additional amine (from 1.0 to 3.0 equiv), LiHMDS (from 1.5 to 6.0 equiv) and XPhos Pd G1 (CAS 1028206-56-5, from 0.05 to 0.2 equiv) are added at RT. The reaction mixture is purged again with nitrogen and the vial is sealed. The reaction mixture is stirred at a temperature ranging from RT to 100° C. for 1 h to 3 h. Then the reaction mixture is cooled down and volatiles are removed in vacuo. The resulting residue is taken up in dichloromethane and water and acidified with acetic acid. The two phases are separated, and the aqueous phase is extracted with dichloromethane. The combined organic layers are washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue is purified by flash chromatography on silica gel to afford the titled compound.

Illustrative Synthesis of Intermediate A212: 3-isopropyl-4-(4-methoxy-1-piperidyl)-1-(2-morpholino-4-pyridyl)pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To a degassed solution of A257 (22 mg, 0.046 mmol, 1.0 equiv) and morpholine (6 μL, 0.069 mmol, 1.5 equiv) in anhydrous THF (1 mL) at RT under nitrogen atmosphere in a sealed vial was added XPhos Pd G1 (CAS 1028206-56-5, 3 mg, 0.0046 mmol, 0.1 equiv) followed by 1 N LiHMDS in THF (138 μL, 0.138 mmol, 3.0 equiv). The reaction mixture was purged with nitrogen, and the vial was sealed. The reaction mixture was stirred at 100° C. for 1.5 h. Additional morpholine (12 μL, 0.138 mmol, 3.0 equiv), 1 N LiHMDS in THF (276 μL, 0.276 mmol, 6.0 equiv) and XPhos Pd G1 (CAS 1028206-56-5, 6 mg, 0.0092 mmol, 0.2 equiv) were added at RT. The reaction mixture was purged again with nitrogen, and the vial was sealed. The reaction mixture was stirred at 100° C. for 1 h. Then the reaction mixture was cooled down and volatiles were removed in vacuo. The resulting residue was taken up in dichloromethane and water and acidified with acetic acid. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system dichloromethane/methanol gradient from 100/0 to 90/10 with 0.1% AcOH) to afford the titled compound.

Method J8: Tandem Methylation and Saponification

60% NaH in mineral oil (6.0 equiv) is added to a solution of an ester/alcohol or a 2-oxo-1,2-dihydropyridin-4-yl/ester (1 equiv) in THF. The reaction mixture is stirred at RT for 5 minutes, and a C₁-C₆ alkyl halide (6.0 equiv) was added. The reaction mixture was stirred at RT for 1-24 hours and then concentrated. The residue was purified by silica gel chromatography to give the ether/carboxylic acid or the 1-methyl-2-oxo-1,2-dihydropyridin-4-yl/carboxylic acid.

Illustrative Synthesis of Intermediate A62: 1-cyclohexyl-3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic Acid

60% NaH in mineral oil (24 mg, 0.60 mmol, 6.0 equiv) was added to a solution of E134 (42 mg, 0.10 mmol) in THF (1 mL). The reaction mixture was stirred at RT for 5 minutes, and methyl iodide (0.037 mL, 0.60 mmol, 6.0 equiv) was added. The reaction mixture was stirred at RT for 16 hours and then concentrated. The residue was purified by silica gel chromatography (DCM/MeOH: 100/0 to 90/10) to give the titled compound.

Method J9: Amide or Carbamate Formation from an Amine

A heterocyclic amine at either the R² or R³ positions can be reacted with an acid chloride or chloroformate dissolved is solvents such as dichloromethane, tetrahydrofuran or DMF at 0° C. to ambient temperature over 0.5-4 hours in the presence a tertiary amine base or an inorganic carbonate base. The reaction mixture is extractively worked up and/or purified chromatographically either by flash chromatography or by preparative HPLC.

Illustrative Synthesis of Intermediate A225: 4-[(1-acetyl-4-piperidyl)methoxy]-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To A261 as a trifluoroacetic acid salt (0.43 g, 0.83 mmol, 1 equiv) in anhydrous dichloromethane (10 mL) at 0° C. was added triethyl amine (0.69 mL, 4.98 mmol, 6 equiv) followed by acetyl chloride (CAS 75-36-5, 119 μL, 1.66 mmol, 2 equiv). The reaction mixture was stirred at RT for 1 h. The reaction mixture was diluted with dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (eluent system: dichloromethane/methanol gradient from 100/0 to 95/5) to afford the titled compound.

Illustrative Synthesis of Intermediate A237: 3-cyclobutyl-4-[(1-methoxycarbonyl-4-piperidyl)methoxy]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To A261 as a trifluoroacetic acid salt (0.43 g, 0.83 mmol, 1 equiv) in anhydrous dichloromethane (10 mL) at 0° C. was added triethylamine (0.69 mL, 4.98 mmol, 6 equiv) followed by methyl chloroformate (CAS: 79-22-1, 128 μL, 1.66 mmol, 2 equiv). The reaction mixture was stirred at RT for 1 h. The reaction mixture was diluted with dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was taken up in a mixture of THF (1.5 mL), methanol (1.5 mL) and aqueous 2 M sodium hydroxide (0.17 mL) and stirred at RT for 1.5 h. The mixture was concentrated in vacuo. The residue was diluted with ethyl acetate and water and acidified with 1 M HCl (0.34 mL). The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo to afford the titled compound which was used as such.

Illustrative Synthesis of Intermediate A249: 1-cyclohexyl-4-[2-(dimethylamino)pyrimidin-5-yl]-3-(1-methoxycarbonylazetidin-3-yl)pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Diisopropylethylamine (0.55 mL, 3.12 mmol, 6.0 equiv) and DMAP (13 mg, 0.104 mmol, 0.2 equiv) were added to a solution of A248 (220 mg, 0.52 mmol, 1 equiv) in dichloromethane (2 mL). The mixture was cooled to 0° C. and methyl chloroformate (CAS: 79-22-1, 81 μL, 0.104 mmol, 2.0 equiv) was added. The reaction mixture was warmed up to RT and stirred for 1.5 h. The reaction mixture was partitioned between dichloromethane and water. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phase were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by preparative HPLC to afford the titled compound.

Method J10: Nucleophilic Substitution on the Central Core with Amines

A mixture of the chloride or triflate intermediate HP (1.0 equiv), the amine as free base or hydrochloride salt (from 1 to 10 equiv) and DIPEA (from 1 to 15 equiv) in anhydrous acetonitrile and DMSO or N,N-dimethylacetamide in a sealed tube or a round bottom flask is heated at a temperature ranging from 50 to 130° C. for 1 h to several days (up to 8 days). The reaction mixture is cooled to RT. The resulting residue is either purified by precipitation or by flash chromatography on silica gel to afford the titled compound or alternatively partitioned between either dichloromethane or ethyl acetate and water. The two phases are then separated, and the aqueous phase is extracted with either ethyl acetate or dichloromethane. The combined organic phases are dried, filtered and concentrated in vacuo, and the resulting crude mixture is either used as such or purified by flash chromatography on silica gel to afford the titled compound.

Alternatively, a mixture of the chloride or triflate intermediate HP (1.0 equiv), the amine as free base or hydrochloride salt (from 1 to 10 equiv) and triethylamine (from 1 to 15 equiv) in N,N-dimethylacetamide is heated with microwave irradiation at a temperature ranging from 130 to 150° C. for 5 to 20 min. DBU (1 equiv) was added, and the reaction mixture is again heated with microwave irradiation for 1 to 4 hours at 130 to 150° C. Upon cooling, solids are collected and then precipitated from a solvent such as acetonitrile.

Illustrative Synthesis of Intermediate A081: 3-cyclobutyl-1-phenyl-4-[4-(1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic Acid

A suspension of intermediate HP10 (328 mg, 1.0 mmol), 1,4′-bipiperidine (253 mg, 1.50 mmol) and triethylamine (350 μL, 2.5 mmol) in anhydrous DMA (800 μL) was heated in a Biotage® Initiator microwave synthesizer at 150° C. for fifteen minutes. DBU (180 μL, 1.2 mmol) was added, and the reaction mixture was heated with microwave irradiation at 150° C. for one hour and 45 minutes, brought to room temperature, diluted with water (8 mL) and washed with 1:2 EtOAc/MTBE. The aqueous phase was acidified with 3 M aqueous citric acid (400 μL) to precipitate the product, which was collected by filtration, washed with water and dried under vacuum to give the titled compound (423 mg). ¹H NMR (400 MHz, DMSO-d₆, 120° C.) δ ppm 8.32 (d, J=8.1 Hz, 2H), 7.54-7.48 (m, 2H), 7.32-7.26 (m, 2H), 4.02 (p, J=8.1 Hz, 1H), 3.63-3.58 (m, 2H), 3.00-2.91 (m, 2H), 2.63-2.57 (m, 4H), 2.56-2.41 (m, 5H), 2.16-1.91 (m, 4H), 1.82-1.69 (m, 2H), 1.60-1.51 (m, 4H), 1.48-1.39 (m, 2H).

Illustrative Synthesis of Intermediate A268: 3-cyclobutyl-4-(4-morpholino-1-piperidyl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

A suspension of intermediate HP10 (230 mg, 0.70 mmol), 4-(piperidin-4-yl)morpholine (177 mg, 1.05 mmol) and triethylamine (245 μL, 1.76 mmol) in anhydrous DMA (600 μL) was heated in a Biotage® Initiator microwave synthesizer at 140° C. for five minutes. DBU (105 μL, 0.70 mmol) was added, and the reaction mixture was heated with microwave irradiation at 140° C. for three hours, brought to room temperature and filtered through a C18 column (MeOH/H₂O). The filtrate was concentrated, and the residual solids were washed with EtOAc, boiled in MeCN and allowed to cool to room temperature. The solid was collected by filtration, rinsed with acetonitrile and dried under vacuum to give the titled compound (305 mg). ¹H NMR (400 MHz, DMSO-d₆, 90° C.) δ ppm 8.34-8.30 (m, 2H), 7.54-7.48 (m, 2H), 7.30-7.25 (m, 2H), 4.00 (p, J=8.1 Hz, 1H), 3.62-3.58 (m, 4H), 3.56-3.53 (m, 2H), 2.97-2.89 (m, 1H), 2.76-2.68 (m, 1H), 2.56-2.51 (m, 4H), 2.45-2.41 (m, 3H), 2.11-1.94 (m, 4H), 1.85-1.77 (m, 1H), 1.74-1.63 (m, 2H), 1.55-1.44 (m, 1H).

Illustrative Synthesis of Intermediate A270: 3-cyclobutyl-4-[4-(2-morpholinoethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

A suspension of intermediate HP10 (164 mg, 0.50 mmol), 4-(2-(piperidin-4-yl)ethyl)morpholine (149 mg, 0.75 mmol) and triethylamine (175 μL, 1.26 mmol) in anhydrous DMA (400 μL) was heated in a Biotage® Initiator microwave synthesizer at 150° C. for fifteen minutes. DBU (90 μL, 0.60 mmol) was added, and the reaction mixture was heated by microwave irradiation at 150° C. for one hour, brought to room temperature, diluted with water (8 mL) and concentrated. The residue was slurried in acetonitrile and the solids were collected by filtration to give the titled compound (155 mg).

Illustrative Synthesis of Intermediate A284: 3-cyclobutyl-4-[(3R)-3-(hydroxymethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

A suspension of 4-chloro-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (HP10, 164 mg, 0.50 mmol), (R)-piperidin-3-ylmethanol (86 mg, 0.75 mmol) and triethylamine (175 μL, 1.26 mmol) in anhydrous DMA (400 μL) was heated in a microwave reactor at 150° C. for fifteen minutes. DBU (90 μL, 0.60 mmol) was added, and the reaction mixture was heated in the reactor at 150° C. for one hour, brought to room temperature, diluted with water (8 mL), concentrated, and purified by preparative HPLC on a Waters® T3 column (30 mm×100 mm) with a 20 to 100% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound (156 mg). ¹H NMR (400 MHz, CD₂Cl₂) δ ppm 7.84 (d, J=8.1 Hz, 2H), 7.21-7.13 (m, 3H), 6.92 (t, J=7.4 Hz, 1H), 3.81 (tt, J=8.5, 8.4 Hz, 1H), 3.54-3.46 (m, 1H), 3.43-3.20 (m, 3H), 2.57-2.24 (m, 6H), 2.04-1.88 (m, 2H), 1.84-1.71 (m, 1H), 1.63-1.49 (m, 3H), 0.95-0.79 (m, 1H).

Illustrative Synthesis of Intermediate A408: 1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

A suspension of the 4-chloro-1-(4-fluorophenyl)-3-isopropyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (267 mg, 0.80 mmol, HP11), 4-morpholinopiperidine (204 mg, 1.2 mmol) and triethylamine (280 μL, 2.0 mmol) in anhydrous DMA (700 μL) was heated in a microwave reactor at 150° C. for fifteen minutes. DBU (145 μL, 0.96 mmol) was added, and the reaction mixture was heated at 150° C. two hours, brought to room temperature, diluted with water (7 mL) and washed twice with 1:2 EtOAc/MTBE. The aqueous phase was acidified with aqueous citric acid to pH 5, and the solids were collected by filtration, washed with water and dried under vacuum to give the titled compound.

Illustrative Synthesis of Compound A413: 3-cyclobutyl-4-[4-(hydroxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

To a solution of HP10 (0.502 g, 1.532 mmol) and 4-piperidinemethanol (0.441 g, 3.83 mmol) in N,N-dimethylacetamide (DMA, 1.5 mL) was added diisopropylethylamine (1.5 mL, 8.59 mmol), and the reaction mixture was then stirred at 150° C. for 12 hours. The reaction mixture was then partitioned between dichloromethane and 1 N HCl. The organic fraction was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on silica gel, eluting with a gradient of 0-5% MeOH/DCM to give the titled compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41 (qd, J=12.2, 3.7 Hz, 2H), 1.60 (dtdd, J=13.2, 10.0, 6.2, 3.6 Hz, 1H), 1.83 (dd, J=13.3, 3.4 Hz, 2H), 1.87-2.12 (m, 3H), 2.36 (dtd, J=11.8, 8.5, 3.1 Hz, 2H), 2.51 (dd, J=9.3, 2.3 Hz, 1H), 2.76-2.96 (m, 2H), 3.54 (dd, J=9.4, 6.2 Hz, 2H), 3.94 (p, J=8.4 Hz, 1H), 4.55 (s, 1H), 7.24-7.33 (m, 2H), 7.47-7.58 (m, 2H), 8.30 (d, J=8.0 Hz, 2H).

Method J11: Tandem Nucleophilic Substitution/Saponification

The intermediate ester (1 equiv) is suspended in a mixture of appropriate alcohol for the nucleophilic substitution and THF. 1 N NaOH (from 17 to 19 equiv) is added, and the reaction mixture is stirred at RT or 50° C. until full conversion is observed. 1 N HCl (2 equiv) and a phosphate buffer solution (pH 6.2) are added. The mixture is concentrated under reduced pressure, and the crude residue is partitioned between water and dichloromethane. The organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound.

Illustrative Synthesis of A343: 3-cyclobutyl-1-(2-ethoxypyrimidin-4-yl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

The intermediate ester E422 (30 mg, 57 μmol) was suspended in a mixture of ethanol (8 mL) and THF (3 mL). 1 N NaOH (1 mL, 1 mmol) was added, and the reaction mixture was stirred at RT for 2 hours. 1N HCl (1 mL, 1 mmol) and a phosphate buffer solution (pH 6.2, 5 mL) were added. The mixture was concentrated under reduced pressure, and the crude residue was partitioned between water and dichloromethane. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound, A343.

Method I12: S_(N)Ar on Fluoropyridine

The (6-fluoro-pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (1 eq) is heated together with the amine (1.05 eq) and DIPEA (1.25 eq) in NMP at 100° C. for 18 hours. Mixture is diluted with EtOAc and water. Isolation of the organic layer and subsequent concentration yields the desired product.

Illustrative Synthesis of Compound A405: 3-Cyclobutyl-1-cyclohexyl-4-[6-(4-cyclopropyl-piperazin-1-yl)-pyridin-3-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

3-Cyclobutyl-1-cyclohexyl-4-(6-fluoro-pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (200 mg, 0.51 mmol) was heated together with 1-cyclopropylpiperazine ([20327-23-5], 64 μL, 0.53 mmol) and DIPEA (110 μL, 0.64 mmol) in NMP (2 mL) at 100° C. for 18 hours. The mixture was diluted with EtOAc and water. Isolation of the organic layer and subsequent concentration yielded the titled compound.

Method J13: Suzuki with Alkyl-BF₃ Salts

-   -   LG³ is a leaving group suitable for the coupling reaction     -   G^(x) is -G^(3B) or -G^(3B)-L¹-G^(3C)

The aryl halide (1 eq) is mixed together with the alkyl-BF3 salt (1.5 eq), Pd(dppf)Cl₂.DCM (CAS 95464-05-4, 0.05 eq) and Cs₂CO₃ (3 eq) in a mixture of THF/H₂O (10/1). The mixture is put under N₂ atmosphere and heated at 80° C. overnight.

If the method is performed on an ester, the ester can be subsequently hydrolyzed to the acid by the addition of LiOH (2 eq) and heating at 50° C. The titled compound is isolated by acidifying with citric acid till pH=6 and extraction with EtOAc. Concentration, possibly followed by chromatographic purification, gives the titled compound.

Illustrative Synthesis of Compound A361: 3-Cyclobutyl-1-(4-fluoro-phenyl)-4-(4-morpholin-4-yl-piperidin-1-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

HP19 (352 mg, 0.98 mmol) was mixed together with the potassium trifluorido{[4-(morpholin-4-yl)piperidin-1-yl]methyl}borate (426 mg, 1.47 mmol), Pd(dppf)Cl₂.DCM (CAS 95464-05-4, 40 mg, 0.05 mmol) and Cs₂CO₃ (959 mg, 2.94 mmol) in a mixture of THF/H₂O (10/1, 5 mL). The mixture was put under a N₂ atmosphere and heated at 80° C. overnight. Next, LiOH (82 mg, 2 mmol) was added, and the mixture was heated at 50° C. The titled compound was isolated by acidifying with citric acid till pH=6 and extraction with EtOAc. Concentration, followed by automated preparative chromatographic purification, gave the titled compound.

Method I14: Suzuki and Subsequent Hydrolysis

The arylchloride (1 eq) is mixed with the boronic ester (or acid) (1.5 eq), Pd(dppf)Cl₂.DCM (CAS 95464-05-4, 0.1 eq) and DIPEA (3 eq) in a mixture of water/dioxane (1/2). The resulting mixture is stirred at 120° C. for 18 hours. Next, LiOH (2 eq) is added, and the mixture is heated at 40° C. After acidifying with 2 M HCl solution, extraction with EtOAc gives an organic phase that is concentrated to give the titled compound.

Illustrative Synthesis of Compound A365: 3-cyclobutyl-1-cyclohexyl-4-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Intermediate HP25 (140 mg, 0.40 mmol), 4-(2-morpholinoethyl)phenylboronic acid (142 mg, 0.60 mmol, CAS#1150114-55-8), Pd(dppf)₂Cl₂ (33 mg, 0.04 mmol) and DIPEA (211 μL, 1.20 mmol) were heated at 120° C. in a mixture of water and dioxane (3 mL, 1:2 water/dioxane). After overnight stirring, LiOH (34 mg, 0.81 mmol) was added, and the resulting mixture was stirred at 40° C. until the hydrolysis was finished. Next, the mixture was diluted with EtOAc and water. After separation, the aqueous phase was acidified with 2 N HCl and subsequently extracted with DCM. The resulting organic phase was dried and concentrated to give the titled compound.

Synthesis of A271: 4-[(3aR,7aS)-1-acetyl-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Step 1: Rac-4-[(3aR,7aS)-1-(tert-butoxycarbonyl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Intermediate HP10 (164 mg, 0.50 mmol), the tert-butyl rac-(3aR,7aS)-octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (181 mg, 0.80 mmol, CAS#848410-13-9) and diisopropylethylamine (175 μL, 1.0 mmol) were heated in DMSO (350 μL) at 120° C. for a day, brought to room temperature, and partitioned between EtOAc and 2:1 water/brine (600 μL). The aqueous phase was separated and extracted thrice with EtOAc, and the combined organic phases were acidified with TFA, concentrated and chromatographed on silica (0.1% TFA in 1:1 EtOAc/heptane) to give the titled compound (274 mg). ¹H NMR (501 MHz, methanol-d₄) δ ppm 1.50 (s, 9H), 1.94-2.27 (m, 6H), 2.42-2.51 (m, 2H), 2.52-2.66 (m, 3H), 2.95-3.06 (m, 1H), 3.37-3.58 (m, 5H), 3.94-4.00 (m, 1H), 4.02-4.07 (m, 1H), 7.31-7.35 (m, 1H), 7.44 (s, 1H), 7.50-7.55 (m, 2H), 8.24-8.28 (m, 2H).

Step 2: Sodium Rac-3-cyclobutyl-4-[(3aR,7aS)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

rac-4-[(3aR,7aS)-1-(tert-Butoxycarbonyl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (1.00 g, <1.9 mmol) was dissolved into anhydrous CH₂Cl₂ (8.0 mL), treated with TFA (2.0 mL), stirred at room temperature for two hours and then concentrated. The residue was redissolved into CH₂Cl₂, treated with aqueous K₂HPO₄ and basified to pH 11+ with aqueous NaOH. Brine was added, and the mixture was extracted with 10% MeOH/CH₂Cl₂. The separated organic phase was dried (Na₂SO₄), passed through a short column of Na₂SO₄ and concentrated to give the titled compound (452 mg). ¹H NMR (500 MHz, methanol-d₄) δ ppm 1.69-1.77 (m, 1H), 1.98-2.21 (m, 5H), 2.40-2.66 (m, 6H), 2.94-3.01 (m, 2H), 3.15-3.3 (m, 3H), 3.32-3.36 (m, 1H), 4.07-4.15 (m, 1H), 7.24-7.28 (m, 1H), 7.38 (s, 1H), 7.47-7.51 (m, 2H), 8.35-8.38 (m, 2H); MS (ESI) m/z 418 (M+H)⁺.

Step 3: 4-[(3aR,7aS)-1-acetyl-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Sodium rac-3-cyclobutyl-4-[(3 aR,7aS)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate (209 mg, 0.50 mmol) and N-methylmorpholine (220 μL, 2.0 mmol) were suspended in DMF (2.5 mL) and chilled with a water ice bath. A solution of acetyl chloride (50 μL, 0.70 mmol) in dichloromethane (500 μL) was added dropwise, and the mixture was stirred for two minutes before the bath was removed. The cloudy solution was stirred another thirty minutes at room temperature before being diluted with EtOAc and placed directly on silica for chromatography (EtOAc, then 0 to 20% MeOH/MeCN, then 0.1% TFA/19.9% MeOH/80% MeCN) to give rac-4-[(3aR,7aS)-1-acetyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (236 mg).

The racemate was then subjected to preparative supercritical fluid chromatography set to maintain a maximum back pressure of 100 MPa using a Chiralcel® OJ-H (21×250 mm) column with the sample at a concentration of 10 mg/mL in methanol using 35% methanol in CO₂ at a flow rate of 45 mL/minute to provide both enantiomers separately. The first enantiomer eluted (retention time=5.4 minutes), and the second enantiomer eluted (retention time=7.4 minutes) as the titled compound (stereochemistry arbitrarily assigned). ¹H NMR (400 MHz, DMSO-d₆, 120° C.) δ ppm 1.98 (s, 3H), 1.88-2.22 (m, 6H), 2.40-2.59 (m, 4H), 2.98-3.07 (m, 1H), 3.15-3.19 (m, 1H), 3.31-3.61 (m, 4H), 3.78-3.83 (m, 1H), 3.99-4.13 (m, 2H), 7.27-7.32 (m, 1H), 7.34 (s, 1H), 7.49-7.55 (m, 2H), 8.29-8.35 (m, 2H).

Synthesis of A222: 4-(4-morpholinophenyl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

4-(4-Morpholinyl)benzaldehyde (CAS 1204-86-0, 241 mg, 1.26 mmol, 1 equiv), pyruvic acid (CAS 127-17-3, 88 μL, 1.26 mmol, 1 equiv) and 5-amino-1-phenylpyrazole (CAS 826-85-7, 200 mg, 1.26 mmol, 1 equiv) were combined in a sealed tube. Acetic acid (5 mL) was added, and the vial was sealed. The reaction mixture was heated under microwave irradiation at 160° C. for 20 min. The reaction mixture was cooled down and concentrated in vacuo. The resulting residue was purified by preparative HPLC to afford the tiled compound.

TABLE XIII List of acids Int. Structure Name SM method MW Mes A001

4-(4- methoxyphenyl)- 3-methyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid — 926282- 55-5 — — A002

3-methyl-4-(4- morpholinophenyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 1131- 18-6 J2 Specific example 414 415 A003

4-(4- methoxyphenyl)- 3-methyl-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP06, 92721- 83-0 J2 373 374 A004

1-(3-chloro-4- methyl-phenyl)-4- (4- methoxyphenyl)- 3-methyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP06, 866472- 29-9 J2 407 408 A005

4-[4- (dimethylamino) phenyl]-3- isopropyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP02, AMP04 J2 400 401 A006

4-(4- dimethylamino- phenyl)-3-methyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E006 J1 372 373 A007

1-(3,5- difluorophenyl)- 3-methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 1232796- 65-4 J2 450 451 A008

1-(3- chlorophenyl)-3- methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 40401- 41-0 J2 448 449 A009

1-(3- fluorophenyl)-3- methyl-4-(4- morpholinophenyl) pyrazolo[3,4- d]pyridine-6- carboxylic acid ALP01, 105438- 45-7 J2 432 433 A010

1-(3- methoxyphenyl)- 3-methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 92721- 94-3 J2 444 445 A011

3-methyl-4-(4- morpholinophenyl)- 1-[3- (trifluoromethyl) phenyl]pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 345-07- 3 J2 482 483 A012

1-(3,5- dimethylphenyl)- 3-methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 890010- 89-6 J2 442 443 A013

3-methyl-4-(4- morpholinophenyl)- 1-[4- (trifluoromethoxy) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP01, 497141- 59-0 J2 414 415 A014

3-methyl-4-(4- morpholinophenyl)- 1-[3- (trifluoromethoxy) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP01, AMP01 J2 498 499 A015

1-(3,4- difluorophenyl)- 3-methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP02 J2 450 451 A016

3-methyl-4-(6- morpholino-3- pyridyl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E009 J1 415 416 A017

4-(4- dimethylamino- phenyl)-3-methyl-1- [3- (trifluoromethyl) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP02, 345-07- 3 J2 440 441 A018

cyclohexyl-4-[2- (dimethylamino) pyrimidin-5-yl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP03, AMP23 J2 408 409 A019

4-[4- (dimethylamino) phenyl]-3- isopropyl-1-(6- methoxy-3- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP02, AMP16 J2 431 432 A020

3-isopropyl-4-(4- morpholinophenyl)- 1- tetrahydropyran- 3-yl-pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP25 J2 450 451 A021

4-[4-[3- (dimethylamino) azetidin-1- yl]phenyl]-3- methyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E011 J1 427 428 A022

1-cyclohexyl-3- methyl-4-(6- morpholino-3- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP05, 56547- 82-1 J2 421 422 A023

1-cyclohexyl-4- [2- (dimethylamino) pyrimidin-5-yl]-3- methyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP03, 56547- 82-1 J2 380 381 A024

1-[3- (dimethylamino) phenyl]-4-[2- (dimethylamino) pyrimidin-5-yl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP03, AMP06 J2 445 446 A025

3-isopropyl-4-(2- morpholinopyrimidin- 5-yl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP04, AMP04 J2 444 445 A026

3-isopropyl-4-(2- morpholinopyrimidin- 5-yl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E003 J1 450 451 A027

1-cyclopentyl-4- [6- (dimethylamino)- 3-pyridyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP21, AMP26 J2 393 394 A028

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-(2- morpholinopyrimidin- 5- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E016 J1 487 488 A029

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-(6- morpholino-3- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E015 J1 486 487 A030

4-[2- (dimethylamino) pyrimidin-5-yl]-3- isopropyl-1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP03, AMP10 J2 487 488 A031

4-[6- (dimethylamino)- 3-pyridyl]-3- isopropyl-1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP21, AMP10 J2 486 487 A032

1-cyclohexyl-4- [6- (dimethylamino)- 3-pyridyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP21, AMP23 J2 407 408 A033

3-methyl-4-(6- morpholino-3- pyridyl)-1-[3- (trifluoromethyl) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP05, 345-07- 3 J2 483 484 A034

1-(2,4- difluorophenyl)- 3-methyl-4-(6- morpholino-3- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP05, 380569- 79-9 J2 451 452 A035

1-(2,4- difluorophenyl)- 3-methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 380569- 79-9 J2 450 451 A036

3-methyl-1- phenyl-4-(1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E004 J1 336 337 A037

3-cyclobutyl-4-(4- morpholinophenyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP29 J2 454 455 A038

1-[3-(azetidin-1- yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E002 J1 497 498 A039

3-isopropyl-4-(4- morpholinophenyl)- 1-(3-pyrrolidin- 1- ylphenyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E005 J1 511 512 A040

1-(4,4- difluorocyclohexyl)- 3-isopropyl-4- (4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP24 J2 484 485 A041

1-[3-(3,3- dimethylazetidin- 1-yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E012 J1 525 526 A042

3-isopropyl-1-(m- tolyl)-4-(1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E039 J1 378 379 A043

3-isopropyl-1-[3- (3- methoxyazetidin- 1-yl)phenyl]-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E008 J1 527 528 A044

1-[3-(3- fluoropyrrolidin- 1-yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E013 J1 529 530 A045

1-cyclohexyl-3- isopropyl-4-[6- [methyl(tetra- hydropyran-4- yl)amino]-3- pyridyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E014 J1 477 478 A046

4-(4- acetamidophenyl)- 1-cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E021 J1 420 421 A047

3-isopropyl-1-[3- [2- methoxyethyl(methyl) amino]phenyl]- 4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid A242 J7 529 530 A048

4-[4-(4-cyano-1- piperidyl)phenyl]- 1-[3- (dimethylamino) phenyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E023 J1 508 509 A049

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-[4-[2- methoxyethyl(methyl) amino]phenyl] pyrazolo[3,4- b]pyridine-6- carboxylic acid E024 J1 487 488 A050

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-1-[3- (dimethylamino) phenyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E025 J1 509 510 A051

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-[6-[2- methoxyethyl(methyl) amino]-3- pyridyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E026 J1 488 489 A052

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- isopropyl-1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E027 J1 551 552 A053

3-isopropyl-4-[6- [2- methoxyethyl(methyl) amino]-3- pyridyl]-1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E028 J1 530 531 A054

1-cyclohexyl-4- [6-(3,3- difluoropyrrolidin- 1-yl)-3-pyridyl]- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A250 J5 469 470 A055

3-cyclobutyl-4-[6- [2- methoxyethyl(methyl) amino]-3- pyridyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E017 J1 457 458 A056

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E018 J1 Specific example 478 479 A057

3-cyclobutyl-4-[6- [methyl(tetrahydro- pyran-4- yl)amino]-3- pyridyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E019 J1 483 484 A058

3-cyclobutyl-4-[4- [2- methoxyethyl(methyl) amino]phenyl]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E020 J1 456 457 A059

4-[4-(4-cyano-1- piperidyl)phenyl]- 1-cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E022 J1 471 472 A060

3-isopropyl-4-[6- [methyl(tetrahydro- pyran-4- yl)amino]-3- pyridyl]-1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E029 J1 556 557 A061

3-isopropyl-4-[4- [2- methoxyethyl(methyl) amino]phenyl]- 1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E030 J1 529 530 A062

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-[6- [methyl(tetrahydro- pyran-4- yl)amino]-3- pyridyl]pyrazoIo [3,4-b]pyridine-6- carboxylic acid E031 J1 514 515 A063

3-isopropyl-4-(3- methoxy-1- piperidyl)-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E088 J1 408 409 A064

3-isopropyl-4-(4- methoxy-1- piperidyl)-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E048 J1 408 409 A065

1-cyclohexyl-4- [6-(2,6- dimethylmorpholin- 4-yl)-3- pyridyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A250 J5 Specific example 477 478 A066

1-cyclohexyl-4- [6-(2,2- dimethylmorpholin- 4-yl)-3- pyridyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A250 J5 477 478 A067

4-[2-(4-cyano-1- piperidyl)pyrimidin- 5-yl]-1-[3- (dimethylamino) phenyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E034 J1 510 511 A068

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-[2- [methyl(tetrahydro- pyran-4- yl)amino]pyrimidin- 5- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E032 J1 515 516 A069

3-isopropyl-4-(4- morpholinophenyl)- 1-(2- morpholino-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E066 J1 528 529 A070

4-[6-(4-cyano-4- methyl-1- piperidyl)-3- pyridyl]-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A250 J5 486 487 A071

4-[2-(4-cyano-1- piperidyl)pyrimidin- 5-yl]-3- isopropyl-1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E037 J1 552 553 A072

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-[4- [methyl(tetrahydro- pyran-4- yl)amino]phenyl] pyrazolo[3,4- b]pyridine-6- carboxylic acid E035 J1 513 514 A073

3-isopropyl-4-[4- [methyl(tetrahydro- pyran-4- yl)amino]phenyl]- 1-(3- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E036 J1 555 556 A074

3-isopropyl-4-[2- methoxyethyl(methyl) amino]-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E094 J1 382 383 A075

4-[4-[3- (dimethylamino) pyrrolidin-1- yl]phenyl]-3- methyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E038 J1 441 442 A076

4-[4-(4-cyano-1- piperidyl)phenyl]- 3-cyclobutyl-1- cyclohexyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E040 J1 483 484 A077

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- cyclobutyl-1- cyclohexyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E041 J1 484 485 A078

4-(4- acetamidophenyl)- 1-(3,5- difluorophenyl)- 3-(1- methoxycarbonyl azetidin-3- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E042 J1 521 522 A079

1-cyclohexyl-4- [6-(3-fluoro-1- piperidyl)-3- pyridyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A250 J5 465 466 A080

1-cyclohexyl-3- isopropyl-4-[6-(3- methoxypyrrolidin- 1-yl)-3- pyridyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid A250 J5 463 464 A081

3-cyclobutyl-1- phenyl-4-[4-(1- piperidyl)-1- piperidyl]pyrazolo- [3,4-b]pyridine- 6-carboxylic acid HP10 J10 Specific example 459 460 A082

3-isopropyl-4-[4- (methoxymethyl)- 1-piperidyl]-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E082 J1 422 423 A083

3-isopropyl-4-[4- (2-methoxyethyl)- 1-piperidyl]-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E087 J1 436 437 A084

4-[2-(4-cyano-1- piperidyl)pyrimidin- 5-yl]-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E049 J1 473 474 A085

1-cyclohexyl-3- isopropyl-4-[2- [methyl(tetrahydro- pyran-4- yl)amino]pyrimidin- 5- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E051 J1 478 479 A086

1-cyclohexyl-3- isopropyl-4-[2-[2- methoxyethyl(methyl) amino]pyrimidin- 5- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E050 J1 452 453 A087

3-isopropyl-4-[4- [2- methoxyethyl(methyl) amino]phenyl]- 1-(3-pyrrolidin- 1- ylphenyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E045 J1 513 514 A088

1-(3,4- difluorophenyl)- 3-isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E057 J1 478 479 A089

3-isopropyl-4-(4- morpholinophenyl)- 1-(6- morpholino-2- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E058 J1 528 529 A090

3-isopropyl-4-[4- [methyl(tetrahydro- pyran-4- yl)amino]phenyl]- 1-(3-pyrrolidin-1- ylphenyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E046 J1 539 540 A091

3-cyclobutyl-4-[4- [methyl(tetrahydro- pyran-4- yl)amino]phenyl]- 1-(3-pyrrolidin-1- ylphenyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E047 J1 551 552 A092

3-isopropyl-4-(4- methylsulfonyl-1- piperidyl)-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E089 J1 456 457 A093

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- isopropyl-1-[3- (trifluoromethyl) phenyl]pyrazolo[3, 4-b]pyridine-6- carboxylic acid E052 J1 534 535 A094

4-[4-(4-cyano-1- piperidyl)phenyl]- 3-isopropyl-1-[3- (trifluoromethyl) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E065 J1 533 534 A095

3-isopropyl-1-(m- tolyl)-4-(8-oxa-3- azaspiro[4.5]decan- 3- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E095 J1 434 435 A096

1-cyclohexyl-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E076 J1 400 401 A097

1-[6- (dimethylamino)- 2-pyridyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid E053 J1 486 487 A098

3-isopropyl-4-(4- morpholinophenyl)- 1-[3- (trifluoromethoxy) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E054 J1 526 527 A099

4-(2,2-difluoro-6- azaspiro[2.4]heptan- 6-yl)-3- isopropyl-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E075 J1 426 427 A100

4-[6-[bis(2- methoxyethyl) amino]-3-pyridyl]-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A250 J5 495 496 A101

1-cyclohexyl-3- isopropyl-4-[6- [methyl(tetrahydro- furan-3- yl)amino]-3- pyridyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid A250 J5 463 464 A102

1-(4- fluorophenyl)-3- isopropyl-4-[2- [methyl(tetrahydro- pyran-4- yl)amino]pyrimidin- 5- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E064 J1 490 491 A103

4-(2,6-difluoro-4- methoxy-phenyl)- 1-(3-fluoro-5- methoxy-phenyl)- 3-methyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E059 J1 443 444 A104

4-[4-(4-cyano-1- piperidyl)phenyl]- 1-(3,5- difluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E060 J1 501 502 A105

4-[4-(4-cyano-1- piperidyl)phenyl]- 1-(3- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E061 J1 483 484 A106

3-isopropyl-4-[4- [2- methoxyethyl(methyl) amino]phenyl]- 1-[3- (trifluoromethyl) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E062 J1 512 513 A107

3-isopropyl-4-[6- [methyl(tetrahydro- pyran-4- yl)amino]-3- pyridyl]-1-[3- (trifluoromethyl) phenyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E063 J1 539 540 A108

4-[2-(4-cyano-1- piperidyl)pyrimidin- 5-yl]-1-(2,4- difluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E068 J1 503 504 A109

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-1-(2,4- difluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E069 J1 502 503 A110

4-[4-(4-cyano-1- piperidyl)phenyl]- 1-(2,4- difluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E070 J1 501 502 A111

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-(1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E083 J1 407 408 A112

4-(4-cyano-1- piperidyl)-1-[3- (dimethylamino) phenyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E086 J1 432 433 A113

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E081 J1 437 438 A114

3-(1- methylcyclobutyl)- 4-(4- morpholinophenyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E067 J1 468 469 A115

4-[4- (fluoromethyl)-1- piperidyl]-3- isopropyl-1-(m- tolyl)pyrazolo[3,4- b]pyridine-6- carboxylic acid HP16 J4 410 411 A116

3-cyclobutyl-4-(4- methoxy-1- piperidyl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E071 J1 406 407 A117

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- isopropyl-1- tetrahydropyran- 3-yl-pyrazolo[3,4- b]pyridine-6- carboxylic acid E073 J1 474 475 A118

3-cyclobutyl-4-[4- (2-oxo-2- pyrrolidin-1-yl- ethoxy)-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E080 J1 503 504 A119

1-[3- (dimethylamino) phenyl]-3- isopropyl-4-[4- (methoxymethyl)- 1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E072 J1 451 452 A120

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- isopropyl-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E084 J1 536 537 A121

3-cyclobutyl-4-(4- isopropoxy-1- piperidyl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E077 J1 434 435 A122

3-cyclobutyl-4-[3- (methoxymethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E079 J1 420 421 A123

3-isopropoxy-4- (4- morpholinophenyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E090 J1 458 459 A124

1-(4- fluorophenyl)-3- isopropyl-4-[4- (methoxymethyl)- 1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E092 J1 426 427 A125

4-[4-(4-cyano-1- piperidyl)phenyl]- 3-isopropyl-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E093 J1 535 536 A126

1-(4- fluorophenyl)-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E091 J1 412 413 A127

4-(4-butoxy-1- piperidyl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E096 J1 454 455 A128

1-(4- fluorophenyl)-4- (4-isobutoxy-1- piperidyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E098 J1 454 455 A129

1-(4- fluorophenyl)-3- isopropyl-4-(4- methoxy-4- methyl-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E097 J1 426 427 A130

1-(4- fluorophenyl)-3- isopropyl-4-(3- oxa-7- azaspiro[3.5]nonan- 7- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E099 J1 424 425 A131

4-[3- (difluoromethyl)- 1-piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E100 J1 432 433 A132

1-(4- fluorophenyl)-3- isopropyl-4-(8- oxa-2- azaspiro[3.5]nonan- 2- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E101 J1 424 425 A133

1-(4- fluorophenyl)-3- isopropyl-4-(4- oxa-8- azaspiro[4.5]decan- 8- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E102 J1 438 439 A134

3-cyclobutyl-4-[4- (2-methoxyethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E104 J1 434 435 A135

4-(2- azaspiro[3.4]octan- 2-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E105 J1 402 403 A136

3-cyclobutyl-4-[4- (methoxymethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E106 J1 420 421 A137

4-(3- azabicyclo[3.1.0] hexan-3-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E107 J1 374 375 A138

3-cyclobutyl-4- (cyclohexylmethoxy)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 405 406 A139

3-cyclobutyl-1- phenyl-4-(1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E103 J1 376 377 A140

4-(2- azaspiro[3.5]nonan- 2-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E115 J1 416 417 A141

4-(4-cyano-1- piperidyl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E114 J1 401 402 A142

3-cyclobutyl-4-(4- methylsulfonyl-1- piperidyl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E113 J1 454 455 A143

3-isopropyl-4-(4- methoxy-1- piperidyl)-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E110 J1 464 465 A144

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- cyc!obutyl-1-(2- pyrrolidin-1-yl-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E112 J1 548 549 A145

3-cycIobutyl-1- phenyl-4-(2- tetrahydropyran- 4- ylethoxy)pyrazolo [3,4-b]pyridine-6- carboxylic acid HP10 J3 421 422 A146

3-cyclobutyl-4- [(2S)-2-fluoro-2- tetrahydropyran- 4-yl-ethoxy]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10, ALC01 J3 439 440 A147

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- cyclobutyl-1-(2- morpholino-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E121 J1 564 565 A148

3-cyclobutyl-1- phenyl-4- (tetrahydropyran- 4- ylmethoxy) pyrazolo [3,4-b]pyridine- 6-carboxylic acid HP10 J3 Specific example 407 408 A149

3-cyclobutyl-4-[3- (methoxymethyl) azetidin-1-yl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E116 J1 392 393 A150

4-(7- azaspiro[2.5]octan- 7-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E125 J1 402 403 A151

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3-(3,3- difluorocyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E118 J1 514 515 A152

4-[6-(4- cyanopiperidin-1- yl)pyridin-3-yl]- 3-[(1s,3s)-3- methoxycyclobutyl]- 1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E117 J1 508 509 A153

3-cyclobutyl-4-[2- methoxyethyl (methyl)amino]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E126 J1 380 381 A154

3-cyclobutyl-4- (2,2-difluoro-6- azaspiro[2.4]heptan- 6-yl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E122 J1 424 425 A155

3-cyclobutyl-4-(9- oxa-2- azaspiro[3.5]nonan- 2-yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E123 J1 418 419 A156

3-cyclobutyl-4-(7- oxa-2- azaspiro[3.5]nonan- 2-yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E124 J1 418 419 A157

4-(6- azaspiro[3.3]heptan- 6-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E128 J1 388 389 A158

4-[4- (benzyloxymethyl)- 1-piperidyl]-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E127 J1 496 497 A159

3-cyclobutyl-4- {[(1s,4s)-4- methoxycyclohexyl] oxy}-1-phenyl- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 421 422 A160

3-cyclobutyl-4- {[(1r,4r)-4- methoxycyclohexyl] oxy}-1-phenyl- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 421 422 A161

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3-(3,3- dimethylcyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E119 J1 506 507 A162

1-cyclohexyl-3- isopropyl-4-[4- (methoxymethyl)- 1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E134 J8 Specific example 414 415 A163

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3-(3- fluorocyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid (cis) A258 Sepa- ration by prep HPLC 496 497 A164

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3-(3- fluorocyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid trans A258 Sepa- ration by prep HPLC 496 497 A165

3-cyclobutyl-4- [(2R)-2-fluoro-2- tetrahydropyran- 4-yl-ethoxy]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10, ALC02 J3 439 440 A166

3-cyclobutyl-4- [(3,3- difluorocyclopentyl) methoxy]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 427 428 A167

3-cyclobutyl-4-[2- (1,1-dioxo-1,4- thiazinan-4- yl)ethoxy]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 470 471 A168

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- isopropyl-1-(2- morpholino-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E138 J1 552 553 A169

1-(4- fluorophenyl)-3- isopropyl-4-[4-(1- methoxy-1- methyl-ethyl)-1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E136 J8 454 455 A170

3-cyclobutyl-4-[4- [(1S)-2- (dimethylamino)- 1-fluoro-ethyl]-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E135 J1 465 466 A171

3-cyclobutyl-4- [(3,3-difluoro-1- methyl- cyclobutyl)methoxy]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 427 428 A172

4-[(1-acetyl-4- fluoro-4- piperidyl)methoxy]- 3-cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 466 467 A173

3-cyclobutyl-4-(3- morpholinopropoxy)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 Specific example 436 437 A174

3-cyclobutyl-4- [(3-methyloxetan- 3-yl)methoxy]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 393 394 A175

3-cyclobutyl-4-[4- (1-methoxyethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E143 J8 434 435 A176

3-cyclobutyl-1- phenyl-4-[4- (2,2,2-trifluoro-1- methoxy-1- methyl-ethyl)-1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E144 J8 502 503 A177

4-[6-[bis(2- methoxyethyl) amino]-3-pyridyl]-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E145 J1 501 502 A178

4-[6-[bis(2- methoxyethyl) amino]-3-pyridyl]-3- isopropyl-1-(2- morpholino-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E149 J1 575 576 A179

3-isopropyl-4-[4- (methoxymethyl)- 1-piperidyl]-1-(2- morpholino-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid E147 J6 Specific example 494 495 A180

3-cyclobutyl-4-[4- methoxy-4- (methoxymethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E146 J8 450 451 A181

1- (cyclobutylmethyl)- 3-isopropyl-4- [4- (methoxymethyl)- 1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E154 J1 400 401 A182

1-isobutyl-3- isopropyl-4-[4- (methoxymethyl)- 1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E155 J1 388 389 A183

4-[6-(4- cyanopiperidin-1- yl)pyridin-3-yl]- 3-[(1r,3r)-3- methylcyclobutyl]- 1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E151 J1 492 493 A184

3-[(1-tert- butoxycarbonyl- 4-piperidyl)oxy]- 4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E152 J1 623 624 A185

3-isopropyl-4-[4- (methoxymethyl)- 1-piperidyl]-1-(2- morpholinopyrimidin- 4- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E160 J1 495 496 A186

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-1- phenyl-3- tetrahydrofuran-3- yloxy- pyrazolo[3,4- b]pyridine-6- carboxylic acid E159 J1 510 511 A187

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3- (oxetan-3-yloxy)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E164 J1 496 497 A188

1-[3- (dimethylamino) phenyl]-3- isopropyl-4- (tetrahydropyran- 4- ylmethoxy)pyrazolo [3,4-b]pyridine- 6-carboxylic acid HP07 J3 438 439 A189

1-(4- fluorophenyl)-3- isopropyl-4- (tetrahydropyran- 4- ylmethoxy)pyrazolo [3,4-b]pyridine- 6-carboxylic acid HP11 J3 413 414 A190

1-(4- fluorophenyl)-3- isopropyl-4-(2- tetrahydropyran- 4- ylethoxy)pyrazolo [3,4-b]pyridine-6- carboxylic acid HP11 J3 427 428 A191

3-cyclobutyl-4-[4- (1-methoxy-1- methyl-ethyl)-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E163 J8 448 449 A192

4-[3- (dimethylamino) propoxy]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11 J3 400 401 A193

1-(4- fluorophenyl)-3- isopropyl-4-(3- morpholinopropoxy) pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11 J3 442 443 A194

1-(4- fluorophenyl)-3- isopropyl-4-[(3- methyloxetan-3- yl)methoxy]pyrazolo [3,4- b]pyridine-6- carboxylic acid HP11 J3 399 400 A195

1-(4- fluorophenyl)-3- isopropyl-4- (tetrahydrofuran- 2- ylmethoxy)pyrazolo [3,4-b]pyridine- 6-carboxylic acid HP11 J3 399 400 A196

3-cyclobutyl-4-[3- (dimethylamino) propoxy]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 394 395 A197

3-cyclobutyl-1- phenyl-4-[3-(1- piperidyl)propoxy] pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 434 435 A198

4-[(3,3-difluoro- 1-methyl- cyclobutyl)methoxy]- 1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11 J3 433 434 A199

1-(4- fluorophenyl)-3- isopropyl-4-[3-(1- piperidyl)propoxy] pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11 J3 440 441 A200

1-(4- fluorophenyl)-3- isopropyl-4-[2- methoxy-1- (methoxymethyl) ethoxy]pyrazolo[3, 4-b]pyridine-6- carboxylic acid HP11 J3 417 418 A201

1-(4- fluorophenyl)-4- [4-(1-hydroxy-1- methyl-ethyl)-1- piperidyl]-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E166 J1 440 441 A202

3-cyclobutyl-1-(4- fluorophenyl)-4- [4- (methoxymethyl)- 1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E167 J1 438 439 A203

3-cyclobutyl-1-(4- fluorophenyl)-4- (tetrahydropyran- 4- ylmethoxy)pyrazolo [3,4-d]pyridine- 6-carboxylic acid E171 J1 425 426 A204

3-cyclobutyl-4-[4- (1-hydroxy-1- methyl-ethyl)-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E170 J1 434 435 A205

4-[4- (dimethylamino)- 1-piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E174 J1 425 426 A206

1-(4- fluorophenyl)-3- isopropyl-4-[4-(1- methyl-4- piperidyl)-l- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E175 J1 479 480 A207

4-[(1-acetyl-4- piperidyl)methoxy]- 1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E176 J1 454 455 A208

1-(4- fluorophenyl)-3- isopropyl-4-[(1- methoxycarbonyl- 4- piperidyl)methoxy] pyrazolo[3,4- b]pyridine-6- carboxylic acid E178 J1 470 471 A209

3-cyclobutyl-4- (1,1-dioxo-1,4- thiazinan-4-yl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E196 J1 426 427 A210

3-cyclobutyl-1- phenyl-4-(4- propoxy-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E078 J1 434 435 A211

3-cyclobutyl-4-(1- oxa-7- azaspiro[3.5]nonan- 7-yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E085 J1 418 419 A212

3-isopropyl-4-(4- methoxy-1- piperidyl)-1-(2- morpholino-4- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid A257 Specific example J7 480 481 A213

3-cyclobutyl-4-(1- methoxycarbonyl- 3,3a,4,6,7,7a- hexahydro-2H- pyrrolo[3,2- c]pyridin-5-yl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E129 J1 476 477 A214

4-(1-acetyl- 3,3a,4,6,7,7a- hexahydro-2H- pyrrolo[3,2- c]pyridin-5-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E132 J1 460 461 A215

3-isopropyl-4-(4- methoxy-1- piperidyl)-1-(6- morpholino-2- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid A259 J7 480 481 A216

3-cyclobutyl-4-[4- (fluoromethyl)-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J4 Specific example 408 409 A217

4-(3- azaspiro[5.5]undecan- 3-yl)-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J4 444 445 A218

3-cyclobutyl-4-[4- (cyclopentoxy)-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E139 J1 460 461 A219

3-cyclobutyl-4-[4- (cyclohexoxy)-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E140 J1 474 475 A220

3-cyclobutyl-4-[4- (cyclopropylmethoxy)- 1-piperidyl]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E141 J1 446 447 A221

4-(4- methoxyphenyl)- 3-methyl-1-(2- methylpropyl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP06, 3524- 36-5 J2 339 340 A222

4-(4- morpholinophenyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid 127-17- 3, 1204- 86- 0, 826- 85-7 Specific example 400 401 A223

1-isopropyl-4-(4- methoxyphenyl)- 3-methyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP06, 1124- 16-9 J2 325 326 A224

1-cyclopropyl-3- methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP15 J2 378 379 A225

4-[(1-acetyl-4- piperidyl)methoxy]- 3-cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A261 J9 Specific example 448 449 A226

1-cyclohexyl-3- methyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 56547- 82-1 J2 420 421 A227

4-(4-cyano-1- piperidyl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E142 J1 407 408 A228

3-isopropyl-4-[4- (methoxymethyl)- 1-piperidyl]-1-(1- methyl-6-oxo- pyridazin-3- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E157 J1 440 441 A229

1-(4- fluorophenyl)-3- isopropyl-4-[2- methoxyethyl(methyl) amino]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E165 J1 386 387 A230

1-(4- fluorophenyl)-3- isopropyl-4-[2-(1- methyl-2- piperidyl)ethoxy] pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11 J3 440 441 A231

4-[(1-acetyl-4- fluoro-4- piperidyl)methoxy]- 1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11, ALC03 J3 472 473 A232

1-(4- fluorophenyl)-3- isopropyl-4-[2- [isopropyl(oxetan- 3- yl)amino]ethoxy] pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11, ALC04 J3 456 457 A233

1-(4- fluorophenyl)-3- isopropyl-4-[(4- isopropylmorpholin- 3- yl)methoxy]pyrazolo [3,4- b]pyridine-6- carboxylic acid HP11, ALC04 (re- arrange- ment) J3 456 457 A234

4-(1,4-dioxan-2- ylmethoxy)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11, ALC05 (re- arrange- ment) J3 415 416 A235

1-(4- fluorophenyl)-3- isopropyl-4-[2- (oxetan-3- yloxy)ethoxy] pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11, ALC05 J3 415 416 A236

1-(2,6- dimethylpyridin- 4-yl)-4-[4- (methoxymethyl) piperidin-1-yl]-3- (propan-2-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E195 J1 437 438 A237

3-cyclobutyl-4- [(1- methoxycarbonyl- 4- piperidyl)methoxy]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid A261 J9 Specific example 464 465 A238

4-(4- azidophenyI)-1- [3- (dimethylamino) phenyl]-3-(propan- 2-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E199 J1 441 442 A239

3-cyclobutyl-4-(4- isopropylpiperazin- 1-yl)-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E158 J1 419 420 A240

4-(4- cyclobutylpiperazin- 1-yl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E162 J1 437 438 A241

1-(4- fluorophenyl)-3- isopropyl-4-[4- (2,2,2- trifluoroethyl) piperazin-1- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E156 J1 465 466 A242

1-(3- bromophenyl)-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP05 J2 520- 522 521- 523 A243

3-tert-butyl-1- cyclopentyl-4-(6- morpholino-3- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP05, AMP37 J2 449 450 A244

4-(1-tert- butoxycarbonyl- 4-piperidyl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E197 J1 482 483 A245

3-isopropyl-4-(6- morpholino-3- pyridyl)-1- phenyl- pyrazo!o[3,4- b]pyridine-6- carboxylic acid E007 J1 443 444 A246

4-(4- bromophenyl)-3- methyl-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP19, 1131- 18-6 J2 407- 409 408- 410 A247

1-cyclohexyl-3- isopropyl-4-(6- morpholino-3- pyridyl)pyrazolo [3,4-b]pyridine-6- carboxylic acid ALP05, AMP23 J2 449 450 A248

3-(azetidin-3-yl)- 1-cyclohexyl-4- [2- (dimethylamino) pyrimidin-5- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP03, AMP38 J2 421 422 A249

1-cyclohexyl-4- [2- (dimethylamino) pyrimidin-5-yl]-3- (1- methoxycarbonyl azetidin-3- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid A248 J9 Specific example 479 480 A250

4-(6-chloro-3- pyridyl)-1- cyclohexyl-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP07, AMP23 J2 398- 400 399- 401 A251

1-cyclohexyl-3- cyclopropyl-4-[6- (dimethylamino)- 3- pyridyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E033 J1 405 406 A252

1-[3-(3- benzyloxyazetidin- 1-yl)phenyl]-3- isopropyl-4-(4- morpholinophenyl) pyrazolo[3,4- b]pyridine-6- carboxylic acid A242 J7 603 604 A253

3-cyclobulyl-4-[4- [(1,1-dioxo-1,4- thiazinan-4- yl)methyl]-4- methoxy-1- piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E150 J8 553 554 A254

3-isopropyl-4-(4- morpholinophenyl)- 1- tetrahydrofuran-3- yl-pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, AMP27 J2 436 437 A255

1-(3- fluorophenyl)-3- isopropyl-4-[6- [methyl(tetrahydro- pyran-4- yl)amino]-3- pyridyl]pyrazolo [3,4-b]pyridine-6- carboxylic acid E137 J1 489 490 A256

4-(4- morpholinophenyl)- 3-oxo-1-phenyl- 2H-pyrazolo[3,4- b]pyridine-6- carboxylic acid ALP01, 70373- 98-7 J2 416 417 A257

1-(2-bromo-4- pyridyl)-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E108 J1 473- 475 474- 476 A258

4-[6-(4-cyano-1- piperidyl)-3- pyridyl]-3-(3- fluorocyclobutyl)- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E120 J1 496 497 A259

1-(6-bromo-2- pyridyl)-3- isopropyl-4-(4- methoxy-1- piperidyl)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E133 J1 473- 475 474- 476 A260

3-cyclobutyl-1- phenyl-4- (tetrahydrofuran- 2- ylmethoxy)pyrazolo [3,4-b]pyridine- 6-carboxylic acid HP10 J3 393 394 A261

3-cyclobutyl-1- phenyl-4-(4- piperidylmethoxy) pyrazolo[3,4- b]pyridine-6- carboxylic acid A262 I25 406 407 A262

4-[(1-tert- butoxycarbonyl- 4- piperidyl)methoxy]- 3-cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 506 507 A263

4-[(1-tert- butoxycarbonyl- 4- piperidyl)methoxy]- 1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11 J3 512 513 A264

3-cyclobutyl-4-[2- (1-methyl-2- piperidyl)ethoxy]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 434 435 A265

3-cyclobutyl-4-[2- methoxy-1- (methoxymethyl) ethoxy]-1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 411 412 A266

3-cyclobutyl-4-[2- [isopropyl(oxetan- 3- yl)amino]ethoxy]- 1-phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J3 450 451 A267

4-[4- (cyanomethyl)-4- hydroxy-1- piperidyl]-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E179 J1 431 432 A268

3-cyclobutyl-4-(4- morpholino-1- piperidyl)-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J10 Specific example 461 462 A269

3-cyclobutyl-1- phenyl-4-[4- (2,2,2- trifluoroethyl) piperazin-1- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E180 J1 459 460 A270

3-cyclobutyl-4-[4- (2- morpholinoethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J10 Specific example 489 490 A271

4-[(3aR,7aS)-1- acetyl- 3,3a,4,6,7,7a- hexahydro-2H- pyrrolo[3,2- c]pyridin-5-yl]-3- cyclobutyl-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J10, I25, J9 Specific example 459 458 (ESI-) A272

3-isopropyl-1-(2- morpholino-4- pyridyl)-4- (tetrahydropyran- 4- ylmethoxy)pyrazolo [3,4-b]pyridine- 6-carboxylic acid E181 J6 481 482 A273

4-(4- ethoxycarbonyl- piperazin-1-yl)-1- (4-fluorophenyl)- 3-isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E184 J1 455 456 A274

1-(4- fluorophenyl)-3- isopropyl-4-(3- methyl-2-oxo-1- oxa-3,8- diazaspiro[4.5] decan-8- yl)pyrazolo[3,4- b]pyridine-6- carboxylic acid E185 J1 467 468 A275

1-(4- fluorophenyl)-3- isopropyl-4-[3- (trifluoromethyl) piperazin-1- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E186 J1 451 452 A276

1-(4- fluorophenyl)-3- isopropyl-4-[4-(2- methoxyethyl) piperazin-1- yl]pyrazolo[3,4- b]pyridine-6- carboxylic acid E187 J1 441 442 A277

4-(2,4-dioxo- 1,3,8- triazaspiro[4.5] decan-8-yl)-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E188 J1 466 467 A278

4-[4- (ethoxymethyl)-4- fluoro-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E189 J1 458 459 A279

4-[4-fluoro-4-(2- methoxyethoxy- methyl)-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E190 J1 488 489 A280

4-[(3R,4R)-3- fluoro-4-hydroxy- 1-piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E191 J1 416 417 A281

4-[4-fluoro-4- (methoxymethyl)- 1-piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E192 J1 444 445 A282

4-[3-fluoro-3-(2- methoxyethoxy- methyl)-1- piperidyl]-1-(4- fluorophenyl)-3- isopropyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid E193 J1 488 489 A283

1-(4- fluorophenyl)-3- isopropyl-4-[4-(1- piperidyl)-1- piperidyl]pyrazolo [3,4-b]pyridine- 6-carboxylic acid E194 J1 465 466 A284

3-cyclobutyl-4- [(3R)-3- (hydroxymethyl)- 1-piperidyl]-1- phenyl- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J10 Specific example 406 407 A285

3-cyclobutyl-1- phenyl-4-{4- [(pyrrolidin-1- yl)methyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E357 J1, Specific example 459 460 A286

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[2- (methoxymethyl) morpholin-4- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E354 J1 523 523 A287

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[4-(propan-2- yl)piperazin-1- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E355 J1 520 521 A288

3-cyclobutyl-1-(4- fluorophenyl)-4- (4-methoxy[1,4′- bipiperidin]-1′- yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E356 J1 507 508 A289

3-cyclobutyl-4- (4,4-difluoro[1,4′- bipiperidin]-1′- yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E358 J1 513 514 A290

4-[4-(2- cyanomorpholin- 4-yl)piperidin-1- yl]-3-cyclobutyl- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E359 J1 505 505 A291

3-cyclobutyl-1-(4- fluorophenyl)-4- [4-(2-oxa-5- azabicyclo[2.2.1] heptan-5- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E360 J1 491 492 A292

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[methyl(oxan- 4- yl)amino]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E361 J1 507 508 A293

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[3- (trifluoromethyl) pyrrolidin-1- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E362 J1 531 532 A294

4-[4-(3- cyanopyrrolidin- 1-yl)piperidin-1- yl]-3-cyclobutyl- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E363 J1 488 489 A295

4-(3-cyano[1,4′- bipiperidin]-1′- yl)-3-cyclobutyl- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E364 J1 502 503 A296

3-cyclobutyl-4-(3- fluoro[1,4′- bipiperidin]-1′- yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E365 J1 495 496 A297

3-cyclobutyl-1-(4- fluorophenyl)-4- [4-(3- methoxyazetidin- 1-yl)piperidin-1- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E366 J1A 479 480 A298

3-cyclobutyl-1-(4- fluorophenyl)-4- [3- (trifluoromethyl) [1,4′-bipiperidin]- 1′-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E367 J1A 545 546 A299

3-cyclobutyl-1-(4- fluorophenyl)-4- (3-methoxy[1,4′- bipiperidin]-1′- yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E368 J1A 507 508 A300

3-cyclobutyl-4-[4- (2,2- dimethylmorpholin- 4-yl)piperidin- 1-yl]-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E369 J1A 508 508 A301

3-cyclobutyl-4- {4-[4- (ethoxycarbonyl) piperazin-1- yl]piperidin-1- yl}-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E370 J1A 550 551 A302

3-cyclobutyl-1-(4- fluorophenyl)-4- [1-(propan-2- yl)octahydro-5H- pyrrolo[3,2- c]pyridin-5-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E371 J1 477 478 A303

3-cyclobutyl-4-(1- cyclobutylocta- hydro-5H- pyrrolo[3,2- c]pyridin-5-yl)-1- (4-fluorophenyl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E372 J1 489 490 A304

3-cyclobutyl-1-(4- fluorophenyl)-4- [1-(oxetan-3- yl)octahydro-5H- pyrrolo[3,2- c]pyridin-5-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E373 J1 491 492 A305

3-cyclobutyl-1-(4- fluorophenyl)-4- [1-(oxan-4- yl)octahydro-5H- pyrrolo[3,2- c]pyridin-5-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E374 J1 519 520 A306

3-cyclobutyl-4-(4- fluoro[1,4′- bipiperidin]-1′- yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E375 J1 495 496 A307

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[(2- methoxyethyl) (methyl)amino] piperidin-1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E376 J1A 481 482 A308

3-cyclobutyl-1-(4- fluorophenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E377 J1 479 480 A309

4-([1,4′- bipiperidin]-1′- yl)-3-cyclobutyl- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E378 J1 477 478 A310

3-cyclobutyl-1-(4- fluorophenyl)-4- [3-(morpholin-4- yl)-1-oxa-8- azaspiro[4.5]decan- 8-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E381 J1 535 536 A311

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[2-(morpholin- 4- yl)ethyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E382 J1 507 508 A312

3-cyclobutyl-4- {4-[2-(4- methylpiperidin- 1- yl)ethyl]piperidin- 1-yl}-1-phenyl- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E383 J1 501 502 A313

3-cyclobutyl-4-[4- (4- cyclopropylpiperazin- 1- yl)piperidin-1-yl]- 1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E384 J1 500 501 A314

3-cyclobutyl-1- phenyl-4-[4- (propan-2- yl)piperazin-1- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E385 J1 419 420 A315

3-cyclobutyl-4-[4- (methoxymethyl) piperidin-1-yl]-1- (2- methoxypyridin- 4-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E388 J1 451 452 A316

3-cyclobutyl-4-[4- (methoxymethyl) piperidin-1-yl]-1- [2-(oxan-4- yl)pyridin-4-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E391 J1A 505 506 A317

3-cyclobutyl-1-(2- methoxypyridin- 4-yl)-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E394 J1A 492 493 A318a

3-cyclobutyl-1-(3- methylphenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E395 J1A Specific example 475 476 A318b

3-cyclobutyl-1-(3- methoxyphenyl)- 4-[4-(morpholin- 4-yl)piperidin-1- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E396 J1A 491 492 A319

3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1-[4- (trifluoromethyl) phenyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E397 J1A 529 530 A320

3-cyclobutyl-1-(4- fluoro-3- methylphenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E398 J1A 493 494 A321

3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1-[3- (trifluoromethyl) phenyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E399 J1A 529 530 A322

3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1-{2-[(propan-2- yl)oxy]pyridin-4- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E400 J1A 520 521 A323

1-[2- (benzyloxy)pyridin- 4-yl]-3- cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E401 J1A 568 569 A324

3-cyclobutyl-1-(2- hydroxypyridin-4- yl)-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E402 J1A 478 479 A325

3-cyclobutyl-1-[2- (difluoromethoxy) pyridin-4-yl]-4- [4-(morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E403 J1A 528 529 A326

3-cyclobutyl-1-(3- fluorophenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E404 J1A 479 480 A327

3-cyclobutyl-1- (2,2-difluoro-2H- 1,3-benzodioxol- 5-yl)-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E405 J1A 541 542 A328

3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1-[2-(oxan-4- yl)pyridin-4-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E407 J1A 546 547 A329

3-cyclobutyl-4-[1- (4,4- difluorocyclohexyl) piperidin-4-yl]- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E414 J1A 512 513 A330

3-cyclobutyl-1-(4- fluorophenyl)-4- [1-(propan-2- yl)piperidin-4-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E415 J1A 436 437 A331

3-cyclobutyl-1-(4- fluorophenyl)-4- [1-(oxan-4- yl)piperidin-4-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E416 J1A 478 479 A332

3-cyclobutyl-1-(4- fluorophenyl)-4- {1-[(oxan-4- yl)methyl]piperidin- 4-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E417 J1A 492 493 A333

3-cyclobutyl-4- {1-[(2,5- dimethoxyoxolan- 3- yl)methyl]piperidin- 4-yl}-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E418 J1A 538 539 A334

3-cyclobutyl-1-(4- fluorophenyl)-4- [1-(3,3,3- trifluoropropyl) piperidin-4-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E419 J1A 490 491 A336

3-cyclobutyl-4-[1- (cyclopropylmethyl) piperidin-4-yl]- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E421 J1A 448 449 A337

3-cyclobutyl-4- {4-[2-(4- methylpiperidin- 1- yl)ethyl]piperidin- 1-yl}-1-phenyl- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E412 J1A 501 502 A338

3-cyclobutyl-4-[4- (ethoxymethyl)-4- fluoropiperidin-1- yl]-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E408 J1 452 453 A339

3-cyclobutyl-4- {4-fluoro-4-[(2- methoxyethoxy) methyl]piperidin-1- yl}-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E409 J1 482 483 A340

3-cyclobutyl-4- {3-fluoro-3-[(2- methoxyethoxy) methyl]piperidin-1- yl}-1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E410 J1 482 483 A341

3-cyclobutyl-4-[4- fluoro-4- (methoxymethyl) piperidin-1-yl]-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E411 J1 438 439 A342

3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1-{2-[(propan-2- yl)oxy]pyrimidin- 4-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E422 J11 521 522 A343

3-cyclobutyl-1-(2- ethoxypyrimidin- 4-yl)-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E422 J11 Specific example 507 508 A344

3-cyclobutyl-1-(4- fluorophenyl)-4- (4-methoxy[1,4′- bipiperidin]-1′- yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E424 J1A 507 508 A345

3-cyclobutyl-4-[4- (morpholin-4- yl)cyclohexyl]-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E433 J1A 460 461 A346

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[4-(propan-2- yl)piperazin-1- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E434 J1 520 521 A347

1-cyclohexyl-3- [(propan-2- yl)oxy]-4-(4-{[4- (propan-2- yl)piperazin-1- yl]methyl}phenyl)- 1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E435 J1 519 520 A348

1-cyclohexyl-4- {4-[(4- methoxypiperidin- 1- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E436 J1 506 507 A349

1-cyclohexyl-4- {4-[(5- methylhexahydro pyrrolo[3,4- c]pyrrol-2(1H)- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E437 J1 517 518 A350

1-cyclohexyl-4- (4-formylphenyl)- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E425 J1 407 408 A351

4-{4-[5-(tert- butoxycarbonyl) hexahydropyrrolo [3,4-c]pyrrole- 2(1H)- carbonyl]phenyl}- 1-cyclohexyl-3- [(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E439 J1A 617 618 A352

1-cyclohexyl-4- [4-(5- methylhexahydro pyrrolo[3,4- c]pyrrole-2(1H)- carbonyl)phenyl]- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E440 J1A 531 532 A353

1-cyclohexyl-4- {4-[3- (dimethylamino) azetidine-1- carbonyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E441 J1A 505 506 A354

1-cyclohexyl-4- {4-[(8-methyl-2- oxa-5,8- diazaspiro[3.5] nonan-5- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E444 J1A 533 534 A355

4-[4-(4-cyano-1- methylpiperidin- 4-yl)phenyl]-1- cyclohexyl-3- [(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E445 J1A 501 502 A356

3-cyclobutyl-1-(4- fluorophenyl)-4- [4-(3- fluoropyrrolidin- 1-yl)piperidin-1- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E427 J1 481 482 A357

4-[4-(3- cyanoazetidin-1- yl)piperidin-1-yl]- 3-cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E428 J1 474 475 A358

3-cyclobutyl-1-(4- fluorophenyl)-4- [4-(3- methoxypyrrolidin- 1-yl)piperidin- 1-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E429 J1 493 494 A360

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[1-(morpholin- 4- yl)ethyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E460 J1 507 508 A361

3-cyclobutyl-1-(4- fluorophenyl)-4- {[4-(morpholin-4- yl)piperidin-1- yl]methyl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP19 J13 Specific example 493 494 A362

3-cyclobutyl-1-(4- fluorophenyl)-4- (4-hydroxy[1,4′- bipiperidin]-1′- yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E492 J1 493 494 A363

4-([1,4′- bipiperidin]-1′- yl)-3-cyclobutyl- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E493 J1 493 494 A364

3-cyclobutyl-1- cyclohexyl-4-{4- [(morpholin-4- yl)methyl]phenyl}- 1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP25, 364794- 79-6 J14 474 475 A365

3-cyclobutyl-1- cyclohexyl-4-{4- [2-(morpholin-4- yl)ethyl]phenyl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid HP25, 1150114- 55-8 J14 488 489 A366

3-cyclobutyl-1- cyclohexyl-4-[4- (2-methylpyridin- 4-yl)piperazin-1- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E461 J1 474 475 A367

3-cyclobutyl-1- cyclohexyl-4-{4- [1-(morpholin-4- yl)ethyl]phenyl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid HP25, 1206594- 12-8 J14 488 489 A368

3-cyclobutyl-1- cyclohexyl-4-{4- [4-(propan-2- yl)piperazin-1- yl]phenyl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP25, 1073354- 18-3 J14 501 502 A369

3-cyclobutyl-1- cyclohexyl-4-[6- (4- methylpiperazin- 1-yl)pyridin-3- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid A407, 109-01- 3 J12 474 475 A370

3-cyclobutyl-1- cyclohexyl-4-{6- [4-(2- methoxyethyl) piperazin-1- yl]pyridin-3-yl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid A407, 13484- 40-7 J12 518 519 A371

3-cyclobutyl-1- cyclohexyl-4-{4- [4-(propan-2- yl)piperazin-1- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E462 J1 508 509 A372

4-[(3S)-4-benzyl- 3- methylpiperazin- 1-yl]-3- cyclobutyl-1- cyclohexyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E463 J1 487 488 A373

4-[(3R)-4-benzyl- 3- methylpiperazin- 1-yl]-3- cyclobutyl-1- cyclohexyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E464 J1 487 488 A374

3-cyclobutyl-4-[4- (4- cyclopropylpiper- azin-1- yl)piperidin-1-yl]- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E465 J1 518 519 A375

3-cyclobutyl-4-(9- cyclopropyl-3,9- diazaspiro[5.5] undecan-3-yl)-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E466 J1 503 504 A376

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[(pyrrolidin-1- yl)methyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E467 J1 477 478 A377

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[4-(2- methoxyethyl) piperazin-1- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E468 J1 536 537 A378

3-cyclobutyl-1-(4- fluorophenyl)-4- [9-(oxetan-3-yl)- 3,9- diazaspiro[5.5] undecan-3-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E469 J1 519 520 A379

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[4-(oxetan-3- yl)piperazin-1- yl]piperidin-1- yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E470 J1 534 535 A380

1-cyclohexyl-4- {4-[(morpholin-4- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E473 J1 479 479 A381

1-cyclohexyl-4- [4-(4- methylpiperazine- 1- carbonyl)phenyl]- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E474 J1 506 506 A382

3-cyclobutyl-1- cyclohexyl-4-[4- (pyridin-4- yl)piperazin-1- yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E475 J1 461 461 A383

3- (cyclobutyloxy)- 1-cyclohexyl-4- {4-[(morpholin-4- yl)methyl]phenyl}- 1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E476 J1 491 491 A384

1-cyclohexyl-4- {4-[4- (dimethylamino) piperidine-1- carbonyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E477 J1 534 535 A385

1-cyclohexyl-4- {4-[(piperidin-1- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E478 J1 477 477 A386

1-cyclohexyl-4- {4-[(4- methylpiperazin- 1- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E479 J492 492 492 A387

1-cyclohexyl-3- [(propan-2- yl)oxy]-4-{4- [(pyrrolidin-1- yl)methyl]phenyl}- 1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E480 J1 463 463 A388

3-cyclobutyl-1-(4- fluorophenyl)-4- {[4- (methoxymethyl) piperidin-1- yl]methyl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E481 J1 453 453 A389

3-cyclobutyl-1-(4- fluorophenyl)-4- [(morpholin-4- yl)methyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E471 J1 410 411 A390

3-cyclobutyl-1-(4- fluorophenyl)-4- [(4- methylpiperazin- 1-yl)methyl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E472 J1 423 424 A391

4-(4-cyano[1,4′- bipiperidin]-1′- yl)-3-cyclobutyl- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E485 J1 502 503 A392

1-cyclohexyl-4- {4-[(4- cyclopropylpiperazin- 1- yl)methyl]phenyl}- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E482 J1 518 518 A393

1-cyclohexyl-4- [4-(4- cyclopropylpiperazin- 1-yl)phenyl]- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E484 J1 503 504 A394

3-cyclobutyl-4- [(1- cyclopropylpiperidin- 4- yl)methoxy]-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP26 J3 464 465 A395

1-cyclohexyl-3- [(propan-2- yl)oxy]-4-{4-[4- (propan-2- yl)piperazin-1- yl]phenyl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E483 J1 505 506 A396

3-cyclobutyl-1-(4- fluorophenyl)-4- {[1-(oxan-4- yl)piperidin-4- yl]methoxy}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP26 ALC08 J3 508 509 A397

3-cyclobutyl-4- [(1-- cyclohexylpiperidin- 4-yl)methoxy]- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP26 ALC07 J3 506 507 A398

3-cyclobutyl-4- [(1- cyclobutylpiperidin- 4-yl)methoxy]- 1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP26 ALC06 J3 478 479 A399

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[4- (methoxycarbonyl) piperazin-1- yl]piperidin-1- yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E486 J1 536 537 A400

4-[4-(4- acetylpiperazin-1- yl)piperidin-1-yl]- 3-cyclobutyl-1-(4- fluorophenyl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E487 J1 520 521 A401

3-cyclobutyl-1- cyclohexyl-4-{4- [(morpholin-4- yl)methyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E488 J1 481 482 A402

3-cyclobutyl-1- cyclohexyl-4-{4- [2-(morpholin-4- yl)ethyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E489 J1 495 496 A403

3-cyclobutyl-1- cyclohexyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E490 J1 467 468 A404

3-cyclobutyl-1-(4- fluorophenyl)-4- {4-[(morpholin-4- yl)methyl]piperidin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E491 J1 493 494 A405

3-cyclobutyl-1- cyclohexyl-4-[6- (4- cyclopropylpiperazin- 1-yl)pyridin- 3-yl]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid A407, 20327- 23-5 J12 Specific example 500 501 A406

3-cyclobutyl-1- cyclohexyl-4-{6- [4-(propan-2- yl)piperazin-1- yl]pyridin-3-yl}- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid A407, 4318- 42-7 J12 502 503 A407

3-cycIobutyl-1- cyclohexyl-4-(6- fluoropyridin-3- yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP25, 351019- 18-6 J14 394 395 A408

1-(4- fluorophenyl)-4- [4-(morpholin-4- yl)piperidin-1-yl]- 3-(propan-2-yl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid HP11, 442563- 55-5 J10 Specific example 467 468 A409

3-cyclobutyl-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1-phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J10 461 462 A410

3-cyclobutyl-1-[3- (difluoromethoxy) phenyl]-4-[4- (morpholin-4- yl)piperidin-1-yl]- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E510 J1 527 528 A411

1-cyclohexyl-4- (4-{[3- (dimethylamino) azetidin-1- yl]methyl}phenyl)- 3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E426 J1A 491 492 A412

1-(4- fluorophenyl)-4- (4-methoxy[1,4′- bipiperidin]-1′- yl)-3-[(propan-2- yl)oxy]-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E511 J1A 511 512 A413

3-cyclobutyl-4-[4- (hydroxymethyl) piperidin-1-yl]-1- phenyl-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid HP10 J10, Specific example 406 407 A414

3-cyclobutyl-1- (4-fluorophenyl)- 4-(9-methyl-3,9- diazaspiro[5.5] decan-3-yl)-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E515 J1 477 478 A415

3-cyclobutyl-4- [4- (ethoxycarbonyl) piperazin-1-yl]-1- (4-fluorophenyl)- 1H-pyrazolo[3,4- b]pyridine-6- carboxylic acid E516 J1 467 468 A416

3-cyclobutyl-1- (4-fluorophenyl)- 4-{4-[(2- methylpropoxy) carbonyl]piperazin- 1-yl}-1H- pyrazolo[3,4- b]pyridine-6- carboxylic acid E517 J1 495 496 Method X1: Synthesis of Sulfonamide

A procedure similar to that described in J. Org. Chem. (1968) 33(2), 897 is followed: A round bottomed flask is charged with the sulfonyl chloride and diethyl ether (0.06 M), sealed with a septum and cooled in an ice bath. To the cooled solution is slowly added two molar equivalents of a dioxane solution of ammonia (0.5 M), and then the cold bath is removed. After 16 hours, the resulting heterogeneous mixture is filtered through filter paper. Volatiles are removed from the filtrate via rotary evaporation to give the sulfonamide which is used without further purification.

Illustrative Synthesis of S2: Methyl 3-sulfamoylpropanoate

A dioxane solution of ammonia (0.5 M, 10.5 mL, 5.25 mmol, 2.05 equiv) was added at 0° C. to a solution of methyl 3-(chlorosulfonyl)propanoate (CAS: 15441-07-3, 0.476 g, 2.55 mmol) in diethyl ether (10 mL). The reaction mixture was stirred at 0° C. for 1 hour and then 16 hours at RT. The reaction mixture was filtered, and the filtrate was concentrated to give the titled compound which was used without further purification.

Method X2: Synthesis of Sulfonamide

Synthesis of 3-morpholinopropane-1-sulfonamide S10

Step 1: 3-(morpholin-4-yl)propane-1-sulfonyl Chloride

3-Morpholinopropanesulfonic acid (CAS: 1132-61-2, 0.63 g, 3.0 mmol) was added to thionyl chloride (4.0 mL, 54.8 mmol, 18 equiv). Dimethylformamide (0.1 mL, 1.2 mmol, 0.4 equiv) was added, and the reaction mixture was stirred at RT for 5 hours. The reaction mixture was diluted with dichloromethane (4 mL) and dropped into heptane. Precipitation occurred, and the supernatant was removed. The residue dissolved in dichloromethane was dropped into pentane. The supernatant was removed, and the solid dried to give 3-morpholinopropanesulfonyl chloride hydrochloride.

Step 2: N,N-bis[(2,4-dimethoxyphenyl)methyl]-3-(morpholin-4-yl)propane-1-sulfonamide

Bis(2,4-dimethoxybenzyl)amine (CAS: 20781-23-1, 0.32 g, 1.0 mmol, 1.0 equiv) and potassium carbonate (0.28 g, 2.0 mmol, 2.0 equiv) were added to a solution of 3-morpholinopropanesulfonyl chloride hydrochloride (0.26 g, 1.0 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at RT for 8 hours. The reaction mixture was concentrated and the residue partitioned between water and ethyl acetate. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with heptane/ethyl acetate (100/0 to 0/100) to give N,N-bis[(2,4-dimethoxyphenyl)methyl]-3-morpholino-propane-1-sulfonamide.

Step 3: 3-(morpholin-4-yl)propane-1-sulfonamide

Trifluoroacetic acid (0.8 mL, 10.4 mmol, 39 equiv) was added to a solution of N,N-bis[(2,4-dimethoxyphenyl)methyl]-3-morpholino-propane-1-sulfonamide (0.135 g, 0.27 mmol) in dichloromethane (4 mL). The reaction mixture was stirred at RT for 16 hours and was added to a saturated aqueous solution of sodium hydrogencarbonate. The mixture was extracted with ethyl acetate and then with a 9:1 mixture of dichloromethane/isopropanol. The organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound.

As an alternative preparation of S10, 3-chloropropane-1-sulfonamide (3.15 g, 20.0 mmol), morpholine (1.84, 21.0 mmol), sodium carbonate (4.24 g, 40.0 mmol) and sodium iodide (300 mg, 2.0 mmol) were heated in anhydrous dioxane (70 mL) at 70° C. for a day. The suspension was permitted to cool towards room temperature and then filtered through diatomaceous earth with an MTBE rinse. The filtrate was concentrated and chromatographed on silica (0 to 4% concentrated aqueous NH₄OH/CH₃CN) to give the titled compound (1.47 g). ¹H NMR (400 MHz, CDCl₃) δ ppm 5.41 (s, 2H), 3.70 (t, J=4.7 Hz, 4H), 3.23 (t, J=7.2 Hz, 2H), 2.54-2.43 (m, 6H), 2.10-2.02 (m, 2H); MS (DCI) m/z 209 (M+H)⁺.

Method X3. Synthesis of Sulfonamide

Synthesis of (2S)-2-(4-methylpiperazine-1-carbonyl)pyrrolidine-1-sulfonamide S11

The titled compound may be prepared by the method described in Ebden, et al. PCT Int. Appl. WO2004 011443, example 25, substituting N-methylpiperidine hydrochloride for dimethylamine hydrochloride. To 1-(tert-butoxycarbonyl)-L-proline (5.0 g) in DCM (50 mL) at 5° C. was added dicyclohexylcarbodiimide (5.22 g) and N-hydroxysuccinimide (2.91 g). The mixture was stirred at this temperature for 16 hours. The solid was filtered, and the filtrate cooled to 5° C. To this mixture was added triethylamine (9.80 mL) and N-methylpiperidine hydrochloride (4.7 g). The mixture was stirred at room temperature for 2 days, H₂O (50 mL) was added, and the phases were separated. The organic fraction was washed with saturated sodium carbonate (2×20 mL) and brine (20 mL). This was then dried (MgSO₄) and concentrated to dryness to afford tert-butyl (2S)-2-(4-methylpiperazine-1-carbonyl)pyrrolidine-1-carboxylate. This was then treated with 4 M aqueous HCl (20 mL), stirred at room temperature 3 hours, and concentrated in vacuo to dryness. A solution of the residue in dioxane was then treated with 2 grams of triethylamine and 10 grams of sulfamide, and the mixture was heated at reflux for 3 days before cooling. Solids were removed by filtration and washed with methanol. The combined filtrate and washing are concentrated in vacuo, and the residue was purified by column chromatography to give the titled compound.

Method X4. Synthesis of Sulfonamide

Synthesis of 4-(4-methylpiperazine-1-carbonyl)piperidine-1-sulfonamide S12

A solution of (4-methylpiperazin-1-yl)(piperidin-4-yl)methanone hydrochloride in dioxane was treated with 5 equivalents of triethylamine and 10 equivalents of sulfamide and heated at reflux for 3 days. The mixture was then cooled and filtered, and the solids were washed with methanol. The filtrate and washings were concentration in vacuo, and the residue was purified by column chromatography to give the titled compound.

Method X4B. Synthesis of Sulfamides

A solution of amine hydrochloride (from 1 to 2 equiv.) in dioxane is treated with triethylamine (from 1.1 to 2.2 equiv), and sulfamide (from 1 to 2 equiv) and refluxed until full conversion is observed. The mixture is then cooled to RT, and the residue is purified by flash column chromatography to give the desired sulfamide derivative.

Illustrative Synthesis of Compound S14

A solution of 3-methoxypyrrolidine hydrochloride ([136725-50-3], 136 mg, 0.98 mmol) in dioxane (2 mL) was treated with triethylamine (0.2 mL, 1.4 mmol) and sulfamide (7803-58-9, 130 mg, 1.3 mmol), and the mixture was refluxed for 16 hours. The mixture was then cooled to RT, and the residue was purified by column chromatography eluted with DCM/MeOH (9/1) to give the titled compound.

Method X5. Synthesis of Sulfamides

Step 1: Benzyl (chlorosulfonyl)carbamate

A solution of chlorosulfonylisocyanate ([1189-71-5], 1 eq) in anhydrous DCM (2.5 vol.) is cooled down in an ice batch under argon atmosphere. Benzyl alcohol ([100-51-6], 1 eq) is added dropwise over a 15 minutes period. The reaction mixture is stirred for 5 minutes and allowed to warm up to RT. The reaction mixture is worked up when no more starting material remained, by adding n-pentane. The precipitate is filtered, washed with n-pentane, and dried at 40° C. under reduced pressure to give the titled compound.

Step 2: N-Benzyloxycarbonyl Protected Sulfamide

A solution of amine (1 eq) and N,N-diisopropylethylamine (1.2 eq) in anhydrous DCM (10 vol.) is cooled down in an ice bath under an argon atmosphere. The compound from Step 1 (1.2 eq) is added, and after 5 minutes, the solution is allowed to warm up to RT. The reaction mixture is worked up when no more starting material remained, by adding water. The organic phase is diluted, separated, and washed successively with an aqueous 1 M HCl solution and a saturated aqueous solution of NaCl. The organic phase is dried over magnesium sulfate, filtered and concentrated in vacuo. The crude sample is either purified by flash column chromatography or suspended in a mixture of n-heptane/ethyl acetate (9/1), refluxed for 15 minutes, and then left cooling down to RT. The precipitate is collected by filtration, washed with a mixture of n-heptane/ethyl acetate (9/1), and dried at 40° C. under reduced pressure to give the desired N-benzyloxycarbonyl protected sulfamide.

Step 3: N-Deprotected Sulfamide

A solution of N-benzyloxycarbonyl protected sulfamide (1 eq) in THF or MeOH (20 vol.) is degassed with nitrogen. 20% Pd(OH)₂ w/w is added, and the reaction mixture is purged with H2. The mixture is stirred at room temperature under a hydrogen atmosphere (balloon) until no more starting material is observed. Additional 20% Pd(OH)₂ is added if necessary. The reaction mixture is filtered over a diatomaceous earth pad that is washed with THF or MeOH. The filtrate is concentrated in vacuo. The residue is purified by preparative HPLC or by flash column chromatography or used as such in the next step.

Illustrative Synthesis of Intermediate S15: 4-(methoxymethyl)piperidine-1-sulfonamide

Step 1: Benzyl (chlorosulfonyl)carbamate

A solution of chlorosulfonylisocyanate ([1189-71-5], 8.1 g, 57.4 mmol) in anhydrous DCM (20 mL) was cooled down in an ice bath under an argon atmosphere. Benzyl alcohol ([100-51-6], 5.9 mL, 57.4 mmol) was added dropwise over a 15 minutes period. The reaction mixture was stirred for 5 minutes and allowed to warm up to RT. After 10 minutes, n-pentane (20 mL) was added, and the resulting mixture was stirred at RT for 30 minutes. The precipitate was collected by filtration, washed with n-pentane, and dried at 40° C. under reduced pressure to give the titled compound.

Step 2. Benzyl [4-(methoxymethyl)piperidine-1-sulfonyl]carbamate

A solution of 4-(methoxymethyl)piperidine hydrochloride ([399580-55-3], 1.0 g, 6.0 mmol) and N,N-diisopropylethylamine (2.3 mL, 13.3 mmol) in anhydrous DCM (10 mL) was cooled down in an ice bath under an argon atmosphere. Benzyl (chlorosulfonyl)carbamate from Step 1 (1.8 g, 7.2 mmol) was added and after 5 minutes, and the solution was allowed to warm up to RT. After 3 hours, water (10 mL) and DCM (10 mL) were added, and stirring was continued for 15 minutes. The organic phase was separated, washed successively with an aqueous 1 M HCl solution (2×10 mL), and a saturated aqueous solution of NaCl (10 mL). The organic phase was dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography eluting with a gradient of DCM/MeOH to give the titled compound.

Step 3: 4-(methoxymethyl)piperidine-1-sulfonamide

A solution of compound from Step 2 (570 mg, 1.8 mmol) in THF (11 mL) was degassed with nitrogen. 20% Pd(OH)₂ (w/w, 114 mg) was added, and the reaction mixture was purged with H2. The mixture was stirred for 20 hours at RT under a hydrogen atmosphere (balloon). The reaction mixture was filtered over a diatomaceous earth pad that was washed with THF. The filtrate was concentrated in vacuo to give the titled compound.

TABLE XIV List of sulfonamides Int. Structure Name SM method MW Mes S1

2- morpholinoethane- sulfonamide 103654- 84-8 X1 194 S2

methyl 3- sulfamoylpropanoate 15441- 07-3 X1 Specific example 167 S3

cyanomethane- sulfonamide 27869- 04-1 X1 120 S4

tetrahydrofuran-3- sulfonamide 1207346- 29-9 X1 151 S5

benzyl N-(2- sulfamoylethyl) carbamate 52530- 50-4 X1 258 259 S6

methyl 2- sulfamoylacetate 52530- 50-4 X1 153 S7

benzyl 3- sulfamoylpyrrolidine- 1-carboxylate 1035173- 74-0 X1 284 S8

tetrahydro-2H- pyran-4- sulfonamide 1058131- 55-7 X1 165 S9

benzyl 4- sulfamoylpiperidine- 1-sulfonamide 287953- 54-2 X1 298 S10

3- morpholinopropane- 1-sulfonamide 1132- 61-2 X2 Specific example 208 209 S11

(2S)-2-(4- methylpiperazine-1- carbonyl)pyrrolidine- 1-sulfonamide 15761- 39-4 X3 Specific example 276 S12

4-(4- methylpiperazine- 1-carbonyl)piperidine- 1-sulfonamide 1018826- 44-2 X4 Specific example 290 S13

3- fluoropyrrolidine- 1-sulfonamide 7803- 58-9, 169750- 17-8 X4B 168 S14

3- methoxypyrrolidine- 1-sulfonamide 7803- 58-9, 169750- 50-3 X4B Specific example 180 S15

4- (methoxymethyl) piperidine-1- sulfonamide 1189- 71-5, 399580- 55-3 X5 Specific example 208 S16

piperidine-1- sulfonamide 1189- 71-5, 110-89- 4 X5 164 S17

3-fluoroazetidine- 1-sulfonamide 1189- 71-5, 617718- 46-4 X5 154 S18

azetidine-1- sulfonamide 1189- 71-5, 503-29- 7 X5 136 S19

(2R)-2- (methoxymethyl) pyrrolidine-1- sulfonamide 1189- 71-5, 84025- 81-0 X5 194 S20

N-oxan-4- ylsulfuric diamide 1189- 71-5, 38041- 19-9 X5 180 S21

N-methyl-N-oxan- 4-ylsulfuric diamide 1189- 71-5, 220641- 87-2 X5 194 S22

3,3- difluoroazetidine- 1-sulfonamide 1189- 71-5, 288315- 03-7 X5 172 S23

N-methoxysulfuric diamide 1189- 71-5, 593-56- 6 X5 126 S24

3-(morpholin-4- yl)pyrrolidine-1- sulfonamide 1189- 71-5, 53617- 37-1 X5 235 S25

4- cyclopropylpiperazine- 1-sulfonamide 1189- 71-5, 20327- 23-5 X5 205 S26

4-(2- methoxyethyl) piperazine-1- sulfonamide 1189- 71-5, 13484- 40-7 X5 223 S27

3- methoxyazetidine- 1-sulfonamide 1189- 71-5, 148644- 09-1 X5 166 S28

morpholine-4- sulfonamide 1189- 71-5, 110-91- 8 X5 166 Method Y1: Synthesis of Acylsulfonamide and Acylsulfamate from Carboxylic Acid

EDC.HCl (CAS 25952-538, 1.0 to 4.0 equiv) is added at RT to a stirring solution of carboxylic acid, sulfonamide or sulfamate (from 1.0 to 4.0 equiv) and 4-(dimethylamino) pyridine (CAS 1122-58-3, from 0.1 to 2.0 equiv) in dichloromethane or/and THF or/and acetone or/and acetonitrile. The reaction mixture is stirred at RT until full conversion is observed. The reaction mixture can be worked up or the solvent can be evaporated and the residue is purified by precipitation, by flash column chromatography or by preparative HPLC to yield the titled acylsulfonamide or acylsulfamide. To work up the reaction mixture, the solvent can be evaporated, and the residue is then partitioned between dichloromethane and water. The organic phase is successively washed with a saturated aqueous solution of NaHCO₃, aqueous 0.5 N HCl and brine. The organic phase is separated, dried over sodium sulfate, filtered and concentrated in vacuo. Alternatively, the reaction mixture may be concentrated without an extractive workup. The residue is purified either by precipitation, by flash column chromatography or by preparative HPLC to yield the titled acylsulfonamide or acylsulfamate.

Alternatively, acylsulfonamides or acylsulfamates can be prepared in the following manner. A solution of the carboxylic acid (1 eq) in dichloromethane, dichloroethane or dimethylformamide can be treated with carbodiimidazole (1-2.5 eq) stirred at ambient temperature to 65° C. for from 0.5-3 hours. Then the sulfonamide or sulfamate (1-3 eq) and optional potassium bis(trimethylsilyl)amide, sodium hydride, or triethylamine followed by 1,8-diazabicycloundec-7-ene (1-3 eq) and optional 4-(dimethylamino)pyridine (1-2 eq) can be added, and the reaction mixture is stirred at 20-60° C. for 2-16 hours. The reaction mixture can then be concentrated and the residue purified.

Illustrative Synthesis of Compound 71: 4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

EDC.HCl (CAS 25952-538, 24.6 g, 128.3 mmol) was added at RT to a stirring solution of intermediate A056 (30.7 g, 64.1 mmol), methanesulfonamide (CAS 3144-09-0, 12.2 g, 128.3 mmol) and 4-(dimethylamino) pyridine (CAS 1122-58-3, 3.1 g, 25.7 mmol) in DCM (1 L). The reaction mixture was stirred at RT for 1.5 hours. The solution was diluted with DCM (700 mL), washed successively with a saturated aqueous solution of sodium hydrogencarbonate (500 mL), aqueous 0.5 N HCl (500 mL) and a saturated aqueous solution of NaCl (500 mL). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude sample was purified by flash column chromatography eluting with DCM/ethyl acetate. The compound was suspended in acetonitrile and refluxed until complete dissolution. The warm solution was poured in hot water (700 mL), and the mixture was refluxed for 2 hours. The reaction volume was reduced to one third under a flow of nitrogen at 80° C. The precipitate was collected by filtration and dried at 40° C. under reduced pressure.

Illustrative Synthesis of Compound 256: 3-cyclobutyl-N-(2-methoxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

To a 4 mL vial charged with stir bar was added 3-cyclobutyl-4-[4-(methoxymethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A136, 40 mg, 0.095 mmol) dissolved in 600 μL of dichloroethane followed by carbodiimidazole (34 mg, 0.21 mmol) in 600 μL of dichloroethane. The mixture was stirred at 42° C. for two hours. Then 2-methoxyethanesulfonamide (40 mg, 3 eq, 0.28 mmol) was then added followed by 1,8-diazabicycloundec-7-ene (43 uL, 3 eq, 0.28 mmol). The resultant mixture was heated at 60° C. for 16 hours. After completion of reaction, the reaction mixture was concentrated, dissolved in DMSO, and purified by reverse phase HPLC (C18, 0-100% CH₃CN/water (0.1% TFA)). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/min (0-0.5 min 10% A, 0.5-6.0 min linear gradient 10-100% A, 6.0-7.0 min 100% A, 7.0-8.0 min linear gradient 100-10% A) to afford the title compound.

Illustrative Synthesis of Compound 328: 3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-4-(4-morpholino-1-piperidyl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A268, 139 mg, 0.30 mmol) and carbonyl diimidazole (73 mg, 0.45 mmol) were stirred in anhydrous DMF (2 mL) at room temperature for 50 minutes. Then methanesulfonamide (57 mg, 0.60 mmol) was added, followed by triethylamine (125 μL, 0.90 mmol), and the suspension was stirred overnight. DBU (45 μL, 0.30 mmol) was added dropwise to the suspension, which was stirred for more than forty minutes before additional DBU (22.5 L, 0.15 mmol) was added, and the solution was heated at 50° C. for more than 4 hours. The reaction mixture was then purified by preparative HPLC on a preparatory Waters® Atlantis® T3 column (30 mm×100 mm) with a 20 to 100% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 40 mL/min to give the titled compound (70 mg).

Illustrative Synthesis of Compound 331: 3-cyclobutyl-N-(methanesulfonyl)-4-{4-[2-(morpholin-4-yl)ethyl]piperidin-1-yl}-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-4-[4-(2-morpholinoethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A270, 118 mg, 0.24 mmol) and carbonyl diimidazole (78 mg, 0.48 mmol) were stirred in anhydrous DMF (1.5 mL) at room temperature for one hour. Then methanesulfonamide (46 mg, 0.48 mmol) and triethylamine (67 μL, 0.48 mmol) were added, followed by slow, dropwise addition of DBU (54 μL, 0.36 mmol). The reaction mixture was stirred for about another 30 minutes, diluted with water (8 mL), concentrated and purified by preparative HPLC on a preparatory Waters® Atlantis® T3 column (30 mm×100 mm) with a 20 to 100% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 40 mL/min to give the titled compound (46 mg).

Illustrative Synthesis of Compound 332: 4-[(3aR,7aS)-1-acetyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

4-[(3aR,7aS)-1-Acetyl-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-5-yl]-3-cyclobutyl-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A271, <0.5 mmol) and carbonyl diimidazole (243 mg, 1.5 mmol) were stirred in anhydrous DMF (4 mL) at room temperature for an hour. Then triethylamine (210 μL, 1.5 mmol) and a solution of 3-(morpholin-4-yl)propane-1-sulfonamide (S10, 313 mg, 1.5 mmol) in anhydrous acetonitrile (400 μL) were added, followed by slow dropwise addition of DBU (75 μL, 0.50 mmol). The reaction mixture was stirred for an hour, more DBU (45 μL, 0.30 mmol) was added dropwise, and the reaction mixture was stirred another hour before being diluted with water (20 mL), concentrated and purified by preparative HPLC on a preparatory Waters® Atlantis® T3 column (30 mm×100 mm) with a 5 to 100% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 40 mL/min to give the titled compound (74 mg).

Illustrative Synthesis of Compound 347: 3-cyclobutyl-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-4-[(oxan-4-yl)methoxy]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-1-phenyl-4-(tetrahydropyran-4-ylmethoxy)pyrazolo[3,4-b]pyridine-6-carboxylic acid (A148, 102 mg, 0.25 mmol) and carbonyl diimidazole (61 mg, 0.38 mmol) were stirred in anhydrous DMF (1.6 mL) at room temperature for one hour. Then a solution of 3-(morpholin-4-yl)propane-1-sulfonamide (S10, 104 mg, 0.50 mmol) in DMF (0.4 mL) and triethylamine (70 μL, 0.50 mmol) were added, followed by slow, dropwise addition of DBU (56 μL, 0.37 mmol). The reaction mixture was stirred for another thirty minutes, diluted with water (8 mL), concentrated and purified by preparative HPLC on a Waters® Atlantis® T3 column (30 mm×100 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 50 mL/min to give the titled compound (61 mg).

Illustrative Synthesis of Compound 349: 3-cyclobutyl-4-[(3R)-3-(hydroxymethyl)piperidin-1-yl]-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-4-[(3R)-3-(hydroxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A284, 57 mg, 0.14 mmol) and carbonyl diimidazole (46 mg, 0.28 mmol) were stirred in anhydrous DMF (1.0 mL) at room temperature for about one hour. Then methanesulfonamide (27 mg, 0.28 mmol) and triethylamine (39 μL, 0.28 mmol) were added, followed by slow, dropwise addition of DBU (31.5 μL, 0.21 mmol). The reaction mixture was stirred more than 30 minutes, diluted with water (8 mL), concentrated and purified by preparative HPLC on a Waters® Atlantis® T3 C18 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 50 mL/min to give the titled compound (17 mg).

Illustrative Synthesis of Compound 350: 3-cyclobutyl-4-[(3R)-3-(hydroxymethyl)piperidin-1-yl]-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-4-[(3R)-3-(hydroxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A284, 61 mg, 0.15 mmol) and carbonyl diimidazole (49 mg, 0.30 mmol) were stirred in anhydrous DMF (1.0 mL) at room temperature for about one hour. Then a solution of 3-(morpholin-4-yl)propane-1-sulfonamide (S10, 63 mg, 0.30 mmol) in anhydrous acetonitrile (200 μL) and triethylamine (42 μL, 0.30 mmol) were added, followed by slow, dropwise addition of DBU (34 μL, 0.23 mmol). The reaction mixture was stirred for more than 30 minutes, diluted with water (8 mL), concentrated and purified by preparative HPLC on a Waters® Atlantis® T3 C18 column (30×150 mm) with a 40 to 70% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 50 mL/min to the titled compound (30 mg).

Illustrative Synthesis of Compound 365: 4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(methanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-1-phenyl-4-[4-(1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic acid (A081, 51 mg, 0.11 mmol) and carbonyl diimidazole (28 mg, 0.17 mmol) were stirred in anhydrous DMF (600 μL) at room temperature for an hour. Then methanesulfonamide (21 mg, 0.22 mmol) and triethylamine (31 μL, 0.22 mmol) were added, followed by DBU (25.5 L, 0.17 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with water (5 mL), concentrated and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate at 50 mL/min to give the titled compound (30 mg).

Illustrative Synthesis of Compound 411: 1-(4-fluorophenyl)-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

1-(4-Fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A408, 70 mg, 0.15 mmol) and carbonyl diimidazole (37 mg, 0.23 mmol) were stirred in anhydrous DMF (800 μL) at room temperature for an hour. Then methanesulfonamide (29 mg, 0.30 mmol) and triethylamine (42 μL, 0.30 mmol) were added, followed by slow addition of DBU (34 μL, 0.23 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 413: N-(ethanesulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

1-(4-Fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A408, 70 mg, 0.15 mmol) and carbonyl diimidazole (37 mg, 0.23 mmol) were stirred in anhydrous DMF (800 μL) at room temperature for an hour. Then ethanesulfonamide (33 mg, 0.30 mmol) and triethylamine (42 μL, 0.30 mmol) were added, followed by slow addition of DBU (34 μL, 0.23 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 414: N-(cyclopropanesulfonyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

1-(4-Fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A408, 70 mg, 0.15 mmol) and carbonyl diimidazole (37 mg, 0.23 mmol) were stirred in anhydrous DMF (800 μL) at room temperature for an hour. Then cyclopropanesulfonamide (36 mg, 0.30 mmol) and triethylamine (42 μL, 0.30 mmol) were added, followed by slow addition of DBU (34 μL, 0.23 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 427: 4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(ethanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-1-phenyl-4-[4-(1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic acid (A081, 92 mg, 0.20 mmol) and carbonyl diimidazole (49 mg, 0.30 mmol) were stirred in anhydrous DMF (1.0 mL) at room temperature for 90 minutes. Then ethanesulfonamide (44 mg, 0.40 mmol) and triethylamine (56 μL, 0.40 mmol) were added, followed nearly 15 minutes later by slow addition DBU (45 μL, 0.30 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 40 to 70% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 428: 4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(cyclopropanesulfonyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-1-phenyl-4-[4-(1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic acid (A081, 92 mg, 0.20 mmol) and carbonyl diimidazole (49 mg, 0.30 mmol) were stirred in anhydrous DMF (1.0 mL) at room temperature for 90 minutes. Then cyclopropanesulfonamide (49 mg, 0.40 mmol) and triethylamine (56 μL, 0.40 mmol) were added, followed nearly 15 minutes later by slow addition DBU (45 μL, 0.30 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 454: 4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-[3-(morpholin-4-yl)propane-1-sulfonyl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

To a suspension of the 3-cyclobutyl-1-phenyl-4-[4-(1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic acid (46 mg, 0.10 mmol, A081) and carbonyl diimidazole (29 mg, 0.18 mmol) in anhydrous DMF (400 μL) was added pyridine (81 μL, 1.0 mmol). The mixture was stirred nearly ten minutes at room temperature and then another 15 minutes at 50° C. before being brought to room temperature. In a separate vial, 3-morpholinopropane-1-sulfonamide (42 mg, 0.20 mmol) under nitrogen was dissolved into anhydrous DMF (400 μL) and treated with 1 M potassium bis(trimethylsilyl)amide in THF (190 μL, 0.19 mmol), stirred ten minutes to give a suspension and then treated dropwise with the contents of the first vial, which were transferred with a DMF (200 μL) rinse. The mixture was stirred at room temperature for three days, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 35 to 65% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 658: 3-cyclobutyl-N-(ethanesulfonyl)-N-methyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (45 mg, 0.10 mmol, A409) dissolved in dichloromethane (500 μL) was treated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (18 mg, 0.12 mmol) in dichloromethane (500 μL), dimethyl amino pyridine (24 mg, 0.2 mmol) and N-methylethanesulfonamide (13 mg, 0.11 mmol). The mixture was then stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved DMSO and purified by reverse phase HPLC (C18, 0-100% CH₃CN/water (0.1% TFA)). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-0.5 minute 10% A, 0.5-6.0 minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient 100-10% A) gave the titled compound.

Method Y2: Synthesis of Acylsulfonamide

Synthesis of Compounds 289 & 298: 3-({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)propanoic Acid and 3-cyclobutyl-N-[3-(dimethylamino)-3-oxopropane-1-sulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

Step 1: 3-({3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl}sulfamoyl)propanoic Acid

A solution of LiOH (0.0189 g, 0.45 mmol, 2.1 equiv) in H₂O (1 mL) was added to a solution of compound 288 (0.123 g, 0.216 mmol) in THF. The reaction mixture was stirred for 30 min and then concentrated. The residue was partitioned between dichloromethane (100 mL) and an aqueous H₃PO₄/NaH₂PO₄ buffer (1.0 M, pH 2, 100 mL). The organic phase was washed with brine, dried over MgSO₄, filtered and concentrated to give compound 289 (carboxylic acid).

Step 2: 3-cyclobutyl-N-[3-(dimethylamino)-3-oxopropane-1-sulfonyl]-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

BOP (CAS: 56602-33-6, 0.037 g, 0.084 mmol, 1.2 equiv) was added to a solution of compound 289 (0.0378 g, 0.0680 mmol) in dichloromethane (4 mL). After 10 minutes, a THF solution of dimethylamine (2.0 M, 0.25 mL, 0.50 mmol, 7.3 equiv) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was charged onto a column of silica gel and eluted with CH₂Cl₂/iPrOH (20:1) to yield the titled compound. ¹H NMR (400 MHz, CDCl₃/CD₃OD) δ ppm 7.99 (d, J=8.25, 2H), 7.51 (t, J=8.0 Hz, 2H), 7.44 (s, 1H), 7.32 (t, J=7.4, 1H), 3.98 (pent, J=8.4 Hz, 1H), 3.67-3.59 (m, 2H), 3.50 (t, J=6.5 Hz, 2H), 3.40-3.33 (m, 2H), 3.37 (s, 3H), 3.14 (t, J=6.5 Hz, 2H), 2.94-2.84 (m, 2H), 2.6-2.49 (m, 2H), 2.44-2.34 (m, 2H), 2.38 (s, 6H), 2.12-1.79 (m, 5H), 1.60-1.48 (m, 2H)

Method Y3: Synthesis of Acylsulfonamide

Potassium iodide (0.3 equiv) is added to a solution of alkylchloride in acetonitrile. The amine (15 to 20 equiv) is added, and the vial is sealed. The reaction mixture is stirred at RT or 50° C. for 16 hours. After concentration, the residue is partitioned between water and dichloromethane. The organic phase is washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. If necessary, the residue was purified either by precipitation in pentane or by silica gel chromatography.

Illustrative Synthesis of Compound 290: N-[3-(dimethylamino)propane-1-sulfonyl]-1-(4-fluorophenyl)-4-[4-(methoxymethyl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

KI (2 mg, 0.012 mmol, 0.3 equiv) was added to a solution of N-(3-chloropropylsulfonyl)-1-(4-fluorophenyl)-3-isopropyl-4-[4-(methoxymethyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxamide (AC01, 20 mg, 0.035 mmol) in acetonitrile (3 mL). The vial was sealed, and the reaction mixture was saturated with gaseous dimethylamine. The reaction mixture was stirred at RT for 16 hours. After concentration, the residue was partitioned between water and dichloromethane. The organic phase was washed with brine, dried over MgSO₄, filtered and concentrated to give the titled compound.

Method Y4: Synthesis Via Carboxamide

Step 1

Oxalyl chloride (0.40 mL, 4.7 mmol, 9.6 equiv) and a drop of dimethylformamide are added to a solution of carboxylic acid (0.49 mmol) in dichloromethane (2 mL). After effervescence has ceased, the vial is sealed, and the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is concentrated in vacuo, and to the residue is added a dioxane solution of ammonia (0.5 M, 10.0 mL, 5.0 mmol, 10 equiv). After 1 hour, volatiles are then removed via rotary evaporation. The residue is purified by silica gel chromatography (dichloromethane/ethyl acetate, 4:1) to give the intermediate carboxamide.

Step 2

NaH (60% in mineral oil, 21 equiv to 50 equiv) is added to a solution of carboxamide in dry THF. After effervescence has ceased, sulfonyl chloride (1.4 to 2.0 equiv) is added. The reaction mixture is stirred at room temperature for several hours. An aqueous solution of malate buffer (1.0 M sodium malate/disodium malate, pH 4.5, 4 mL) is slowly added. After 5 minutes, the mixture is combined with chloroform or dichloromethane and stirred. The organic phase is collected and concentrated in vacuo. The residue is purified by preparative HPLC or by flash column chromatography to give the titled compound.

Illustrative Synthesis of Compound 287: 3-cyclobutyl-N-(3,5-dimethyl-1,2-oxazole-4-sulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

Step 1

Oxalyl chloride (0.40 mL, 4.7 mmol, 9.6 equiv) and a drop of dimethylformamide were added to a solution of A136 (0.207 g, 0.49 mmol) in dichloromethane (2 mL). After effervescence had ceased, the vial was sealed, and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, and to the residue was added a dioxane solution of ammonia (0.5M, 10.0 mL, 5.0 mmol, 10 equiv). After 1 hour, volatiles were then removed via rotary evaporation. The residue was purified by silica gel chromatography (CH₂Cl₂/EtOAc, 4:1) to give 3-cyclobutyl-4-[4-(methoxymethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxamide.

Step 2

NaH (60% in mineral oil, 0.080 g, 2.0 mmol, 21 equiv) was added to a solution of 3-cyclobutyl-4-[4-(methoxymethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxamide (0.041 g, 0.098 mmol) in dry THF (2 mL). After effervescence has ceased, 3,5-dimethylisoxazole-4-sulfonyl chloride (CAS: 877861-76-2, 0.038 g, 0.19 mmol, 1.9 equiv) was added. The reaction mixture was stirred at room temperature for 16 h. An aqueous solution of malate buffer (1.0 M sodium malate/disodium malate, pH 4.5, 4 mL) was slowly added. After 5 minutes, the mixture was combined with chloroform and agitated. The organic phase was collected and concentrated in vacuo. The residue was purified by preparative HPLC to give the titled compound.

Method Y5: Synthesis of Acylsulfonamide or Acylsulfamide from a Carboxylic Acid Chloride

Oxalyl chloride (CAS 79-37-8, 1.5 equiv) and 3 drops of dimethylformamide are added at 0° C. to a solution of carboxylic acid in dichloromethane. After 1 h of stirring at room temperature, additional oxalyl chloride (CAS 79-37-8, 1.5 equiv) is added. After 30 minutes of stirring, the reaction mixture is cooled to 0° C. and sulfonamide (3.0 equiv) followed by triethylamine (2.0 equiv) are added. The reaction mixture is stirred at room temperature for 3 h and then concentrated in vacuo. The residue is partitioned between a saturated aqueous solution of sodium hydrogencarbonate and dichloromethane. The organic phase is dried over MgSO₄, filtered and concentrated in vacuo. The residue dissolved in dichloromethane is precipitated by addition to a mixture of diethyl ether/pentane. The solid collected by filtration is purified by silica gel chromatography to give the titled compound.

Alternatively, oxalyl chloride (5-10 equivalents) is added to a mixture of carboxylic acid (1 equiv) in dichloromethane followed by stirring at ambient temperature over 8-24 hours. The reaction mixture is diluted with dichloromethane and concentrated several times followed by drying under vacuum. The carboxylic acid chloride (1 equiv) is then combined with sulfonamide (2 equiv) and triethylamine (2.5-5 equiv) in dichloromethane with stirring at ambient temperature over 1-24 hours. The reaction mixture is concentrated and purified by preparative HPLC.

Illustrative Synthesis of Compound 3: 3-methyl-4-[4-(morpholin-4-yl)phenyl]-1-phenyl-N-(trifluoromethanesulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

Oxalyl chloride (CAS 79-37-8, 0.012 mL, 0.15 mmol, 1.5 equiv) and 3 drops of dimethylformamide were added at 0° C. to a solution of A002 (41 mg, 0.1 mmol) in dichloromethane (2 mL). After 1 h of stirring at room temperature, additional oxalyl chloride (CAS 79-37-8, 0.012 mL, 0.15 mmol, 1.5 equiv) was added. After 30 minutes of stirring, the reaction mixture was cooled to 0° C. and trifluoromethanesulfonamide (CAS 421-85-2, 48 mg, 0.3 mmol, 3.0 equiv) followed by triethylamine (0.029 mL, 0.2 mmol, 2.0 equiv) were added. The reaction mixture was stirred at room temperature for 3 h and then concentrated in vacuo. The residue was partitioned between a saturated aqueous solution of sodium hydrogencarbonate and dichloromethane. The organic phase was dried over MgSO₄, filtered and concentrated. The residue dissolved in dichloromethane was precipitated by addition to a mixture of diethyl ether/pentane. The solid collected by filtration was purified by silica gel chromatography (heptane/EtOAc 100/0 to 0/100) to give the titled compound.

Illustrative Synthesis of Compound 383: 3-cyclobutyl-N-(morpholine-4-sulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A suspension of 3-cyclobutyl-4-(4-morpholino-1-piperidyl)-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A268, 0.0511 g, 0.111 mmol) and (COCl)₂ (18 μL, 0.206 mmol) in CH₂Cl₂ (0.40 mL) with catalytic DMF was stirred for 90 minutes, concentrated, and re-dissolved in CH₂Cl₂ (0.40 mL). To this mixture was added morpholine-4-sulfonamide (0.0213 g, 0.128 mmol), DMAP (0.0141 g, 0.115 mmol), and triethylamine (18 μL, 0.129 mmol), and the mixture was stirred overnight. The reaction mixture was then diluted with saturated NaHCO₃, extracted with CH₂Cl₂, concentrated, and chromatographed on silica gel (25% acetone/CH₂Cl₂) and re-chromatographed (2.5% CH₃OH/CH₂Cl₂) and precipitated (methanol/methyl tert-butyl ether) to give the titled compound (0.0267 g, 0.044 mmol, 40% yield).

Illustrative Synthesis of Compound 432: 3-cyclobutyl-N-[methyl(propyl)sulfamoyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A vial was charged with 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl chloride (35 mg, 0.08 mmol, prepared as described below for the synthesis of compound 437) dissolved in 500 μL of dichloromethane followed by N-methyl-N-propylsulfonamide (2 eq, 0.15 mmol) in 500 μL of dichloromethane and neat triethylamine (38 μL, 4 eq, 0.32 mmol). The mixture was then stirred at room temperature for one hour. After completion of reaction, the mixture was concentrated, and the residue was dissolved in DMSO and purified by reverse phase HPLC (C18, 0-100% CH₃CN/water (0.1% TFA)). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-0.5 minute 10% A, 0.5-6.0 minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient 100-10% A) to afford the title compound.

Illustrative Synthesis of Compound 437: 3-cyclobutyl-N-(ethanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

To a suspension of 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A409, 0.8117 g, 1.759 mmol) in dichloromethane (10 mL) was added oxalyl chloride (1 mL, 11.4 mmol) dropwise, and the mixture was stirred at RT overnight. The reaction mixture was diluted with more dichloromethane (11 mL) and concentrated under vacuum. This process was repeated two additional times. The resultant yellow solid material, which was kept under vacuum for one hour to give 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl chloride.

To a suspension of 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carbonyl chloride (0.050 g, 0.104 mmol) in dichloromethane (1.5 mL) was added ethanesulfonamide (0.023 g, 0.208 mmol) and triethylamine (0.051 mL, 0.365 mmol), and the mixture was stirred at RT for overnight. The reaction mixture was concentrated under vacuum and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with an escalating gradient of acetonitrile in 10 mM aqueous ammonium acetate to the titled compound.

Method Y6: Protecting Group Removal

Protecting groups, known to one of skill in the art can be removed using appropriate procedures known to remove such protecting groups. Specific illustrations for select protecting group removal are provided in the examples below.

Benzyl Ether Removal

Illustrative Synthesis of Compound 366: 3-cyclobutyl-N-(2-hydroxyethanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A solution of AC05 (8 mg, 0.013 mmol) in THF (5 mL) was degassed with nitrogen. Palladium hydroxide (2 mg, 25% w/w) was added, and the reaction mixture was stirred under hydrogen atmosphere (balloon) for 3 hours. The reaction mixture was then filtered on Dicalite® diatomaceous earth, and the filtrate was concentrated in vacuo. The residue dissolved in dichloromethane (1 mL) was precipitated by addition to heptane. The collected solid was dried in vacuo to yield the titled compound.

Illustrative Synthesis of Compound 105: 1-[3-(3-hydroxyazetidin-1-yl)phenyl]-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A solution of AC02 (38 mg, 0.06 mmol) in a mixture of EtOH/THF (1/2 mL) was degassed with nitrogen. 10% Pd/C (5 mg) was added. The reaction mixture was degassed with H₂ for 5 min, and then was stirred for 48 hours at room temperature under hydrogen atmosphere (balloon). Additional 10% Pd/C (5 mg) was added, and the reaction mixture was stirred for 18 hours at room temperature under hydrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to give the titled compound.

Benzyl Carbamate Removal

Illustrative Synthesis of Compound 368: 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-(piperidine-4-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A solution of AC03 (60 mg, 0.09 mmol) in ethanol (10 mL) was degassed with nitrogen. Palladium hydroxide (15 mg, 25% w/w) was added, and the reaction mixture was stirred at RT under hydrogen atmosphere (balloon) for 16 hours. The reaction mixture was filtered, and the cake washed with THF, MeOH and chloroform. The filtrate was concentrated in vacuo. The residue dissolved in dichloromethane was precipitated by addition to a mixture of diethyl ether and pentane. The obtained solid was dried in vacuo to yield the titled compound.

Phthalimide Removal

Illustrative Synthesis of Compound 261: N-(2-aminoethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

Hydrazine hydrate (50-60% in water, 0.015 mL, 0.2 mmol, 6.7 equiv) was added to a solution of 3-cyclobutyl-N-[2-(1,3-dioxoisoindolin-2-yl)ethylsulfonyl]-4-[4-(methoxymethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxamide (compound 260, 20 mg, 0.03 mmol) in ethanol (3 mL). The reaction mixture was refluxed for 3 hours and then concentrated in vacuo. The residue was partitioned between a saturated aqueous solution of sodium hydrogencarbonate and dichloromethane. The organic phase was dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane/acetone 95/5 to 85/15) to give the titled compound.

Tert-Butyl Carbamate Removal

Illustrative Synthesis of Compound 258: 4-[6-(4-cyanopiperidin-1-yl)pyridin-3-yl]-N-(methanesulfonyl)-1-phenyl-3-[(piperidin-4-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

Trifluoroacetic acid (0.1 mL, 1.0 mmol, 23 equiv) was added to a solution of tert-butyl 4-[4-[6-(4-cyano-1-piperidyl)-3-pyridyl]-6-(methylsulfonylcarbamoyl)-1-phenyl-pyrazolo[3,4-b]pyridin-3-yl]oxypiperidine-1-carboxylate (compound 259, 30 mg, 0.043 mmol) in dichloromethane (1 mL). The reaction mixture was stirred at room temperature until completion of the reaction. The reaction mixture was quenched with a saturated solution of sodium bicarbonate. The obtained precipitate was collected by filtration, washed with water and dried to yield the titled compound.

Illustrative Synthesis of Compound 631: 1-cyclohexyl-4-[4-(hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carbonyl)phenyl]-N-(methanesulfonyl)-3-[(propan-2-yl)oxy]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

AC15 (18 mg, 26 μmol) was dissolved in dichloromethane (5 mL) and 4 M HCl in dioxane (0.5 mL, 2 mmol) was added. The solution was stirred at room temperature for two hours and then concentrated in vacuo. The residue was suspended in DCM and washed with a phosphate buffer solution (pH 6.2). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound.

Method Y7: Azide Displacement of Alkyl Halide

Synthesis of Compound 327: 4-(4-azidophenyl)-N-(3-azidopropane-1-sulfonyl)-1-[3-(dimethylamino)phenyl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

AC06 (160 mg, 0.275 mmol, 1 equiv) in anhydrous DMSO (2 mL) at RT under nitrogen atmosphere was added sodium azide (CAS 26628-22-8, 36 mg, 0.550 mmol, 2.0 equiv). The reaction mixture was stirred at 80° C. for 1 h. Then the reaction mixture was cooled down, diluted with dichloromethane, washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting crude mixture was purified by preparative HPLC to afford the titled compound.

Method Y8: Synthesis of Acylsulfamide

EDC.HCl (CAS 25952-538, 1.0 to 4.0 equiv) is added at RT to a stirring solution of carboxylic acid, sulfamide (from 1 to 4.0 equiv) and 4-(dimethylamino) pyridine (CAS 1122-58-3, from 0.2 to 2 equiv) in dichloromethane or/and THF or/and acetonitrile. The reaction mixture is stirred at RT until complete conversion. The solvent can be evaporated under reduced pressure. The residue can be worked up or purified by preparative HPLC. The work up consists in dissolving the sample in DCM and washing it with water and/or a saturated aqueous solution of NaHCO₃. The organic phase is separated, dried over sodium sulfate, filtered and concentrated in vacuo. The residue is purified either by flash column chromatography or by preparative HPLC to yield the titled compound.

Alternatively, acylsulfamides can be prepared in the following manner. A solution of the carboxylic acid (1 eq) in dichloromethane, dichloroethane or dimethylformamide can be treated with carbodiimidazole (1-2.5 eq) stirred at ambient temperature to 65° C. for 0.5-3 hours. Then the sulfamide (1-3 eq) and optional potassium bis(trimethylsilyl)amide or triethylamine followed by 1,8-diazabicycloundec-7-ene (1-3 eq) and optional 4-(dimethylamino)pyridine (1-2 eq) can be added, and the reaction mixture is stirred at 20-60° C. for 2-16 hours. The reaction mixture can then be concentrated or extractively worked up. The residue can be purified by precipitation, silica gel flash chromatography, or preparative HPLC.

Illustrative Synthesis of Compound 379: 3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-{4-[2-(methoxymethyl)morpholin-4-yl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

EDC.HCl ([25952-538], 58 mg, 0.46 mmol) was added at RT to a stirred solution of A286 (120 mg, 0.23 mmol), N,N-dimethylsulfamide (58 mg, 0.46 mmol) and 4-(dimethylamino) pyridine (CAS 1122-58-3, 58 mg, 0.46 mmol) in a mixture of dichloromethane/acetonitrile (1:1, 4 mL). The reaction mixture was stirred at RT for 20 hours. The solvent was evaporated at 40° C. under a nitrogen flow. The residue was purified by preparative HPLC to yield the titled compound as formate salt.

Illustrative Synthesis of Compound 380: 3-cyclobutyl-N-(morpholine-4-sulfonyl)-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A suspension of 3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A285, 0.1498 g, 0.326 mmol) and carbonyl diimidazole (0.0795 g, 0.490 mmol) in dimethylformamide (DMF) (1.0 mL) was stirred for 2.5 hours, and then morpholine-4-sulfonamide (0.0815 g, 0.490 mmol, [25999-04-6]), DMAP (0.0444 g, 0.363 mmol), and DBU (0.075 mL, 0.498 mmol) were added. The resultant mixture was stirred overnight. The reaction mixture was then diluted with water (10 mL), extracted with dichloromethane (3×8 mL), dried (Na₂SO₄), and chromatographed (7% CH₃OH/CH₂Cl₂) and triturated (10 volumes methyl tert-butyl ether/5 volumes methanol) to give the titled compound (0.0602 g, 0.099 mmol, 30% yield).

Illustrative Synthesis of Compound 388: 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-[4-(pyrrolidin-1-yl)piperidine-1-sulfonyl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A 4-mL vial was charged with 3-cyclobutyl-4-[4-(methoxymethyl)-1-piperidyl]-1-phenyl-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A136, 35 mg, 0.09 mmol) dissolved in 600 μL of dichloroethane followed by carbonyldiimidazole (27 mg, 0.18 mmol) in 600 μL of dichloroethane, and the mixture was stirred at 40° C. for two hours. To this mixture was then added 4-(pyrrolidin-1-yl)piperidine-1-sulfonamide (40 mg, 3 eq, 0.28 mmol) followed by 1,8-diazabicycloundec-7-ene (42 μL, 3 eq, 0.28 mmol), and the mixture was heated at 60° C. for 16 hours. The mixture was concentrated, and the residue was dissolved in DMSO and purified by reverse phase HPLC (C18, 0-100% CH₃CN/water (0.1% TFA)). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-0.5 minute 10% A, 0.5-6.0 minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient 100-10% A) to afford the title compound.

Illustrative Synthesis of Compound 412: N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

1-(4-Fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (A408, 70 mg, 0.15 mmol) and carbonyl diimidazole (37 mg, 0.23 mmol) were stirred in anhydrous DMF (800 μL) at room temperature for an hour. Then N,N-dimethylsulfamide (37 mg, 0.30 mmol) and triethylamine (42 μL, 0.30 mmol) were added, followed by slow addition of DBU (34 μL, 0.23 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 40 to 70% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 426: 4-([1,4′-bipiperidin]-1′-yl)-3-cyclobutyl-N-(dimethylsulfamoyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

3-Cyclobutyl-1-phenyl-4-[4-(1-piperidyl)-1-piperidyl]pyrazolo[3,4-b]pyridine-6-carboxylic acid (A081, 92 mg, 0.20 mmol) and carbonyl diimidazole (49 mg, 0.30 mmol) were stirred in anhydrous DMF (1.0 mL) at room temperature for 90 minutes. Then N,N-dimethylsulfamide (50 mg, 0.40 mmol) and triethylamine (56 μL, 0.40 mmol) were added, followed nearly 15 minutes later by slow addition DBU (45 μL, 0.30 mmol). The reaction mixture was stirred 30 minutes at room temperature, diluted with methanol and purified by preparative HPLC on a Waters® Sunfire™ C8 column (30×150 mm) with a 30 to 60% gradient of acetonitrile in 10 mM aqueous ammonium acetate to give the titled compound.

Illustrative Synthesis of Compound 652: 3-cyclobutyl-1-[3-(difluoromethoxy)phenyl]-N-(dimethylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A solution of 3-cyclobutyl-1-[3-(difluoromethoxy)phenyl]-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (0.0536 g, 0.102 mmol, A410) and 1,1′-carbonyldiimidazole (0.0253 g, 0.156 mmol) in N,N-dimethylformamide (DMF) (0.40 mL) was stirred at 60° C. for 1 hour. Then N,N-dimethylsulfamide (0.0192 g, 0.155 mmol), DMAP (0.0138 g, 0.113 mmol), and DBU (0.023 mL, 0.153 mmol) were added, and the mixture was stirred for 2.5 hours. The mixture was diluted with water (10 mL), extracted with DCM (4×8 mL), dried (Na₂SO₄), and concentrated. The residue was purified by chromatography on silica gel (0-3% isopropanol/DCM) to give the titled compound

Method Y9: De-Benzylation

A vial is loaded with benzylated acylsulfonamide (1.0 equiv) and 10% Pd on charcoal (0.1 equiv). The vial is sealed, evacuated and back-filled with N₂ and THF/MeOH 1:1 is added by syringe. The reaction mixture is evacuated and back-filled with H₂ three times, and the reaction mixture is stirred overnight at 50° C. The mixture is filtered on a Pall-Seitz thick paper filter and concentrated in vacuo. The residue is dissolved in MeOH, filtered over a 0.45 μM plug filter and purified by means of semi-preparative HPLC (0.1% TFA in water/CH₃CN). The compound is dissolved in DCM, 4 M HCl in dioxane is added, and the mixture was concentrated in vacuo to afford the debenzylated compound.

Illustrative Synthesis of Compound 517: 3-cyclobutyl-1-(4-fluorophenyl)-N-(methylsulfamoyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A vial was loaded with N-[benzyl(methyl)sulfamoyl]-3-cyclobutyl-1-(4-fluorophenyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxamide (AC16, 1.0 equiv., 0.151 mmol, 100 mg) and 10% Pd on charcoal (0.1 equiv., 0.015 mmol, 16 mg). The vial was sealed, evacuated and back-filled with N₂, and THF/MeOH 1:1 (2 mL) was added by syringe. The reaction mixture was evacuated and back-filled with H₂ three times, and the reaction mixture was stirred overnight at 50° C. The mixture was filtered on a Pall-Seitz thick paper filter and concentrated in vacuo. The residue was dissolved in MeOH, filtered over a 0.45 μM plug filter and purified by means of semi-preparative HPLC (0.1% TFA in water/CH₃CN). The compound was dissolved in DCM, and then 4 M HCl in dioxane (0.1 mL) was added and the mixture was concentrated in vacuo to afford the titled compound.

Method Y10: Acylsulfonamide N-Alkylation

An acylsulfonamide is treated with a C₁-C₆ alkyl halide or C₁-C₆ alkyl halide in the presence of a base such as but not limited to sodium bicarbonate or cesium carbonate in acetonitrile or N,N-dimethylformamide or a mixture thereof at room temperature to 70° C. over 8-60 hours. The reaction mixture is optionally quenched with water. The mixture may be optionally extractively worked up and concentrated or simply concentrated. The residue can be purified by precipitation, chromatography on silica gel, or by preparative HPLC to give the N-alkylated acylsulfonamide.

Illustrative Synthesis of Compound 656: 3-cyclobutyl-N-(methanesulfonyl)-N-methyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A mixture of 3-cyclobutyl-N-(methanesulfonyl)-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide dihydrochloride (0.0318 g, 0.052 mmol, compound 328), iodomethane (4.86 μl, 0.078 mmol), and Cs₂CO₃ (0.0506 g, 0.155 mmol) in N,N-dimethylformamide (DMF) (0.25 mL) was stirred at RT for 1 hour, and at 60° C. overnight. The mixture was then quenched with water, concentrated, and chromatographed on silica gel (5% MeOH/DCM) and re-chromatographed (15-25% acetone/DCM) to give the titled compound.

Illustrative Synthesis of Compound 657: 3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-N-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A mixture of 3-cyclobutyl-N-(methanesulfonyl)-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxamide (0.0508 g, 0.102 mmol, compound 185), iodomethane (10 μL, 0.161 mmol), and NaHCO₃ (0.0265 g, 0.315 mmol) in acetonitrile (0.40 mL) was stirred at RT overnight. N,N-Dimethylformamide (DMF) (0.20 mL) was added, and the mixture was heated to 60° C. for 5 hours (little reaction). Then, additional iodomethane (10 μL, 0.161 mmol) and NaHCO₃ (0.0265 g, 0.315 mmol) were added, and the mixture was stirred at 60° C. overnight. The mixture was diluted with water, extracted with DCM, dried (Na₂SO₄), and chromatographed on silica gel (2% EtOAc/DCM) to give the titled compound.

Synthesis of Compound 386: N-(2-acetamidoethanesulfonyl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-

A solution of AC08 (42 mg, 0.06 mmol) in a mixture of THF (6 mL) and acetic anhydride (0.1 mL, 1.0 mmol) was degassed with nitrogen. 10% Pd/C (9 mg, 0.008 mmol) was added and the reaction mixture was purged with H2. The mixture was stirred for 16 hours at RT under a hydrogen atmosphere (balloon). The reaction mixture was filtered over a pad of diatomaceous earth that was then washed with THF. The filtrate was concentrated in vacuo, and the residue was purified by flash column chromatography eluted with DCM/MeOH (20/1) to give the titled compound.

Synthesis of Compound 387: 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-phenyl-N-(pyrrolidine-3-sulfonyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide

A solution of AC09 (103 mg, 0.15 mmol) in a mixture of THF (8 mL), ethanol (8 mL), acetic acid (1 mL), and aqueous 1 M HCl (1 mL) was degassed with nitrogen. 10% Pd(OH)₂ (21 mg, 0.015 mmol) was added, and the reaction mixture was purged with H2. The mixture was stirred for 16 hours at RT under a hydrogen atmosphere (balloon). The reaction mixture was filtered over a pad of diatomaceous earth that was washed with THF. The filtrate and wash were concentrated in vacuo. The residue was partitioned between chloroform (100 mL) and aqueous 1 M NaOH (50 mL). The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluted with DCM/MeOH (20/1) to give the titled compound.

Synthesis of AC10: 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methylpyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Step 1: Ethyl 1-(2-chloro-6-methylpyridin-4-yl)-3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

To a solution of E168 (64 mg, 0.17 mmol) in dichloromethane (4 mL) at RT was added 2-chloro-6-methylpyridine-4-boronic acid ([1320397-15-6], 43 mg, 0.25 mmol), copper(II) acetate ([142-71-2], 56 mg, 0.31 mmol) and pyridine (66 μL, 0.81 mmol). The reaction mixture was stirred at room temperature under air for 72 hours. The reaction mixture was filtered through a pad of diatomaceous earth. Solids were washed with dichloromethane, and the filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel eluted with ethyl acetate/n-heptane (0/1 to 1/0) to give the titled compound.

Step 2: Ethyl 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methylpyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

A solution of the compound from the previous step (50 mg, 0.1 mmol) in ethanol (20 mL) was degassed with nitrogen. 10% Pd/C (5 mg, 0.005 mmol) was added, and the reaction mixture was purged with H2. The mixture was stirred for 16 hours at RT under a hydrogen atmosphere (balloon). The reaction mixture was filtered through a pad of diatomaceous earth that was washed with ethanol. The filtrate was concentrated in vacuo to give the titled compound.

Step 3: 3-cyclobutyl-4-[4-(methoxymethyl)piperidin-1-yl]-1-(2-methylpyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

The previous compound (50 mg, 0.1 mmol) was dissolved ethanol (5 mL), and aqueous 1 N sodium hydroxide (0.5 mL, 0.5 mmol) was added at RT. The solution was stirred for 16 hours. A phosphate buffer was added (pH 6.2). The solvent was partially removed under reduced pressure, and the resulting mixture was extracted twice with chloroform. The combined organic phases were dried over magnesium sulfate, filtered and concentrated under reduced pressure to give the titled compound.

Synthesis of AC13: 4-[1-(ethoxycarbonyl)piperidin-4-yl]-1-(4-fluorophenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

Step 1: Methyl 1-(4-fluorophenyl)-4-(piperidin-4-yl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate Hydrogen Chloride (1/1) HCl Salt

E197 (1.7 g, 3.42 mmol) was dissolved into 4 M HCl in dioxane (25.7 mL, 102 mmol), stirred at room temperature for two hours, and then concentrated in vacuo to give the titled compound.

Step 2: Methyl 4-[1-(ethoxycarbonyl)piperidin-4-yl]-1-(4-fluorophenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylate

Ethyl chloroformate (67 μL, 0.7 mmol) was added dropwise at RT to a stirring solution of the compound from Step 1 (200 mg, 0.42 mmol) and DIPEA (294 μL, 1.7 mmol) in anhydrous DCM (2 mL). The reaction was complete after 2 hours. The reaction solution was diluted with DCM (10 mL) and washed with water (5 mL). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the titled compound.

Step 3: 4-[1-(ethoxycarbonyl)piperidin-4-yl]-1-(4-fluorophenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic Acid

The compound from Step 2 (196 mg, 0.42 mmol) was dissolved in THF (5 mL) and aqueous 2 N sodium hydroxide (1.05 mL, 2.1 mmol) was added at RT. The solution was stirred for 20 hours. The resulting mixture was diluted with water (10 mL) and then acidified with aqueous 2 N HCl (1.05 mL). The aqueous phase was extracted twice with DCM. The combined organic phases were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the titled compound.

TABLE XVa List of intermediate acylsulfonamides Int. Structure Name SM method MW Mes AC01

N-(3-chloropropane-1-sulfonyl)- 1-(4-fluorophenyl)-4-[4- (methoxymethyl)piperidin-1-yl]-3- (propan-2-yl)-1H-pyrazolo[3,4- b]pyridine-6-carboxamide A124, 35578- 28-0 Y1 566 567 AC02

1-{3-[3-(benzyloxy)azetidin- 1-yl]phenyl}-N-(methanesulfonyl)- 4-[4-(morpholin-4-yl)phenyl]-3- (propan-2-yl)-1H-pyrazolo[3,4- b]pyridine-6-carboxamide A252, 3144- 09-0 Y1 680 681 AC03

benzyl 4-({3-cyclobutyl-4-[4- methoxymethyl)piperidin-1-yl]-1- phenyl-1H-pyrazolo[3,4-b]pyridine- 6-carbonyl}sulfamoyl)piperidine-1- carboxylate A136, S9 Y1 700 701 AC04

N-[3-(benzyloxy)propane-1- sulfonyl]-3-cyclobutyl-4-[4- (methoxymethyl)piperidin-1-yl]-1- phenyl-1H-pyrazolo[3,4-b]pyridine- 6-carboxamide A136, 1408646- 99-0 Y1 631 632 AC05

N-[2-(benzyloxy)ethanesulfonyl]- 3-cyclobutyl-4-[4- (methoxymethyl)piperidin-1-yl]-1- phenyl-1H-pyrazolo[3,4-b]pyridine- 6-carboxamide A136, 881407- 21-2 Y1 617 618 AC06

4-(4-azidophenyl)-N-(3- chloropropane-1-sulfonyl)-1-[3- (dimethylamino)phenyl]-3-(propan- 2-yl)-1H-pyrazolo[3,4-b]pyridine- 6-carboxamide A238, 35578- 28-0 Y1 580 581 AC07

N-(chloromethanesulfonyl)-3- cyclobutyl-4-[4- (methoxymethyl)piperidin-1-yl]-1- phenyl-1H-pyrazolo[3,4-b]pyridine- 6-carboxamide A136 Y1 532- 534 533-535 AC08

benzyl [2-({3-cyclobutyl-4-[4- (methoxymethyl)piperidin-1-yl]-1- phenyl-1H-pyrazolo[3,4-b]pyridine- 6-carbonyl}sulfamoyl)ethyl]- carbamate A136, S5 Y1 660 661 AC09

benzyl 3-({3-cyclobutyl-4-[4- (methoxymethyl)piperidin-1- yl]-1-phenyl-1H- pyrazolo[3,4-b]pyridine- 6-carbonyl}sulfamoyl)- pyrrolidine-1-carboxylate A136, S7 Y1 686 687 AC10

3-cyclobutyl-4-[4- (methoxymethyl)piperidin- 1-yl]-1-(2-methylpyridin-4-yl)- 1H-pyrazolo[3,4-b]pyridine- 6-carboxylic acid E168 Specific example 435 436 AC11

N-[2-(benzyloxy)ethanesulfonyl]- 3-cyclobutyl-1-(4-fluorophenyl)- 4-[4-(morpholin-4-yl)piperidin- 1-yl]-1H-pyrazolo[3,4- b]pyridine-6-carboxamide A308 Y1 676 677 AC12

N-[2-(benzyloxy)ethanesulfonyl]- 3-cyclobutyl-1-(4-fluorophenyl)- 4-{4-[2-(piperidin-1-yl)ethyl]- piperidin-1-yl}-1H-pyrazolo[3,4- b]pyridine-6-carboxamide A311 Y1 704 705 AC13

4-[1-(ethoxycarbonyl)piperidin- 4-yl]-1-(4-fluorophenyl)-3-(propan- 2-yl)-1H-pyrazolo[3,4-b]pyridine- 6-carboxylic acid E197 Specific example 454 455 AC14

1-cyclohexyl-4-(4-formylphenyl)- N-(methanesulfonyl)-3-[(propan- 2-yl)oxy]-1H-pyrazolo[3,4- b]pyridine-6-carboxamide A350 Y1 484 485 AC15

tert-butyl 5-(4-{1-cyclohexyl-6- [(methanesulfonyl)carbamoyl]- 3-[(propan-2-yl)oxy]-1H- pyrazolo[3,4-b]pyridin-4- yl}benzoyl)hexahydro- pyrrolo[3,4-c]pyrrole-2(1H)- carboxylate A351 Y1 694 695 AC16

N-[benzyl(methyl)sulfamoyl]-3- cyclobutyl-1-(4-fluorophenyl)- 4-[4-(morpholin-4-yl)piperidin- 1-yl]-1H-pyrazolo[3,4- b]pyridine-6-carboxamide A308, 15205- 37-5 Y8 662 662 AC17

N-[3-(benzyloxy)propane-1- sulfonyl]-3-cyclobutyl-1-(4- fluorophenyl)-4-[4- (methoxymethyl)piperidin-1-yl]- 1H-pyrazolo[3,4-b]pyridine- 6-carboxamide A202, 1408646- 99-0 Y1 649 650

Lengthy table referenced here US10259810-20190416-T00001 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US10259810-20190416-T00002 Please refer to the end of the specification for access instructions.

Determination of Biological Activity

Cellular Assays

Measuring CFTR Cell Surface Expression of CFTR-ΔF508 Using PathHunter® U2OS CFTR-ΔF508 Cells

The PathHunter® U2OS CFTR-ΔF508 cell assay (DiscoveRx) measures the expression of CFTR-ΔF508 at the plasma membrane. CFTR-ΔF508 has a folding defect leading to absence of protein at the plasma membrane. This assay is used to evaluate the capacity of compounds to increase the expression of CFTR-ΔF508 at the plasma membrane. The CFTR-ΔF508 is tagged with a ProLink™ peptide which can complement with plasma membrane expressed enzyme acceptor protein (EA-MEM). When both the ProLink™ and EA-MEM acceptor are in close proximity, i.e. both are located at the plasma membrane; a functional enzyme is formed of which the activity can be measured. The amount of CFTR-ΔF508 that can be rescued to the plasma membrane is correlated with the amount of functional enzyme that can be measured.

There are several ways to measure the capacity of compounds to rescue CFTR-ΔF508 to the plasma membrane; either compounds are evaluated on their own and the impact on plasma membrane levels is measured or compounds are evaluated in combination with a co-corrector, i.e. a compound that rescues CFTR-ΔF508 to the plasma membrane but rescue can be enhanced by addition of compounds due to a complementary mode of action.

Activity of Compounds in Combination with Co-Corrector:

For this purpose, PathHunter® U2OS CFTR-ΔF508 cells (DiscoveRx; custom made were cultured in AssayComplete™ U2OS Cell Culture medium (DiscoveRx; 92-0018GK3) as per manufacturer's instructions. For compound testing, cells were seeded in white 384-well plates (Greiner; 781080) at five thousand cells/well in 25 μL AssayComplete™ Cell Plating 5 Reagent (DiscoveRx; 93-0563R5A) and incubated overnight at 37° C., 5% CO₂. On day two, 5 L of test compounds diluted in Cell Plating 5 Reagent were added to the cells with a final dimethyl sulfoxide (DMSO) concentration of 0.1%. In order to measure synergy with a co-corrector (3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid), 3 μM of co-corrector was added along with test compounds. All cell plates contained 3 μM of co-corrector or DMSO as positive and negative controls, respectively. Cells were incubated with compounds for twenty to twenty-four hours at 37° C., 5% CO₂. On day three, plates were placed at room temperature for thirty minutes and then 15 μL of substrate (PathHunter® Flash Detection Kit, DiscoveRx; 93-0247) was added per well. After one hour of incubation at room temperature in the dark, the luminescence signal was measured on a plate reader (Envision®, Perkin Elmer). Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

Activity of Compounds for their Intrinsic Corrector Capacity:

For this purpose PathHunter® U2OS CFTR-ΔF508 cells (DiscoveRx; custom made as described above) were cultured in AssayComplete™ U2OS Cell Culture medium (DiscoveRx; 92-0018GK3) as per manufacturer's instructions. For compound testing, cells were seeded in white 384-well plates (Greiner; 781080) at five thousand cells/well in 25 μL AssayComplete™ Cell Plating 5 Reagent (DiscoveRx; 93-0563R5A) and incubated overnight at 37° C., 5% CO₂. On day two, 5 μL of test compounds diluted in Cell Plating 5 Reagent were added to the cells with a final DMSO concentration of 0.1%. All cell plates contained 3 μM corrector (3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid) or DMSO as positive and negative controls, respectively. Cells were incubated with compounds for twenty to twenty-four hours at 37° C., 5% CO₂. On day three, plates were placed at room temperature for thirty minutes and then 15 L of substrate (PathHunter® Flash Detection Kit, DiscoveRx; 93-0247) was added per well. After one hour of incubation at room temperature in the dark, the luminescence signal was measured on a plate reader (Envision®, Perkin Elmer). Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

Activity of Compounds in Presence of Human Serum

To evaluate the impact of plasma protein binding of compounds on their biological activity, the PathHunter® U2OS CFTR-ΔF508 assay was run in the presence of 40% human serum (Sigma; H4522). For this purpose PathHunter® U2OS CFTR-ΔF508 cells (DiscoveRx; custom made) were cultured in AssayComplete™ U2OS Cell Culture medium (DiscoveRx; 92-0018GK3) as per manufacturer's instructions. For compound testing, cells were seeded in white 384-well plates (Greiner; 781080) at five thousand cells/well in 25 μL AssayComplete™ Cell Plating 5 Reagent (DiscoveRx; 93-0563R5A) containing 40% human serum and incubated overnight at 37° C., 5% CO₂. On day two, 5 μL of test compounds diluted in Cell Plating 5 Reagent were added to the cells with a final DMSO concentration of 0.1%. All cell plates contained 3 μM corrector (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid) or DMSO as positive and negative controls respectively. Cells were incubated with compounds for twenty to twenty-four hours at 37° C., 5% CO₂. On day three, plates were placed at room temperature for thirty minutes, and then 15 L of substrate (PathHunter® Flash Detection Kit, DiscoveRx; 93-0247) was added per well. After one hour of incubation at room temperature in the dark, the luminescence signal was measured on a plate reader (Envision®, Perkin Elmer). Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

Activity of Compounds in Presence of Human Serum

To evaluate the impact of plasma protein binding of compounds on their biological activity, the PathHunter® U2OS CFTR-ΔF508 was run in the presence of 40% human serum (Sigma; H4522). For this purpose PathHunter® U2OS CFTR-ΔF508 cells (DiscoveRx; custom made) were cultured in AssayComplete™ U2OS Cell Culture medium (DiscoveRx; 92-0018GK3) as per manufacturer's instructions. For compound testing, cells were seeded in white 384-well plates (Greiner; 781080) at five thousand cells/well in 25 μL AssayComplete™ Cell Plating 5 Reagent (DiscoveRx; 93-0563R5A) and incubated overnight at 37° C., 5% CO₂. On day two, the medium was replaced with 25 μL of primary human airway epithelial cell air-liquid interface medium or ALI medium, a 50:50 mixture of DMEM (Dulbecco's Modified Eagle Medium, Invitrogen; 41966-029) and LHC Basal Medium (Invitrogen; 12677-019) with additives as described in Table XVII) and containing 40% human serum. One hour later, 5 μL of test compounds diluted in ALI medium were added to the cells with a final DMSO concentration of 0.1%. All cell plates contained 3 μM corrector (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid) or DMSO as positive and negative controls respectively. Cells were incubated with compounds for twenty to twenty-four hours at 37° C., 5% CO₂. On day three, plates were placed at room temperature for thirty minutes and then washed twice with PBS (phosphate buffered saline) followed by the addition of 15 μL of substrate (PathHunter® Flash Detection Kit, DiscoveRx; 93-0247) per well. After one hour of incubation at room temperature in the dark, the luminescence signal was measured on a plate reader (Envision®, Perkin Elmer). Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

TABLE XVII Final concentration Ingredient in medium Provider Cat# BSA 0.5 mg/mL Sigma A7638 bovine pituitary extract 10 μg/mL Sigma P1476 Insulin 0.87 μM Sigma I9278 transferrin 0.125 μM Sigma T0665 hydrocortisone 0.21 μM Sigma H0396 triiodothyronine 0.01 μM Sigma T6397 Epinephrine 0.01 μM Sigma E4250 epidermal growth factor 5 ng/mL Invitrogen PHG0313 All-trans retinoic acid 5 × 10⁻⁸ M Sigma R-2625 o-Phosphoethanolamine 0.5 μM Sigma P-0503 ethanolamine 0.5 μM Sigma E0135 zinc sulfate (ZnSO4•7H2O) 3.0 μM Sigma Z0251 pen/strep 100 U/mL Sigma 15140-122 ferrous sulfate 1.5 × 10⁻⁶ M Sigma F8048 magnesium chloride 6 × 10−4 Sigma M2670 hexahydrate calcium chloride dihydrate 1.1 × 10⁻⁴ M Fluka 21097 Trace elements: — sodium selenite 30 nM Sigma S5261 manganese chloride 1 nM Sigma M8054 tetrahydrate sodium metasilicate 500 nM Sigma S5904 nonahydrate ammonium molybdate 1 nM Sigma M1019 tetrahydrate ammonium metavanadate 5 nM Sigma 398128 nickel(II)sulfate 1 nM Fluka 72280 hexahydrate (Sigma) (N4882) tin(II) chloride dihydrate 0.5 nM Sigma 243523 Measuring CFTR Cell Surface Levels Using HRP-Tagged ΔF508-CFTR Expressing CFBE Cells

The HRP-tagged ΔF508-CFTR cell assay measures the expression of CFTR-ΔF508 at the plasma membrane. CFTR-ΔF508 has a folding defect leading to absence of protein at the plasma membrane. This assay is used to evaluate the capacity of compounds to increase the expression of CFTR-ΔF508 at the plasma membrane. The CFTR-ΔF508 is tagged with HRP (horse radish peroxidase enzyme) within the ECL4 (Extracellular loop 4) of CFTR (Phuan, P.-W. et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol. Pharmacol. 86, 42-51 (2014)). When HRP-tagged ΔF508-CFTR is present at the plasma membrane, the HRP enzyme activity can be measured. The amount of CFTR-ΔF508 that can be rescued to the plasma membrane is correlated with the amount of functional enzyme that can be measured.

There are several ways to measure the capacity of compounds to rescue CFTR-ΔF508 to the plasma membrane; either compounds are evaluated on their own and the impact on plasma membrane levels is measured or compounds are evaluated in combination with a co-corrector, i.e. a compound that rescues CFTR-ΔF508 to the plasma membrane but rescue can be enhanced by addition of compounds due to a complementary mode of action.

Activity of Compounds in Combination with Co-Corrector:

For this purpose doxycycline-inducible ΔF508-CFTR-HRP expressing CFBE4lo− cells (obtained from Gergely Lukacs, McGill University) were maintained in MEM (Minimum Essential Medium, Gibco; 31095) supplemented with 10% fetal bovine serum (Hyclone; SV30160.03) under puromycin (3 μg/mL) and G418 selection (0.2 mg/mL). For compound testing, cells were seeded at 4000 cells/well in white 384-well plates (Greiner; 781080) in 50 μL of medium containing 0.5 μg/mL doxycycline and incubated for 68 hours at 37° C., 5% CO₂. On day four, 10 μL of test compounds diluted in PBS (phosphate buffered saline) were added to the plates at a final DMSO concentration of 0.1%. In order to measure compound synergy with a co-corrector, 3 μM co-corrector (3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid) was added along with test compounds. All compound plates contained negative controls (DMSO) and positive controls (3 μM co-corrector). Cell plates were incubated at 33° C., 5% CO₂ for 20 hours. On day five, the cells were washed five times with phosphate-buffered saline, and HRP activity was assayed by the addition of 50 μL/well of HRP substrate (SuperSignal™ West Pico Chemiluminescent Substrate, Thermo Scientific; 34080). After incubation for 15 minutes in the dark, the chemiluminescence was measured using a plate reader (EnVision®, Perkin Elmer). Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

TABLE XVIII Illustrative EC₅₀ measured by CFTR cell surface levels using HRP-tagged ΔF508-CFTR expressing CFBE cells in the presence of a co-corrector. Compound # % Activation EC₅₀ (nM) 1 297.2 1186 2 431.5 1122 4 405.8 297.9 5 362.75 371.75 6 387.1 510.7 7 420.63 554.03 8 441.85 853.8 9 335 505.05 10 606.5 442.65 11 381.33 455.35 12 364.15 713.8 13 341.75 1471 14 335.6 1368 15 346.15 852.15 16 649.9 458.65 17 320 1120 18 217.8 1110 19 304.05 1632.5 20 417.5 545.9 21 440.1 525.3 22 371.55 502.6 23 468.85 573.35 24 380.5 743.95 25 437.17 640.17 26 449.7 1548 27 365.2 714 28 354.45 942.15 29 591.4 823.7 30 580.97 215.37 31 423.27 203.8 32 526 234 33 315.6 470.95 34 462.55 355.9 35 509.7 348.4 36 572.93 245.77 37 457.25 1163.1 38 447.7 581.23 39 378.63 507.77 40 373.43 422.67 41 253.3 1141 42 226.3 378.5 43 627 289.4 44 412.63 276.27 45 438.4 202.94 46 643.27 445.83 47 408.77 1604.3 48 417.8 1152.5 49 338 1996.7 50 300 1075.5 51 420.67 311.5 52 257.85 992.4 53 572.78 647.2 54 593.12 463.62 55 341.65 1047.4 56 336.75 838.1 57 440 657.2 58 352.5 421.8 59 534.8 482.5 60 323.63 351.47 61 415.3 506.2 62 631.2 531.8 63 368.48 285.56 64 362.45 443.65 65 332.05 463.55 66 332.85 6670 67 371.62 241.18 68 456.6 847.1 69 362.03 403.63 70 342.85 409.6 71 447.8 263.55 72 400.9 5611 73 423.35 490.05 74 424.82 357.1 75 387.16 290.54 76 581.37 632.67 77 449.85 831.2 78 520.7 660.5 79 501.6 555 80 457.5 389.5 81 646.44 253.16 82 535.93 383.03 83 567.7 424.5 84 468.2 408.1 85 570.16 232.1 86 489.56 255.04 87 623.62 456.46 88 546.2 412.73 89 609.48 396.26 90 384.95 388.85 91 619.45 890.95 92 367.67 278.4 93 456.5 270.4 94 421.53 341.9 95 611.7 649.15 96 707.5 473.05 97 692.82 277.25 98 360.15 393.3 99 601.15 336.8 100 340.6 3221 101 455.4 409.2 102 458.75 536.55 103 501.03 409.03 104 411.33 344.37 105 457.85 698.9 106 348.1 393.95 107 219.4 3340 108 428.3 509.45 109 571.3 634.1 110 665.7 336.37 111 596.8 377.83 112 472.8 884.2 113 455.63 235.17 114 277.45 951.6 115 389.6 664.65 116 438.37 630.5 117 417.92 200 118 469 280 119 389.93 331.37 120 351.03 347.9 121 368.6 281.8 122 405.9 280.57 123 365.8 238.9 124 447.23 312.03 125 520.33 463.17 126 487.53 322.17 127 449.1 251.85 128 529.57 251.93 129 307.3 790.25 130 496.9 540.3 131 465.1 580.65 132 417.2 881.65 133 417.7 335.87 134 435.8 236.8 135 512.9 373.43 136 428.1 72.26 137 339.7 638.35 138 433.83 235.77 139 335.5 764.83 140 377.9 380.65 141 414.63 221.37 142 376.93 78.407 143 217.8 833.55 144 674.7 242.99 145 271.43 636.17 146 357.55 96.872 147 363.93 99.92 148 448.03 169.85 149 299.95 259.05 150 380.65 318.29 151 387.15 108.87 152 409.9 107.85 153 290.05 130.35 154 447.85 203.45 155 555.45 229.66 156 636.47 360.2 157 542.17 358.74 158 512.45 266.75 159 270.3 483.27 160 490.4 201.8 161 574.1 354.83 162 331.53 304.16 163 342.3 111.91 164 492.45 387.6 165 534.2 884.65 166 408.53 309.97 167 429.4 81.765 168 581.55 409.8 169 519.3 284.36 170 425.6 721.7 171 289.23 312.2 172 462.4 207.07 173 183.2 432.9 174 545 468.45 175 461.1 200.23 176 390.43 208.64 177 263.9 385.45 178 381.73 231.52 179 248.85 405.85 180 290.53 300.17 181 357.93 435.4 182 397.6 258.1 183 498.57 213.78 184 282.7 574.4 185 546.7 145.09 186 381.87 530.53 187 308.87 69.253 188 405.37 159.6 189 409.6 236.27 190 502.4 1240.4 191 317.93 161.26 192 254.6 865.7 193 341.37 589.17 194 427.45 370.65 195 387.47 191.69 196 387.1 231.43 197 390.8 193.94 198 321.57 465.7 199 304.63 316.4 200 318.27 94.83 201 379.9 292.47 202 299.4 254.83 203 224.63 328.1 204 288.6 490.35 205 416.4 856 206 387.03 890.4 207 284.87 174.71 208 419.15 363.65 209 393.6 230.87 210 390.57 173.74 211 288.3 292.9 212 290.43 324.03 213 469.6 336.5 214 250.55 383.85 215 569.35 47.87 216 456.1 299.5 217 418.27 257.13 218 476.9 238.67 219 524.4 230.26 220 389.9 207.87 221 492.2 77.24 222 247.3 1788.2 223 438.2 371 224 453.1 482 225 427.95 578.55 226 392.95 386.1 227 378.2 307.3 228 395.1 334.9 229 418.65 366.1 230 440.1 179.98 231 329.9 518.2 232 199.75 1726.5 233 206.57 1925.3 234 128.3 >10000 235 257.55 2485 236 497.5 93.19 237 264.05 222.18 238 347.55 218.6 239 431.55 1235.2 240 312.8 138.7 241 488.15 82.165 242 459.15 202.77 243 204.1 3330 244 290.6 413.5 245 460 693.6 246 331.65 77.25 247 281.7 220.67 248 450.6 221.44 249 468.15 231.26 250 440.4 372 251 488.7 367 252 310.75 1691 253 454.4 250.85 254 312.1 370 255 365.8 3330 256 508.63 147.3 257 451.25 74.3 258 127.1 >10000 260 664.07 129.88 261 129.3 >10000 262 420.17 523.02 263 475.45 403.78 264 478.6 3330 265 427.8 2138 266 328.87 230.63 267 433 57.095 268 122.05 >10000 269 275.45 97.25 270 327.9 730.83 271 260.47 1016.5 272 451.2 43.33 273 344.05 111.1 274 300 398.1 275 269.85 138 276 417.25 42.905 277 355.4 127.1 278 388.5 88.315 279 530.6 227.4 280 323.37 1010.2 281 398.47 242.33 282 379.95 89.015 283 326.85 265.5 284 348.7 219.8 285 327.57 246 286 500.55 158.6 287 450.9 128.29 288 566.4 74.34 289 366.4 3330 290 382.2 535.7 291 420.07 590.9 292 422.55 564.7 293 317.1 479.7 294 548.45 22.065 295 298.07 697.2 296 329.13 167.8 297 423.43 77.2 298 481.2 81.025 299 267.2 2514.5 300 266.55 109.26 301 376.6 1136.4 302 401.45 1799.6 303 339.95 834.25 304 507 56.145 305 267 2443 306 321.1 82.395 307 299.25 1278.8 308 328.85 2492.5 309 303.6 224.05 310 251.5 923.65 311 241.35 1060.6 312 291.5 1882.5 313 319.75 1749 314 375.8 693.1 315 315.5 101.55 316 555.55 24.4 317 450.35 48.825 318 359.5 184.25 319 232 979.57 320 590.6 82.663 321 314.37 496.53 322 342.75 61.415 323 292.85 372.05 324 259.7 1635.4 325 309.8 152.6 326 325.3 729.7 327 433.9 99.9 328 554.2 185.7 329 318.4 777.1 330 285.4 124.3 331 546.05 38.185 332 448.25 624.3 336 232.42 282.15 337 532.3 30.55 338 344.25 945.55 339 295.5 402.1 340 319.2 785.8 341 165.4 3330 342 336.5 207.1 343 356.9 566.3 344 374.5 1061 345 301.1 222.8 346 375.1 253.45 347 301.15 54.26 348 468.65 723.5 349 327.9 424.45 350 274.6 286.95 351 232.5 81.07 352 158.4 2778 353 193.45 346.44 354 351 232.2 355 278.4 377.1 356 372 48.27 357 229.8 129.5 358 242.33 89.854 359 236.25 298.9 360 182.8 100.72 361 204.1 181.2 362 195.75 413.8 363 415.8 116.2 364 575 553 365 469.95 271.05 366 443.7 82.67 367 526.17 81.56 368 350.23 361 369 444 105.88 370 343.2 691.05 371 271.9 1926.5 372 615.7 2560 373 580.5 85.76 374 426.05 195.67 375 546.75 241.45 376 496.8 51.61 377 485.55 102.74 378 318.6 657.55 379 440.55 61.09 380 309.17 127.16 381 432.09 155.99 382 500.01 158.29 383 412.20 94.26 384 391.35 1443 385 393.53 64 386 385.05 684.75 387 168.9 160.7 388 364.5 195.93 389 305.1 297.3 390 350.17 139.8 391 441.15 85.535 392 421.4 138.66 393 533.65 20.77 394 366.87 47.877 395 327.95 126.69 396 385.8 55.037 397 381.8 48.963 398 324.03 73.623 399 388.77 44.157 400 365.43 156.83 401 595.1 61.98 402 471.42 116.35 403 507.35 25.628 404 370 125.8 405 326.9 101.86 406 311.35 181.65 407 494.15 124.02 408 466.58 199.45 409 481.1 108.14 410 529.58 82.442 411 505 478.2 412 436.4 200.6 413 455.9 90.59 414 508.3 158.6 415 598 69.31 416 458.65 64.97 417 539.75 91.905 418 512.9 220.8 419 505.65 277.1 420 486.65 209.2 421 512.9 124.75 422 434.33 204.27 423 376.85 108.84 424 453.88 92.203 425 462.85 166.45 426 385.3 82.03 427 419.5 162.5 428 434.7 77.27 429 422.8 205.15 430 383.7 89.87 431 568.8 47.003 432 514.83 65.943 433 563.8 49.01 434 470.37 59.51 435 474.8 82.825 436 568.6 71.07 437 563.64 155.81 438 541.5 380.5 439 374.6 381 440 543.55 55.44 441 393.27 196.47 442 342 1110 443 332.5 183.9 444 361.3 235.1 445 671.25 59.11 446 669.9 77.435 447 543.1 64.69 448 431.1 180.75 AC07 466.9 76.57 450 443.25 246.25 451 391 2102 452 478.25 941.8 453 385.1 319 454 430.2 639.4 456 457.7 93.273 457 508 139.41 458 282.8 920.4 459 388.87 96.053 460 306.75 505.05 461 364.1 177.2 462 495.1 106.85 463 490.6 194.5 464 423.3 170.38 465 293.15 360.35 466 522.47 64.097 467 229.15 270.35 468 443.05 524.2 469 469.4 125.4 470 485.5 114.8 471 446.07 122.4 472 399.79 249.47 473 370.7 43.935 474 390.2 524.45 475 289.95 112.32 476 355.65 151 477 536.7 34.725 478 476.7 126.64 479 524.1 108.95 480 545.77 87.11 481 285.65 154.25 482 436.4 61.63 483 438.2 56.15 484 485.6 142.1 485 399.1 90.217 486 569 180.5 487 404.63 68.97 488 488.15 682.55 489 280 241.2 490 303.9 692.6 491 490.9 487.8 492 483.4 43.91 493 480.78 94.585 494 551.8 37.085 495 469.08 66.152 496 374.65 242.9 497 378.25 287.65 498 456.3 95.12 499 439.6 71.165 500 330.05 84.215 501 403.55 124.3 502 383.8 176.9 503 433.2 404.7 504 404.8 210.05 505 389 54.11 506 308.95 941.25 507 580.4 95.4 508 448.8 90.31 509 527.9 118.4 510 428.8 170.9 511 432.95 78.94 512 415.25 65.265 513 476.3 66.74 514 540.3 97.07 515 479.2 52.88 516 545.3 56.56 517 520.08 75.79 518 189.55 3125.5 519 252.3 1023.3 520 207.1 923.7 521 217.3 711.5 522 525.66 79.788 523 451.33 100.04 524 398.75 307.55 525 460.3 73.968 526 472.58 106.56 527 500 53.775 528 357.9 834.45 529 444.13 22.557 530 464.6 22.955 531 349.65 63.465 532 342.83 472.67 533 322.45 220.95 534 289.35 344.1 535 670.35 1251.9 536 341.15 280.1 537 417.1 50.845 538 427.95 357.55 539 429.3 38.63 540 443.3 102.59 541 457.2 114.95 542 320.3 216.1 543 336.1 139.25 544 344.9 1996.4 545 318.7 1905.4 546 335.3 181.9 547 372.95 348.5 548 556.9 553.5 549 476.35 180.4 550 605.45 173.15 551 403.1 382.3 552 364.2 130.43 553 494.3 233.25 554 481 56.86 555 432.55 104.12 556 595.8 136.2 557 474.4 116.35 558 571.35 106.46 559 291.03 154.3 560 544.45 66.1 561 509.4 43.023 562 589.55 77.645 563 542.9 111.13 564 587.4 40.75 565 637.53 69.86 566 708.8 400.42 567 539.8 56.343 568 461 46.295 569 436.13 88.907 570 412.9 208.3 571 487.9 77.77 572 412.9 225.1 573 467.57 58.533 574 283.3 541.9 575 361.3 87.8 576 443.5 54.673 577 379.3 104.7 578 462.3 107.6 579 420.5 318.8 580 387.45 52.425 581 191.3 760.8 582 245.15 271.05 583 480.15 47.595 584 337.55 272.35 585 509.7 247.75 586 618.65 37.12 587 504.6 398.2 588 571.2 29 589 422.95 148 590 487.9 31.395 591 384 1592 592 518.55 56.8 593 366.7 193.7 594 308.05 181.45 595 231.9 1430 596 304.8 1908 597 433.93 110.63 598 153.9 10000 599 285.2 269.7 600 326.1 1618 601 273.9 625 602 359.1 581.4 603 344.65 156.3 604 268.3 300 605 395.8 723 606 513.7 468.6 607 484.3 667.1 608 365.7 54.765 609 414.2 108.91 610 375.5 118.72 611 236.7 2620 612 320.8 3330 613 152.9 10000 614 381.35 170.65 615 450.85 130 616 341.15 294.35 617 324.25 978.45 618 295.9 702.35 619 277.25 374.7 621 348.55 76.95 622 251.25 308.6 623 424.77 55.623 624 274.15 549.2 625 353.87 125.87 626 418.4 111.06 627 348.57 24.793 628 477.32 131.66 629 546.75 266.92 630 593.42 374.58 631 352.63 2986.2 632 466.83 153.9 633 400.44 206.9 634 439.44 78.79 635 449.25 73.852 636 388.85 434.18 637 413.4 971.25 638 606.08 95.005 639 464.55 74.532 640 416.48 107.31 641 443.12 46.265 642 430.9 97.285 643 445.25 496.82 644 529.95 160.16 645 384.37 244.21 646 447.9 259.12 647 337.07 112.2 648 288.85 110.15 649 231.7 152.35 650 592.45 96.375 651 532.4 127.6 652 499.65 24.855 654 347.6 114.46 656 289.68 71.475 657 270.75 196.82 658 270.6 148.53 659 290.95 130.45 660 172.1 235.5 661 227.45 135.34 662 346.65 104.39 663 206.5 102.86 664 230.48 172.5 665 271.8 100.86 666 266.6 121.58 667 225.5 85.485 668 307.4 257.2 669 394 244.4 670 477.6 191.3 671 346.1 107 672 422.4 127.3 Activity of Compounds for their Intrinsic Corrector Capacity:

For this purpose doxycycline-inducible ΔF508-CFTR-HRP expressing CFBE4lo− cells (obtained from Gergely Lukacs, McGill University) were maintained in MEM (Gibco; 31095) supplemented with 10% fetal bovine serum (Hyclone; SV30160.03) under puromycin (3 μg/mL) and G418 selection (0.2 mg/mL). For compound testing, cells were seeded at 4000 cells/well in white 384-well plates (Greiner; 781080) in 50 μL medium containing 0.5 μg/mL doxycycline and incubated for 68 hours at 37° C., 5% CO₂. On day four, μL test compounds diluted in PBS were added to the plates at a final DMSO concentration of 0.1%. All compound plates contained negative controls (DMSO) and positive controls (3 M corrector, 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid). Cell plates were incubated at 33° C., 5% CO₂ for 20 hours. On day five, the cells were washed five times with phosphate-buffered saline, and HRP activity was assayed by the addition of 50 μL/well of HRP substrate (SuperSignal™ West Pico Chemiluminescent Substrate, Thermo Scientific; 34080). After incubation for 15 minutes in the dark, chemiluminescence was measured using a plate reader (EnVision®, Perkin Elmer). Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

TABLE XIX Illustrative EC₅₀ measured by CFTR cell surface levels using HRP-tagged ΔF508-CFTR expressing CFBE cells. Compound # % Activation EC₅₀ (nM)  1 138.85 1628.9  2 226.75 1867  3 53.08 3340  4 246.7 838.35  5 184.6 476.6  6 232.1 808.3  7 245 636  8 270.6 899.55  9 143.05 785.9  10 418.25 572.5  11 164.7 556.52  12 161.15 1072.5  13 153.85 2361  14 148.9 1429.5  15 151.65 1192.5  16 469.75 543.05  17 140.75 1225.5  18 64.675 2267  19 140.85 2652.5  20 210.3 669.15  21 264.25 685.3  22 161.5 731.65  23 287.3 883.5  24 193.75 887.75  25 247.23 996.8  26 202.25 1847.5  27 145.5 1219  28 149.7 1218  29 328.4 645.05  30 369.93 436.27  31 203.4 318.2  32 277.65 372.25  33 109 2578.5  34 292.95 610.75  35 265.23 542.1  36 384.57 415.9  37 222.85 1662  38 182 849.97  39 143.4 838.2  40 147.1 450.97  41 52.497 816.53  42 45.225 2123  43 379.67 299.47  44 203.87 404.4  45 210.97 326.73  46 457.3 706.07  47 169.73 1862  48 160.9 1195.9  49 115.3 2566.7  50 109.8 1683.5  51 172.4 456.57  52 75.755 1153  53 376.8 671.1  54 386.92 779.92  55 126.75 1220.2  56 122.1 1177  57 219.65 1024.5  58 196.2 756.33  59 317.3 777.47  60 160.43 394.4  61 184.35 1003  62 350.85 595.75  63 179.68 548.28  64 152.75 935.35  65 162.33 1532.5  66 142.65 1861.4  67 181.96 361.86  68 253.3 1079  69 182.08 631.68  70 167.8 621.35  71 260.66 350  72 232.5 2226.5  73 254.1 657.45  74 253.38 549.12  75 225.82 489.92  76 430.87 528.07  77 296.45 639  78 333.2 1878.3  79 280.9 1227  80 258.38 436.18  81 495.8 384.52  82 366.27 472.07  83 391.5 547.1  84 311.7 659.8  85 426.04 420.84  86 329.92 637.3  87 422.84 408.78  88 389.73 474.4  89 422.78 645.7  90 163.75 485.6  91 388.15 381.7  92 175.77 552.8  93 224.23 501.2  94 193.5 614.33  95 355.6 837.85  96 406.6 366.9  97 444.85 399.2  98 154 555.55  99 414.8 409.65 100 113 2475 101 254.85 838.65 102 233.9 897.2 103 263.8 535.87 104 239.6 496.9 105 258.1 908.4 106 162.75 525.9 107 64.54 3340 108 218.05 560.55 109 381.05 612.85 110 451.8 358.13 111 411.63 444.3 112 254.85 699.5 113 262.33 464.4 114 130.85 1136 115 216.05 1050 116 295.57 957.23 117 281.88 332.78 118 289.93 397.63 119 188.53 519.5 120 169.2 553.7 121 159.13 652.53 122 184.53 469.67 123 153.8 428.27 124 288.1 544.77 125 369.87 988.13 126 309.17 597.03 127 301.45 517.9 128 357.47 515.83 129 187.5 1326.5 130 318.25 541.35 131 314.35 429.85 132 244 1270.5 133 222.33 412.87 134 229.87 465.2 135 299.63 695.8 136 262.38 154.65 137 131.8 1173.2 138 252.9 333.73 139 163.83 806.07 140 210.3 733.5 141 233.07 287.2 142 203.17 254.9 143 107.15 1110 144 531.6 416.52 145 112.03 1039.4 146 201.23 356.08 147 176.47 358.63 148 273.33 547.73 149 122.3 385.75 150 220.98 576.45 151 228.95 346.65 152 242.35 357.15 153 146.7 354.95 154 275.65 532.9 155 439.5 454.35 156 411 438.63 157 327.8 460.03 158 359.1 622 159 103.02 661.2 160 285.57 309.47 161 406.4 729.53 162 169 445.43 163 175.4 441.8 164 295.25 594.45 165 373.95 1781 166 235.2 439.43 167 260.6 313.35 168 399.2 338.2 169 344.25 426.22 170 213.5 974.85 171 143.4 787.07 172 280.03 329.77 173 51.395 412.4 174 347.9 753.6 175 270.5 337.5 176 190.4 337.3 177 99.405 829.6 178 202.8 346.9 179 89.165 878.85 180 129.5 570.07 181 137.73 397.87 182 207.57 501.43 183 302 389.5 184 95.405 719.25 185 331.6 241.45 186 209.57 616.13 187 160 223.43 188 214.93 274.5 189 236.2 420.6 190 284.8 966.55 191 161.23 305.6 192 81.49 1135 193 175.23 1067.5 194 213.75 744.5 195 225.2 369.7 196 188.47 339.43 197 220.2 397 198 135.73 632.97 199 142.6 481.47 200 163.43 315.7 201 200.8 402.17 202 147.23 595.43 203 82.59 1015.5 204 117.6 977.95 205 208.5 955.55 206 169.03 1396.1 207 141.93 339.73 208 190.55 402.45 209 247.6 380.97 210 205.57 285.6 211 114.4 608.15 212 114.63 620.9 213 267.5 546.25 214 103.6 1010.8 215 374.57 274.4 216 275.67 765.67 217 246.77 458.47 218 268.37 390.4 219 381.1 764.1 220 202.5 347.9 221 322.15 420.05 222 65.685 1423.2 223 258.95 469.5 224 228.8 544.2 225 215.35 456.25 226 206.7 445.05 227 216.8 448.6 228 217.9 489.9 229 174.2 414.1 230 243.75 406.1 231 162.9 939.25 232 71.64 1678 233 58.34 2438 234 17.89 >10000 235 102.76 3271 236 309.83 316.47 237 120 453.2 238 159.83 600.57 239 184.6 999.25 240 176.67 376.63 241 261.93 366.43 242 242.1 282.83 243 78.11 3340 244 182.7 381.2 245 228 495.1 246 112.1 371 247 126.8 460 248 234.6 371 249 187.6 371 250 232.7 514 251 273.3 634 252 115.2 396.5 253 174.6 675.6 254 117.5 399.8 255 122.3 1881 256 331.85 220.65 257 272.4 370 258 8.829 >10000 260 473.35 1868.6 261 26.85 >10000 262 232.07 597.87 263 260.1 444.83 264 242.5 969.2 265 240.8 3330 266 161.5 332 267 274.8 171.6 268 5.213 >10000 269 120.6 246.4 270 161.5 1493 271 63.905 1952 272 268.2 96.55 273 182.4 562.4 274 159.05 842.5 275 138.8 467.7 276 356.7 779.3 277 155.4 251.1 278 233.7 119.5 279 308.4 533.7 280 121.9 1007 281 230.15 456.5 282 127.8 129.3 283 141.2 477 284 154.4 275.7 285 125.5 293.8 286 264 326.8 287 204.9 183.2 290 200.4 617.4 291 219.5 3330 292 217.9 1057 293 113.3 622.2 294 319.6 62.24 295 129.6 1052 296 154.7 396.5 297 193.9 99.18 298 312.9 282.1 299 81.41 3330 300 119.9 309.4 303 149.9 3330 304 308.2 202.9 306 146.7 157.7 307 172.7 3330 309 149 444.3 310 66.84 691.9 315 154.87 218.03 316 380.5 182.8 317 269.6 93.52 318 183.45 411.25 319 34.315 297.7 320 376.35 309.35 322 158.25 128.05 323 144.6 1366 325 151.4 334.8 326 167.1 2384.5 327 239.4 145.2 328 380.5 2186 329 163.85 158.2 330 133.1 213.45 331 347.15 136.25 333 180 82.765 334 121.75 167.4 335 171.65 149.85 336 107.2 419.9 337 404.9 133.58 339 142.05 1401 340 138.95 1392 346 195.8 308.2 347 131.4 263 348 293.6 5969.5 349 161.7 512.3 350 104.21 357.15 351 50.87 73.45 352 27.44 5000 353 56.22 87.86 354 113.7 122.9 355 102.4 160.5 356 188.25 105.3 357 72.83 115.2 365 313 1670 366 264 297.9 367 364.5 311.4 368 185 1359 369 292.7 100.6 370 172.2 1490 371 121.3 2744 373 368.2 72.97 374 240.7 254.3 375 321.6 570.9 376 355.7 117.4 377 261.3 129 378 160 1327 379 268.45 141.1 380 131.7 279.3 381 247.15 424.06 382 305.9 260.6 383 202.9 149.8 384 228 2862 385 227.5 120.95 386 237.85 2116 387 60.58 462 388 192.8 217.9 389 165 556.1 390 188.2 176.9 391 247.7 77.1 392 240.05 150.45 393 423.6 51.37 394 194.35 99.53 395 209.2 473.8 396 222.9 121.35 397 234.5 154.55 398 173.7 181.5 399 237.5 72.075 400 180.65 163.05 401 400.8 104.1 402 303.5 312.28 403 389.2 30.18 404 181.2 185.6 405 160.8 190.7 406 125.95 240.8 407 331.45 496.9 408 272.74 689.62 409 245.4 154.9 410 337.42 212.87 415 365.4 165.4 416 288 141.9 417 307.45 189.7 418 321.3 320.9 419 293 448.1 420 283.1 472 421 308 250.1 422 222.8 318.5 423 175.55 140.1 424 249.25 244.25 425 280.2 277.1 426 143.7 301.6 429 252.1 378 430 170.05 231.3 431 344.95 109.3 432 243.6 118.5 433 361.5 96.46 434 245.2 57.74 435 269.9 135.9 436 393.3 344 437 353.8 257 438 337 391.8 439 166.8 550 440 334.8 129 441 196.1 350 442 146.8 307.3 444 162.5 344.7 445 393.1 110.7 447 330.9 243.5 448 258.2 476.9 AC07 268.5 139.5 450 253.5 617.5 451 184.1 1698 452 239.8 408.4 453 149.3 403 454 168.1 1670 456 268.4 157.7 457 272.2 128.5 458 124.4 794.4 459 225.65 148.95 460 125.8 595.6 461 212.3 209.4 462 317.4 775.5 463 263.9 419.1 464 277.5 306.3 465 131.6 312.8 466 318.7 175.8 469 253.8 203.9 470 275.4 231.1 471 240.2 230.2 472 210.57 680.74 473 166.3 70.76 474 194.5 580.5 475 140.1 178.8 476 134.2 215 477 341.4 117 478 295.4 2639 479 305.7 196.6 480 322.45 135.7 481 114.2 278.1 482 214.1 88.17 483 212.7 84.88 484 216.9 124.3 485 218.55 155.15 486 332.5 467.3 487 203.53 174.87 488 246.55 655.45 489 99.6 141.5 490 139.7 1546 491 204.5 248.3 492 311 79.93 493 275.2 174.6 494 315.4 109.8 495 242.05 217.1 496 199.9 281.8 497 195.7 410.4 498 288.1 144.3 499 287.5 186.4 500 137.5 173.5 501 188.7 210.7 502 214.2 345.4 503 203.4 418.8 504 206.4 300.8 505 187.5 92.57 506 144.1 3330 507 309.4 136.8 508 217.5 182.2 509 333.2 326.6 510 234.9 297.6 511 248.55 88.31 512 222.27 120.97 513 278.5 100.5 514 301.4 149.8 515 287.1 179.2 516 322.7 120.2 517 320.5 183.95 518 35.86 10000 519 114.4 3330 520 60 1056 521 31.93 10000 522 317.9 114.21 523 236.53 123.6 524 209.35 525 525 274.75 137.75 526 269.23 152.72 527 295.95 79.095 528 185.8 859.1 529 278.55 60.605 530 323.1 54.43 531 182.8 234.05 532 151.95 521.25 533 156.3 221.85 534 105 240.7 535 385.8 389 536 125.1 224.8 537 214.5 112.2 538 228.9 2073 539 234.5 71.71 540 248.8 123.3 541 231.7 444.2 542 153.2 266.8 543 115.7 238.2 544 135.3 3330 545 112.7 3330 546 138.05 325.2 548 307.2 654.3 549 276.9 232.9 550 347 361 551 197.8 763.15 553 293 1732 554 269.45 108.15 555 235.5 358.77 556 386 64.67 557 248.5 252 558 399.1 531.6 560 260.4 96.34 561 311.6 107.08 562 341.3 70.505 563 298.9 198.3 564 361.35 117.81 565 373.15 181.8 566 365.1 112.3 567 312.2 139.4 568 240.65 77.465 569 220.77 112.18 570 235.8 496.2 571 268.15 128.75 572 237.55 295.1 573 270.53 104.32 574 129.9 2756 575 202.65 147.4 576 257.15 139.41 577 187.15 256.6 578 309.25 152.15 579 205 375.87 580 201.52 130.88 581 33.38 370 582 75.38 370 583 269.7 178.2 584 164.3 176.7 585 316.6 1242 586 331.67 52.367 587 277.1 234.6 588 366.8 125.95 589 193.6 199.6 590 290.3 86.7 591 189.1 795.1 592 300.8 182.6 593 157.8 189.7 594 135.7 518.85 595 58.87 1519 596 104.3 1381 597 214.3 130.2 598 28.03 10000 599 88.94 331.3 600 126.5 1213 601 112 2177 602 133.6 1177 603 136.2 282.7 604 86.51 490.4 605 207.5 317.5 606 283.8 973 607 272.6 342 608 194.67 103.52 609 202.53 249.1 610 182.13 185.8 611 77.39 3330 612 108.7 875.8 613 30.09 10000 614 172 211.3 615 255.3 482.5 616 144.05 348.1 617 137.1 871.25 618 112.8 420.6 619 102.8 680.25 621 160.45 172.9 622 89.445 568.4 623 238.53 112.73 624 100.59 1203.1 625 182.2 222.97 626 206.6 150.83 627 162.47 82.293 628 283.25 425.38 629 337.34 517.05 630 339.64 738.66 631 122.53 3336.7 632 252.75 304.4 633 180.46 345.2 634 227.46 199.84 635 216.38 154.84 636 182.7 572.78 637 191.88 2502.2 638 398.98 241.05 639 238.35 131.92 640 203.62 174.7 641 205.35 74.852 642 222 234.88 643 181.65 505.98 644 266.9 253.35 645 194.33 331.1 646 236.13 400.12 647 164.47 215.73 648 109.65 315.7 649 69.12 370 650 385.4 115.06 651 317.85 205.75 652 289.03 84.117 654 73.925 5075.4 656 102.63 99.61 657 98 281.48 658 99.025 252.5 659 96.44 141.95 660 34.92 932 661 67.125 154.65 662 134.35 123.75 663 57.9 234.35 664 70.082 277.62 665 101.9 259.35 666 99.775 255.6 667 75.435 208.1 668 89.495 384.5 669 334.9 211.35 670 399.2 276.75 671 252.95 273.5 672 362.9 330.9 673 423.5 288.5 675 398.1 315.6 674 389.5 155.9 676 251.1 251.3 677 458.5 170.7 678 345.1 220.9 679 476.9 131.7 680 351.2 339.1 681 366.2 172 682 260.8 297.2 683 354.9 252.9 684 356.9 114.6 685 144.3 769.9 YFP-Halide Influx Assay for the CFTR-ΔF508 Mutation

The YFP halide influx assay measures the functionality of the Cystic Fibrosis Transmembrane Conductance regulator (CFTR) channels in the cystic fibrosis bronchial epithelium cell line CFBE4lo−. The fluorescence of the yellow fluorescent protein (YFP) variant YFP H148Q, I152 L or variant YFP H148Q, I152 L & F47 L is substantially quenched by iodine, a halide that is efficiently transported by CFTR. The assay is thus used to evaluate the effect of corrector compounds on CFTR channel function by measuring the extent of YFP signal quenching. (Galietta, L. J. V., Haggie, P. M., Verkman, A. S., 2001. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett. 499, 220-224. doi: 10.1016/S0014-5793(01)02561-3; Nagai, T., Ibata, K., Park, E. S., Kubota, M., Mikoshiba, K., Miyawaki, A., 2002. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20, 87-90. doi: 10.1038/nbt0102-87). For this purpose, CFBE4lo− cells were seeded in 96-well plates (6000 CFBE cells/well). One day after seeding, the CFBE cells were transduced with adenoviral vectors that direct the expression of the CFTR ΔF508 mutant and of the YFP reporter. Cells were treated with test compounds for 24 hours at 37° C. to allow trafficking of corrected CFTR to the membrane. The next day the CFTR channels were activated by treatment with the cAMP inducer forskolin (10.67 μM) and potentiator, N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide (0.5 μM), in 1×D-PBS (from Gibco, Cat n#14090-091) for 20 minutes prior to addition of an I⁻ solution (137 mM NaI, 2.7 mM KI, 1.76 mM KH₂PO₄, 10.1 mM Na₂HPO₄, 5 mM glucose). The potentiator, 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide, was used in place of N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide in some assays. The I⁻ induced quenching of fluorescence is recorded immediately after injection of I⁻ for 7 seconds. The capacity of a compound to increase number of channels, and therefore overall halide influx is directly correlated with the decrease in fluorescence, and is expressed as (1−(fluorescence after 7 seconds (F)/fluorescence before injection (F0))) and an EC₅₀ can be derived from a (1−F/F0) vs compound concentration plot.

TECC Assay

Primary Bronchial Epithelial Cells Protocol

The TECC (Tranepithelial Clamp Circuit, EP-design) assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) by measuring the short circuit current (I_(sc)) generated over the basolateral and apical membrane of lung epithelial cells. In TECC the transepithelial potential PD and transepithelial resistance (R_(t)) are measured in an open circuit and transformed to I_(eq) using Ohm's law. 24 Wells can be measured simultaneously allowing a higher throughput compared to Ussing chambers.

For this purpose, bronchial epithelial cells isolated from CF patients homozygous for the CFTR ΔF508 mutation (hAEC-CF, Epithelix, Geneva, Switzerland; McGill University, Montreal, Qc; Asterand, Detroit, Mich.; University of North Carolina, Chapel Hill, N.C.) are plated on type IV collagen-coated Transwell® supports (Costar). Human airway epithelia are generated by provision of an air-liquid interface for 21 days to form well-differentiated polarized cultures that resemble in vivo pseudo-stratified ciliated epithelium (Fulcher, M. L., Gabriel, S., Burns, K. A., Yankaskas, J. R., Randell, S. H., 2005. Well-differentiated human airway epithelial cell cultures. Methods Mol. Med. 107, 183-206). The differentiated cells are treated with test corrector compound(s) (corrector alone or in combination with co-corrector, 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid (“acute”) or test corrector compounds, co-corrector and potentiator, N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide (“chronic”) for 24 hours basolaterally to allow sufficient expression of properly folded CFTR protein on the membrane. All compound plates contained negative controls (DMSO) and positive controls (0.15 μM, 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid).

For electrophysiological recording of the “acute” experiments, the human airway epithelia are mounted in the TECC heating plate and kept at 37° C. The epithelia are bathed in a NaCl-Ringer solution (120 mM NaCl, 25 mM NaHCO₃, 1.2 mM CaCl₂, 1.2 mM MgCl₂, 0.8 mM KH₂PO₄, 0.8 mM K₂HPO₄, pH 7.4, 5 mM glucose) on both the basolateral and apical sides. Apical amiloride is used to inhibit the endogenous epithelial sodium channel (ENaC) currents while forskolin is applied on both apical and basolateral side to stimulate CFTR. CFTR activity is measured by addition of forskolin followed by addition of a potentiator, N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide, on both sides. The potentiator, 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide, was used in place of N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide in some assays. Measurements are done during a 20 minute timeframe with recordings every 2 minutes. The increase in I_(eq) is used as a measure for the increased CFTR activity, EC₅₀ values can be generated by measuring impact of different concentrations of compound on I_(eq) on primary cells, for this purpose each transwell is treated with a different compound concentration for 24 hours. Inhibitor-172, an inhibitor specific for CFTR, is used to test the specificity of the tested compounds. Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

TABLE XX Illustrative acute TECC assay response with and without the presence of a co-corrector. Compound % Activity at % Activity at % Activity at 3 μM with # 3 μM (Ieq*) 10 μM (Ieq*) co-corrector (Ieq*)  10 591.84  11 351  13 74.32 174.53 104 102.36 *Ieq refers to calculations based on the maximum current.

For electrophysiological recording of the “chronic” experiments, the human airway epithelia are mounted in the TECC heating plate for electrophysiological measurement and kept at 37° C. The epithelia are bathed in a NaCl-Ringer solution (120 mM NaCl, 25 mM NaHCO₃, 1.2 mM CaCl₂, 1.2 mM MgCl₂, 0.8 mM KH₂PO₄, 0.8 mM K₂HPO₄, pH 7.4, 5 mM glucose) on both the basolateral and apical sides. Test compounds (corrector, co-corrector, 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid, and potentiator, N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide), are re-added to the recording solution prior to measurement. The potentiator, 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide (1.5 μM), was used in place of N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide in some assays (for Compound numbers >370). Apical amiloride is used to inhibit the endogenous ENaC currents while forskolin is applied on both apical and basolateral side to stimulate CFTR. Measurements are done during a 20 minute timeframe with recordings every 2 minutes. The increase in I_(eq) is used as a measure for the increased CFTR activity, EC₅₀ values can be generated by measuring impact of different concentrations of compound on I_(eq) on primary cells, for this purpose each transwell is treated with a different compound concentration. Inhibitor-172, an inhibitor specific for CFTR, is used to test the specificity of the tested compounds. Raw data were normalized to percentage activity values using the equation: 100×(Sample−Negative control)/(Positive control−Negative Control).

TABLE XXI Illustrative chronic TECC assay response. % % Activity % Activity Activity EC₅₀ at at EC₅₀ Compound at 1 μM (nM) 1 μM 3 μM (nM) # (Ieq*) (Ieq*) (AUC**) (AUC**) (AUC**)  30 450 <30  34 270 <30  63 325 40  71 270 19.5  74 240 <30  75 316 30  80 250 19.3  85 120 >1000  86 210 30  87 150 <30  91 250 <30  93 220 <30  95 180 10  96 310 <30 104 720 <30 110 170 <30 113 310 32 117 81 >1000 119 157 >1000 121 206 74 128 235 <30 136 233.2 23.5 142 250 <300 144 350 12 146 310 30 150 100 152 482.77 16 155 200 4 158 370.9 160 190 160 167 260 32 168 282.45 38.2 169 210 2.1 177 419.90 >100 185 453 45.4 187 180 >1000 188 257.3 190 269 51 193 317.57 198 477.39 199 627.48 >1000 200 364.3 201 250 <300 207 441.31 215 320 45 219 298.20 221 245.9 40 226 530 56 228 240 32 229 430 20 230 265.44 27 236 434.22 80 238 521.96 240 288.71 140 241 400 <10 242 308.45 14 243 165.81 244 238.89 245 628.25 246 301.36 61 247 422.93 81 248 275.96 249 271.29 250 331.21 251 336.34 252 248.51 263 399.85 77 267 130 269 172.35 270 250 297 272 285.35 273 197.06 274 224.99 >300 279 109 291 255.92 294 21 297 470.97 ≤30 298 318059 304 194.54 316 452.88 45 317 311.08 24 318 439.94 320 215.3 322 440.86 323 217.91 325 317.57 328 531.7 423.1 96 331 537.3 10 334 345.13 100 337 299.50 340 216.53 348 343.24 200 365 521.8 200 366 427.95 369 583.16 8.3 370 226.54 379 370 43 380 250 381 441 4105 382 204.7 347 100 383 299 2 385 12.3 396 259.4666 397 251.7766 399 244.7508 400 230 402 345.045 12.1 404 433.3333 405 323.3333 406 235 407 310 48.94 408 430 21 409 420 149.8 410 233.3333 1.582 415 196.1812 28.4 416 288.6036 118.9 417 256.6667 418 196.6667 19.19 420 223.3333 0 421 193.3333 45.63 422 320 423 365 39.83 424 462.0976 429 180 83.75 431 280 440 696.6667 2.98 441 236.6667 205.8 445 406.6667 447 330 448 116.8948 456 261.1621 469 293.3333 108.2 470 210 471 296.6667 472 181.0865 34.24 473 243.3333 474 226.6667 480 548.575 484 380 487 340 493 271.4141 370.8 495 262.4635 517 309.141 522 666.6667 21.95 523 460.2177 525 477.2665 50.35 526 400 14.23 527 370.693 529 520 19.11 530 326.6667 535 335.0294 537 261.5724 541 320 546 282.0317 549 373.3333 242.7 551 239.0643 552 235.2857 555 296.6667 107 558 221.9818 4.74 559 231.6378 561 620 562 289.8854 569 1156.667 570 377.5594 575 246.6667 576 225.798 578 936.6667 583 613.3333 51.3 589 236.6667 590 220.4586 594 320 597 263.3333 599 116.6667 605 726.6667 608 442.1916 609 306.6667 611 176.7495 614 407.7118 621 256.6667 623 433.3333 624 310 625 403.3333 626 387.4854 627 446.6667 628 473.0586 88.4 629 153.3918 6.848 630 125.1944 47.07 631 156.9645 632 237.1158 29.28 633 204.5 634 137.5 638 341.3493 11.24 645 246.4648 646 276.7167 23.45 647 420.0246 150.7 648 366.0679 649 224.5026 654 293.3333 656 197.5908 657 357.6409 658 260.3278 659 251.6549 *Ieq refers to calculations based on the maximum current. **AUC is the full area under the curve upon forskolin stimulation.

Information on protein binding of compounds can be retrieved from incubation of compounds in the presence of 40% human serum. For this purpose the differentiated cells are treated basolaterally with test compounds in medium containing 40% human serum (Sigma; H4522) for 24 hours. For electrophysiological recording, the human airway epithelia are mounted in the TECC heating plate and kept at 37° C. The epithelia are bathed in a NaCl-Ringer solution (120 mM NaCl, 25 mM NaHCO₃, 1.2 mM CaCl₂, 1.2 mM MgCl₂, 0.8 mM KH₂PO₄, 0.8 mM K₂HPO₄, pH 7.4, 5 mM glucose) on both the basolateral and apical sides. Test compounds (corrector, co-corrector, 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid, and potentiator, N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide), are re-added to the recording solution prior to measurement. Apical amiloride is used to inhibit the endogenous ENaC currents while forskolin is applied on both apical and basolateral side to stimulate CFTR. Measurements are done during a 20 minute timeframe with recordings every 2 minutes. The increase in I_(eq) is used as a measure for the increased CFTR activity, EC₅₀ values can be generated by measuring impact of different concentrations of compound on I_(eq) on primary cells, for this purpose each transwell is treated with a different compound concentration. Inh-172, an inhibitor specific for CFTR, is used to test the specificity of the tested compounds.

It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. Various changes and modifications to the described embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations, or methods, or any combination of such changes and modifications of use of the invention, may be made without departing from the spirit and scope thereof.

LENGTHY TABLES The patent contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US10259810B2). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

What is claimed is:
 1. A compound, which is

wherein one or more hydrogen atoms are replaced by deuterium; or a pharmaceutically acceptable salt thereof.
 2. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a potentiator or one or more correctors.
 3. The pharmaceutical composition of claim 2, wherein the potentiator is selected from the group consisting of: Ivacaftor (VX-770, N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide); CTP-656; NVS-QBW251; FD1860293; PTI-808; GLPG1837; GLPG2451; 2-(2-fluorobenzamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide; 2-(2-hydroxybenzamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; 2-(1-hydroxycyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; 5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; 2-(2-hydroxy-2-methylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; 2-(1-(hydroxymethyl)cyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; 2-(3-hydroxy-2,2-dimethylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-methyl-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-cyclopropyl-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-isopropyl-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide; 5-tert-butyl-N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-ethyl-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-3-ethyl-4-methyl-1H-pyrazole-5-carboxamide; 2-(2-hydroxypropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxamide; 4-bromo-N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-5-methyl-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-methyl-1H-pyrazole-3-carboxamide; 2-(2-hydroxy-3,3-dimethylbutanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide; 2-[(2-hydroxy-4-methyl-pentanoyl)amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; 5-(2-methoxy-ethoxy)-1H-pyrazole-3-carboxylic acid (3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-amide; N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-4-(3-methoxypropyl)-1H-pyrazole-3-carboxamide; N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-4-(2-ethoxyethyl)-1H-pyrazole-3-carboxamide; 2-[[(2S)-2-hydroxy-3,3-dimethyl-butanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; 2-[[(2R)-2-hydroxy-3,3-dimethyl-butanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; 2-[(2-hydroxy-2,3,3-trimethyl-butanoyl)amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; [5-[(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)carbamoyl]pyrazol-1-yl]methyl dihydrogen phosphate; [3-[(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)carbamoyl]pyrazol-1-yl]methyl dihydrogen phosphate; N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-4-(1,4-dioxan-2-yl)-1H-pyrazole-3-carboxamide; 5,5,7,7-tetramethyl-2-[[(2S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propanoyl]amino]-4H-thieno[2,3-c]pyran-3-carboxamide; 2-[[(2S)-2-hydroxypropanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide; 3-amino-N-(2-hydroxy-2-methylpropyl)-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; 3-amino-N-[(4-hydroxy-1-methylpiperidin-4-yl)methyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; 3-amino-N-(3-hydroxy-2,2-dimethylpropyl)-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; 3-amino-5-[(4-fluorophenyl)sulfonyl]-N-[(1-hydroxycyclopropyl)methyl]pyridine-2-carboxamide; 3-amino-5-[(4-fluorophenyl)sulfonyl]-N-[(2R)-3,3,3-trifluoro-2-hydroxypropyl]pyridine-2-carboxamide; 3-amino-5-[(3-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-methylpropyl)pyridine-2-carboxamide; 3-amino-N-[2-(cyclopropylamino)-2-oxoethyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; (3-amino-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(azetidin-1-yl)methanone; (3-amino-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl) [3-(hydroxymethyl)azetidin-1-yl]methanone; (3-amino-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone; 3-amino-N-[(2R)-2-hydroxy-3-methoxypropyl]-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; (3-amino-5-{[2-fluoro-4-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(3-hydroxyazetidin-1-yl)methanone; (3-amino-5-{[2-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)(3,3-difluoroazetidin-1-yl)methanone; rac-3-amino-N-[(3R,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-5-{[2-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; 3-amino-5-[(4,4-difluoropiperidin-1-yl)sulfonyl]-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-2-carboxamide; (3-amino-5-{[2-(trifluoromethoxy)phenyl]sulfonyl}pyridin-2-yl)[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; 3-amino-N-(2-hydroxy-4-methylpentyl)-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; (3-amino-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridin-2-yl)(3-hydroxy-3-methylazetidin-1-yl)methanone; 3-amino-N-(3,3,3-trifluoro-2-hydroxypropyl)-5-{[4-(trifluoromethyl)piperidin-1-yl]sulfonyl}pyridine-2-carboxamide; 3-amino-N-[2-hydroxy-1-(4-methoxyphenyl)ethyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide; 3-amino-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-2-carboxamide; 3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(2S)-2-hydroxypropyl]pyridine-2-carboxamide; 3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(2R)-2-hydroxy -3-methoxypropyl]pyridine-2-carboxamide; 3-amino-N-[2-oxo-2-(propan-2-ylamino)ethyl]-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; (3-amino-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridin-2-yl)[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; 3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(3R)-tetrahydrofuran-3-ylmethyl]pyridine-2-carboxamide; (3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}pyridin-2-yl)[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; 3-amino-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[(3S)-tetrahydrofuran-3-ylmethyl]pyridine-2-carboxamide; 3-amino-5-{[2-fluoro-4-(trifluoromethoxy)phenyl]sulfonyl}-N-[(3S)-tetrahydrofuran-3-ylmethyl]pyridine-2-carboxamide; 3-amino-N-[2-hydroxy-3-(2,2,2-trifluoroethoxy)propyl]-5-{[4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; 3-amino-N-(3-tert-butoxy-2-hydroxypropyl)-5-{[2-fluoro-4-(trifluoromethyl)phenyl]sulfonyl}pyridine-2-carboxamide; [3-amino-5-(phenylsulfonyl)pyridin-2-yl][3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; {3-amino-5-[(3-fluorophenyl)sulfonyl]pyridin-2-yl}[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone; and 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide.
 4. The pharmaceutical composition of claim 2, wherein the one or more correctors are selected from the group consisting of: Lumacaftor (VX-809); 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide (VX-661); PTI-801; VX-983; GLPG2665; VX-152; VX-440; FDL169; FDL3 04; FD2052160; FD2035659; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-methyl-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methyl-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]cyclohexanecarboxylic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]cyclohexanecarboxylic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-fluoro-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-({3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methyl-3,4-dihydro-2H-chromen-2-yl]benzoyl}amino)-1-methylcyclopentanecarboxylic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methyl-3,4-dihydro-2H-chromen-2-yl]-N-[(2R)-2,3-dihydroxypropyl]benzamide; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(2-methoxyethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-7-(benzyloxy)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(2-fluoroethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-2-yl]cyclohexanecarboxylic acid; 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-8-fluoro-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid; rac-3-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic acid; rac-4-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic acid; 3-[(2S,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic acid; 3-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic acid; rac-3-[(2R,4S,6S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-phenyltetrahydro-2H-pyran-2-yl]benzoic acid; 3-[(2S,4R,6R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-phenyltetrahydro-2H-pyran-2-yl]benzoic acid; 3-[(2R,4S,6S)-4-({[ 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-6-phenyltetrahydro-2H-pyran-2-yl]benzoic acid; 4-[(2R,4S)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)tetrahydro-2H-pyran-2-yl]benzoic acid; 3-cyclobutyl-4-[4-(morpholin-4-yl)piperidin-1-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid; 3-cyclobutyl-1-phenyl-4-{4-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid; 5-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]pyrazine-2-carboxylic acid; 6-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]pyridine-3-carboxylic acid; trans-4-[(2S,4S)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; 6-[(2R,4R)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]pyridine-3-carboxylic acid; trans-4-[(2S,4S)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; ethyl trans-4-[(2S,4S)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylate; cis-4-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; trans-4-[(2S,4S)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; 1-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclopropane-1-carboxylic acid; trans-4-[(2R,4R)-4-{[(5S)-2,2-difluoro-5-methyl-6,7-dihydro-2H,5H-indeno[5,6-d][1,3]dioxole-5-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; trans-4-[(2R,4R)-4-{[(5S)-2,2-difluoro-5-methyl-6,7-dihydro-2H,5H-indeno[5,6-d][1,3]dioxole-5-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; trans-4-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-methoxy-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; trans-4-[(2R,4R)-7-(difluoromethoxy)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid; and trans-4-[(2R,4R)-4-{[(7R)-2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxole-7-carbonyl]amino}-7-(trifluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]cyclohexane-1-carboxylic acid.
 5. A pharmaceutical formulation for treating a CFTR mediated disease in a subject comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of one or two CFTR modulators and one CFTR amplifier.
 6. The pharmaceutical formulation of claim 5, wherein the CFTR modulators are either CFTR potentiators or CFTR correctors.
 7. The pharmaceutical formulation of claim 6, wherein the CFTR potentiators are selected from the group consisting of Ivacaftor (VX-770), CTP-656, NVS-QBW251, FD1860293, PTI-808, GLPG2451, GLPG1837, and N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide and 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide.
 8. A pharmaceutical composition comprising a compound of 3-cyclobutyl-N-(dimethylsulfamoyl)-1-(4-fluorophenyl)-4-(4-methoxy[1,4′-bipiperidin]-1′-yl)-1H-pyrazolo[3,4-b]pyridine-6-carboxamide, or a pharmaceutically acceptable salt thereof, and a potentiator or one or more correctors. 